

CURRICULUM VITAE: DANIEL J. WALLACE, M.D., F.A.C.P., M.A.C.R

Updated July 13, 2021

Personal Information:

Address: 8750 Wilshire Blvd, Suite 350
Beverly Hills, CA 90211

Phone: 310-652-0010

Fax: 310-360-4812

E-mail: danielwallac@gmail.com, daniel.wallace@cshs.org

Education:

- University of Southern California, M.D., 1970-1974
- University of Southern California, BA Medicine, 1967-1970

Postgraduate Training:

- Rheumatology Fellow, UCLA School of Medicine, Los Angeles, CA, 1977-1979
- Medical Resident, Cedars-Sinai Medical Center, Loss Angeles, CA, 1975-1977
- Medical Intern, Rhode Island (Brown University) Hospital, Providence, RI, 1974-1975

Medical Boards and Licensure:

- Board Certified, Rheumatology subspecialty, 1982
 - California License No. G-30533
- Board Certified, American Board of Internal Medicine, 1978
- Diplomate, National Board of Medical Examiners, 1975

Present Appointments:

- Board of Directors, Lupus Therapeutics Board, 2020-
- Board of Directors, Lupus Research Alliance 2020-
- Member, OMERACT Sjogren's Domain Special Interest Group, 2019-
- Member, FNIH Biomarkers Sjogren's Committee 2019-
- Member, Medical Policy Committee, United Rheumatology, 2017-
- Board of Governors, Cedars-Sinai Medical Center, 2016-
- Professor of Medicine, Cedars-Sinai Medical Center, 2012-
- Member, Sjogren's Foundation Medical Advisory Board 2010-
- Associate Director, Rheumatology Fellowship Program, Cedars-Sinai Medical Center, 2010-
- Expert Reviewer, Medical Board of California, 2007-
- Professor of Medicine, David Geffen School of Medicine at UCLA, 1995-
- Medical Director, Wallace Rheumatic Studies 1994-

Honorary Appointments:

- Master, American College of Rheumatology, 2015-Present
- Organizing Committee, Lupus (Quebec, Canada), 2014
- Fellow, American College of Physicians (FACP), 1985-Present
- Member, Royal College of Physicians (London), 1985-Present
- Fellow, American College of Rheumatology (FACR), 1979-2015

Hospital Appointments:

- Cedars-Sinai Medical Center, Beverly Hills, CA
 - Division of Rheumatology Executive Committee, 2011-Present
 - Clinical Academic Promotions and Appointment Council, 2011-2014
 - Chairman of Department of Medicine Search Committee, 2011-2012
 - Pharmacy Gamma Globulin Committee, 2002-Present
 - Performance Improvement Committee, 1991-1996
 - Clinical Chief of Rheumatology, 1991-1996
 - Division of Rheumatology Reappointment/Peer Review, 1988-Present
 - Hospital Peer Review Committee, 1986-1989 and 1992-1994
 - Medical Advisory Committee, 1985-1988 and 1991-1996
 - Chairman, Medical Peer Review, 1985-1987
 - Member, Medical Peer Review, 1982-1989
 - Intern Selection Committee, 1979-1993
- UCLA Center for the Health Sciences, Los Angeles, CA
 - Attending Physician, 1981-Present
- City of Hope Medical Center, Duarte, CA
 - Chief Rheumatology Consultant, 1980-1988

Prior Academic Appointments:

- Clinical Professor, UCLA School of Medicine, 1988-1995
- Assistant Clinical Professor, UCLA School of Medicine, 1981-1988
- Assistant Clinical Professor, USC School of Medicine, 1979-1981

Organizations and Positions Held:

- Lupus Research Alliance
 - Lupus Therapeutics Board of Directors, 2020-Present
 - Executive Board, Lupus Clinical Investigative Network, 2016-Present
 - Co-chairman, Lupus Industry Council, 2016-2019
- OMERACT Sjogren's Domain Special Interest Group
 - Member, 2019
- FNIH Biomarkers Sjogren's Committee
 - Member, 2019-Present
- Master, American College of Rheumatology
 - Rheumatology Research Foundation, Ambassador, 2018
 - Lupus Abstract Selection Committee, 2010-2015
 - Nominating Committee, 2005-2007
 - Chairman, 1995-1999
 - Research & Education Foundation Board of Directors, 1993-1999
 - Nominations Committee, 1991-1994
 - Chairman, 1990-1991
 - Lupus Council, 1986-Present
 - Committee on Rheumatologic Practice, 1982-1985
- 23andme
 - Scientific Advisory Board for Lupus, 2015-Present
- NYU Judith and Stewart Colton Center for Autoimmunity, NYU Langone Medical Center

- External Advisory Committee, 2014-Present
- Lupus Research Institute
 - Co-Chairman, Industrial Relations Council, 2012-Present
 - Member, Lupus Clinical Trials Consortium (LCTC), 2005-2010
 - Board of Directors, 2000-2015
- Lupus Foundation of America
 - Co-chairman, 1999-2000
 - Vice President, 1999-2000
 - Member, Board of Directors, 1991-1998
 - Co-Chair, Los Angeles Chapter Medical Advisory Board, 1989-1999
 - National Medical Advisory Board, 1988-2000
- NIH Lupus Biomarkers Committee
 - Committee Member, 2004-2010
- SLICC (Systemic Lupus International Coordinating Committee)
 - Member, 2003-Present
- Maryland Lupus Foundation
 - Medical Advisory Board, 2001-2004
- Scleroderma Foundation, Southern California
 - Board of Directors, 2001-2004
- Lupus LA
 - Founder, 2000-Present
- Member, Los Angeles County Medical Association, 1979-Present
- Sjogren's Syndrome Foundation
 - Medical Advisory Board, 1997-Present
- American Board of Internal Medicine
 - Examination writer for Internal Medicine Boards, 1994, 1995
- American Fibromyalgia Syndrome Association
 - Medical Advisory Board, 1994-Present
- Arthritis Foundation Pacific Region
 - Board of Directors, Southern California, 1994-2006
 - Chairman 1990-1995
 - LA. Metro Committee Chairman, 1989-1994
 - Community Services Committee, 1989-1994
 - Medical and Scientific Committee, 1989-1994
 - Institutional Grants Committee, 1989-1994
 - Fibromyalgia Subcommittee, 1988-Present
 - Representative, National House of Delegates, 1987, 1990
- United Scleroderma Foundation
 - Board of Directors, 1990-1997
- The American Lupus Society (merged with Lupus Foundation of America, 1996)
 - National Medical Advisory Board, 1988-1996
 - Los Angeles Chapter Medical Advisory Board, 1980-1996
 - Los Angeles Chapter Chief Medical Advisor, San Fernando Valley Medical Advisory Board, 1980-1996
- American Society for Apheresis
 - Medical Executive Committee, 1987-1989
 - Editor, ASFA Newsletter, 1987-1989

- Member, 1980-Present
- Member, California Medical Association, 1979-Present
- Member, American Medical Association, 1979-Present
- Member, Southern California Rheumatism Society, 1979-Present

Laboratory Experience:

- Cedars-Sinai Lupus Research Laboratory, 1990-Present
- Therapeutic apheresis project, Cedars-Sinai Medical Center, 1977-1997
- USC Cancer Virology Laboratory, Dr Murray Gardner and J. Earle Office, PhD, 1972-1974
 - retroviruses and aging.
- Summer research fellow, Cedars-Sinai Medical Center, 1968-1970
 - under Dr Leon Morgenstern, Chairman, Department of Surgery, dealing with wound healing of intestinal anastomoses and synthesizing trypsin inhibitor.

Publication Review Experience:

- Editorial Board, Future Rheumatology, 2006-2016
- Editor-in-Chief, Current Rheumatology Reviews, 2005-2008
- Editorial Board, Journal of Clinical Rheumatology, 2003-Present
- Editorial Board, Journal of Rheumatology, 1999-Present
- Editorial Board, Journal of Musculoskeletal Pain, 1999-Present
- Editorial Board, Arthritis & Rheumatism, 1998-2003
- Editorial Board, Bulletin on the Rheumatic Diseases, 1998-2004
- Editorial Board, Lupus, 1997-Present
- Editor, Current Opinion in Rheumatology, Lupus issues, 1994-2000
- Editorial Board, Journal of Clinical Apheresis, 1982-2004
- Reviewer for over 50 medical journals

Honors

- Jane Wyman Humanitarian Award, Arthritis Foundation, 2018
- Innovation Award for Community Service, Los Angeles County Medical Association, 2017
- Lupus Foundation of Northern California, Outstanding Commitment to Treatment and Research, 2016
- Sjogren's Syndrome Foundation, Healthcare Professional Leadership Award, 2012
- Medical Achievement Award, SLE Foundation, 2011
- Top Doctor, US News and World Report, 2011-Present
- Founder's Award, Lupus LA, SLE Foundation, 2008
- James R Klinenberg Achievement Award, Arthritis Foundation Southern California Chapter, 2004
- Achievement Award, SLE Foundation, 2002
- "Spirit of Hope" Award, Southern California Scleroderma Foundation, 2001
- Outstanding Service Award, Lupus Foundation of America, 1997
- Jane Wyman Humanitarian Award, Arthritis Foundation, 1996
- Best Doctors in Los Angeles, Los Angeles Magazine, 1996
- Expert Consultant, Medical Board of California, 1995-Present
- "The Best Doctors in America," Woodward/White, Aiken, SC, 1994
- Lupus Hall of Fame, The American Lupus Society, 1989
- Best Doctors in the United States, Town and Country Magazine, October 1989

- Humanitarian Award, Lupus Foundation of America, 1989, 1991
- Globus Award, Best Medical Paper, Mt. Sinai J Medicine, 1984-1985

Research Grants

- PCORI, \$8,000, 2021
 - “Implementing the DeCision- AID for Lupus (Ideal strategy)”, Principal Investigator: Jasvinder A. Singh, MD, MPH, IND/IDE Sponsor: University of Alabama at Birmingham, Funded by: Patient-Centered Outcomes Research Institute
- Department of Defense Grant, Award ID: CSR206754, 2020-2021, \$164,000
 - Cedars-Sinai Precision Health RFP 2020 Decision Notification, “Investigating the link between elevated IDH2 levels and epigenetic regulation of type I interferons in Lupus” Contact Principal Investigator: Dr. Caroline Jefferies, Role: Co Investigator
- NIH Grant, # U01AR076092-01A1 #101,320, Direct costs awarded: \$1,289,962, Total costs awarded: \$1,500,000, 2020
 - “SLE Treatment with N-acetylcystine, (SNAC)”, Principal Investigator: Andras Perl, Role: Co-Principal Investigator
- Center for Disease Control, CDC RFA DP15-1511, \$5,000, 2017-2021
 - “Developing and Disseminating Programs to Build Sustainable Lupus Awareness, Knowledge, Skills and Partnerships”, Co-Investigators with Lupus Foundation of America
- NIH/NIAMS, #U34 AR067392, 2015-2017
 - “Hydroxychloroquine Treatment for Prevention of Systemic Lupus Erythematosus”, Planning grant for a multicenter, placebo-controlled trial of hydroxychloroquine in incomplete lupus patients to determine whether this can ameliorate, delay or prevent progression to SLE. Olsen & Karp (MPIs), Role: Co-investigator
- Department of Defense, Award Number W81XWH-13-1-0392, 2014
 - Subject: Introduction and Contact Information for the Protocol, “A Phase Ib Study of Milatuzumab Administered Subcutaneously in Patients with Active Systemic Lupus Erythematosus (SLE),” Submitted by Daniel Wallace MD, Cedars-Sinai Medical Center, Los Angeles, California in Support of Proposal, “CD74 Immunotherapy of Systemic Lupus Erythematosus,” William Wegener MD, Immunomedics, Incorporated, Morris Plains, New Jersey, Proposal Log Number PR121764, HRPO Log Number A-17786
- NIH Grant, #R34A114453, 2014-2015
 - “Mesenchymal Stem Cell Therapy for Active Systemic Lupus Erythematosus”, Planning grant. The goal is to complete protocol development and set up administrative and regulatory structures at participating trial sites for implementation of a multicenter trial of MSCs for patients with active SLE. Gilkeson & Kamen (MPIs), Role: Co-investigator
- NIH/NIAMS Grant, Oklahoma Sjogren’s Syndrome Center of Research Translation, #P50AR060804-03, 2013-2016
 - The overall specific aim is to establish the Oklahoma Sjogren’s Syndrome Center of Research Translation (OSSCORT) with the goal of bridging the gap between the advances in the basic-science understanding of Sjogren’s syndrome and clinical research geared to improving better diagnostics, disease predictors, and prognostic tests, as well as to advance therapeutic options, Sivils (PI), Role: Co-Investigator
- Autoimmune Centers of Excellence, 2012-2016
 - “BASJ02-A randomized, double-blind, placebo-controlled trial of Baminercept, a omphotoxin-B receptor fusion, protein, for the treatment of primary Sjogren’s syndrome”, Role: Principal Investigator

- Cedars-Sinai Medical Group, France Foundation, \$150,000, 2012-Present
 - “Improving the Recognition, Diagnosis, and Referral Patterns of Patients with Systemic Lupus Erythematosus Through Enhanced Care Coordination and Practice Efficiencies” – A QI/PI CME Demonstration Project, Role: Principal Investigator
- Canadian Arthritis Society, 2009-2011
 - “Lymphoma Risk in SLE: A Consequence of Immune Suppression or Stimulation?” The purpose of this research is to help identify SLE patients at highest risk for lymphoma and provide guidance regarding the appropriate use of ISDs in both inducing and maintaining remission in SLE. Clarke/Bernatsky (PI), role: Co-Investigator
- NIH Grant, #N01A115416, 2008-2012
 - “The use of abatacept in lupus nephritis”, Role: Co-investigator, HHSN268200700036C, Langford (PI)
- NIH Grant, #N01-AR-4-2273, 2007-2010
 - “Rituxan in the treatment of refractory adult and juvenile dermatomyositis (DM) and adult polymyositis”, Role: Co-investigator
- Alliance for Lupus Research, \$72,500, 2006-2008
 - “Concurrent Pilot Studies in Giant Cell Arteritis and Takayasu Arteritis to Examine the Safety, Efficacy, and Immunologic Effects of Abatacept (CTLA4-IG) in large Vessel Vasculitis.” The purpose of this study is to determine the effectiveness and safety of the medication abatacept in giant cell arteritis or Takayasu’s arteritis, role: Co-Investigator
- Aspreva, \$62,500, 2006-Present
 - “The role of mycophenolate mofetil in patients with extra-renal lupus.” A study to investigate pro inflammatory HDL cholesterol as an indication of risk for atherosclerosis in subjects with systemic lupus erythematosus.
- NIH Grant, Lupus Foundation of America, NIH-NIAMS ARO051871-013, 2004-2009
 - “AROSE: Revising ACR diagnostic/classification criteria for lupus”
- NIH/NIAID Grant, #U19 AI056363, 2003-2016
 - “Mechanisms of B Cell Responses in Autoimmune Diseases”, This Autoimmunity Center of Excellence based at Duke University focuses on the modulation of B cell responses in autoimmune diseases. St. Clair (PI), Role: Co-Investigator
- NIH Grant, Grant #R01AR4912501, National Institute of Arthritis, Musculoskeletal and Skin Disorders, 2003-Present
 - “Brain Connections: Cognitive function in SLE”, Co-investigator with Dr. Michelle Petri
- Food and Drug Administration, RF 412-3324A, \$24,000, 2000-2002
 - “Comparison of IV cyclophosphamide to mycophenolate mofetil for induction therapy of active Class III-IV nephritis in systemic lupus erythematosus.” Co-investigator with M Weisman for Cedars effort
- American Fibromyalgia Syndrome Association, \$24,600, 1998-1999
 - “The role of the Th-1/Th-2 axis in fibromyalgia”
- NIH Grant, Agency Award #2Ro1AR4252-04, \$442,670, 1997-1999
 - “Abnormal IL-6 Production in SLE”, Co-investigator with Dr. Mariana Linker-Israeli
- NIH Grant, Agency Award #2Ro1AR4252-04, \$350,000, 1994-1996
 - “Interleukin-6 genetic polymorphisms”, Co-investigator with Dr. Mariana Linker-Israeli
- Winthrop Pharmaceuticals Grant, \$7,500, 1991-1993
 - “Cytokines and their influence on hydroxychloroquine”
- The American Lupus Society Grant, \$28,000, 1990-1992
 - “An index of lupus literature”

- Winthrop Pharmaceuticals Grant, \$5,000, 1989-1999
 - “The role of hydroxychloroquine on lipids”
- Parker Foundation Grant, \$76,250, 1983-1985
 - “Selective immunoadsorption in rheumatoid arthritis”
- Haemonetics Research Institute Grant, \$25,000, 1982
 - “The immunology of apheresis”
- Kroc Foundation Grant, \$59,000, 1981-1982
 - “Apheresis in systemic lupus erythematosus”
- Haemonetics Research Institute Grant, \$25,000, 1980-1981
 - “Double-blind controlled trial of apheresis in rheumatoid arthritis”
- BSRG Cedars-Sinai Research Grant, \$10,000, 1978-1979
 - “Apheresis in rheumatoid arthritis”
- Department of Defense, LR170141, 2018
 - “Inflammation and Metabolic Reprogramming of Lupus Monocytes – Mechanism of the Pathobiology of Lupus Cardiovascular Disease”, Caroline Jefferies (PI), Role: Co-Investigator

Department of Defense Review Panels

- “Lupus Grants Review”, 2016
- “Gulf War Illness Research Program”, 2010, 2019

Data Safety and Monitoring Board (DSMB)

- NIAID Autoimmune Centers for Excellence, Clinical Research Program, UM-1 Grants, 2018
- Department of Defense, Peer Review of Autoimmune Grant Proposals, 2016
- Novo Nordisk Anti IL-21, Protocol NN8828-4002, 2012- 2013
- Celecoxib for rheumatoid arthritis, 2006

Past Drug Study Collaborative Protocols:

- Protocol 20-FMS1-BETTER Biomarker evaluation for the differential diagnosis and monitoring of fibromyalgia compared to autoimmune rheumatic diseases, other pain syndromes, and normal subjects, 2020
- Pfizer SLE: A Phase 2B, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study to Evaluate the Efficacy and Safety Profile of PF-06700841 in Participants with Active Systemic Lupus Erythematosus (SLE), 2019-2020
- Abbvie SLE: A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus, 2019-2021
- Amgen SLE: A Phase 1b/2a Study to Evaluate the Safety and Efficacy of AMG 592 in Subjects With Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy, 2019-2020
- RA Study: OSCO-P2201: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study to Evaluate the Efficacy and Safety of Oral SKI-O-703 in Patients With Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies, 2019-2020
- Lilly SLE Extension: Eli Lilly and Company / A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE), 2019-2021

- Sobi.ANAKIN-301 The anaSTILLs Study, A Randomized, Double-blind, Placebo-Controlled, Multicenter, Phase 3 Efficacy and Safety Study of 2 Dose Levels of Subcutaneous Anakinra (Kineret) in Patients with Still's Disease (SJIA and AOSD), 2018-2019
- Krill Oil Study, A Double-Blind, Placebo-Controlled Randomized, Multicenter Study to Assess Changes in Omega-3 Index in Erythrocytes and Health Benefit after 24 Weeks of Daily Consumption of AKBM-3031 (Omega-3 Phospholipids from krill), Followed by a 24 Week Open-Label Extension, in Patients with Systemic Lupus Erythematosus (SLE), 2018-2020, Lupus Clinical Investigators Network (LuCIN)
- Protocol I4V-MC-JAIA, A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus, Eli Lilly, 2018-2021
- Auronia Extension Study, A Randomized, Controlled, Double-blind, Continuation Study Comparing the Long-term Safety and Efficacy of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Subjects with Lupus Nephritis, 2018-2020
- Lupuzor Extension Phase 3 Study 1PP-20110L006, Lupuzor Extension, An Open-Label Study of the Safety and Tolerability of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients with Systemic Lupus Erythematosus, 2018-2020
- Protocol CNTO1275SLE3001; Phase 3, A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Subjects with Active Systemic Lupus Erythematosus, Janssen, 2018
- A Phase 1, Randomized, Multi-centered, Double-blind, sponsor open, Placebo-controlled, Single and Multiple Dose- escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06835375 in Subjects with Seropositive Systemic Lupus Erythematosus or Rheumatoid Arthritis, 2018, Pfizer
- 2017, AstraZeneca SPOCS D3461R00001, Prospective Observational Cohort of patients with moderate-to-severe SLE to characterize cross-sectional and longitudinal disease activity, treatment patterns and effectiveness, outcomes and comorbidities, healthcare resource utilization, and the impact of SLE on quality of life by type I interferon gene expression
- Exagen 17-SLE1 CARE Study, Clinical Laboratory Assessments and Recommendations for Lupus, 2017
- GA30044, A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC- 0853 in Patients with Moderate to Severe Active Systemic Lupus Erythematosus, 2017
- AMPEL, A Randomized, Double-Blind, Active Comparator-Controlled, Crossover Study to Assess the Capacity of Delayed-Release Prednisone (RAYOS®) Compared to Immediate-Release Prednisone to Improve Fatigue and Control Morning Symptoms in Subjects with Generalized Systemic Lupus Erythematosus, 2017
- GILEAD A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib and GS-9876 in Female Subjects with Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE), 2017
- Aurina Pharma, A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg Twice Daily) with Placebo in Achieving Renal Response in Subjects with Active Lupus Nephritis, 2017
- Protocol: MS200527-0018, 2017 A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects with Systemic Lupus Erythematosus (SLE), 2017
- A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients with Sjogren 's Syndrome, 2017

- Protocol SL0023, UCB, A Multi-Centered, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Followed by an Observation Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects with Moderate to Severely Active Systemic Lupus Erythematosus, Phase 2B, 2016
- RSLV-132 Protocol 132-03, Resolve A Phase 2A, Double-Blind, Placebo Controlled Study of RSLV-132 in Subjects with Systemic Lupus Erythematosus, 2016
- Protocol I4V-MC-JAHH, Lilly, A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE), 2016
- A Phase III, Randomized, Multicenter, Double-Blind, Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA), 2016-2017
- Janssen, A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus, 2016
- WA29748 Genentech Lupus Nephritis study, A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of obinutuzumab in patients with ISN/RPS 2003 Class III or IV nephritis, 2016
- EMR Serono Research & Development Institute, Protocol EMR200527-002 Protocol Title: A Phase Ib study to evaluate the safety, tolerability, PK and Biological Effect of MSC2364447 in systemic lupus erythematosus, 2015-2017
- A 52-week, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of a 200-mcg dose of IPP-201101 plus standard of care in patients with SLE, ImmuPharm-Orion-Simbec (Lupuzor), 2015
- An open-label, Non-randomized, 52-week study to evaluate treatment Holidays and rebound phenomenon after treatment with Belimumab 10mg/kg in Systemic Lupus Erythematosus subjects, 2015-2016
- An International, Open Label, Randomized Controlled Trial Comparing Rituximab with Azathioprine as Maintenance Therapy in Relapsing ANCA-Associated Vasculitis (RITAZAREM) 2014-2020
- Pharmacokinetic Evaluations of Tabalumab Following Subcutaneous Administration by Prefilled Syringe or Auto Injector in Patients with Systemic Lupus Erythematosus, 2014-2015
- Protocol IMMU-115-04: A Phase Ib Study of Milatuzumab Administered Subcutaneously in Patients with Active Systemic Lupus Erythematosus (SLE) 2014
- A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects with Systemic Lupus Erythematosus (SLE), 2013
- Ignyta – Molecular Analysis in Biological Specimens from Subjects with Rheumatoid Arthritis (RA) Protocol – IGN- RA104
Ignyta – Molecular Analysis in Biological Specimens from Subjects with Systemic Lupus Erythematosus (SLE) and Non-Lupus Control Protocol – IGN-SLE104, 2013-2014
- Nodality – Characterization of Immune Alterations in Systemic Lupus Erythematosus (SLE) using Single Cell Network Profiling (SCNP) Protocol 2012087 SLE Landscaping, 2013-2014
- A phase 111, Multicenter, Randomized, Double-blind Placebo-controlled Study to Assess The efficacy and Safety of Tocilizumab in Subjects with Giant Cell Arteritis, Roche, 2013-2015
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BIIB023 in Subjects with Lupus Nephritis, Biogen, 2012-2013
- A Study to Evaluate the Efficacy and Safety of R333 6% Ointment Administered Topically to DLE and SLE Patients with Active Cutaneous Discoid Lesions, Rigel, 2012-2013

- Protocol WA 27893: Prospective, observational safety study of patients with Granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis treated with rituximab, Genentech 2012-2014
- A longitudinal observational study of CXCR5, CXCL13 and other biomarkers in patients with lupus and healthy control subjects, Sanofi, 2012-2015
- A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of subcutaneous LY2127399 in patients with systemic lupus erythematosus (SLE), 2012- 2014, Lilly, 2012-2015
- A dose escalation, multi-center study to evaluate the safety, tolerability and proof of mechanism of DV1179 in Subjects with Systemic Lupus Erythematosus, Dynavax, 2012
- OMRF Sjogren's Studies: Gene Expression Profiling in Primary Sjogren's Syndrome, 2012-2014
- A Double Blind, Randomized, Placebo-controlled, Multicenter, dose ranging study to evaluate the efficacy and safety of PF-04236921 in subjects with Systemic Lupus Erythematosus, Pfizer, 2012-2013.
- A Randomized, Double-Blind, Placebo-controlled, multiple dose, parallel, Multiple dose-level study to evaluate the safety, tolerability and efficacy of AMG 557 in (SLE) subjects with active Lupus Arthritis, Amgen, 2012-2014
- A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo Controlled, 52-week study to evaluate the efficacy and safety of Belimumab (HGS1066) in Adult subjects of Black Race with Systemic Lupus Erythematosus (SLE), Human Genome Sciences, 2012
- Vasculitis Clinical Research Consortium (VCRC) Genetic Repository DNA Protocol, 2011-2016,
- A study to learn about the safety, effectiveness and effects on the body of abatacept in large vessel vasculitis. Concurrent pilot studies in Giant cell arteritis and Takayasu's arteritis, Vasculitis Clinical Research Consortium, 2011-2012
- ACR/EULAR Diagnostic and Classification Criteria for Vasculitis, ACR, EULAR, Vasculitis Foundation, Oxford University, 2011-2012
- Protocol Summacta WA22762, 2011 –2014
- UCB, Inc. - A Phase 3, Multicenter, open label, extension study to assess the safety and tolerability of Epratuzumab treatment in Systemic Lupus Erythematosus Subjects (Embody 4) Protocol SL0012, 2011
- UCB, Inc. - A Phase 3, Randomized, Double blind, placebo controlled, multicenter study of the Efficacy and Safety of Four 12-Week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects with Moderate to Severe Disease (Embody1). Protocol SL0009, 2011-2012
- Teva Pharmaceutical Industries, LLC - A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Active Lupus Nephritis Patients, in Combination with Standard of Care (Mycophenolate Mofetil and Steroids) Protocol LN-LAQ-201, 2011-2012
- Eli Lilly and Company – A Phase 3, MultiCenter, Randomized, Double-Blind, Placebo Controlled study to evaluate the efficacy and safety of Subcutaneous LY2127399 in patients with Systemic Lupus Erythematosus (SLE), Protocol H9B-MC- BCDS, 2011-2012
- GlaxoSmithKline - Lupus Impact Tracker: A Longitudinal Validation Study Protocol GHO-09-1621, 2011-2012
- IRBIS (Internal Registry for Biologics in SLE) Phase I, Retrospective data collection, SLICC (Systemic Lupus International Collaborative Clinics), 2010-2012, Phase II and III, 2012
- Hp-MMP 9 levels in humans: a pilot study, 2010

- Concurrent pilot studies in Giant cell arteritis and Takayasu's arteritis to examine the safety, efficacy, and immunologic effects of abatacept (CTLA4-Ig) in large vessel vasculitis, 2010
- Studies of B cell abnormalities in Systemic Lupus Erythematosus via MiRNA, 2010-2011
- Study of Epratuzumab in systemic lupus erythematosus, NCT00383513, 2010
- Duke Autoimmunity Pregnancy Registry (DAP Registry), 2010-2012
- UCB. - Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of certolizumab pegol in subjects with adult-onset active and progressive psoriatic arthritis (PsA), 2010-2011
- UCB - A phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of certolizumab pegol in subjects with active axial spondyloarthritis (AS001), 2010-2011
- Sanofi Aventis US Inc. - A randomized double blind-placebo controlled dose ranging study to evaluate the efficacy and safety of SAR153191 in patients with Ankylosing Spondylitis (AS). Protocol Number: DRI11073 – ALIGN, 2010-2011
- Cephalon, Inc. - A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of CEP-33457 in Patients with Systemic Lupus Erythematosus, 2010
- TEVA Pharma - A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Systemic Lupus Erythematosus Patients with Active Lupus Arthritis. PROTOCOL LA-LAQ-202, 2010 NCT01085084
- Study of Lymphoma in Systemic Lupus Erythematosus, SLICC (Systemic Lupus International Collaborative Clinics), 2009-2011
- Roche - A randomized, double-blind, parallel group study of the safety and effect on clinical outcome of tocilizumab SC versus tocilizumab IV, in combination with traditional disease modifying anti-rheumatoid arthritis drugs (DMARDs), in patients with moderate to severe active rheumatoid arthritis, 2009
- Cedars Sinai Medical Center, Cross Cultural Spanish Validation of Lupus Pro: A Patient Reported Outcome Measure for Lupus, 2009
- SLICC, Lymphoma Risk in SLE: A Consequence of Immune Suppression or Stimulation? 2009-Lupus Clinical Trials Consortium, Inc., LCTC Lupus Data Registry, 2009-2010.
- Roche Laboratories Inc. ML22533/A, an open-label, randomized study to evaluate the safety, tolerability and efficacy of tocilizumab (TCZ) monotherapy or TCZ in combination with non-biologic disease modifying antirheumatic drugs (DMARDs) in patients with active rheumatoid arthritis who have an inadequate response to current non-biologic or biologic DMARDs, 2009-2011.
- Array BioPharma Inc. 797-201, A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study To Investigate The Safety, Efficacy, Pharmacokinetics and Pharmacodynamics Of 12 Weeks Of Treatment With ARRY-371797 In Patients With Active Ankylosing Spondylitis And Inadequate Response To Conventional Therapy, 2009
- Immune Tolerance Network: Protocol ITN034AI, A randomized, double-blind, controlled, phase II Multicenter trial of CTLA4Ig (Abatacept) Plus Cyclophosphamide vs Cyclophosphamide Alone in the Treatment of Lupus Nephritis, 2009-2010
- Crescendo Bioscience, Inc. CR10, Index for Rheumatoid Arthritis Measurement (InFoRM) Study, 2009
- Amgen (AMG 827) 20070264, A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 827 in Subjects with Rheumatoid Arthritis, 2009-2010

- Genentech IFN4575g, A phase II, Randomized, Double-blind, placebo-controlled study to evaluate the efficacy and safety of Rontalizumab (rhuMAb IFNalpha) in patients with moderately to severely active Systemic Lupus Erythematosus, 2009
- Novo Nordisk NN8360-3559, A randomized, double-blind, placebo-controlled, single dose-escalation and multiple dose extension trial of NNC 0152-0000-0001 administered i.v. or s.c. in subjects with Systemic Lupus Erythematosus, 2009
- UCB C87094, A Phase IIIB, multi-centre study with a 12-week double-blind, placebo-controlled, randomized period, followed by an open-label extension phase to evaluate the safety and efficacy of certolizumab pegol administered to patients with active rheumatoid arthritis, 2008-2010
- BMS IM 101-167, A Phase IIb, Multicenter, Randomized, Withdrawal study to evaluate the Immunogenicity and safety of Subcutaneously Administered Abatacept in Adults with Active Rheumatoid Arthritis, 2008
- Human Genome Sciences C1066, A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B₂), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE) who Completed the Phase 3 Protocol HGS1006-C1056 in the United States, 2008
- UCB SL0007, A Phase IIB, Randomized, Double Blind, Placebo controlled, dose and dose regimen-ranging study of the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus erythematosus patients with Active Disease, 2008-2009
- The systemic lupus erythematosus (SLE) activity gene expression (SAGE) study, XDx protocol SL 105, 2007-2009
- BMS Lupus Nephritis IM 101-075, A sequential adaptive phase II/III multi-center, randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of Abatecept versus Placebo on a background of Mycophenolate Mofetil and Glucocorticoids in subjects with active Proliferative Glomerulonephritis due to Systemic Lupus Erythematosus (SLE), 2007
- Human Genome Sciences C1056, A Phase 3, Multi-Center, Randomized, Double-Blind, placebo-controlled, 76-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B[™]), a Fully Human Monoclonal Anti- BlyS Antibody, in Subjects with SLE, 2007-2010.
- Medimmune MPI-CP152, A Phase IB, Multicenter, Randomized, Double-blind, Placebo-controlled, dose escalation study with an open label extension to evaluate the safety and tolerability of multiple intravenous doses of MEDI-545, a fully human Anti-Interferon-Alpha Monoclonal Antibody, in patients with Systemic Lupus Erythematosus 2007-2010.
- UCB SL0006, An Open-Label Re-Treatment Trial for Patients Previously Randomized into the SL0003 and SL0004, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studies of Epratuzumab in patients with SLE, 2007
- Genentech IFN 3958g, A Phase I, Randomized, Double-blind, Placebo-controlled, escalating single and multiple dose study of the safety, tolerability, and Pharmacokinetics of rhuMAb IFNalpha in adults with mildly active SLE, 2007-2009.
- A Multi Center, open label, continuation trial of lymphostat b antibody (monoclonal anti-blyS antibody) in subject with Systemic Lupus Erythematosus (SLE) who completed the phase 2 protocol lbsl02. Protocol LBSL9, Human Genome Sciences, 2006
- "A Phase III, Randomized, Double-Blind, Placebo Controlled, Multicenter study to evaluate the Efficacy and Safety of Rituximab in Subjects with ISN/RPS Class III or IV Lupus Nephritis" Protocol Lunar, Genentech, 2006-2008
- MedImmune, 2006-2008

- A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate Safety and Tolerability of a Single IV Dose of MEDI-545, a Fully Human Monoclonal Antibody Directed Against Interferon Alpha Subtypes, in Patients Who Have Mild Systemic Lupus Erythematosus (SLE) With Cutaneous Involvement. Protocol MI-CP126, An Exploratory study to characterize biomarker assays in healthy subjects and in subjects with Rheumatoid Arthritis. Protocol 92005637, Amgen 2006-2007
- A Phase III, Multicenter, Open-Label, Continuation Trial of LymphoStat-B Antibody (Monoclonal Anti-BLyS Antibody) in Subjects with Rheumatoid Arthritis (RA) who Completed the Phase II LBRA 01. Protocol LBRA99, Human Genome Sciences, 2006-2009
- A Phase 2 study to evaluate the safety, tolerability and activity of fontolizumab (HuZaf) in patients with active rheumatoid arthritis, Protocol ZAF-711, sponsored by Protein Design Labs, Inc (PDL), 2006-2007
- Immunomedics, 2005-2006
- A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center study of Epratuzumab in Patients with Active Systemic Lupus Erythematosus. Protocol Immu-103-03, 2005-2009
- A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of Ocrelizumab compared to placebo in patients with active Rheumatoid Arthritis continuing Methotrexate treatment. Protocol WA20494/ACT3985g, Genentech, 2005- 2007
- Genmab, 2005-2007
- A double-blind, randomised, placebo controlled, dose escalating, multi-center phase I/II trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with active rheumatoid arthritis who have previously failed one or more disease modifying anti-rheumatic drugs. Protocol Hx-CD20-403, 2005
- A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 623 following multidose administration in subjects with SLE, Amgen, 2005-2006
- A Phase Ib, multi-centre, double-blind, placebo-controlled, dose-escalating, single dose study to assess the safety, pharmacokinetics and pharmacodynamics of TACI-Fc5 when administered subcutaneously to patients with SLE, Serono, 2005-2006
- A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects with Systemic Lupus Erythematosus (SLE), Human Genome Sciences, 2005-2007
- A phase III, Randomized, Double blind, Placebo controlled, multi center study of Epratuzumab in patients with acute severe SLE Flares Excluding the Renal or Neurologic Systems, Immunomedics, 2005-2006
- A Multi national, Multi center, randomized, double blind, placebo controlled, multiple dose, four arm study to assess the efficacy, tolerability and safety, of three different doses of Edratide (TV-4710) Subcutaneous injections in SLE patients, TEVA, 2005-2007
- A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II/III Study to Evaluate the Efficacy and Safety of Rituximab in Subjects with Moderate to Severe SLE, Genentech, 2005-
- A Phase IIB MultiCenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy with Glucocorticosteroids vs. Placebo plus Glucocorticosteroids in the Treatment of Active SLE and the Prevention of Subsequent Lupus Flares, BMS, 2005-2007
- Amgen B cell: An exploratory study to characterize the variability in circulating B cell populations in subjects with systemic lupus erythematosus (SLE), 2004-2006

- Orphan Medical, Inc.: Protocol OMC-SXB-26: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi- Center Trial Comparing the Effects of Orally Administered Xyrem (sodium oxybate) with Placebo for the Treatment of Fibromyalgia, 2004-2005
- Phase 1 Single Ascending Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of TRU-015 Administered Intravenously in Subjects with Rheumatoid Arthritis. Protocol 15001, Trubion 2004
- Scios: Protocol B007: A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy of Oral SCIO-469 in Subjects with Active Rheumatoid Arthritis Who are not Receiving DMARDS Other than Hydroxychloroquine, 2004-2006
- LJP: Protocol 394-90-14: A Randomized, Double-Blind, Placebo-Controlled, Four-Arm Parallel-Group, Multicenter, Multinational Safety and Efficacy Trial of 100mg and 300mg of LJP 394 in Systemic Lupus Erythematosus (SLE) Patients with a History of Renal Disease, 2004-2007.
- Wyeth Research: Protocol 3140A1-200-WW: A Double-Blind, Placebo-Controlled, Parallel, Randomized Study to Evaluate the Efficacy and Safety of 3 Oral Dose Levels of TMI-005 in Subjects with Active Rheumatoid Arthritis on a Background of Methotrexate, 2004-2005.
- Prometheus Imuran SLE: An Open Label Safety and Efficacy Trial of Imuran for Patients with Systemic Lupus Erythematosus, 2004-2006
- Bio-rad, Collection of Prospective Samples for Investigational Studies of Bio-Rad BioPlex 2200 ANA Screen on the BioPlex 2200, 2004
- SLICC (Systemic lupus erythematosus International Coordinating Committee) Registry for Human Genome Science, LBRA01, A Phase 2, Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to evaluate the safety, tolerability and Efficacy of LymphoStat-B™ (LSB) in subjects with RA, 2004-2005
- Atherosclerosis, 2003, Registry for central nervous system lupus, 2003
- Abbott, M02-537, A Multicenter continuation trial for Patients Completing Study M02-518 and M02-570 of the Human Anti-TNF Monoclonal Antibody Adalimumab (D2E7) in Patients with Moderate to Severely Active Psoriatic Arthritis, 2003-2006
- Prometheus, 03-MTX-02, Measurement of Methotrexate and Folate Polyglutamate Levels and MTHFR Polymorphisms in a Cross-Section of Rheumatoid Arthritis Patients to Assess Correlations of Toxicity and Efficacy, 2003-2006
- Novartis, CCOX189A2335, A 13-Week, multicenter, international, randomized, double-blind, placebo-controlled, parallel-group study of COX189 200mg in patients with rheumatoid arthritis using naproxen 500mg b.i.d. as comparator, 2003-2004
- IDEC, 102-20/WAI17042, A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination with MTX in Subjects with Active Rheumatoid Arthritis Who have had an inadequate Response to MTX and Anti-TNFalpha Therapies 2003
- Glaxo Smith Kline, CXA20006, A Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Phase 2, Parallel Group, dose-ranging Finding study To assess the Safety and efficacy of GW406381 Administered For 42 days to Subjects with Rheumatoid Arthritis, 2003-2005
- Amgen MRI, The use of MRI to Describe and Identify the Early Findings Leading to Foot Erosions in High Risk Subjects with Rheumatoid Arthritis, 2003
- Centocor OPPOSITE, Open label, Pilot Protocol of Patients with Rheumatoid Arthritis who switch to Infliximab after incomplete response to etanercept, 2003-2005
- Centocor, A multicenter, double-blind trial of anti TNF alpha chimeric monoclonal antibody (Infliximab) for the treatment of subjects with psoriatic arthritis, 2003-2005

- Cipher Canada, A double-blind, randomized, placebo-controlled, multi-dose, Phase III, parallel group study of Tramadol ER in the relief of signs and symptoms of osteoarthritis of the hip and knee, 2003-2005
- Genelabs, The use of GL701 in the prevention of osteoporosis in patients on corticosteroids with lupus erythematosus, 2003-2005
- Amgen, Rheumatoid arthritis DMARD intervention and utilization study (RADIUS 2), 2002-2005
- Abbott, A multicenter study of the safety of human anti-TNF monoclonal antibody D2E7 in subjects with active rheumatoid arthritis, 2002
- Janssen Pharmaceutica Products, L.P., CIS-USA-154, Limited access protocol for the use of oral cisapride in the treatment of refractory gastroesophageal reflux disease and other gastrointestinal motility disorders, 2002-2005
- Scios, Inc., 782.344, A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study of SCIO-469 in Patients with Active Rheumatoid Arthritis Receiving Methotrexate, 2002-2004
- Isis Pharmaceuticals, Inc., ISIS 104838-CS7, A Double-blind, placebo-controlled, randomized trial of the safety, efficacy, and pharmacokinetic profile of ISIS 104838 (TNF[®]- antisense oligonucleotide) subcutaneous injections in active rheumatoid arthritis patients, 2002-2004
- Amgen, Inc., 20020103 KONTROL, Psychometric Assessment of the Cedars-Sinai Health Related Quality of Life (CSHQ- RA) Instrument in Rheumatoid Arthritis Subjects Receiving Kineret[®] (Anakinra) Therapy, 2002-2003.
- Immunex Corporation, 016.0037, Multicenter, Double-blind, Placebo-Controlled, Randomized Phase 3 Study of Etanercept in the Treatment of patients with Ankylosing Spondylitis, 2002-2003
- Immunex Corporation, 016.0034, Rheumatoid Arthritis DMARD Intervention and Utilization Study (RADIUS 1), 2001-2003. Immunex Corporation, 016.0036, Phase 3 Randomized, Double-Blind, Placebo-controlled Study of 50mg Etanercept (Enbrel[®]) Administered SC Once Weekly in Patients with Active Rheumatoid Arthritis, 2002-2003
- Cypress Bioscience, Inc., FMS-021, A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Milnacipran for Treatment of Fibromyalgia, 2002-2003.
- XOMA, HURA 501.02, A Phase II, Double-blind, Placebo-controlled Study to Determine the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Efalizumab in Subjects with Moderate to Severe Rheumatoid Arthritis on a Stable Dose of Methotrexate, 2002-2004
- Centocor, START Protocol CO1168T41, A randomized, double-blind trial of the safety of TNF-alpha chimeric monoclonal antibody (Infliximab) in combination with methotrexate compared to methotrexate alone in patients with rheumatoid arthritis on standard disease modifying anti-rheumatic background therapy, 2001-2003.
- Optime Therapeutics, LEDA.C.001, A phase II study of the safety and efficacy of topical liposome-encapsulated diclofenac analgesic (LEDA) in patients with osteoarthritis of the knee, 2001-2002
- Pharmacia, 872-IFL-0513-004, Clinical protocol for a double-blind, placebo-controlled, randomized six week comparison study for the efficacy of valdecoxib 20 mg q d and rofecoxib 25 mg q d in relieving the signs and symptoms of osteoarthritis of the knee, 2001-2002
- Proctor and Gamble, The effect of testosterone patch on activity of systemic lupus erythematosus, 2001
- Knoll, DE020, A multicenter 2 year continuation study of the human anti-TNF antibody D2E7 administered as a subcutaneous injection in patients with rheumatoid arthritis, 2001
- Vertex, VX00-745-102, A 12 week, randomized, double-blind, placebo-controlled, dose-ranging study of VX-745 in patients with rheumatoid arthritis, 2001-2002

- Allergan, 192371-011-01, A multicenter, double masked, randomized, vehicle controlled parallel group study of the safety and efficacy of cyclosporin ophthalmic emulsion used twice daily for 6 months in patients with moderate to severe keratoconjunctivitis, 2001-2002
- Amgen, 2000223, A multicenter double-blind study to evaluate the safety and efficacy of anakinra (r0metHul IL-ra) and entanercept in subjects with rheumatoid arthritis using methotrexate, 2001
- Bristol-Myers Squibb, IM 101-101, A multicenter, randomized, double-blind, placebo controlled study to evaluate the safety and efficacy of intravenous infusions of BMS-188667 given monthly in combination with sub-cutaneous injections of etanercept given twice weekly to subjects with active rheumatoid arthritis, 2001-2008
- Hoffman-LaRoche, WA15541c, A double-blind, randomized, placebo controlled study to evaluate the safety and efficacy of Ro32-3555 (Trocade) as adjunct to background antirheumatoid therapy, in preventing structural damage in rheumatoid arthritis, 2000-2002
- Centocor, MEDIII Pso-A-1, A multicenter placebo, controlled, double blind, randomized study of anti-TNF chimeric monoclonal antibody (cA2, infliximab) in patients with active psoriatic arthritis, 2000-2002
- La Jolla Pharmaceuticals, LJP 394-90-09, A randomized, double-blind, placebo-controlled, multicenter safety and efficacy trial of LJP 394 in systemic lupus erythematosus (SLE) patients with a history of renal disease, 2000-2002
- Knoll DE013, A prospective multicenter randomized double-blind active comparator-controlled parallel-groups study comparing the fully human monoclonal antibody TNF alpha antibody D2E7 every second week with methotrexate given weekly and the combination of D2E7 and methotrexate administered over 2 years in patients with early rheumatoid arthritis, 2000-2008
- Knoll, Study of New Onset Rheumatoid Arthritis (SONORA), 2000-2006
- Knoll DE031: A multicenter randomized double-blind placebo-controlled study of the safety of human anti-TNF monoclonal antibody D2E7 in patients with active rheumatoid arthritis, 2000-2008
- Fujisawa, a randomized double-blind placebo controlled study to assess the efficacy and safety of prograf (tacrilimus) in the treatment of rheumatoid arthritis in patients who have failed one or more disease modifying antirheumatic drugs, 2000-2002
- Amgen, A double-blind extension study to provide treatment with PEGylated recombinant human methionyl soluble tumor necrosis factor Type I (PEG sTNF-R1) to subjects completing trials TNF 980246 and TNF 990136, 2000 Fujisawa, An open-label, long-term study to evaluate the safety of Prograf (tacrilimus) for the treatment of rheumatoid arthritis, 2000-2002
- Knoll, A multicenter Phase II study of the human anti-TNF antibody D2E7 administered as subcutaneous injections in rheumatoid arthritis patients treated with methotrexate, 2000-2001
- Merck, A randomized, placebo-controlled, parallel group, double-blind study to evaluate the safety and efficacy of rofecoxib 25 mg and celecoxib 200 mg in patients with osteoarthritis of the knee or hip, 2000
- Knoll, A multicenter randomized placebo-controlled Phase II study of the human anti-TNF D2E7 administered as subcutaneous injections in rheumatoid arthritis patients treated with methotrexate, 1999-2001
- Searle, Clinical protocol of a multicenter, double-blind, placebo-controlled randomized, comparison study of the efficacy and safety of 3 valdecoxib doses and naproxen in treating the symptoms and signs of rheumatoid arthritis, 1999-2001
- Searle, Clinical protocol to evaluate the long-term safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis, 1999-2001

- Cypress, A post approval, market preference, unblinded general experience study to gather additional information about the ProSORBA column in general rheumatology practice settings, 1999-2000
- Centocor, An open-label trial of anti-TNF chimeric monoclonal antibody Infliximab in patients with active rheumatoid arthritis, 1999-2000
- IDEC, Phase II randomized, double blind, placebo-controlled, multiple center, multiple dose, dose finding safety, tolerance and efficacy study of IDEC-131 in patients with active SLE, 1999-2000
- Anergen, A phase I double blind, randomized placebo controlled, dose escalation study to evaluate the safety, tolerability and biological activity of a 2-week induction course and 1 maintenance cycle of AG 4263 in subjects with rheumatoid arthritis, 1999-1999
- Biogen C99-1021, An open label, multiple dose study to evaluate the efficacy, safety and pharmacokinetics of BG 9588 (anti CD40 antibody) in subjects with proliferative lupus glomerulonephritis, 1999-2001
- Zeneca, Randomized, double blind placebo controlled, parallel group multicenter trial to assess the analgesic efficacy and tolerability of treatment with multiple doses of 1600 mg ZD6416 bid compared with treatment with placebo in patients with osteoarthritis of the hip or knee, 1999-1999
- Merck, Randomized, double-blind multicenter study to evaluate tolerability and effectiveness of rofecoxib (MK-0966) 25 mg/d vs naproxen 500 mg bid in patients with osteoarthritis, 1999-2000
- Merck, An active comparator and placebo controlled, parallel group, double-blind 52 week study to assess safety and efficacy of MK-0966 in rheumatoid arthritis patients, 1999-2000
- Amgen, A randomized, placebo controlled double-blind, multicenter, dose-finding study to evaluate the safety and efficacy of weekly administration of PEGylated recombinant methionyl human soluble tumor necrosis factor receptor Type I (PEGsTNF-RI) in patients with rheumatoid arthritis, 1999-2000
- Roche, Randomized, double-blind trial of Ro32-3555 (Trocade) for rheumatoid arthritis, 1998-2000
- Smith Kline, SB 217969/Clenolixib (Open Label), for rheumatoid arthritis 1998-1999
- La Jolla Pharmaceuticals/Abbott, LJP 394 for Lupus nephritis, open label #90-11, 1998-2000
Merck, MK-0966 for osteoarthritis, 1998-1999
- Smith Kline, SB 217969/Clenolixib for Rheumatoid Arthritis, 1998-1999
- Biogen, Anti-CD40L therapy for lupus nephritis, 1998-1999
- Merck, MK-0966 for Rheumatoid Arthritis, 1998
- Boehringer-Ingelheim, Meloxicam for Rheumatoid Arthritis, 1998-1999
Boehringer-Ingelheim, Meloxicam for Osteoarthritis, 1998-1999
- Immunex, Open-label trial of TNA-alpha (Enbrel) for Rheumatoid Arthritis, 1997
- Immunex, Double-blind trial of TNF-alpha (Enbrel) for Rheumatoid Arthritis, 1997-1999
- Genelabs, Dehydroepiandrosterone (DHEA) for Lupus, 1994-1997, an open label and double-blind trial
La Jolla Pharmaceuticals, LJP 394 for Lupus Nephritis, 1996-1999, Double-blind trial
- Smith-Kline, Namebutone for Osteoarthritis, 1991-1992
- Sandoz, Sandostatin in Fibromyalgia, 1990-1991
- Winthrop, Hydroxychloroquine-methotrexate, 1988-1992 in RA
Rorer, Calcitonin in Fibromyalgia, 1989

Books

1. DJ Wallace, BH Hahn, editors. Dubois' lupus erythematosus and related syndromes. 9th ed. Edinburgh: Elsevier; 2019. 800 p.

2. Wallace DJ, Hahn BH. Dubois' lupus erythematosus and related syndromes. 9th ed. Philadelphia (PA): Elsevier; 2018.
3. Wallace DJ, Wallace JB. Making sense of fibromyalgia. 2nd ed. New York: Oxford University Press; 2014. 257 p.
4. Wallace DJ. Lupus: the essential clinician's guide. New York: Oxford University Press; 2014. 115 p.
5. Wallace DJ. The lupus book: a guide for patients and their families. New York: Oxford University Press; 2013.
6. Wallace DJ, Hahn BH. Dubois' Lupus Erythematosus and Related Syndromes. 8th ed. Philadelphia (PA): Elsevier Saunders; 2013. 694 p.
7. Weisman M. Rheumatoid arthritis. New York: Oxford University Press; 2011. 90 p. (Wallace DJ, editor. Oxford American Rheumatology Library)
8. Wallace DJ, editor. The Sjogren's book: Sjogren Syndrome Foundation. 4th ed. New York: Oxford University Press; 2012, 395 p.
9. Clauw DJ, Wallace DJ. Fibromyalgia: the essential clinician's guide. New York. Oxford University Press; 2009.
10. Wallace DJ. Lupus: the essential clinician's guide. New York: Oxford University Press; 2008.
11. Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. 7th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2007. 1441 p.
12. Wallace DJ. The lupus book: a guide for patients and their families. New York: Oxford University Press; 2005. 291 p.
13. Wallace DJ, Clauw DJ. Fibromyalgia and other central pain syndromes. Philadelphia (PA): Lippincott Williams & Wilkins; 2005. 421 p.
14. Wallace DJ, editor. The new Sjogren's syndrome handbook: revised and expanded 3rd ed. New York: Oxford University Press; 2005. 265 p.
15. Wallace DJ, Wallace JB. Fibromyalgia: an essential guide for patients and their families. New York: Oxford University Press; 2003. 196 p.
16. Wallace DJ, Wallace JB. All about fibromyalgia. New York: Oxford University Press; 2002. 258 p.
17. Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. 6th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2002. 1348 p.
18. Lane NE, Wallace DJ. All about osteoarthritis. New York: Oxford University Press; 2001. 258 p.
19. Wallace DJ. The lupus book: new and revised. New York: Oxford University Press; 2000. 271 p.
20. Wallace DJ, Wallace JB. Making sense of fibromyalgia. New York: Oxford University Press; 1999. 242 p.
21. Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus, 5th ed. Baltimore (MD): Lippincott Williams & Wilkins; 1997.
22. Wallace DJ. The Lupus Book. New York: Oxford University Press; 1995. 258 p.
23. Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus, 3rd ed. Philadelphia (PA): Lea & Febiger; 1993. 953 p.
24. Wallace DJ, Dubois EL, editors. Dubois' lupus erythematosus, 3rd ed. Philadelphia (PA): Lea & Febiger; 1987. 775 p.

Book Chapters/Supplements

1. Forbess L, Wallace DJ, Jefferies C. Systemic Lupus Erythematosus. 2nd edition. Tsokos GC, editor. Philadelphia: Elsevier; c2020. Chapter 45, The Lung in Systemic Lupus Erythematosus; p. 427-38.
2. Ross L, Kim T, Wallace DJ, Weisman M, Johnson JP. Steinmetz: Benzel's spine surgery. 5th edition. Philadelphia: Elsevier; c2020. Chapter 151, Deformity surgery for ankylosing spondylitis.

3. Pavlakis P, Lawrence-Ford T, Mahajan S, Lewis J, Varadhachary A, Briggs I, Goldberg E, Wallace DJ, Mandel S. In Sjogren's syndrome: a clinical handbook. Vivino F, editor. Elsevier; c2020. Diagnosis and management of central nervous system Sjögren's syndrome; p. 189-203.
4. Wallace DJ, Venuturupalli RS. *Rheum Dis Clin N Am* 2018. Philadelphia: Elsevier; c2019. Chapter 45, Preface: best practices and challenges to the practice of rheumatologists; p. xv-xvi.
5. Lee CH, Wallace DJ. *Rheum Dis Clin N Am* 2018. Philadelphia: Elsevier; c2019. Chapter 45, Best practices and challenges to the practice of rheumatologists; p. 79-85.
6. Wallace DJ. Biologic and systemic agents in dermatology. Yamauchi P, editor. Cham Switzerland: Springer; c2018. Systemic and biologic agents for lupus erythematosus; p. 377-90.
7. Wallace DJ, Weisman MH. *Rheumatology*. 6th edition. Hochberg MC, Gravallese E, Silman A, Smolen J, Weinblatt ME, Weisman MH, editors. Philadelphia (PA): Elsevier; c2018. Chapter 135, Clinical features of systemic lupus erythematosus; p. 35.1-35.12.
8. Wallace DJ, editor. Biological therapies in lupus. *Lupus*. 2016 Sep;25(10):1069. doi: 10.1177/0961203316652949. PubMed PMID: 27497250.
9. Wallace DJ. Sleep and psychosomatic medicine. 2nd edition. Pandi- Perumal SR, Narasimhan M, Kramer M, editors. Boca Raton (FL): CRC Press; c2016. Fibromyalgia and the neurobiology of sleep; p. 127-36.
10. Wallace DJ. *Rheumatology*. 5th edition. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Philadelphia (PA): Saunders Elsevier; c2014. Chapter 134, Management of nonrenal and non-central nervous system lupus; p. 1099-106.
11. Goldenberg DM, Wallace DJ. Immunotherapeutic agents for SLE. Shoenfeld Y, Meroni PL, Cervera R, editors. London (UK): Future Medicine Ltd; c2012. Epratuzumab in SLE; p. 56–68.
12. Wallace DJ. Targeted treatment of the rheumatic diseases. Weisman M, et al, editors. Philadelphia (PA): Saunders Elsevier; c2009. Management of nonrenal systemic lupus erythematosus 2; p. 91-107.
13. Hallegua DS, Wallace DJ. Principles and practice of geriatric sleep medicine. Pandi-Perumal SR, Monti JM, Monjan AA, editors. Cambridge: Cambridge University Press; c2009. Sleep and fibromyalgia in the elderly; p. 160-6.
14. Wallace DJ. Encyclopedia of stress. 2nd edition. Fink G, editor. Oxford (UK): Elsevier; c2007. Systemic lupus erythematosus p. 708-12.
15. Wallace DJ. Sleep and psychosomatic medicine. Pandi-Perumal SR, Ruoti RR, Kramer M, editors. Abington (UK): Informa Healthcare; c2007. Fibromyalgia and the neurobiology of sleep; p. 249-59.
16. Shinada S, Wallace DJ. Cutaneous lupus erythematosus. Berlin: Springer; c2004. Laboratory features of cutaneous lupus; p. 311-22.
17. Wallace DJ. *Rheumatology*. 3rd edition. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Edinburgh: Mosby; c2003. Severe lupus; p. 1419-26.
18. Wallace D. Conn's current therapy 2000. Rakel RE, editor. Philadelphia (PA): WB Saunders; c1999. Autoimmune connective tissue disorders; p. 774-8.
19. Wallace D, Metzger AL. Arthritis and allied conditions: a textbook of rheumatology. 13th edition. Koopman WJ, editor. Baltimore (MD): Williams and Wilkins; c1997. Systemic lupus erythematosus: clinical aspects and treatment; p. 1319-45.
20. Silverman S, Gluck O, Silver D, Tesser J, Wallace D, Neumann K, Metzger A, Morris R. Immunology of silicones. Potter M, Rose NR, editors. Heidelberg, Germany: Springer-Verlag Berlin; c1996. The prevalence of autoantibodies in symptomatic and asymptomatic patients with breast implants and patients with fibromyalgia; p. 317-22. (Also published as *Curr Top Microbiol Immunol* 1996;210:317-22.)

21. Wallace DJ, Metzger AL, Ashman RF. Manual of allergy and immunology. 3rd edition. Lawlor G, Fischer T, Adelman D, editors. Boston (MA): Little, Brown & Company; c1995. Rheumatic diseases; p. 303-52.
22. Wallace DJ. Systemic lupus erythematosus. McCune WJ, editor. Philadelphia (PA): WB Saunders; c1994. Chapter 20, Antimalarial agents and lupus; p. 243-63. Rheumatic Disease Clinics North America
23. Wallace DJ. Bailliere's clinical rheumatology. Panush R, Lane N, editors. London: Bailliere Tindall; c1994. Chapter 8, Does stress or trauma cause aggravate rheumatic disease? 149-59.
24. Wallace D, Metzger AL, A decade of lupus. Aladjem H, editor. Rockville (MD): Lupus Foundation of America; c1991. The antiphospholipid syndrome; p. 126-7.
25. Wallace DJ, Peter JB, Bowman RL, Wormsley SB, Silverman S. Advances in pain research and therapy: myofascial pain and fibromyalgia. vol 17. Friction JR, Awad EA, editors. New York: Raven Press; c1992. Fibromyalgia, cytokines, fatigue syndromes, and immune regulation; p. 277-87.
26. Wallace D. Proceedings of the 2nd International Conference on S.L.E. Singapore: Professional Postgraduate Services; c1989. The treatment of mild lupus; p. 126-9.
27. Klinenberg JR, Wallace DJ. Diagnosis and management of rheumatic diseases. Katz W, editor. Philadelphia (PA): Lippincott; c1988. New and experimental therapeutic modalities; p. 855-8.
28. Wallace DJ, Goldfinger D, Nichols S, Goodman D, Fichman M, Stewart M, Klinenberg JR. Proceedings of the First International Congress of the World Apheresis Association. Uda T, Shlokawa Y, Inoue N, editors. USA: ISAO Press; c1987. A controlled study on the use of plasmapheresis in steroid/immunosuppressive resistant systemic lupus erythematosus with nephrotic syndrome; p. 91-102.
29. Goldfinger D, Wallace D, Klinenberg J. Plasma exchange therapy. Borgerg H, Reuther R, editors. Stuttgart: GeorgThiemeVerlag; c1981. Plasma-lymphocytapheresis for the treatment of rheumatoid arthritis; p. 215-9.

Articles or Letters to the Editor in Peer Reviewed Publications:

1. Wallace DJ. [COVID-19 in patients with rheumatic disease: finally, a denominator](#). Lancet Rheumatol. 2021 Jul;3(7):e462-e463. doi: 10.1016/S2665-9913(21)00121-1. Epub 2021 Apr 28. PubMed PMID: 33942032; PubMed Central PMCID: PMC8081402.
2. Chaichian Y, Wallace DJ. [Innovative Trials and New Opportunities in SLE](#). Rheum Dis Clin North Am. 2021 Aug;47(3):481-99. doi: 10.1016/j.rdc.2021.04.010. Epub 2021 Jun 16. Review. PubMed PMID: 34215375.
3. Hanly JG, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke AE, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR, Gladman DD, Urowitz MB, Bruce IN, Petri M, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jonsen A, Alarcón GS, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Farewell V. [Neuropsychiatric events in systemic lupus erythematosus](#). Arthritis Rheumatol. 2021 May 27. doi: 10.1002/art.41876. [Epub ahead of print] PubMed PMID: 34042329.
4. Elkhailifa M, Orbai AM, Magder LS, Petri M, Alarcón GS, Gordon C, Merrill J, Fortin PR, Bruce IN, Isenberg D, Wallace D, Nived O, Ramsey-Goldman R, Bae SC, Hanly JG, Sanchez-Guerrero J, Clarke AE, Aranow C, Manzi S, Urowitz M, Gladman DD, Kalunian K, Werth VP, Zoma A, Bernatsky S, Khamashta M, Jacobsen S, Buyon JP, Dooley MA, Vollenhoven RV, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim S, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr. [Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset](#). Lupus. 2021 Jul;30(8):1283-1288. doi: 10.1177/09612033211014248. Epub 2021 May 6. PubMed PMID: 33957797.

5. Wallace DJ, Figueras F, Wegener WA, Goldenberg DM. [Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor \(MIF\) receptor, for systemic lupus erythematosus \(SLE\)](#). *Ann Rheum Dis*. 2021 Jul;80(7):954-955. doi: 10.1136/annrheumdis-2020-219803. Epub 2021 Feb 22. PubMed PMID: 33619162.
6. Skaggs BJ, Grossman J, Sahakian L, Perry L, FitzGerald J, Charles-Schoeman C, Gorn A, Taylor M, Moriarty J, Ragavendra N, Weisman M, Wallace DJ, Hahn BH, McMahon M. [A panel of biomarkers associates with increased risk for cardiovascular events in women with systemic lupus erythematosus](#). *ACR Open Rheumatol*. 2021 Apr;3(4):209-220. doi: 10.1002/acr2.11223. Epub 2021 Feb 19. PubMed PMID: 33605563; PubMed Central PMCID: PMC8063147.
7. Aringer M, Brinks R, Dörner T, Daikh D, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Schmajuk G, Tani C, Tedeschi SK, Touma Z, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Cziráj L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Costenbader K, Johnson SR. [European League Against Rheumatism \(EULAR\)/American College of Rheumatology \(ACR\) SLE classification criteria item performance](#). *Ann Rheum Dis*. 2021 Feb 10;. doi: 10.1136/annrheumdis-2020-219373. [Epub ahead of print] PubMed PMID: 33568386.
8. Chew C, Reynolds JA, Lertratanakul A, Wu P, Urowitz M, Gladman DD, Fortin PR, Bae SC, Gordon C, Clarke AE, Bernatsky S, Hanly JG, Isenberg D, Rahman A, Sanchez-Guerrero J, Romero-Diaz J, Merrill J, Wallace D, Ginzler E, Khamashta M, Nived O, Jönsen A, Steinsson K, Manzi S, Kalunian K, Dooley MA, Petri M, Aranow C, van Vollenhoven R, Stoll T, Alarcón GS, Lim SS, Ruiz-Irastorza G, Peschken CA, Askanase AD, Kamen DL, İnanç M, Ramsey-Goldman R, Bruce IN. [Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort](#). *Rheumatology (Oxford)*. 2021 Feb 8. doi: 10.1093/rheumatology/keab090. [Epub ahead of print] PubMed PMID: 33555325.
9. Wallace DJ, Isenberg DA, Morand EF, Vazquez-Mateo C, Kao AH, Aydemir A, Pudota K, Ona V, Aranow C, Merrill JT. [Safety and clinical activity of atacicept in the long-term extension of the Phase IIb ADDRESS II study in systemic lupus erythematosus](#). *Rheumatology (Oxford)*. 2021 Feb 6. doi: 10.1093/rheumatology/keab115. [Epub ahead of print] PubMed PMID: 33547784.
10. Ramsey-Goldman R, Alexander RV, Conklin J, Arriens C, Narain S, Massarotti EM, Wallace DJ, Collins CE, Saxena A, Putterman C, Brady K, Kalunian KC, Weinstein A. [A multianalyte assay panel with cell-bound complement activation products predicts transition of probable lupus to american college of rheumatology-classified lupus](#). *ACR Open Rheumatol*. 2021 Feb;3(2):116-123. doi: 10.1002/acr2.11219. Epub 2021 Feb 4. PubMed PMID: 33538130; PubMed Central PMCID: PMC7882535.
11. Barber MRW, Hanly JG, Su L, Urowitz MB, St Pierre Y, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Dooley MA, Fortin PR, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón GS, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Farewell V, Stoll T, Buyon J, Clarke AE. [Economic evaluation of damage accrual in an International Systemic Lupus Erythematosus Inception Cohort using a multistate model approach](#). *Arthritis Care Res (Hoboken)*. 2020 Dec;72(12):1800-8. doi: 10.1002/acr.24092. PMID: 31609532.

12. Legge A, Kirkland S, Rockwood K, Andreou P, Bae SC, Gordon C, Romero-Diaz J, Sanchez-Guerrero J, Wallace DJ, Bernatsky S, Clarke AE, Merrill JT, Ginzler EM, Fortin PR, Gladman DD, Urowitz MB, Bruce IN, Isenberg DA, Rahman A, Alarcón GS, Petri M, Khamashta MA, Dooley MA, Ramsey-Goldman R, Manzi S, Zoma AA, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, van Vollenhoven RF, Jonsen A, Nived O, Ramos-Casals M, Kamen DL, Kalunian KC, Jacobsen S, Peschken CA, Askanase A, Hanly JG. [Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index \(SLICC-FI\)](#). *Arthritis Care Res (Hoboken)*. 2020 Nov 5. doi: 10.1002/acr.24504. [Epub ahead of print] PubMed PMID: 33152181; PubMed Central PMCID: PMC8096857.
13. Johnson SR, Brinks R, Costenbader KH, Daikh D, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Cziráj L, Doria A, Graninger WB, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Aringer M. [Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities](#). *Ann Rheum Dis*. 2020 Oct;79(10):1333-9. doi: 10.1136/annrheumdis-2020-217162. Epub 2020 Aug 14. PMID: 32816709.
14. Wang DH, Wallace DJ. [New insights into systemic lupus erythematosus therapies: 2010-2020](#). *J Clin Rheumatol*. 2020 Oct 15. doi: 10.1097/RHU.0000000000001603. [Epub ahead of print] PubMed PMID: 33065630.
15. Tumurkhuu G, Chen S, Montano EN, Ercan Laguna D, De Los Santos G, Yu JM, Lane M, Yamashita M, Markman JL, Blanco LP, Kaplan MJ, Shimada K, Crother TR, Ishimori M, Wallace DJ, Jefferies CA, Arditi M. [Oxidative DNA damage accelerates skin inflammation in pristane-induced lupus model](#). *Front Immunol*. 2020;11:554725. doi: 10.3389/fimmu.2020.554725. eCollection 2020. PubMed PMID: 33072095; PubMed Central PMCID: PMC7541920.
16. Urowitz MB, Gladman DD, Farewell V, Su J, Romero-Diaz J, Bae SC, Fortin PR, Sanchez-Guerrero J, Clarke AE, Bernatsky S, Gordon C, Hanly JG, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Ginzler E, Alarcón GS, Chatham WW, Petri MA, Bruce IN, Khamashta MA, Aranow C, Dooley MA, Manzi S, Ramsey-Goldman R, Nived O, Jönsen A, Steinsson K, Zoma AA, Ruiz-Irastorza G, Lim SS, Kalunian KC, İnanc M, van Vollenhoven R, Ramos-Casals M, Kamen DL, Jacobsen S, Peschken CA, Askanase A, Stoll T. [Accrual of atherosclerotic vascular events in a multicenter inception systemic lupus erythematosus cohort](#). *Arthritis Rheumatol*. 2020 Oct;72(10):1734-1740. doi: 10.1002/art.41392. Epub 2020 Aug 25. PubMed PMID: 32515554.
17. Scofield RH, Sharma R, Pezant N, Kelly JA, Radfar L, Lewis DM, Kaufman CE, Cioli S, Harris J, Grundahl K, Rhodus NL, Wallace DJ, Weisman MH, Venuturupalli S, Brennan MT, Koelsch KA, Lessard CJ, Montgomery CG, Sivils KL, Rasmussen A. [American Indians have a higher risk of Sjögren's syndrome and more disease activity than European Americans and African Americans](#). *Arthritis Care Res (Hoboken)*. 2020 Aug;72(8):1049-56. doi: 10.1002/acr.24003. Epub 2020 Jul 5. PubMed PMID: 31199565; PubMed Central PMCID: PMC6911033.
18. Bernatsky S, Ramsey-Goldman R, Urowitz MB, Hanly JG, Gordon C, Petri MA, Ginzler EM, Wallace DJ, Bae SC, Romero-Diaz J, Dooley MA, Peschken CA, Isenberg DA, Rahman A, Manzi S, Jacobsen S, Lim SS, van Vollenhoven R, Nived O, Kamen DL, Aranow C, Ruiz-Irastorza G, Sanchez-Guerrero J, Gladman DD, Fortin PR, Alarcón GS, Merrill JT, Kalunian KC, Ramos-Casals M, Steinsson K, Zoma A, Askanase A, Khamashta MA, Bruce I, Inanc M, Clarke AE. [Cancer risk in a](#)

- [large inception SLE cohort: effects of demographics, smoking, and medications](#). Arthritis Care Res (Hoboken). 2020 Aug 19;10.1002/acr.24425. doi: 10.1002/acr.24425. Epub ahead of print. PMID: 32813314; PMCID: PMC7892637.
19. Petri M, Goldman DW, Alarcón GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace D, Nived O, Ramsey-Goldman R, Bae SC, Hanly JG, Sanchez-Guerrero J, Clarke AE, Aranow C, Manzi S, Urowitz M, Gladman DD, Kalunian K, Werth VP, Zoma A, Bernatsky S, Khamashta M, Jacobsen S, Buyon JP, Dooley MA, van Vollenhoven R, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim S, Inanç M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr, Magder LS. [A comparison of 2019 EULAR/ACR SLE classification criteria with two sets of earlier SLE classification criteria](#). Arthritis Care Res (Hoboken). 2020 May 20. doi: 10.1002/acr.24263. [Epub ahead of print] PubMed PMID: 32433832.
 20. James JA, Guthridge JM, Chen H, Lu R, Bourn RL, Bean K, Munroe ME, Smith M, Chakravarty E, Baer AN, Noaiseh G, Parke A, Boyle K, Keyes-Elstein L, Coca A, Utset T, Genovese MC, Pascual V, Utz PJ, Holers VM, Deane KD, Sivils KL, Aberle T, Wallace DJ, McNamara J, Franchimont N, St Clair EW. [Unique Sjögren's syndrome patient subsets defined by molecular features](#). Rheumatology (Oxford). 2020 Apr 1;59(4):860-8. doi: 10.1093/rheumatology/kez335. PMID: 31497844; PMCID: PMC7188221.
 21. Sandhu VK, Wei J, Thomson LEJ, Berman DS, Schapira J, Wallace D, Weisman MH, Bairey Merz CN, Ishimori ML. [Five-year follow-up of coronary microvascular dysfunction and coronary artery disease in systemic lupus erythematosus: results from a community-based lupus cohort](#). Arthritis Care Res (Hoboken). 2020 Jul;72(7):882-7. doi: 10.1002/acr.23920. Epub 2020 Jun 4. PubMed PMID: 31058466; PubMed Central PMCID: PMC6832763.
 22. Arriens C, Alexander RV, Narain S, Saxena A, Collins CE, Wallace DJ, Massarotti E, Conklin J, Kalunian KC, Putterman C, Ramsey-Goldman R, Buyon JP, Askanase A, Furie RA, James JA, Bello GA, Manzi S, Ahearn J, O'Malley T, Weinstein A, Dervieux T. [Cell-bound complement activation products associate with lupus severity in SLE](#). Lupus Sci Med. 2020 Apr;7(1). doi: 10.1136/lupus-2019-000377. PubMed PMID: 32371480; PubMed Central PMCID: PMC7228655.
 23. Urowitz MB, Gladman DD, Farewell V, Su J, Romero-Diaz J, Bae SC, Fortin PR, Sanchez-Guerrero J, Clarke AE, Bernatsky S, Gordon C, Hanly JG, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Ginzler E, Alarcón GS, Chatham WW, Petri MA, Bruce IN, Khamashta MA, Aranow C, Dooley MA, Manzi S, Ramsey-Goldman R, Nived O, Jönsen A, Steinsson K, Zoma AA, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanç M, van Vollenhoven R, Ramos-Casals M, Kamen DL, Jacobsen S, Peschken CA, Askanase A, Stoll T. [Accrual of atherosclerotic vascular events in a multicenter inception systemic lupus erythematosus cohort](#). Arthritis Rheumatol. 2020 Oct;72(10):1734-40. doi: 10.1002/art.41392. Epub 2020 Aug 25. PMID: 32515554.
 24. Legge A, Kirkland S, Rockwood K, Andreou P, Bae SC, Gordon C, Romero-Diaz J, Sanchez-Guerrero J, Wallace DJ, Bernatsky S, Clarke AE, Merrill JT, Ginzler EM, Fortin PR, Gladman DD, Urowitz MB, Bruce IN, Isenberg DA, Rahman A, Alarcón GS, Petri M, Khamashta MA, Dooley MA, Ramsey-Goldman R, Manzi S, Zoma AA, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, van Vollenhoven RF, Jonsen A, Nived O, Ramos-Casals M, Kamen DL, Kalunian KC, Jacobsen S, Peschken CA, Askanase A, Hanly JG. [Prediction of damage accrual in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index](#). Arthritis Rheumatol. 2020 Apr;72(4):658-66. doi: 10.1002/art.41144. Epub 2020 Feb 12. PubMed PMID: 31631584; PubMed Central PMCID: PMC7113092.
 25. Morand EF, Isenberg DA, Wallace DJ, Kao AH, Vazquez-Mateo C, Chang P, Pudota K, Aranow C, Merrill JT. [Attainment of treat-to-target endpoints in SLE patients with high disease activity in the ataccept phase 2b ADDRESS II study](#). Rheumatology (Oxford). 2020 Oct 1;59(10):2930-8.

doi: 10.1093/rheumatology/keaa029. PubMed PMID: 32107560; PubMed Central PMCID: PMC7516108.

26. Hanly JG, Urowitz MB, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke AE, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, Alarcón GS, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Lim S, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Farewell V. [Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach](#). *Ann Rheum Dis*. 2020 Mar;79(3):356-62. doi: 10.1136/annrheumdis-2019-216150. Epub 2020 Jan 8. PubMed PMID: 31915121.
27. Kim H, Jones AJ, Labadzhyan A, Placencio-Hickok VR, Wallace DJ, Gong J, Hendifar AE. [Raynaud's phenomenon from PD-1 immune checkpoint inhibition](#). *JCO Oncol Pract*. 2020 Oct;16(10):701-2. doi: 10.1200/JOP.19.00333. Epub 2019 Dec 2. PMID: 31790328.
28. Li Y, Higgs RE, Hoffman RW, Dow ER, Liu X, Petri M, Wallace DJ, Dörner T, Eastwood BJ, Miller BB, Liu Y. [A Bayesian gene network reveals insight into the JAK-STAT pathway in systemic lupus erythematosus](#). *PLoS One*. 2019;14(12):e0225651. doi: 10.1371/journal.pone.0225651. eCollection 2019. PubMed PMID: 31790472; PubMed Central PMCID: PMC6886858.
29. Jolly M, Sethi B, O'Brien C, Sequeira W, Block JA, Toloza S, Bertoli A, Blazevic I, Vilá LM, Moldovan I, Torralba KD, Cicognani E, Mazzoni D, Hasni S, Goker B, Haznedaroglu S, Bourre-Tessier J, Navarra SV, Mok CC, Clarke A, Weisman M, Wallace D. [Drivers of satisfaction with care for patients with lupus](#). *ACR Open Rheumatol*. 2019 Dec;1(10):649-56. doi: 10.1002/acr2.11085. eCollection 2019 Dec. PubMed PMID: 31872187; PubMed Central PMCID: PMC6917325.
30. Enocsson H, Wirestam L, Dahle C, Padyukov L, Jönsen A, Urowitz MB, Gladman DD, Romero-Diaz J, Bae SC, Fortin PR, Sanchez-Guerrero J, Clarke AE, Bernatsky S, Gordon C, Hanly JG, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Ginzler E, Alarcón GS, Chatham WW, Petri M, Khamashta M, Aranow C, Mackay M, Dooley MA, Manzi S, Ramsey-Goldman R, Nived O, Steinsson K, Zoma AA, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, van Vollenhoven RF, Ramos-Casals M, Kamen DL, Jacobsen S, Peschken CA, Askanase A, Stoll T, Bruce IN, Wetterö J, Sjöwall C. [Soluble urokinase plasminogen activator receptor \(suPAR\) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus](#). *J Autoimmun*. 2020 Jan;106:102340. doi: 10.1016/j.jaut.2019.102340. Epub 2019 Oct 17. PMID: 31629628.
31. Wallace DJ, Alexander RV, O'Malley T, Khosroshahi A, Hojjati M, Loupasakis K, Alper J, Sherrer Y, Fondal M, Kataria R, Powell T, Ibarra C, Narain S, Massarotti E, Weinstein A, Dervieux T. [Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE](#). *Lupus Sci Med*. 2019 Sep 19;6(1):e000349. doi: 10.1136/lupus-2019-000349. PMID: 31592328; PMCID: PMC6762037.
32. James JA, Guthridge JM, Chen H, Lu R, Bourn RL, Bean K, Munroe ME, Smith M, Chakravarty E, Baer AN, Noaiseh G, Parke A, Boyle K, Keyes-Elstein L, Coca A, Utset T, Genovese MC, Pascual V, Utz PJ, Holers VM, Deane KD, Sivils KL, Aberle T, Wallace DJ, McNamara J, Franchimont N, St Clair EW. [Unique Sjögren's syndrome patient subsets defined by molecular features](#). *Rheumatology (Oxford)*. 2020 Apr 1;59(4):860-8. doi: 10.1093/rheumatology/kez335. PubMed PMID: 31497844; PubMed Central PMCID: PMC7188221.
33. Wallace DJ. Disease activity markers for SLE: Is a little activity more helpful than none? *Lancet Rheumatol*. 2019 Oct 1;1(2):e77-9. doi: [https://doi.org/10.1016/S2665-9913\(19\)30046-3](https://doi.org/10.1016/S2665-9913(19)30046-3).
34. Ramsey-Goldman R, Alexander RV, Massarotti EM, Wallace DJ, Narain S, Arriens C, Collins CE, Saxena A, Putterman C, Kalunian KC, O'Malley T, Dervieux T, Weinstein A. [Complement activation in patients with probable systemic lupus erythematosus and ability to predict progression to American College of Rheumatology-classified systemic lupus erythematosus](#).

- Arthritis Rheumatol. 2020 Jan;72(1):78-88. doi: 10.1002/art.41093. Epub 2019 Nov 25. PMID: 31469249; PMCID: PMC6972605.
35. Wallace DJ. Low-dose interleukin-2 for systemic lupus erythematosus. *Lancet Rheum*. 2019 Sep 1;1(1):e7-8. doi: [https://doi.org/10.1016/S2665-9913\(19\)30019-0](https://doi.org/10.1016/S2665-9913(19)30019-0).
 36. Gholizadeh S, Azizoddin DR, Mills SD, Zamora G, Potemra HMK, Hirz AE, Wallace DJ, Weisman MH, Nicassio PM. [Body image mediates the impact of pain on depressive symptoms in patients with systemic lupus erythematosus](#). *Lupus*. 2019 Aug;28(9):1148-53. doi: 10.1177/0961203319861675. PMID: 31369342.
 37. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR. [2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus](#). *Ann Rheum Dis*. 2019 Sep;78(9):1151-9. doi: 10.1136/annrheumdis-2018-214819. Epub 2019 Aug 5. Review. PubMed PMID: 31383717.
 38. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR. [2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus](#). *Arthritis Rheumatol*. 2019 Sep;71(9):1400-12. doi: 10.1002/art.40930. Epub 2019 Aug 6. PubMed PMID: 31385462; PubMed Central PMCID: PMC6827566.
 39. Hanly JG, Li Q, Su L, Urowitz MB, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke AE, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Steinsson K, Ramsey-Goldman R, Zoma AA, Manzi S, Nived O, Jonsen A, Khamashta MA, Alarcón GS, Svenungsson E, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Ramos-Casals M, Lim SS, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Theriault C, Farewell V. [Peripheral nervous system disease in systemic lupus erythematosus: results from an international inception cohort study](#). *Arthritis Rheumatol*. 2020 Jan;72(1):67-77. doi: 10.1002/art.41070. Epub 2019 Nov 28. PMID: 31390162; PMCID: PMC6935421.
 40. Rasmussen A, Stone DU, Kaufman CE, Hefner KS, Fram NR, Siatkowski RL, Huang AJW, Chodosh J, Rasmussen PT, Fife DA, Pezant N, Grundahl K, Radfar L, Lewis DM, Weisman MH, Venuturupalli S, Wallace DJ, Rhodus NL, Brennan MT, Montgomery CG, Lessard CJ, Scofield RH, Sivils KL. [Reproducibility of ocular surface staining in the assessment of Sjögren syndrome-related keratoconjunctivitis sicca: implications on disease classification](#). *ACR Open Rheumatol*. 2019 Jul;1(5):292-302. doi: 10.1002/acr2.1033. Epub 2019 Jun 7. PubMed PMID: 31453437; PubMed Central PMCID: PMC6710016.

41. Jog NR, Young KA, Munroe ME, Harmon MT, Guthridge JM, Kelly JA, Kamen DL, Gilkeson GS, Weisman MH, Karp DR, Gaffney PM, Harley JB, Wallace DJ, Norris JM, James JA. [Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals](#). *Ann Rheum Dis*. 2019 Sep;78(9):1235-1241. doi: 10.1136/annrheumdis-2019-215361. Epub 2019 Jun 19. PMID: 31217170; PMCID: PMC6692217.
42. Wallace DJ, Tse K, Hanrahan L, Davies R, Petri MA. [Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: survey results from 3127 patients with SLE conducted by the Lupus Foundation of America](#). *Lupus Sci Med*. 2019;6(1):e000317. doi: 10.1136/lupus-2019-000317. eCollection 2019. PubMed PMID: 31168400; PubMed Central PMCID: PMC6519405.
43. Young KA, Munroe ME, Guthridge JM, Kamen DL, Gilkeson GS, Harley JB, Weisman MH, Karp DR, Wallace DJ, James JA, Norris JM. [Screening characteristics for enrichment of individuals at higher risk for transitioning to classified SLE](#). *Lupus*. 2019 Apr;28(5):597-606. doi: 10.1177/0961203319834675. Epub 2019 Mar 7. PMID: 30845880; PMCID: PMC6506346.
44. Mendel A, Bernatsky S, Pineau CA, St-Pierre Y, Hanly JG, Urowitz MB, Clarke AE, Romero-Diaz J, Gordon C, Bae SC, Wallace DJ, Merrill JT, Buyon J, Isenberg DA, Rahman A, Ginzler EM, Petri M, Dooley MA, Fortin P, Gladman DD, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón G, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim S, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Sanchez-Guerrero J, Bruce IN, Costedoat-Chalumeau N, Vinet E. [Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen](#). *Rheumatology (Oxford)*. 2019 Jul 1;58(7):1259-67. doi: 10.1093/rheumatology/kez014. PubMed PMID: 30753683; PubMed Central PMCID: PMC6821299.
45. Wallace DJ, Ginzler EM, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Petri M, Fettiplace J, Roth DA, Ji B, Heath A. [Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus](#). *Arthritis Rheumatol*. 2019 Jul;71(7):1125-34. doi: 10.1002/art.40861. Epub 2019 Jun 5. PubMed PMID: 30771238; PubMed Central PMCID: PMC6617785.
46. Legge A, Kirkland S, Rockwood K, Andreou P, Bae SC, Gordon C, Romero-Diaz J, Sanchez-Guerrero J, Wallace DJ, Bernatsky S, Clarke AE, Merrill JT, Ginzler EM, Fortin P, Gladman DD, Urowitz MB, Bruce IN, Isenberg DA, Rahman A, Alarcón GS, Petri M, Khamashta MA, Dooley MA, Ramsey-Goldman R, Manzi S, Steinsson K, Zoma AA, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, van Vollenhoven RF, Jonsen A, Nived O, Ramos-Casals M, Kamen DL, Kalunian KC, Jacobsen S, Peschken CA, Askanase A, Hanly JG. [Evaluating the properties of a Frailty Index and its association with mortality risk among patients with systemic lupus erythematosus](#). *Arthritis Rheumatol*. 2019 Aug;71(8):1297-307. doi: 10.1002/art.40859. Epub 2019 May 29. PubMed PMID: 30771242; PubMed Central PMCID: PMC6663648.
47. Chaichian Y, Wallace DJ, Weisman MH. [A promising approach to targeting type 1 IFN in systemic lupus erythematosus](#). *J Clin Invest*. 2019 Mar 1;129(3):958-61. doi: 10.1172/JCI127101. Epub 2019 Feb 18. PubMed PMID: 30776023; PubMed Central PMCID: PMC6391084.
48. Wallace DJ, Furie RA, Tanaka Y, de Bono S, Hoffman RW. [Baricitinib for systemic lupus erythematosus - authors' reply](#). *Lancet*. 2019 Feb 2;393(10170):402-3. doi: 10.1016/S0140-6736(18)32749-1. PubMed PMID: 30712893.
49. Wirestam L, Enocsson H, Skogh T, Padyukov L, Jönsen A, Urowitz MB, Gladman DD, Romero-Diaz J, Bae SC, Fortin PR, Sanchez-Guerrero J, Clarke AE, Bernatsky S, Gordon C, Hanly JG, Wallace D, Isenberg DA, Rahman A, Merrill J, Ginzler E, Alarcón GS, Chatham WW, Petri M, Khamashta M, Aranow C, Mackay M, Dooley MA, Manzi S, Ramsey-Goldman R, Nived O, Steinsson K, Zoma A,

- Ruiz-Irastorza G, Lim S, Kalunian K, Inanc M, van Vollenhoven R, Ramos-Casals M, Kamen DL, Jacobsen S, Peschken C, Askanase A, Stoll T, Bruce IN, Wetterö J, Sjöwall C. [Osteopontin and disease activity in patients with recent-onset systemic lupus erythematosus: results from the SLICC inception cohort](#). *J Rheumatol*. 2019 May;46(5):492-500. doi: 10.3899/jrheum.180713. Epub 2019 Jan 15. PubMed PMID: 30647177; PubMed Central PMCID: PMC7339909.
50. Olsen NJ, James JA, Arriens C, Ishimori ML, Wallace DJ, Kamen DL, Chong BF, Liao D, Chinchilli VM, Karp DR. [Study of Anti-Malarials in Incomplete Lupus Erythematosus \(SMILE\): study protocol for a randomized controlled trial](#). *Trials*. 2018 Dec 20;19(1):694. doi: 10.1186/s13063-018-3076-7. PubMed PMID: 30572906; PubMed Central PMCID: PMC6302430.
51. Mendel A, Bernatsky SB, Hanly JG, Urowitz MB, Clarke AE, Romero-Diaz J, Gordon C, Bae SC, Wallace DJ, Merrill JT, Buyon JP, Isenberg DA, Rahman A, Ginzler EM, Petri M, Dooley MA, Fortin PR, Gladman DD, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón GS, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim S, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Sanchez-Guerrero J, Bruce IN, Costedoat-Chalumeau N, Vinet É. [Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort](#). *Ann Rheum Dis*. 2019 Jul;78(7):1010-2. doi: 10.1136/annrheumdis-2018-214434. Epub 2018 Dec 20. PubMed PMID: 30573656; PubMed Central PMCID: PMC6585274.
52. Karp DR, Chong BF, James JA, Arriens C, Ishimori M, Wallace DJ, Liao D, Olsen NJ. [Mock recruitment for the Study of Anti-Malarials in Incomplete Lupus Erythematosus trial](#). *Arthritis Care Res (Hoboken)*. 2019 Nov;71(11):1425-1429. doi: 10.1002/acr.23802. PubMed PMID: 30369087; PubMed Central PMCID: PMC6487234.
53. Hanly JG, Li Q, Su L, Urowitz MB, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke AE, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Steinsson K, Ramsey-Goldman R, Zoma AA, Manzi S, Nived O, Jonsen A, Khamashta MA, Alarcón GS, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Ramos-Casals M, Lim SS, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Theriault C, Farewell V. [Psychosis in systemic lupus erythematosus: results from an international inception cohort study](#). *Arthritis Rheumatol*. 2019 Feb;71(2):281-9. doi: 10.1002/art.40764. Epub 2019 Jan 18. PubMed PMID: 30375754; PubMed Central PMCID: PMC6353684.
54. Bhattacharya J, Pappas K, Toz B, Aranow C, Mackay M, Gregersen PK, Doumbo O, Traore AK, Lesser ML, McMahan M, Utset T, Silverman E, Levy D, McCune WJ, Jolly M, Wallace D, Weisman M, Romero-Diaz J, Diamond B. [Serologic features of cohorts with variable genetic risk for systemic lupus erythematosus](#). *Mol Med*. 2018 Jun 1;24(1):24. doi: 10.1186/s10020-018-0019-4. PubMed PMID: 30134810; PubMed Central PMCID: PMC6016868.
55. Gholizadeh S, Azizoddin DR, Mills SD, Zamora-Racaza G, Potemra HMK, Wallace DJ, Weisman MH, Nicassio PM. [Psychometric validation of the Arthritis Helplessness Index in systemic lupus erythematosus](#). *Lupus*. 2018 Oct;27(12):1980-4. doi: 10.1177/0961203318791765. Epub 2018 Aug 15. PubMed PMID: 30111237; PubMed Central PMCID: PMC6193829.
56. Hanscombe KB, Morris DL, Noble JA, Dilthey AT, Tomblason P, Kaufman KM, Comeau M, Langefeld CD, Alarcon-Riquelme ME, Gaffney PM, Jacob CO, Sivils KL, Tsao BP, Alarcon GS, Brown EE, Croker J, Edberg J, Gilkeson G, James JA, Kamen DL, Kelly JA, McCune J, Merrill JT, Petri M, Ramsey-Goldman R, Reveille JD, Salmon JE, Scofield H, Utset T, Wallace DJ, Weisman MH, Kimberly RP, Harley JB, Lewis CM, Criswell LA, Vyse TJ. [Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans](#). *Hum Mol Genet*. 2018 Nov 1;27(21):3813-3824. doi: 10.1093/hmg/ddy280. PubMed PMID: 30085094; PubMed Central PMCID: PMC6196648.

57. Smith S, Wu PW, Seo JJ, Fernando T, Jin M, Contreras J, Montano EN, Gabhann JN, Cunningham K, Widaa A, McCarthy EM, Molloy ES, Kearns G, Murphy CC, Kong W, Björkbacka H, Kornfeld H, Forbess L, Venuturupalli S, Ishimori M, Wallace D, Weisman MH, Jefferies CA. [IL-16/miR-125a axis controls neutrophil recruitment in pristane-induced lung inflammation](#). JCI Insight. 2018 Aug 9;3(15). doi: 10.1172/jci.insight.120798. eCollection 2018 Aug 9. PubMed PMID: 30089723; PubMed Central PMCID: PMC6129123.
58. Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, Dörner T, Cardiel MH, Bruce IN, Gomez E, Carmack T, DeLozier AM, Janes JM, Linnik MD, de Bono S, Silk ME, Hoffman RW. [Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial](#). Lancet. 2018 Jul 21;392(10143):222-31. doi: 10.1016/S0140-6736(18)31363-1. PubMed PMID: 30043749.
59. Choi MY, Clarke AE, St Pierre Y, Hanly JG, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Dooley MA, Fortin PR, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Alarcón GS, Manzi S, Nived O, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Stoll T, Buyon J, Mahler M, Fritzler MJ. [Antinuclear antibody-negative systemic lupus erythematosus in an international inception cohort](#). Arthritis Care Res (Hoboken). 2019 Jul;71(7):893-902. doi: 10.1002/acr.23712. Epub 2019 Jun 12. PubMed PMID: 30044551; PubMed Central PMCID: PMC7268889.
60. Patel ZH, Lu X, Miller D, Forney CR, Lee J, Lynch A, Schroeder C, Parks L, Magnusen AF, Chen X, Pujato M, Maddox A, Zoller EE, Namjou B, Brunner HI, Henrickson M, Huggins JL, Williams AH, Ziegler JT, Comeau ME, Marion MC, Glenn SB, Adler A, Shen N, Nath SK, Stevens AM, Freedman BI, Pons-Estel BA, Tsao BP, Jacob CO, Kamen DL, Brown EE, Gilkeson GS, Alarcón GS, Martin J, Reveille JD, Anaya JM, James JA, Sivils KL, Criswell LA, Vilá LM, Petri M, Scofield RH, Kimberly RP, Edberg JC, Ramsey-Goldman R, Bang SY, Lee HS, Bae SC, Boackle SA, Cunninghame Graham D, Vyse TJ, Merrill JT, Niewold TB, Ainsworth HC, Silverman ED, Weisman MH, Wallace DJ, Raj P, Guthridge JM, Gaffney PM, Kelly JA, Alarcón-Riquelme ME, Langefeld CD, Wakeland EK, Kaufman KM, Weirauch MT, Harley JB, Kottyan LC. [A plausibly causal functional lupus-associated risk variant in the STAT1-STAT4 locus](#). Hum Mol Genet. 2018 Jul 1;27(13):2392-404. doi: 10.1093/hmg/ddy140. PubMed PMID: 29912393; PubMed Central PMCID: PMC6005081.
61. Presto JK, Okon LG, Feng R, Wallace DJ, Furie R, Fiorentino D, Werth VP. [Computerized planimetry to assess clinical responsiveness in a phase II randomized trial of topical R333 for discoid lupus erythematosus](#). Br J Dermatol. 2018 Jun;178(6):1308-14. doi: 10.1111/bjd.16337. Epub 2018 Apr 17. PubMed PMID: 29336019.
62. Young KA, Munroe ME, Harley JB, Guthridge JM, Kamen DL, Gilkensen GS, Weisman MH, Karp DR, Wallace DJ, James JA, Norris JM. [Less than 7 hours of sleep per night is associated with transitioning to systemic lupus erythematosus](#). Lupus. 2018 Aug;27(9):1524-31. doi: 10.1177/0961203318778368. Epub 2018 May 28. PubMed PMID: 29804502; PubMed Central PMCID: PMC6026567.
63. Bhattacharya J, Pappas K, Toz B, Aranow C, Mackay M, Gregersen PK, Doumbo O, Traore AK, Lesser ML, McMahon M, Utset T, Silverman E, Levy D, McCune WJ, Jolly M, Wallace D, Weisman M, Romero-Diaz J, Diamond B. [Serologic features of cohorts with variable genetic risk for systemic lupus erythematosus](#). Mol Med. 2018 Jun 1;24(1):24. doi: 10.1186/s10020-018-0019-4. PubMed PMID: 30134810; PubMed Central PMCID: PMC6016868.
64. Jolly M, Sequeira W, Block JA, Toloza S, Bertoli A, Blazevic I, Vila LM, Moldovan I, Torralba KD, Mazzoni D, Cicognani E, Hasni S, Goker B, Haznedaroglu S, Bourre-Tessier J, Navarra SV, Mok CC, Weisman M, Clarke AE, Wallace D, Alarcón G. [Sex differences in quality of life in patients with](#)

- [systemic lupus erythematosus](#). *Arthritis Care Res (Hoboken)*. 2019 Dec;71(12):1647-52. doi: 10.1002/acr.23588. Epub 2018 Dec 20. PubMed PMID: 29693320; PubMed Central PMCID: PMC6202275.
65. St Clair EW, Baer AN, Wei C, Noaiseh G, Parke A, Coca A, Utset TO, Genovese MC, Wallace DJ, McNamara J, Boyle K, Keyes-Elstein L, Browning JL, Franchimont N, Smith K, Guthridge JM, Sanz I, James JA. [Clinical efficacy and safety of Baminercept, a lymphotoxin \$\beta\$ receptor fusion protein, in primary Sjögren's syndrome: results from a phase II randomized, double-blind, placebo-controlled trial](#). *Arthritis Rheumatol*. 2018 Sep;70(9):1470-80. doi: 10.1002/art.40513. Epub 2018 Jul 18. PubMed PMID: 29604186; PubMed Central PMCID: PMC6115299.
 66. Kheir JM, Guthridge CJ, Johnston JR, Adams LJ, Rasmussen A, Gross TF, Munroe ME, Bourn RL, Sivils KL, Guthridge JM, Weisman MH, Wallace DJ, Anaya JM, Rojas Villarraga A, Jarvis JN, Harley JB, James JA. [Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus](#). *Lupus Sci Med*. 2018;5(1):e000247. doi: 10.1136/lupus-2017-000247. eCollection 2018. PubMed PMID: 29531773; PubMed Central PMCID: PMC5844376.
 67. Furie RA, Wallace DJ, Aranow C, Fettiplace J, Wilson B, Mistry P, Roth DA, Gordon D. [Long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus: a continuation of a seventy-six-week phase III parent study in the United States](#). *Arthritis Rheumatol*. 2018 Jun;70(6):868-77. doi: 10.1002/art.40439. Epub 2018 Apr 25. PubMed PMID: 29409143; PubMed Central PMCID: PMC6001779.
 68. Wallace DJ. [Editorial: epratuzumab: reveille or requiem? teachable moments for lupus and Sjögren's syndrome clinical trials](#). *Arthritis Rheumatol*. 2018 May;70(5):633-6. doi: 10.1002/art.40427. Epub 2018 Apr 16. PubMed PMID: 29381841.
 69. Smith S, Fernando T, Wu PW, Seo J, Ní Gabhann J, Piskareva O, McCarthy E, Howard D, O'Connell P, Conway R, Gallagher P, Molloy E, Stallings RL, Kearns G, Forbess L, Ishimori M, Venuturupalli S, Wallace D, Weisman M, Jefferies CA. [MicroRNA-302d targets IRF9 to regulate the IFN-induced gene expression in SLE](#). *J Autoimmun*. 2017 May;79:105-11. doi: 10.1016/j.jaut.2017.03.003. Epub 2017 Mar 17. PubMed PMID: 28318807.
 70. Wallace DJ. ['Neuropsychiatric lupus or not? Cerebral hypoperfusion by perfusion-weighted MRI in normal-appearing white matter in primary neuropsychiatric lupus erythematosus' by Papadaki et al](#). *Ann Rheum Dis*. 2019 Jan;78(1):e5. doi: 10.1136/annrheumdis-2018-212937. Epub 2018 Jan 17. PubMed PMID: 29343512.
 71. Hanly JG, Li Q, Su L, Urowitz MB, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke AE, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin P, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Steinsson K, Ramsey-Goldman R, Zoma AA, Manzi S, Nived O, Jonsen A, Khamashta MA, Alarcón GS, Chatham W, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Ramos-Casals M, Lim SS, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Theriault C, Farewell V. [Cerebrovascular events in systemic lupus erythematosus: results from an international inception cohort study](#). *Arthritis Care Res (Hoboken)*. 2018 Oct;70(10):1478-87. doi: 10.1002/acr.23509. Epub 2018 Sep 1. PubMed PMID: 29316357; PubMed Central PMCID: PMC6033693.
 72. Isenberg D, Sturgess J, Allen E, Aranow C, Askanase A, Sang-Cheol B, Bernatsky S, Bruce I, Buyon J, Cervera R, Clarke A, Dooley MA, Fortin P, Ginzler E, Gladman D, Hanly J, Inanc M, Jacobsen S, Kamen D, Khamashta M, Lim S, Manzi S, Nived O, Peschken C, Petri M, Kalunian K, Rahman A, Ramsey-Goldman R, Romero-Diaz J, Ruiz-Irastorza G, Sanchez-Guerrero J, Steinsson K, Sturfelt G, Urowitz M, van Vollenhoven R, Wallace DJ, Zoma A, Merrill J, Gordon C. [Study of Flare Assessment in systemic lupus erythematosus based on paper patients](#). *Arthritis Care Res*

- (Hoboken). 2018 Jan;70(1):98-103. doi: 10.1002/acr.23252. Epub 2017 Dec 8. PubMed PMID: 28388813; PubMed Central PMCID: PMC5767751.
73. Ferreira I, Croca S, Raimondo MG, Matharu M, Miller S, Giles I, Isenberg D, Ioannou Y, Hanly JG, Urowitz MB, Anderson N, Aranow C, Askanase A, Bae SC, Bernatsky S, Bruce IN, Buyon J, Clarke AE, Dooley MA, Fortin P, Ginzler E, Gladman D, Gordon C, Inanc M, Jacobsen S, Kalunian K, Kamen D, Khamashta M, Lim S, Manzi S, Merrill J, Nived O, Peschken C, Petri M, Ramsey-Goldman R, Ruiz-Irastorza G, Sanchez-Guerrero J, Steinson K, Sturfelt GK, van Vollenhoven R, Wallace DJ, Zoma A, Rahman A. [Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study](#). *Arthritis Res Ther*. 2017 Dec 22;19(1):287. doi: 10.1186/s13075-017-1495-6. PubMed PMID: 29273092; PubMed Central PMCID: PMC5741886.
 74. Barber MRW, Hanly JG, Su L, Urowitz MB, St Pierre Y, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Fortin PR, Gladman DD, Sanchez-Guerrero J, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón GS, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Theriault C, Farewell V, Clarke AE. [Economic evaluation of lupus nephritis in the Systemic Lupus International Collaborating Clinics inception cohort using a multistate model approach](#). *Arthritis Care Res (Hoboken)*. 2018 Sep;70(9):1294-302. doi: 10.1002/acr.23480. Epub 2018 Aug 17. PubMed PMID: 29193883; PubMed Central PMCID: PMC6155450.
 75. Merrill JT, Wallace DJ, Wax S, Kao A, Fraser PA, Chang P, Isenberg D. [Efficacy and safety of Atacept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study](#). *Arthritis Rheumatol*. 2018 Feb;70(2):266-76. doi: 10.1002/art.40360. PubMed PMID: 29073347; PubMed Central PMCID: PMC6099253.
 76. Jolly M, Toloza S, Goker B, Clarke AE, Navarra SV, Wallace D, Weisman M, Mok CC. [Disease-specific quality of life in patients with lupus nephritis](#). *Lupus*. 2018 Feb;27(2):257-64. doi: 10.1177/0961203317717082. Epub 2017 Jul 20. PubMed PMID: 28728507.
 77. Langefeld CD, Ainsworth HC, Cunninghame Graham DS, Kelly JA, Comeau ME, Marion MC, Howard TD, Ramos PS, Croker JA, Morris DL, Sandling JK, Almlöf JC, Acevedo-Vásquez EM, Alarcón GS, Babini AM, Baca V, Bengtsson AA, Berbotto GA, Bijl M, Brown EE, Brunner HI, Cardiel MH, Catoggio L, Cervera R, Cucho-Venegas JM, Dahlqvist SR, D'Alfonso S, Da Silva BM, de la Rúa Figueroa I, Doria A, Edberg JC, Endreffy E, Esquivel-Valerio JA, Fortin PR, Freedman BI, Frostegård J, García MA, de la Torre IG, Gilkeson GS, Gladman DD, Gunnarsson I, Guthridge JM, Huggins JL, James JA, Kallenberg CGM, Kamen DL, Karp DR, Kaufman KM, Kottyan LC, Kovács L, Lastrup H, Lauwerys BR, Li QZ, Maradiaga-Ceceña MA, Martín J, McCune JM, McWilliams DR, Merrill JT, Miranda P, Moctezuma JF, Nath SK, Niewold TB, Orozco L, Ortego-Centeno N, Petri M, Pineau CA, Pons-Estel BA, Pope J, Raj P, Ramsey-Goldman R, Reveille JD, Russell LP, Sabio JM, Aguilar-Salinas CA, Scherbarth HR, Scorza R, Seldin MF, Sjöwall C, Svenungsson E, Thompson SD, Toloza SMA, Truedsson L, Tusié-Luna T, Vasconcelos C, Vilá LM, Wallace DJ, Weisman MH, Wither JE, Bhangale T, Oksenberg JR, Rioux JD, Gregersen PK, Syvänen AC, Rönnblom L, Criswell LA, Jacob CO, Sivils KL, Tsao BP, Schanberg LE, Behrens TW, Silverman ED, Alarcón-Riquelme ME, Kimberly RP, Harley JB, Wakeland EK, Graham RR, Gaffney PM, Vyse TJ. [Transancestral mapping and genetic load in systemic lupus erythematosus](#). *Nat Commun*. 2017 Jul 17;8:16021. doi: 10.1038/ncomms16021. PubMed PMID: 28714469; PubMed Central PMCID: PMC5520018.
 78. Sharma R, Harris VM, Cavett J, Kurien BT, Liu K, Koelsch KA, Fayaaz A, Chaudhari KS, Radfar L, Lewis D, Stone DU, Kaufman CE, Li S, Segal B, Wallace DJ, Weisman MH, Venuturupalli S, Kelly JA, Pons-Estel B, Jonsson R, Lu X, Gottenberg JE, Anaya JM, Cunninghame-Graham DS, Huang

- AJW, Brennan MT, Hughes P, Alevizos I, Miceli-Richard C, Keystone EC, Bykerk VP, Hirschfield G, Nordmark G, Bucher SM, Eriksson P, Omdal R, Rhodus NL, Rischmueller M, Rohrer M, Wahren-Herlenius M, Witte T, Alarcón-Riquelme M, Mariette X, Lessard CJ, Harley JB, Ng WF, Rasmussen A, Sivils KL, Scofield RH. [Rare X chromosome abnormalities in systemic lupus erythematosus and Sjögren's syndrome](#). *Arthritis Rheumatol*. 2017 Nov;69(11):2187-92. doi: 10.1002/art.40207. Epub 2017 Oct 12. PubMed PMID: 28692793; NIHMSID:NIHMS1596360.
79. Chan K, Clarke AE, Ramsey-Goldman R, Foulkes W, Tessier Cloutier B, Urowitz MB, Gladman D, Nived O, Romero-Diaz J, Petri M, Ginzler E, Fortin PR, Bae SC, Wallace DJ, Yelin EH, Bernatsky S. [Breast cancer in systemic lupus erythematosus \(SLE\): receptor status and treatment](#). *Lupus*. 2018 Jan;27(1):120-3. doi: 10.1177/0961203317713146. Epub 2017 Jun 8. PubMed PMID: 28595511.
80. Li H, Reksten TR, Ice JA, Kelly JA, Adrianto I, Rasmussen A, Wang S, He B, Grundahl KM, Glenn SB, Miceli-Richard C, Bowman S, Lester S, Eriksson P, Eloranta ML, Brun JG, Gøransson LG, Harboe E, Guthridge JM, Kaufman KM, Kvarnström M, Cunninghame Graham DS, Patel K, Adler AJ, Farris AD, Brennan MT, Chodosh J, Gopalakrishnan R, Weisman MH, Venuturupalli S, Wallace DJ, Hefner KS, Houston GD, Huang AJW, Hughes PJ, Lewis DM, Radfar L, Vista ES, Edgar CE, Rohrer MD, Stone DU, Vyse TJ, Harley JB, Gaffney PM, James JA, Turner S, Alevizos I, Anaya JM, Rhodus NL, Segal BM, Montgomery CG, Scofield RH, Kovats S, Mariette X, Rönnblom L, Witte T, Rischmueller M, Wahren-Herlenius M, Omdal R, Jonsson R, Ng WF, Nordmark G, Lessard CJ, Sivils KL. [Identification of a Sjögren's syndrome susceptibility locus at OAS1 that influences isoform switching, protein expression, and responsiveness to type I interferons](#). *PLoS Genet*. 2017 Jun;13(6):e1006820. doi: 10.1371/journal.pgen.1006820. eCollection 2017 Jun. PubMed PMID: 28640813; PubMed Central PMCID: PMC5501660.
81. Mills SD, Azizoddin D, Racaza GZ, Wallace DJ, Weisman MH, Nicassio PM. [The psychometric properties of the Perceived Stress Scale-10 among patients with systemic lupus erythematosus](#). *Lupus*. 2017 Oct;26(11):1218-23. doi: 10.1177/0961203317701844. Epub 2017 Apr 13. PubMed PMID: 28406052.
82. Choi MY, Clarke AE, St Pierre Y, Hanly JG, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Dooley MA, Fortin P, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Alarcón GS, Manzi S, Nived O, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Buyon J, Mahler M, Fritzler MJ. [The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients](#). *Lupus*. 2017 Sep;26(10):1051-9. doi: 10.1177/0961203317692437. Epub 2017 Feb 23. PubMed PMID: 28420054.
83. Munroe ME, Young KA, Kamen DL, Guthridge JM, Niewold TB, Costenbader KH, Weisman MH, Ishimori ML, Wallace DJ, Gilkeson GS, Karp DR, Harley JB, Norris JM, James JA. [Discerning risk of disease transition in relatives of systemic lupus erythematosus patients utilizing soluble mediators and clinical features](#). *Arthritis Rheumatol*. 2017 Mar;69(3):630-42. doi: 10.1002/art.40004. PubMed PMID: 27863174; PubMed Central PMCID: PMC5329053.
84. Forbess LJ, Bresee C, Wallace DJ, Weisman MH. [Failure of a systemic lupus erythematosus response index developed from clinical trial data: lessons examined and learned](#). *Lupus*. 2017 Aug;26(9):909-16. doi: 10.1177/0961203317692433. Epub 2017 Feb 7. PubMed PMID: 28173737.
85. Zamora-Racaza G, Azizoddin DR, Ishimori ML, Ormseth SR, Wallace DJ, Penserga EG, Sumner L, Ayeroff J, Draper T, Nicassio PM, Weisman MH. [Role of psychosocial reserve capacity in anxiety](#)

- [and depression in patients with systemic lupus erythematosus](#). Int J Rheum Dis. 2018 Apr;21(4):850-8. doi: 10.1111/1756-185X.13033. Epub 2017 Mar 6. PubMed PMID: 28261991.
86. Stone DU, Fife D, Brown M, Earley KE, Radfar L, Kaufman CE, Lewis DM, Rhodus NL, Segal BM, Wallace DJ, Weisman MH, Venuturupalli S, Brennan MT, Lessard CJ, Montgomery CG, Scofield RH, Sivils KL, Rasmussen A. [Effect of tobacco smoking on the clinical, histopathological, and serological manifestations of Sjögren's syndrome](#). PLoS One. 2017;12(2):e0170249. doi: 10.1371/journal.pone.0170249. eCollection 2017. PubMed PMID: 28166540; PubMed Central PMCID: PMC5293551.
87. Wallace DJ, Strand V, Merrill JT, Popa S, Spindler AJ, Eimon A, Petri M, Smolen JS, Wajdula J, Christensen J, Li C, Diehl A, Vincent MS, Beebe J, Healey P, Sridharan S. [Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial](#). Ann Rheum Dis. 2017 Mar;76(3):534-42. doi: 10.1136/annrheumdis-2016-209668. Epub 2016 Sep 26. PubMed PMID: 27672124; PubMed Central PMCID: PMC5446001.
88. Clowse ME, Wallace DJ, Furie RA, Petri MA, Pike MC, Leszczyński P, Neuwelt CM, Hobbs K, Keiserman M, Duca L, Kalunian KC, Galateanu C, Bongardt S, Stach C, Beaudot C, Kilgallen B, Gordon C. [Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind, placebo-controlled trials](#). Arthritis Rheumatol. 2017 Feb;69(2):362-75. doi: 10.1002/art.39856. PubMed PMID: 27598855; PubMed Central PMCID: PMC5299488.
89. Wallace DJ. [Improved strategies for designing lupus trials with targeted therapies: learning from 65 years of experience](#). Lupus. 2016 Sep;25(10):1141-9. doi: 10.1177/0961203316652490. PubMed PMID: 27497258.
90. Young KA, Munroe ME, Guthridge JM, Kamen DL, Niewold TB, Gilkeson GS, Weisman MH, Ishimori ML, Kelly J, Gaffney PM, Sivils KH, Lu R, Wallace DJ, Karp DR, Harley JB, James JA, Norris JM. [Combined role of vitamin D status and CYP24A1 in the transition to systemic lupus erythematosus](#). Ann Rheum Dis. 2017 Jan;76(1):153-8. doi: 10.1136/annrheumdis-2016-209157. Epub 2016 Jun 9. PubMed PMID: 27283331; PubMed Central PMCID: PMC5360632.
91. Wallace DJ. [Does my daughter have lupus?](#) Lupus. 2016 Aug;25(9):957-8. doi: 10.1177/0961203316639382. Epub 2016 Mar 16. PubMed PMID: 26989165.
92. Hanly JG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Clarke AE, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Dooley MA, Fortin P, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Alarcón GS, Fessler BJ, Manzi S, Nived O, Sturfelt GK, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Theriault C, Farewell V. [A longitudinal analysis of outcomes of lupus nephritis in an international inception cohort using a multistate model approach](#). Arthritis Rheumatol. 2016 Aug;68(8):1932-44. doi: 10.1002/art.39674. PubMed PMID: 26991067; PubMed Central PMCID: PMC5858760.
93. Harris VM, Sharma R, Cavett J, Kurien BT, Liu K, Koelsch KA, Rasmussen A, Radfar L, Lewis D, Stone DU, Kaufman CE, Li S, Segal B, Wallace DJ, Weisman MH, Venuturupalli S, Kelly JA, Alarcon-Riquelme ME, Pons-Estel B, Jonsson R, Lu X, Gottenberg JE, Anaya JM, Cunninghame-Graham DS, Huang AJW, Brennan MT, Hughes P, Alevizos I, Miceli-Richard C, Keystone EC, Bykerk VP, Hirschfield G, Xie G, Siminovitich KA, Ng WF, Nordmark G, Bucher SM, Eriksson P, Omdal R, Rhodus NL, Rischmueller M, Rohrer M, Wahren-Herlenius M, Witte T, Mariette X, Lessard CJ, Harley JB, Sivils KL, Scofield RH. [Klinefelter's syndrome \(47,XXY\) is in excess among men with Sjögren's syndrome](#). Clin Immunol. 2016 Jul;168:25-9. doi:

- 10.1016/j.clim.2016.04.002. Epub 2016 Apr 22. PubMed PMID: 27109640; PubMed Central PMCID: PMC4940221.
94. Urowitz MB, Gladman DD, Anderson NM, Su J, Romero-Diaz J, Bae SC, Fortin PR, Sanchez-Guerrero J, Clarke A, Bernatsky S, Gordon C, Hanly JG, Wallace DJ, Isenberg D, Rahman A, Merrill J, Ginzler E, Alarcón GS, Fessler BF, Petri M, Bruce IN, Khamashta M, Aranow C, Dooley M, Manzi S, Ramsey-Goldman R, Sturfelt G, Nived O, Steinsson K, Zoma A, Ruiz-Irastorza G, Lim S, Kalunian KC, İnanç M, van Vollenhoven R, Ramos-Casals M, Kamen DL, Jacobsen S, Peschken C, Askanase A, Stoll T. [Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort.](#) *Lupus Sci Med.* 2016;3(1):e000143. doi: 10.1136/lupus-2015-000143. eCollection 2016. PubMed PMID: 27099765; PubMed Central PMCID: PMC4836282.
95. Rasmussen A, Radfar L, Lewis D, Grundahl K, Stone DU, Kaufman CE, Rhodus NL, Segal B, Wallace DJ, Weisman MH, Venuturupalli S, Kurien BT, Lessard CJ, Sivils KL, Scofield RH. [Previous diagnosis of Sjögren's syndrome as rheumatoid arthritis or systemic lupus erythematosus.](#) *Rheumatology (Oxford).* 2016 Jul;55(7):1195-201. doi: 10.1093/rheumatology/kew023. Epub 2016 Mar 21. PubMed PMID: 26998859; PubMed Central PMCID: PMC6281033.
96. van Vollenhoven RF, Petri M, Wallace DJ, Roth DA, Molta CT, Hammer AE, Tang Y, Thompson A. [Cumulative corticosteroid dose over fifty-two weeks in patients with systemic lupus erythematosus: pooled analyses from the phase III belimumab trials.](#) *Arthritis Rheumatol.* 2016 Sep;68(9):2184-92. doi: 10.1002/art.39682. PubMed PMID: 26992106; PubMed Central PMCID: PMC5129492.
97. Kan H, Nagar S, Patel J, Wallace DJ, Molta C, Chang DJ. [Longitudinal treatment patterns and associated outcomes in patients with newly diagnosed systemic lupus erythematosus.](#) *Clin Ther.* 2016 Mar;38(3):610-24. doi: 10.1016/j.clinthera.2016.01.016. Epub 2016 Feb 19. PubMed PMID: 26907503.
98. Wallace DJ, Silverman SL, Conklin J, Barken D, Dervieux T. [Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products.](#) *Lupus Sci Med.* 2016;3(1):e000127. doi: 10.1136/lupus-2015-000127. eCollection 2016. PubMed PMID: 26870391; PubMed Central PMCID: PMC4746498.
99. Liu K, Kurien BT, Zimmerman SL, Kaufman KM, Taft DH, Kottyan LC, Lazaro S, Weaver CA, Ice JA, Adler AJ, Chodosh J, Radfar L, Rasmussen A, Stone DU, Lewis DM, Li S, Koelsch KA, Igoe A, Talsania M, Kumar J, Maier-Moore JS, Harris VM, Gopalakrishnan R, Jonsson R, Lessard JA, Lu X, Gottenberg JE, Anaya JM, Cunninghame-Graham DS, Huang AJW, Brennan MT, Hughes P, Illei GG, Miceli-Richard C, Keystone EC, Bykerk VP, Hirschfield G, Xie G, Ng WF, Nordmark G, Eriksson P, Omdal R, Rhodus NL, Rischmueller M, Rohrer M, Segal BM, Vyse TJ, Wahren-Herlenius M, Witte T, Pons-Estel B, Alarcon-Riquelme ME, Guthridge JM, James JA, Lessard CJ, Kelly JA, Thompson SD, Gaffney PM, Montgomery CG, Edberg JC, Kimberly RP, Alarcón GS, Langefeld CL, Gilkeson GS, Kamen DL, Tsao BP, McCune WJ, Salmon JE, Merrill JT, Weisman MH, Wallace DJ, Utset TO, Bottinger EP, Amos CI, Siminovitch KA, Mariette X, Sivils KL, Harley JB, Scofield RH. [X chromosome dose and sex bias in autoimmune diseases: increased prevalence of 47,XXX in systemic lupus erythematosus and Sjögren's syndrome.](#) *Arthritis Rheumatol.* 2016 May;68(5):1290-300. doi: 10.1002/art.39560. PubMed PMID: 26713507; PubMed Central PMCID: PMC5019501.
100. Hui-Yuen JS, Reddy A, Taylor J, Li X, Eichenfield AH, Bermudez LM, Starr AJ, Imundo LF, Buyon J, Furie RA, Kamen DL, Manzi S, Petri M, Ramsey-Goldman R, van Vollenhoven RF, Wallace DJ, Askanase A. [Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices.](#) *J Rheumatol.* 2015 Dec;42(12):2288-95. doi:

- 10.3899/jrheum.150470. Epub 2015 Nov 1. PubMed PMID: 26523030; PubMed Central PMCID: PMC5031077.
101. Wallace DJ, Hobbs K, Clowse ME, Petri M, Strand V, Pike M, Merrill JT, Leszczyński P, Neuwelt CM, Jeka S, Houssiau F, Keiserman M, Ordi-Ros J, Bongardt S, Kilgallen B, Galateanu C, Kalunian K, Furie R, Gordon C. [Long-term safety and efficacy of epratuzumab in the treatment of moderate-to-severe systemic lupus erythematosus: results from an open-label extension study.](#) *Arthritis Care Res (Hoboken)*. 2016 Apr;68(4):534-43. doi: 10.1002/acr.22694. PubMed PMID: 26316325.
 102. Hanly JG, O'Keefe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Clarke AE, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Fortin P, Gladman DD, Sanchez-Guerrero J, Petri M, Bruce IN, Dooley MA, Ramsey-Goldman R, Aranow C, Alarcón GS, Fessler BJ, Steinsson K, Nived O, Sturfelt GK, Manzi S, Khamashta MA, van Vollenhoven RF, Zoma AA, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Stoll T, Inanc M, Kalunian KC, Kamen DL, Maddison P, Peschken CA, Jacobsen S, Askanase A, Theriault C, Thompson K, Farewell V. [The frequency and outcome of lupus nephritis: results from an international inception cohort study.](#) *Rheumatology (Oxford)*. 2016 Feb;55(2):252-62. doi: 10.1093/rheumatology/kev311. Epub 2015 Sep 5. PubMed PMID: 26342222; PubMed Central PMCID: PMC4939728.
 103. Isenberg DA, Petri M, Kalunian K, Tanaka Y, Urowitz MB, Hoffman RW, Morgan-Cox M, Ilikuni N, Silk M, Wallace DJ. [Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.](#) *Ann Rheum Dis*. 2016 Feb;75(2):323-31. doi: 10.1136/annrheumdis-2015-207653. Epub 2015 Sep 3. PubMed PMID: 26338095. *nn Rheum Dis*.
 104. Stohl W, Merrill JT, Looney RJ, Buyon J, Wallace DJ, Weisman MH, Ginzler EM, Cooke B, Holloway D, Kaliyaperumal A, Kuchimanchi KR, Cheah TC, Rasmussen E, Ferbas J, Belouski SS, Tsuji W, Zack DJ. [Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod \(AMG 623/A-623\): results from randomized, double-blind phase 1a and phase 1b trials.](#) *Arthritis Res Ther*. 2015 Aug 20;17:215. doi: 10.1186/s13075-015-0741-z. PubMed PMID: 26290435; PubMed Central PMCID: PMC4545922.
 105. Urowitz MB, Isenberg DA, Wallace DJ. [Safety and efficacy of hCDR1 \(Edratide\) in patients with active systemic lupus erythematosus: results of phase II study.](#) *Lupus Sci Med*. 2015;2(1):e000104. doi: 10.1136/lupus-2015-000104. eCollection 2015. PubMed PMID: 26301100; PubMed Central PMCID: PMC4538379.
 106. Bruce IN, O'Keefe AG, Farewell V, Hanly JG, Manzi S, Su L, Gladman DD, Bae SC, Sanchez-Guerrero J, Romero-Diaz J, Gordon C, Wallace DJ, Clarke AE, Bernatsky S, Ginzler EM, Isenberg DA, Rahman A, Merrill JT, Alarcón GS, Fessler BJ, Fortin PR, Petri M, Steinsson K, Dooley MA, Khamashta MA, Ramsey-Goldman R, Zoma AA, Sturfelt GK, Nived O, Aranow C, Mackay M, Ramos-Casals M, van Vollenhoven RF, Kalunian KC, Ruiz-Irastorza G, Lim S, Kamen DL, Peschken CA, Inanc M, Urowitz MB. [Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics \(SLICC\) Inception Cohort.](#) *Ann Rheum Dis*. 2015 Sep;74(9):1706-13. doi: 10.1136/annrheumdis-2013-205171. Epub 2014 May 16. PubMed PMID: 24834926; PubMed Central PMCID: PMC4552899.
 107. Wallace DJ. [The evolution of drug discovery in systemic lupus erythematosus.](#) *Nat Rev Rheumatol*. 2015 Oct;11(10):616-20. doi: 10.1038/nrrheum.2015.86. Epub 2015 Jun 30. Review. PubMed PMID: 26122951.
 108. Modi M, Ishimori ML, Sandhu VK, Wallace DJ, Weisman MH. [Chest pain in lupus patients: the emergency department experience.](#) *Clin Rheumatol*. 2015 Nov;34(11):1969-73. doi: 10.1007/s10067-015-2948-4. Epub 2015 Apr 26. PubMed PMID: 25912215.

109. Sandhu VK, Wallace DJ, Weisman MH. [Monoclonal antibodies, systemic lupus erythematosus, and pregnancy: insights from an open-label study](#). *J Rheumatol*. 2015 Apr;42(4):728-30. doi: 10.3899/jrheum.140952. PubMed PMID: 25834243.
110. Hanly JG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Clarke AE, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Dooley MA, Fortin P, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Alarcón GS, Fessler BJ, Manzi S, Nived O, Sturfelt GK, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Theriault C, Thompson K, Farewell V. [Mood disorders in systemic lupus erythematosus: results from an international inception cohort study](#). *Arthritis Rheumatol*. 2015 Jul;67(7):1837-47. doi: 10.1002/art.39111. PubMed PMID: 25778456; PubMed Central PMCID: PMC4485527.
111. Wallace DJ, Gavin IM, Karpenko O, Barkhordar F, Gillis BS. [Cytokine and chemokine profiles in fibromyalgia, rheumatoid arthritis and systemic lupus erythematosus: a potentially useful tool in differential diagnosis](#). *Rheumatol Int*. 2015 Jun;35(6):991-6. doi: 10.1007/s00296-014-3172-2. Epub 2014 Nov 7. PubMed PMID: 25377646; PubMed Central PMCID: PMC4435905.
112. Orbai AM, Truedsson L, Sturfelt G, Nived O, Fang H, Alarcón GS, Gordon C, Merrill J, Fortin PR, Bruce IN, Isenberg DA, Wallace DJ, Ramsey-Goldman R, Bae SC, Hanly JG, Sanchez-Guerrero J, Clarke AE, Aranow CB, Manzi S, Urowitz MB, Gladman DD, Kalunian KC, Costner MI, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, Van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr, Sigler L, Hameed S, Pham N, Brey R, Weisman MH, McGwin G Jr, Magder LS, Petri M. [Anti-C1q antibodies in systemic lupus erythematosus](#). *Lupus*. 2015 Jan;24(1):42-9. doi: 10.1177/0961203314547791. Epub 2014 Aug 14. PubMed PMID: 25124676; PubMed Central PMCID: PMC4268323.
113. Lertratanakul A, Wu P, Dyer A, Urowitz M, Gladman D, Fortin P, Bae SC, Gordon C, Clarke A, Bernatsky S, Hanly JG, Isenberg D, Rahman A, Merrill J, Wallace DJ, Ginzler E, Khamashta M, Bruce I, Nived O, Sturfelt G, Steinsson K, Manzi S, Dooley MA, Kalunian K, Petri M, Aranow C, Font J, van Vollenhoven R, Stoll T, Ramsey-Goldman R. [25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort](#). *Arthritis Care Res (Hoboken)*. 2014 Aug;66(8):1167-76. doi: 10.1002/acr.22291. PubMed PMID: 24470118; PubMed Central PMCID: PMC4844829.
114. Jolly M, Garris CP, Mikolaitis RA, Jhingran PM, Dennis G, Wallace DJ, Clarke A, Dooley MA, Parke A, Strand V, Alárcon GS, Kosinski M. [Development and validation of the Lupus Impact Tracker: a patient-completed tool for clinical practice to assess and monitor the impact of systemic lupus erythematosus](#). *Arthritis Care Res (Hoboken)*. 2014 Oct;66(10):1542-50. doi: 10.1002/acr.22349. PubMed PMID: 24757021.
115. Bourré-Tessier J, Urowitz MB, Clarke AE, Bernatsky S, Krantz MJ, Huynh T, Joseph L, Belisle P, Bae SC, Hanly JG, Wallace DJ, Gordon C, Isenberg D, Rahman A, Gladman DD, Fortin PR, Merrill JT, Romero-Diaz J, Sanchez-Guerrero J, Fessler B, Alarcón GS, Steinsson K, Bruce IN, Ginzler E, Dooley MA, Nived O, Sturfelt G, Kalunian K, Ramos-Casals M, Petri M, Zoma A, Pineau CA. [Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort](#). *Arthritis Care Res (Hoboken)*. 2015 Jan;67(1):128-35. doi: 10.1002/acr.22370. PubMed PMID: 24838943.
116. Urowitz MB, Gladman DD, Ibañez D, Sanchez-Guerrero J, Romero-Diaz J, Gordon C, Bae SC, Clarke AE, Bernatsky S, Fortin PR, Hanly JG, Isenberg D, Rahman A, Wallace DJ, Ginzler E, Petri M, Bruce IN, Merrill JT, Nived O, Sturfelt G, Dooley MA, Alarcón GS, Fessler B, Steinsson K,

- Ramsey-Goldman R, Zoma A, Khamashta M, Manzi S, van Vollenhoven R, Ramos-Casals M, Aranow C, Stoll T. [American College of Rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort](#). *J Rheumatol*. 2014 May;41(5):875-80. doi: 10.3899/jrheum.130704. Epub 2014 Apr 1. PubMed PMID: 24692526.
117. Parker B, Urowitz MB, Gladman DD, Lunt M, Donn R, Bae SC, Sanchez-Guerrero J, Romero-Diaz J, Gordon C, Wallace DJ, Clarke AE, Bernatsky S, Ginzler EM, Isenberg DA, Rahman A, Merrill JT, Alarcón GS, Fessler BJ, Fortin PR, Hanly JG, Petri M, Steinsson K, Dooley MA, Manzi S, Khamashta MA, Ramsey-Goldman R, Zoma AA, Sturfelt GK, Nived O, Aranow C, Mackay M, Ramos-Casals M, van Vollenhoven RF, Kalunian KC, Ruiz-Irastorza G, Lim SS, Kamen DL, Peschken CA, Inanc M, Bruce IN. [Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort](#). *Ann Rheum Dis*. 2015 Aug;74(8):1530-6. doi: 10.1136/annrheumdis-2013-203933. Epub 2014 Apr 1. PubMed PMID: 24692585; PubMed Central PMCID: PMC4515988.
118. Muller S, Wallace DJ. [The importance of implementing proper selection of excipients in lupus clinical trials](#). *Lupus*. 2014 Jun;23(7):609-14. doi: 10.1177/0961203314525249. Epub 2014 Feb 25. PubMed PMID: 24569394; PubMed Central PMCID: PMC4232263.
119. Martin DA, Churchill M, Flores-Suarez L, Cardiel MH, Wallace D, Martin R, Phillips K, Kaine JL, Dong H, Salinger D, Stevens E, Russell CB, Chung JB. [A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis](#). *Arthritis Res Ther*. 2013 Oct 25;15(5):R164. doi: 10.1186/ar4347. PubMed PMID: 24286136; PubMed Central PMCID: PMC3979125.
120. Urowitz M, Gladman DD, Ibañez D, Sanchez-Guerrero J, Bae SC, Gordon C, Fortin PR, Clarke A, Bernatsky S, Hanly JG, Wallace DJ, Isenberg D, Rahman A, Merrill J, Ginzler E, Alarcón GS, Fessler B, Khamashta M, Steinsson K, Petri M, Dooley M, Bruce IN, Manzi S, Sturfelt G, Nived O, Ramsey-Goldman R, Zoma A, Maddison P, Kalunian K, van Vollenhoven R, Aranow C, Romero Diaz J, Stoll T. [Changes in quality of life in the first 5 years of disease in a multicenter cohort of patients with systemic lupus erythematosus](#). *Arthritis Care Res (Hoboken)*. 2014 Sep;66(9):1374-9. doi: 10.1002/acr.22299. PubMed PMID: 24497416.
121. Strand V, Petri M, Kalunian K, Gordon C, Wallace DJ, Hobbs K, Kelley L, Kilgallen B, Wegener WA, Goldenberg DM. [Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006](#). *Rheumatology (Oxford)*. 2014 Mar;53(3):502-11. doi: 10.1093/rheumatology/ket378. Epub 2013 Nov 22. PubMed PMID: 24273022; PubMed Central PMCID: PMC3930886.
122. Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Zhong ZJ, Freimuth WW, Petri MA. [Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus](#). *J Rheumatol*. 2014 Feb;41(2):300-9. doi: 10.3899/jrheum.121368. Epub 2013 Nov 1. PubMed PMID: 24187095.
123. Hanly JG, Urowitz MB, O'Keefe AG, Gordon C, Bae SC, Sanchez-Guerrero J, Romero-Diaz J, Clarke AE, Bernatsky S, Wallace DJ, Ginzler EM, Isenberg DA, Rahman A, Merrill JT, Petri M, Fortin PR, Gladman DD, Fessler BJ, Alarcón GS, Bruce IN, Dooley MA, Steinsson K, Khamashta MA, Ramsey-Goldman R, Manzi S, Sturfelt GK, Nived O, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Aranow C, Mackay M, Ruiz-Irastorza G, Kalunian KC, Lim SS, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Theriault C, Thompson K, Farewell V. [Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study](#). *Arthritis Rheum*. 2013 Nov;65(11):2887-97. doi: 10.1002/art.38106. PubMed PMID: 24166793.

124. Lu M, Bernatsky S, Ramsey-Goldman R, Petri M, Manzi S, Urowitz MB, Gladman D, Fortin PR, Ginzler EM, Yelin E, Bae SC, Wallace DJ, Jacobsen S, Dooley MA, Peschken CA, Alarcón GS, Nived O, Gottesman L, Criswell LA, Sturfelt G, Dreyer L, Lee JL, Clarke AE. [Non-lymphoma hematological malignancies in systemic lupus erythematosus](#). *Oncology*. 2013;85(4):235-40. doi: 10.1159/000350165. Epub 2013 Oct 2. PubMed PMID: 24107608; PubMed Central PMCID: PMC3880772.
125. McMahon M, Skaggs BJ, Grossman JM, Sahakian L, Fitzgerald J, Wong WK, Lourenco EV, Ragavendra N, Charles-Schoeman C, Gorn A, Karpouzas GA, Taylor MB, Watson KE, Weisman MH, Wallace DJ, Hahn BH. [A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus](#). *Arthritis Rheumatol*. 2014 Jan;66(1):130-9. doi: 10.1002/art.38204. PubMed PMID: 24449580; PubMed Central PMCID: PMC4106468.
126. Wang SL, Wang FF, Chen SL, Shen N, Xue F, Ye P, Bao CD, Gu YY, Yu CZ, Wilson A, Wallace DJ, Weisman MH, Lu LJ. [Expression, localization and clinical application of exogenous Smith proteins D1 in gene transfected HEp-2 cells](#). *Int J Rheum Dis*. 2013 Jun;16(3):303-9. doi: 10.1111/1756-185X.12000. Epub 2012 Oct 22. PubMed PMID: 23981752.
127. Grossman JM, Hahn BH, Mc Mahon MA, FitzGerald JD, Merrill JT, Yazdany J, Wallace DJ, Ramsey-Goldman R. Managing lupus nephritis in pregnant women: comment on the article by Hahn et al: reply. *Arthritis Care Res*. 2013;65:1392.
128. Tessier Cloutier B, Clarke AE, Ramsey-Goldman R, Wang Y, Foulkes W, Gordon C, Hansen JE, Yelin E, Urowitz MB, Gladman D, Fortin PR, Wallace DJ, Petri M, Manzi S, Ginzler EM, Labrecque J, Edworthy S, Dooley MA, Sénécal JL, Peschken CA, Bae SC, Isenberg D, Rahman A, Ruiz-Irastorza G, Hanly JG, Jacobsen S, Nived O, Witte T, Criswell LA, Barr SG, Dreyer L, Sturfelt G, Bernatsky S. [Breast cancer in systemic lupus erythematosus](#). *Oncology*. 2013;85(2):117-21. doi: 10.1159/000353138. Epub 2013 Jul 25. PubMed PMID: 23887245; PubMed Central PMCID: PMC3934367.
129. Moldovan I, Cooray D, Carr F, Katsaros E, Torralba K, Shinada S, Ishimori M, Jolly M, Wilson A, Wallace D, Weisman M, Nicassio P. [Pain and depression predict self-reported fatigue/energy in lupus](#). *Lupus*. 2013 Jun;22(7):684-9. doi: 10.1177/0961203313486948. Epub 2013 May 9. PubMed PMID: 23660302.
130. Rossi EA, Goldenberg DM, Michel R, Rossi DL, Wallace DJ, Chang CH. [Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab](#). *Blood*. 2013 Oct 24;122(17):3020-9. doi: 10.1182/blood-2012-12-473744. Epub 2013 Jul 2. PubMed PMID: 23821660.
131. Wallace DJ. [Ten developments in the use of biologicals for systemic lupus erythematosus](#). *Curr Rheumatol Rep*. 2013 Jul;15(7):337. doi: 10.1007/s11926-013-0337-z. Review. PubMed PMID: 23666467.
132. Wallace DJ. [Quality guidelines for systemic lupus erythematosus: slow but steady progress](#). *J Rheumatol*. 2013 May;40(5):542-3. doi: 10.3899/jrheum.130128. PubMed PMID: 23637374.
133. Ishimori ML, Anderson L, Weisman MH, Mehta PK, Bairey Merz CN, Wallace DJ. [Microvascular angina: an underappreciated cause of SLE chest pain](#). *J Rheumatol*. 2013 May;40(5):746-7. doi: 10.3899/jrheum.121277. PubMed PMID: 23637384.
134. Wallace DJ, Goldenberg DM. [Epratuzumab for systemic lupus erythematosus](#). *Lupus*. 2013 Apr;22(4):400-5. doi: 10.1177/0961203312469692. Review. PubMed PMID: 23553783.
135. Jolly M, Toloza S, Block J, Mikolaitis R, Kosinski M, Wallace D, Durran-Barragan S, Bertoli A, Blazevic I, Vilá L, Cooray D, Moldovan I, Katsaros E, Weisman M, Torralba KM, Alarcón G.

- [Spanish LupusPRO: cross-cultural validation study for lupus](#). *Lupus*. 2013 Apr;22(5):431-6. doi: 10.1177/0961203313476359. PubMed PMID: 23554032.
136. Wallace DJ, Gordon C, Strand V, Hobbs K, Petri M, Kalunian K, Houssiau F, Tak PP, Isenberg DA, Kelley L, Kilgallen B, Barry AN, Wegener WA, Goldenberg DM. [Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies \(ALLEVIATE\) and follow-up](#). *Rheumatology (Oxford)*. 2013 Jul;52(7):1313-22. doi: 10.1093/rheumatology/ket129. Epub 2013 Mar 28. PubMed PMID: 23542611.
137. Petri M, Wallace DJ, Spindler A, Chindalore V, Kalunian K, Mysler E, Neuwelt CM, Robbie G, White WI, Higgs BW, Yao Y, Wang L, Ethgen D, Greth W. [Sifalimumab, a human anti-interferon- \$\alpha\$ monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study](#). *Arthritis Rheum*. 2013 Apr;65(4):1011-21. doi: 10.1002/art.37824. PubMed PMID: 23400715; PubMed Central PMCID: PMC3654174.
138. Bernatsky S, Ramsey-Goldman R, Labrecque J, Joseph L, Boivin JF, Petri M, Zoma A, Manzi S, Urowitz MB, Gladman D, Fortin PR, Ginzler E, Yelin E, Bae SC, Wallace DJ, Edworthy S, Jacobsen S, Gordon C, Dooley MA, Peschken CA, Hanly JG, Alarcón GS, Nived O, Ruiz-Irastorza G, Isenberg D, Rahman A, Witte T, Aranow C, Kamen DL, Steinsson K, Askanase A, Barr S, Criswell LA, Sturfelt G, Patel NM, Sénécal JL, Zummer M, Pope JE, Ensworth S, El-Gabalawy H, McCarthy T, Dreyer L, Sibley J, St Pierre Y, Clarke AE. [Cancer risk in systemic lupus: an updated international multi-centre cohort study](#). *J Autoimmun*. 2013 May;42:130-5. doi: 10.1016/j.jaut.2012.12.009. Epub 2013 Feb 12. PubMed PMID: 23410586; PubMed Central PMCID: PMC3646904.
139. Clowse ME, Wallace DJ, Weisman M, James A, Criscione-Schreiber LG, Pisetsky DS. [Predictors of preterm birth in patients with mild systemic lupus erythematosus](#). *Ann Rheum Dis*. 2013 Sep 1;72(9):1536-9. doi: 10.1136/annrheumdis-2012-202449. Epub 2013 Jan 29. PubMed PMID: 23361085.
140. Bernatsky S, Ramsey-Goldman R, Joseph L, Boivin JF, Costenbader KH, Urowitz MB, Gladman DD, Fortin PR, Nived O, Petri MA, Jacobsen S, Manzi S, Ginzler EM, Isenberg D, Rahman A, Gordon C, Ruiz-Irastorza G, Yelin E, Bae SC, Wallace DJ, Peschken CA, Dooley MA, Edworthy SM, Aranow C, Kamen DL, Romero-Diaz J, Askanase A, Witte T, Barr SG, Criswell LA, Sturfelt GK, Blanco I, Feldman CH, Dreyer L, Patel NM, St Pierre Y, Clarke AE. [Lymphoma risk in systemic lupus: effects of disease activity versus treatment](#). *Ann Rheum Dis*. 2014 Jan;73(1):138-42. doi: 10.1136/annrheumdis-2012-202099. Epub 2013 Jan 8. PubMed PMID: 23303389; PubMed Central PMCID: PMC3855611.
141. Wallace DJ, Kalunian K, Petri MA, Strand V, Houssiau FA, Pike M, Kilgallen B, Bongardt S, Barry A, Kelley L, Gordon C. [Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study](#). *Ann Rheum Dis*. 2014 Jan;73(1):183-90. doi: 10.1136/annrheumdis-2012-202760. Epub 2013 Jan 12. PubMed PMID: 23313811; PubMed Central PMCID: PMC3888603.
142. Wallace DJ, Navarra S, Petri MA, Gallacher A, Thomas M, Furie R, Levy RA, van Vollenhoven RF, Cooper S, Zhong ZJ, Freimuth W, Cervera R. [Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus](#). *Lupus*. 2013 Feb;22(2):144-54. doi: 10.1177/0961203312469259. Epub 2012 Dec 4. PubMed PMID: 23213069.
143. Wu B, Wilson A, Wang FF, Wang SL, Wallace DJ, Weisman MH, Lu LJ. [Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in China](#). *PLoS One*. 2012;7(10):e47373. doi:

- 10.1371/journal.pone.0047373. Epub 2012 Oct 9. PubMed PMID: 23056637; PubMed Central PMCID: PMC3467255.
144. Merrill JT, Ginzler EM, Wallace DJ, McKay JD, Lisse JR, Aranow C, Wellborne FR, Burnette M, Condemi J, Zhong ZJ, Pineda L, Klein J, Freimuth WW. [Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus](#). *Arthritis Rheum*. 2012 Oct;64(10):3364-73. doi: 10.1002/art.34564. PubMed PMID: 22674457.
145. Venuturupalli S, Gudsoorkar V, Wallace D. [Reconsidering antimalarials in systemic lupus erythematosus: developments of translational clinical interest](#). *J Rheumatol*. 2012 Sep;39(9):1769-71. doi: 10.3899/jrheum.111616. PubMed PMID: 22942300.
146. Lu R, Robertson JM, Bruner BF, Guthridge JM, Neas BR, Nath SK, Kelly JA, Moser Sivils KL, Chakravarty EF, Kamen DL, Gilkeson GS, Wallace DJ, Weisman MH, Scofield RH, Harley JB, James JA. [Multiple autoantibodies display association with lymphopenia, proteinuria, and cellular casts in a large, ethnically diverse SLE patient cohort](#). *Autoimmune Dis*. 2012;2012:819634. doi: 10.1155/2012/819634. Epub 2012 Sep 4. PubMed PMID: 22988489; PubMed Central PMCID: PMC3439936.
147. Parker B, Urowitz MB, Gladman DD, Lunt M, Bae SC, Sanchez-Guerrero J, Romero-Diaz J, Gordon C, Wallace DJ, Clarke AE, Bernatsky S, Ginzler EM, Isenberg DA, Rahman A, Merrill JT, Alarcón GS, Fessler BJ, Fortin PR, Hanly JG, Petri M, Steinsson K, Dooley MA, Manzi S, Khamashta MA, Ramsey-Goldman R, Zoma AA, Sturfelt GK, Nived O, Aranow C, Mackay M, Ramos-Casals M, van Vollenhoven RF, Kalunian KC, Ruiz-Irastorza G, Lim S, Kamen DL, Peschken CA, Inanc M, Bruce IN. [Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort](#). *Ann Rheum Dis*. 2013 Aug;72(8):1308-14. doi: 10.1136/annrheumdis-2012-202106. Epub 2012 Sep 3. PubMed PMID: 22945501; PubMed Central PMCID: PMC3711497.
148. McBride JM, Jiang J, Abbas AR, Morimoto A, Li J, Maciucă R, Townsend M, Wallace DJ, Kennedy WP, Drappa J. [Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study](#). *Arthritis Rheum*. 2012 Nov;64(11):3666-76. doi: 10.1002/art.34632. PubMed PMID: 22833362.
149. Wallace DJ, Gudsoorkar VS, Weisman MH, Venuturupalli SR. [New insights into mechanisms of therapeutic effects of antimalarial agents in SLE](#). *Nat Rev Rheumatol*. 2012 Sep;8(9):522-33. doi: 10.1038/nrrheum.2012.106. Epub 2012 Jul 17. Review. PubMed PMID: 22801982.
150. Chatham WW, Wallace DJ, Stohl W, Latinis KM, Manzi S, McCune WJ, Tegzová D, McKay JD, Avila-Armengol HE, Utset TO, Zhong ZJ, Hough DR, Freimuth WW, Migone TS. [Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial](#). *J Rheumatol*. 2012 Aug;39(8):1632-40. doi: 10.3899/jrheum.111587. Epub 2012 Jun 15. PubMed PMID: 22707609.
151. Wang FF, Zhu LA, Zou YQ, Zheng H, Wilson A, Yang CD, Shen N, Wallace DJ, Weisman MH, Chen SL, Lu LJ. [New insights into the role and mechanism of macrophage migration inhibitory factor in steroid-resistant patients with systemic lupus erythematosus](#). *Arthritis Res Ther*. 2012 May 2;14(3):R103. doi: 10.1186/ar3828. PubMed PMID: 22551315; PubMed Central PMCID: PMC3446480.
152. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sánchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc

- M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr, Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, McGwin G Jr, Magder LS. [Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus](#). *Arthritis Rheum*. 2012 Aug;64(8):2677-86. doi: 10.1002/art.34473. PubMed PMID: 22553077; PubMed Central PMCID: PMC3409311.
153. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, Karpouzas GA, Merrill JT, Wallace DJ, Yazdany J, Ramsey-Goldman R, Singh K, Khalighi M, Choi SI, Gogia M, Kafaja S, Kamgar M, Lau C, Martin WJ, Parikh S, Peng J, Rastogi A, Chen W, Grossman JM. [American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis](#). *Arthritis Care Res (Hoboken)*. 2012 Jun;64(6):797-808. doi: 10.1002/acr.21664. PubMed PMID: 22556106; PubMed Central PMCID: PMC3437757.
154. Jolly M, Pickard AS, Block JA, Kumar RB, Mikolaitis RA, Wilke CT, Rodby RA, Fogg L, Sequeira W, Utset TO, Cash TF, Moldovan I, Katsaros E, Nicassio P, Ishimori ML, Kosinsky M, Merrill JT, Weisman MH, Wallace DJ. [Disease-specific patient reported outcome tools for systemic lupus erythematosus](#). *Semin Arthritis Rheum*. 2012 Aug;42(1):56-65. doi: 10.1016/j.semarthrit.2011.12.005. Epub 2012 Apr 4. PubMed PMID: 22480408.
155. Hanly JG, Urowitz MB, Su L, Gordon C, Bae SC, Sanchez-Guerrero J, Romero-Diaz J, Wallace DJ, Clarke AE, Ginzler E, Merrill JT, Isenberg DA, Rahman A, Petri M, Fortin PR, Gladman D, Bruce IN, Steinsson K, Dooley M, Khamashta MA, Alarcón GS, Fessler BJ, Ramsey-Goldman R, Manzi S, Zoma AA, Sturfelt GK, Nived O, Aranow C, Mackay M, Ramos-Casals M, van Vollenhoven R, Kalunian KC, Ruiz-Irastorza G, Lim S, Kamen DL, Peschken CA, Inanc M, Theriault C, Thompson K, Farewell V. [Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study](#). *Ann Rheum Dis*. 2012 Sep;71(9):1502-9. doi: 10.1136/annrheumdis-2011-201089. Epub 2012 Apr 4. PubMed PMID: 22492779; PubMed Central PMCID: PMC4656036.
156. Van Vollenhoven RF, Jacobsen S, Wallace D, Hanly JG, Petri M, Isenberg DA, Clarke AE, Pineau CA, Bernatsky S, Simard JF, Bae S-C, Ramos-Casals M, Diaz-Ligares C, Ruiz-Irastorza G, Martinez-Berriotxo A, Garcia-Hernandez FJ, Castillo-Palma MJ, Saez L, Callejas JL, Rascon J, de Ramon E, Ayala-Gutierrez MM, Camps M, Mild M, Inanc M, Artim-Eisen B, Ramsay-Goldman R, Peschken CA, Squartrito D, Emmi L, Kovacs L, Doria A, Skekanecz Z, Ferraccioli G, Gremese E, Sato EI. Biologics use in SLE in 23 centers—data from the international registry for biologics in SLE. *Annals Rheum Dis*. 2012;71.
157. Goykhman P, Mehta PK, Minissian M, Thomson LE, Berman DS, Ishimori ML, Wallace DJ, Weisman MH, Shufelt CL, Bairey Merz CN. [Subendocardial ischemia and myocarditis in systemic lupus erythematosus detected by cardiac magnetic resonance imaging](#). *J Rheumatol*. 2012 Feb;39(2):448-50. doi: 10.3899/jrheum.110812. PubMed PMID: 22298279.
158. Urowitz MB, Gladman DD, Ibañez D, Fortin PR, Bae SC, Gordon C, Clarke A, Bernatsky S, Hanly JG, Isenberg D, Rahman A, Sanchez-Guerrero J, Wallace DJ, Ginzler E, Alarcón GS, Merrill JT, Bruce IN, Sturfelt G, Nived O, Steinsson K, Khamashta M, Petri M, Manzi S, Ramsey-Goldman R, Dooley MA, van Vollenhoven RF, Ramos M, Stoll T, Zoma A, Kalunian K, Aranow C. [Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort](#). *Arthritis Care Res (Hoboken)*. 2012 Jan;64(1):132-7. doi: 10.1002/acr.20648. PubMed PMID: 21954226.
159. Dillon SP, Kurien BT, Li S, Bruner GR, Kaufman KM, Harley JB, Gaffney PM, Wallace DJ, Weisman MH, Scofield RH. [Sex chromosome aneuploidies among men with systemic lupus erythematosus](#). *J Autoimmun*. 2012 May;38(2-3):J129-34. doi: 10.1016/j.jaut.2011.10.004. Epub 2011 Dec 6. PubMed PMID: 22154021; PubMed Central PMCID: PMC3309073.

160. Jolly M, Pickard AS, Sequeira W, Wallace DJ, Solem CT, Mikolaitis RA, Fogg L, Weisman MH, Block JA, Cash TF. A brief assessment tool for body image in systemic lupus erythematosus. *Body Image*. 2012 Mar;9(2):279-84. doi: 10.1016/j.bodyim.2011.11.001. Epub 2011 Dec 8. PubMed PMID: 22154813.
161. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF. [A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus](#). *Arthritis Rheum*. 2011 Dec;63(12):3918-30. doi: 10.1002/art.30613. PubMed PMID: 22127708; PubMed Central PMCID: PMC5007058.
162. Ramage AE, Fox PT, Brey RL, Narayana S, Cykowski MD, Naqibuddin M, Sampedro M, Holliday SL, Franklin C, Wallace DJ, Weisman MH, Petri M. [Neuroimaging evidence of white matter inflammation in newly diagnosed systemic lupus erythematosus](#). *Arthritis Rheum*. 2011 Oct;63(10):3048-57. doi: 10.1002/art.30458. PubMed PMID: 21618460; PubMed Central PMCID: PMC3167945.
163. Moldovan I, Katsaros E, Carr FN, Cooray D, Torralba K, Shinada S, Ishimori ML, Jolly M, Wallace DJ, Weisman MH, Nicassio PM. [The Patient Reported Outcomes in Lupus \(PATROL\) study: role of depression in health-related quality of life in a Southern California lupus cohort](#). *Lupus*. 2011 Oct;20(12):1285-92. doi: 10.1177/0961203311412097. Epub 2011 Aug 3. PubMed PMID: 21813589.
164. Bagheri S, Wallace DJ. [Prescribing trends for targeted therapies in rheumatoid arthritis among rheumatologists in Southern California, 2008-2010](#). *Arthritis Rheum*. 2011 Nov;63(11):3641. doi: 10.1002/art.30533. PubMed PMID: 21769837.
165. Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI, Robbie G, Levin R, Berney SM, Chindalore V, Olsen N, Richman L, Le C, Jallal B, White B. [Safety profile and clinical activity of sifalimumab, a fully human anti-interferon \$\alpha\$ monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study](#). *Ann Rheum Dis*. 2011 Nov;70(11):1905-13. doi: 10.1136/ard.2010.144485. Epub 2011 Jul 27. PubMed PMID: 21798883.
166. Vinet E, Clarke AE, Gordon C, Urowitz MB, Hanly JG, Pineau CA, Isenberg D, Rahman A, Wallace D, Alarcón GS, Bruce I, Petri M, Dooley MA, Kalunian K, Maddison P, Aranow C, van Vollenhoven R, Bernatsky S. [Decreased live births in women with systemic lupus erythematosus](#). *Arthritis Care Res (Hoboken)*. 2011 Jul;63(7):1068-72. doi: 10.1002/acr.20466. PubMed PMID: 21425248.
167. McMahon M, Skaggs BJ, Sahakian L, Grossman J, FitzGerald J, Ragavendra N, Charles-Schoeman C, Chernishof M, Gorn A, Witztum JL, Wong WK, Weisman M, Wallace DJ, La Cava A, Hahn BH. [High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids](#). *Ann Rheum Dis*. 2011 Sep;70(9):1619-24. doi: 10.1136/ard.2010.142737. Epub 2011 Jun 13. PubMed PMID: 21670088; PubMed Central PMCID: PMC3147230.
168. Hanly JG, Urowitz MB, Jackson D, Bae SC, Gordon C, Wallace DJ, Clarke A, Bernatsky S, Vasudevan A, Isenberg D, Rahman A, Sanchez-Guerrero J, Romero-Diaz J, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Steinsson K, Khamashta M, Alarcón GS, Fessler B, Petri M, Manzi S, Nived O, Sturfelt G, Ramsey-Goldman R, Dooley MA, Aranow C, Van Vollenhoven R, Ramos-Casals M, Zoma A, Kalunian K, Farewell V. [SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus](#). *Ann Rheum Dis*. 2011 Jun;70(6):961-7. doi: 10.1136/ard.2010.138792. Epub 2011 Feb 21. PubMed PMID: 21342917; PubMed Central PMCID: PMC3795436.

169. Wallace DJ. Book Review: Understanding Hughes' Syndrome. Case studies for patients. *J Rheum.* 2011; 38:787.
170. Firooz N, Albert DA, Wallace DJ, Ishimori M, Berel D, Weisman MH. [High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus.](#) *Lupus.* 2011 May;20(6):588-97. doi: 10.1177/0961203310393378. Epub 2011 Mar 24. PubMed PMID: 21436216.
171. Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, Clarke A, Bernatsky S, Vasudevan A, Isenberg D, Rahman A, Wallace DJ, Fortin PR, Gladman D, Romero-Diaz J, Sanchez-Guerrero J, Dooley MA, Bruce I, Steinsson K, Khamashta M, Manzi S, Ramsey-Goldman R, Sturfelt G, Nived O, van Vollenhoven R, Ramos-Casals M, Aranow C, Mackay M, Kalunian K, Alarcón GS, Fessler BJ, Ruiz-Irastorza G, Petri M, Lim S, Kamen D, Peschken C, Farewell V, Thompson K, Theriault C, Merrill JT. [Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus.](#) *Ann Rheum Dis.* 2011 Oct;70(10):1726-32. doi: 10.1136/ard.2010.148502. PubMed PMID: 21893582; PubMed Central PMCID: PMC4664555.
172. Ippolito A, Wallace DJ, Gladman D, Fortin PR, Urowitz M, Werth V, Costner M, Gordon C, Alarcón GS, Ramsey-Goldman R, Maddison P, Clarke A, Bernatsky S, Manzi S, Bae SC, Merrill JT, Ginzler E, Hanly JG, Nived O, Sturfelt G, Sanchez-Guerrero J, Bruce I, Aranow C, Isenberg D, Zoma A, Magder LS, Buyon J, Kalunian K, Dooley MA, Steinsson K, van Vollenhoven RF, Stoll T, Weisman M, Petri M. [Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity.](#) *Lupus.* 2011 Mar;20(3):250-5. doi: 10.1177/0961203310385738. PubMed PMID: 21362750.
173. Mundwiler ML, Maranian P, Brown DH, Silverman JM, Wallace D, Khanna D, Louie J, Furst DE, Weisman MH. [The utility of MRI in predicting radiographic erosions in the metatarsophalangeal joints of the rheumatoid foot: a prospective longitudinal cohort study.](#) *Arthritis Res Ther.* 2009;11(3):R94. doi: 10.1186/ar2737. Epub 2009 Jun 22. PubMed PMID: 19545417; PubMed Central PMCID: PMC2714150.
174. Ishimori ML, Martin R, Berman DS, Goykhman P, Shaw LJ, Shufelt C, Slomka PJ, Thomson LE, Schapira J, Yang Y, Wallace DJ, Weisman MH, Bairey Merz CN. [Myocardial ischemia in the absence of obstructive coronary artery disease in systemic lupus erythematosus.](#) *JACC Cardiovasc Imaging.* 2011 Jan;4(1):27-33. doi: 10.1016/j.jcmg.2010.09.019. PubMed PMID: 21232700.
175. Wallace DJ. [Advances in drug therapy for systemic lupus erythematosus.](#) *BMC Med.* 2010 Nov 29;8:77. doi: 10.1186/1741-7015-8-77. Review. PubMed PMID: 21114845; PubMed Central PMCID: PMC3009611.
176. Rasmussen A, Sevier S, Kelly JA, Glenn SB, Aberle T, Cooney CM, Grether A, James E, Ning J, Tesiram J, Morrissey J, Powe T, Drexel M, Daniel W, Namjou B, Ojwang JO, Nguyen KL, Cavett JW, Te JL, James JA, Scofield RH, Moser K, Gilkeson GS, Kamen DL, Carson CW, Quintero-del-Rio AI, del Carmen Ballesteros M, Punaro MG, Karp DR, Wallace DJ, Weisman M, Merrill JT, Rivera R, Petri MA, Albert DA, Espinoza LR, Utset TO, Shaver TS, Arthur E, Anaya JM, Bruner GR, Harley JB. [The lupus family registry and repository.](#) *Rheumatology (Oxford).* 2011 Jan;50(1):47-59. doi: 10.1093/rheumatology/keq302. Epub 2010 Sep 23. PubMed PMID: 20864496; PubMed Central PMCID: PMC3307518.
177. Ostergaard M, Baslund B, Rigby W, Rojkovich B, Jorgensen C, Dawes PT, Wiell C, Wallace DJ, Tamer SC, Kastberg H, Petersen J, Sierakowski S. Reduced frequency and severity of infusion-related adverse events after change in ofatumumab infusion regimen—Reply to comment by Abeles. *Arthritis Rheum.* 2011;63:305-10.
178. Carr FN, Nicassio PM, Ishimori ML, Moldovan I, Katsaros E, Torralba K, Shinada S, Cooray D, Wallace DJ, Finck S, Jolly M, Wilson AL, Weisman MH. [Depression predicts self-reported](#)

- [disease activity in systemic lupus erythematosus](#). *Lupus*. 2011 Jan;20(1):80-4. doi: 10.1177/0961203310378672. Epub 2010 Oct 11. PubMed PMID: 20937622.
179. Wallace DJ. [Thrombovascular events in systemic lupus erythematosus: comment on the article by Jung et al](#). *Arthritis Rheum*. 2010 Sep;62(9):2824; author reply 2824-5. doi: 10.1002/art.27621. PubMed PMID: 20872599.
180. Isenberg DA, Allen E, Farewell V, D'Cruz D, Alarcón GS, Aranow C, Bruce IN, Dooley MA, Fortin PR, Ginzler EM, Gladman DD, Hanly JG, Inanc M, Kalunian K, Khamashta M, Merrill JT, Nived O, Petri M, Ramsey-Goldman R, Sturfelt G, Urowitz M, Wallace DJ, Gordon C, Rahman A. [An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA](#). *Ann Rheum Dis*. 2011 Jan;70(1):54-9. doi: 10.1136/ard.2010.132068. Epub 2010 Sep 10. PubMed PMID: 20833737.
181. Petri M, Naqibuddin M, Carson KA, Wallace DJ, Weisman MH, Holliday SL, Sampedro M, Padilla PA, Brey RL. [Depression and cognitive impairment in newly diagnosed systemic lupus erythematosus](#). *J Rheumatol*. 2010 Oct;37(10):2032-8. doi: 10.3899/jrheum.091366. Epub 2010 Jul 15. PubMed PMID: 20634244.
182. Østergaard M, Baslund B, Rigby W, Rojkovich B, Jorgensen C, Dawes PT, Wiell C, Wallace DJ, Tamer SC, Kastberg H, Petersen J, Sierakowski S. [Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study](#). *Arthritis Rheum*. 2010 Aug;62(8):2227-38. doi: 10.1002/art.27524. PubMed PMID: 20506254.
183. Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D'Cruz D, Wallace DJ, Bae SC, Sigal L, Becker JC, Kelly S, Raghupathi K, Li T, Peng Y, Kinaszczuk M, Nash P. [The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial](#). *Arthritis Rheum*. 2010 Oct;62(10):3077-87. doi: 10.1002/art.27601. PubMed PMID: 20533545.
184. Urowitz MB, Gladman D, Ibañez D, Bae SC, Sanchez-Guerrero J, Gordon C, Clarke A, Bernatsky S, Fortin PR, Hanly JG, Wallace DJ, Isenberg D, Rahman A, Alarcón GS, Merrill JT, Ginzler E, Khamashta M, Nived O, Sturfelt G, Bruce IN, Steinsson K, Manzi S, Ramsey-Goldman R, Dooley MA, Zoma A, Kalunian K, Ramos M, Van Vollenhoven RF, Aranow C, Stoll T, Petri M, Maddison P. [Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus](#). *Arthritis Care Res (Hoboken)*. 2010 Jun;62(6):881-7. doi: 10.1002/acr.20122. PubMed PMID: 20535799; PubMed Central PMCID: PMC2989413.
185. Wallace DJ, Furie RA, Freimuth WW. Reply to letter to the editor. *Arthritis Care and Research*. 2010;62:582
186. Wallace DJ. [Telomere diseases](#). *N Engl J Med*. 2010 Mar 25;362(12):1150. doi: 10.1056/NEJMc1000801. PubMed PMID: 20335598.
187. Belouski SS, Wallace D, Weisman M, Ishimori M, Hendricks L, Zack D, Vincent M, Rasmussen E, Ferbas J, Chung J. [Sample stability and variability of B-cell subsets in blood from healthy subjects and patients with systemic lupus erythematosus](#). *Cytometry B Clin Cytom*. 2010 Jan;78(1):49-58. doi: 10.1002/cyto.b.20482. PubMed PMID: 19670351.
188. Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, Wallace DJ, Clarke A, Bernatsky S, Isenberg D, Rahman A, Alarcón GS, Gladman DD, Fortin PR, Sanchez-Guerrero J, Romero-Diaz J, Merrill JT, Ginzler E, Bruce IN, Steinsson K, Khamashta M, Petri M, Manzi S, Dooley MA, Ramsey-Goldman R, Van Vollenhoven R, Nived O, Sturfelt G, Aranow C, Kalunian K, Ramos-Casals M, Zoma A, Douglas J, Thompson K, Farewell V. [Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus](#). *Ann*

- Rheum Dis. 2010 Mar;69(3):529-35. doi: 10.1136/ard.2008.106351. Epub 2009 Apr 8. PubMed PMID: 19359262; PubMed Central PMCID: PMC2929162.
189. Lu LJ, Wallace DJ, Navarra SV, Weisman MH. [Lupus registries: evolution and challenges](#). Semin Arthritis Rheum. 2010 Feb;39(4):224-45. doi: 10.1016/j.semarthrit.2008.08.009. Epub 2008 Nov 7. Review. PubMed PMID: 18992923.
190. Robinson D Jr, Aguilar D, Schoenwetter M, Dubois R, Russak S, Ramsey-Goldman R, Navarra S, Hsu B, Revicki D, Cella D, Rapaport MH, Renahan K, Ressler R, Wallace D, Weisman M. [Impact of systemic lupus erythematosus on health, family, and work: the patient perspective](#). Arthritis Care Res (Hoboken). 2010 Feb;62(2):266-73. doi: 10.1002/acr.20077. PubMed PMID: 20191527.
191. Volkmann ER, Grossman JM, Sahakian LJ, Skaggs BJ, FitzGerald J, Ragavendra N, Charles-Schoeman C, Chen W, Gorn A, Karpouzas G, Weisman M, Wallace DJ, Hahn BH, McMahon M. [Low physical activity is associated with proinflammatory high-density lipoprotein and increased subclinical atherosclerosis in women with systemic lupus erythematosus](#). Arthritis Care Res (Hoboken). 2010 Feb;62(2):258-65. doi: 10.1002/acr.20076. PubMed PMID: 20191526; PubMed Central PMCID: PMC2853476.
192. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG. [Efficacy and safety of rituximab in moderately- to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial](#). Arthritis Rheum. 2010 Jan;62(1):222-33. doi: 10.1002/art.27233. PubMed PMID: 20039413; PubMed Central PMCID: PMC4548300.
193. Lu LJ, Wallace DJ, Ishimori ML, Scofield RH, Weisman MH. [Review: Male systemic lupus erythematosus: a review of sex disparities in this disease](#). Lupus. 2010 Feb;19(2):119-29. doi: 10.1177/0961203309350755. Epub 2009 Nov 27. Review. PubMed PMID: 19946032; PubMed Central PMCID: PMC7304291.
194. Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW. [A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus](#). Arthritis Rheum. 2009 Sep 15;61(9):1168-78. doi: 10.1002/art.24699. PubMed PMID: 19714604; PubMed Central PMCID: PMC2758229.
195. Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, Chatham WW, Strand V, Weinstein A, Chevrier MR, Zhong ZJ, Freimuth WW. [Novel evidence-based systemic lupus erythematosus responder index](#). Arthritis Rheum. 2009 Sep 15;61(9):1143-51. doi: 10.1002/art.24698. PubMed PMID: 19714615; PubMed Central PMCID: PMC2748175.
196. Belouski SS, Wallace D, Weisman M, Ishimori M, Hendricks L, Zack D, Vincent M, Rasmussen E, Ferbas J, Chung J. [Sample stability and variability of B-cell subsets in blood from healthy subjects and patients with systemic lupus erythematosus](#). Cytometry B Clin Cytom. 2010 Jan;78(1):49-58. doi: 10.1002/cyto.b.20482. PubMed PMID: 19670351.
197. McMahon M, Grossman J, Skaggs B, Fitzgerald J, Sahakian L, Ragavendra N, Charles-Schoeman C, Watson K, Wong WK, Volkmann E, Chen W, Gorn A, Karpouzas G, Weisman M, Wallace DJ, Hahn BH. [Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus](#). Arthritis Rheum. 2009 Aug;60(8):2428-37. doi: 10.1002/art.24677. PubMed PMID: 19644959; PubMed Central PMCID: PMC2753974.
198. Posalski JD, Ishimori MI, Wallace DJ, Weisman MH. [Does mycophenolate mofetil prevent extra-renal flares in systemic lupus erythematosus? results from an observational study of](#)

- [patients in a single practice treated for up to 5 years](#). *Lupus*. 2009 May;18(6):516-21. doi: 10.1177/0961203308099471. PubMed PMID: 19395453.
199. Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, Wallace DJ, Clarke A, Bernatsky S, Isenberg D, Rahman A, Alarcón GS, Gladman DD, Fortin PR, Sanchez-Guerrero J, Romero-Diaz J, Merrill JT, Ginzler E, Bruce IN, Steinsson K, Khamashta M, Petri M, Manzi S, Dooley MA, Ramsey-Goldman R, Van Vollenhoven R, Nived O, Sturfelt G, Aranow C, Kalunian K, Ramos-Casals M, Zoma A, Douglas J, Thompson K, Farewell V. [Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus](#). *Ann Rheum Dis*. 2010 Mar;69(3):529-35. doi: 10.1136/ard.2008.106351. Epub 2009 Apr 8. PubMed PMID: 19359262; PubMed Central PMCID: PMC2929162.
200. Wallace DJ. [New therapies in systemic lupus erythematosus--trials, troubles and tribulations--working towards a solution: part 2--the politically incorrect version](#). *Lupus*. 2009 Feb;18(2):101-3. doi: 10.1177/0961203308100843. PubMed PMID: 19151109.
201. Askanase AD, Wallace DJ, Weisman MH, Tseng CE, Bernstein L, Belmont HM, Seidman E, Ishimori M, Izmirly PM, Buyon JP. [Use of pharmacogenetics, enzymatic phenotyping, and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus](#). *J Rheumatol*. 2009 Jan;36(1):89-95. doi: 10.3899/jrheum.070968. PubMed PMID: 19040311.
202. Petri M, Naqibuddin M, Carson KA, Wallace DJ, Weisman MH, Holliday SL, Sampedro M, Narayana S, Fox PT, Franklin C, Padilla PA, Brey RL. [Brain magnetic resonance imaging in newly diagnosed systemic lupus erythematosus](#). *J Rheumatol*. 2008 Dec;35(12):2348-54. doi: 10.3899/jrheum.071010. Epub 2008 Sep 15. PubMed PMID: 18793003; PubMed Central PMCID: PMC5278777.
203. Petri M, Naqibuddin M, Carson KA, Sampedro M, Wallace DJ, Weisman MH, Holliday SL, Padilla PA, Brey RL. [Cognitive function in a systemic lupus erythematosus inception cohort](#). *J Rheumatol*. 2008 Sep;35(9):1776-81. Epub 2008 Jul 15. PubMed PMID: 18634154.
204. Wallace DJ. [Are there models for predicting accelerated atherogenesis in systemic lupus erythematosus?](#) *Nat Clin Pract Rheumatol*. 2008 Sep;4(9):450-1. doi: 10.1038/ncprheum0876. Epub 2008 Jul 29. PubMed PMID: 18665150.
205. Wallace DJ. [Celecoxib for lupus](#). *Arthritis Rheum*. 2008 Sep;58(9):2923. doi: 10.1002/art.23808. PubMed PMID: 18759281.
206. Sánchez-Guerrero J, Fragoso-Loyo HE, Neuwelt CM, Wallace DJ, Ginzler EM, Sherrer YR, McIlwain HH, Freeman PG, Aranow C, Petri MA, Deodhar AA, Blanton E, Manzi S, Kavanaugh A, Lisse JR, Ramsey-Goldman R, McKay JD, Kivitz AJ, Mease PJ, Winkler AE, Kahl LE, Lee AH, Furie RA, Strand CV, Lou L, Ahmed M, Quarles B, Schwartz KE. [Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy](#). *J Rheumatol*. 2008 Aug;35(8):1567-75. Epub 2008 Jul 15. PubMed PMID: 18634158.
207. Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T, Linnik MD. [Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial](#). *Arthritis Rheum*. 2008 Aug;58(8):2470-80. doi: 10.1002/art.23673. PubMed PMID: 18668592.
208. Wallace DJ. [New European recommendations \(European League Against Rheumatism 2008\) for the management of lupus erythematosus: American perspective](#). *Pol Arch Med Wewn*. 2008 Jul-Aug;118(7-8):402-3. PubMed PMID: 18714734.
209. Wallace DJ. [Additional components to measuring fatigue in patients with systemic lupus erythematosus: comment on the article by the Ad Hoc Committee on systemic lupus erythematosus response criteria for fatigue](#). *Arthritis Rheum*. 2008 Jul 15;59(7):1049; author reply 1049-50. doi: 10.1002/art.23832. PubMed PMID: 18576308.

210. Petri M, Kasitanon N, Singh S, Link K, Magder L, Bae SC, Hanly JG, Nived O, Sturfelt G, van Vollenhoven R, Wallace DJ, Alarcón GS, Adu D, Avila-Casado C, Bernatsky SR, Bruce IN, Clarke AE, Contreras G, Fine DM, Gladman DD, Gordon C, Kalunian KC, Madaio MP, Rovin BH, Sanchez-Guerrero J, Steinsson K, Aranow C, Balow JE, Buyon JP, Ginzler EM, Khamashta MA, Urowitz MB, Dooley MA, Merrill JT, Ramsey-Goldman R, Font J, Tumlin J, Stoll T, Zoma A. [Systemic lupus international collaborating clinics renal activity/response exercise: comparison of agreement in rating renal response](#). *Arthritis Rheum*. 2008 Jun;58(6):1789-95. doi: 10.1002/art.23802. PubMed PMID: 18512814.
211. Petri M, Kasitanon N, Lee SS, Link K, Magder L, Bae SC, Hanly JG, Isenberg DA, Nived O, Sturfelt G, van Vollenhoven R, Wallace DJ, Alarcón GS, Adu D, Avila-Casado C, Bernatsky SR, Bruce IN, Clarke AE, Contreras G, Fine DM, Gladman DD, Gordon C, Kalunian KC, Madaio MP, Rovin BH, Sanchez-Guerrero J, Steinsson K, Aranow C, Balow JE, Buyon JP, Ginzler EM, Khamashta MA, Urowitz MB, Dooley MA, Merrill JT, Ramsey-Goldman R, Font J, Tumlin J, Stoll T, Zoma A. [Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index](#). *Arthritis Rheum*. 2008 Jun;58(6):1784-8. doi: 10.1002/art.23456. PubMed PMID: 18512819.
212. Antoni CE, Kavanaugh A, van der Heijde D, Beutler A, Keenan G, Zhou B, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman DD, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen JS. [Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial \(IMPACT\)](#). *J Rheumatol*. 2008 May;35(5):869-76. Epub 2008 Mar 15. PubMed PMID: 18381786.
213. Hanly JG, Urowitz MB, Su L, Sanchez-Guerrero J, Bae SC, Gordon C, Wallace DJ, Isenberg D, Alarcón GS, Merrill JT, Clarke A, Bernatsky S, Dooley MA, Fortin PR, Gladman D, Steinsson K, Petri M, Bruce IN, Manzi S, Khamashta M, Zoma A, Font J, Van Vollenhoven R, Aranow C, Ginzler E, Nived O, Sturfelt G, Ramsey-Goldman R, Kalunian K, Douglas J, Qiufen Qi K, Thompson K, Farewell V. [Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study](#). *Arthritis Rheum*. 2008 May 15;59(5):721-9. doi: 10.1002/art.23566. PubMed PMID: 18438902; PubMed Central PMCID: PMC4656032.
214. Gordon C, Wallace DJ, Shinada S, Kalunian KC, Forbess L, Braunstein GD, Weisman MH. [Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus](#). *Rheumatology (Oxford)*. 2008 Mar;47(3):334-8. doi: 10.1093/rheumatology/kem342. Epub 2008 Jan 31. PubMed PMID: 18238794.
215. Driver CB, Wallace DJ, Lee JC, Forbess CJ, Pourrabbani S, Minoshima S, Waxman AD, Weisman MH. [Clinical validation of the watershed sign as a marker for neuropsychiatric systemic lupus erythematosus](#). *Arthritis Rheum*. 2008 Mar 15;59(3):332-7. doi: 10.1002/art.23308. PubMed PMID: 18311758.
216. Hanly JG, Urowitz MB, Siannis F, Farewell V, Gordon C, Bae SC, Isenberg D, Dooley MA, Clarke A, Bernatsky S, Gladman D, Fortin PR, Manzi S, Steinsson K, Bruce IN, Ginzler E, Aranow C, Wallace DJ, Ramsey-Goldman R, van Vollenhoven R, Sturfelt G, Nived O, Sanchez-Guerrero J, Alarcón GS, Petri M, Khamashta M, Zoma A, Font J, Kalunian K, Douglas J, Qi Q, Thompson K, Merrill JT. [Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study](#). *Arthritis Rheum*. 2008 Mar;58(3):843-53. doi: 10.1002/art.23218. PubMed PMID: 18311802; PubMed Central PMCID: PMC4656035.
217. Urowitz MB, Gladman D, Ibañez D, Fortin P, Sanchez-Guerrero J, Bae S, Clarke A, Bernatsky S, Gordon C, Hanly J, Wallace D, Isenberg D, Ginzler E, Merrill J, Alarcón GS, Steinsson

- K, Petri M, Dooley MA, Bruce I, Manzi S, Khamashta M, Ramsey-Goldman R, Zoma A, Sturfelt G, Nived O, Maddison P, Font J, van Vollenhoven R, Aranow C, Kalunian K, Stoll T. [Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort](#). *Arthritis Rheum*. 2008 Feb 15;59(2):176-80. doi: 10.1002/art.23353. PubMed PMID: 18240193.
218. Wallace DJ. [Improving the prognosis of SLE without prescribing lupus drugs and the primary care paradox](#). *Lupus*. 2008 Feb;17(2):91-2. doi: 10.1177/0961203307086267. PubMed PMID: 18250130.
219. Wallace DJ, Gotto J. [Hypothesis: bipolar illness with complaints of chronic musculoskeletal pain is a form of pseudofibromyalgia](#). *Semin Arthritis Rheum*. 2008 Feb;37(4):256-9. doi: 10.1016/j.semarthrit.2007.04.008. Epub 2007 Jun 14. Review. PubMed PMID: 17570468.
220. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D. [Reduced B lymphocyte and immunoglobulin levels after atacept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial](#). *Arthritis Rheum*. 2007 Dec;56(12):4142-50. doi: 10.1002/art.23047. PubMed PMID: 18050206.
221. Urowitz MB, Gladman D, Ibañez D, Fortin P, Sanchez-Guerrero J, Bae S, Clarke A, Bernatsky S, Gordon C, Hanly J, Wallace D, Isenberg D, Ginzler E, Merrill J, Alarcon G, Steinsson K, Petri M, Dooley MA, Bruce I, Manzi S, Khamashta M, Ramsey-Goldman R, Zoma A, Sturfelt G, Nived O, Maddison P, Font J, van Vollenhoven R, Aranow C, Kalunian K, Stoll T, Buyon J. [Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort](#). *Lupus*. 2007;16(9):731-5. doi: 10.1177/0961203307081113. PubMed PMID: 17728367.
222. Ishimori ML, Pressman BD, Wallace DJ, Weisman MH. [Posterior reversible encephalopathy syndrome: another manifestation of CNS SLE](#). *Lupus*. 2007;16(6):436-43. doi: 10.1177/0961203307078682. Review. PubMed PMID: 17664235.
223. Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, Weisman M, Wallace DJ, Crues J, Khanna D, Eckel G, Yeilding N, Callegari P, Visvanathan S, Rojas J, Hegedus R, George L, Mamun K, Gilmer K, Troum O. [Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study](#). *Ann Rheum Dis*. 2007 Jul;66(7):893-9. doi: 10.1136/ard.2006.068304. Epub 2007 Apr 5. PubMed PMID: 17412737; PubMed Central PMCID: PMC1955098.
224. Moder KG, Wener MH, Weisman MH, Ishimori ML, Wallace DJ, Buckeridge DL, Homburger HA. [Measurement of antinuclear antibodies by multiplex immunoassay: a prospective, multicenter clinical evaluation](#). *J Rheumatol*. 2007 May;34(5):978-86. Epub 2007 Apr 1. PubMed PMID: 17407218.
225. Wu H, Boackle SA, Hanvivadhanakul P, Ulgiati D, Grossman JM, Lee Y, Shen N, Abraham LJ, Mercer TR, Park E, Hebert LA, Rovin BH, Birmingham DJ, Chang DM, Chen CJ, McCurdy D, Badsha HM, Thong BY, Chng HH, Arnett FC, Wallace DJ, Yu CY, Hahn BH, Cantor RM, Tsao BP. [Association of a common complement receptor 2 haplotype with increased risk of systemic lupus erythematosus](#). *Proc Natl Acad Sci USA*. 2007 Mar 6;104(10):3961-6. doi: 10.1073/pnas.0609101104. Epub 2007 Feb 22. PubMed PMID: 17360460; PubMed Central PMCID: PMC1820691.
226. Panush RS, Wallace DJ, Dorff RE, Engleman EP. [Retraction of the suggestion to use the term "Reiter's syndrome" sixty-five years later: the legacy of Reiter, a war criminal, should not be eponymic honor but rather condemnation](#). *Arthritis Rheum*. 2007 Feb;56(2):693-4. doi: 10.1002/art.22374. PubMed PMID: 17265506.

227. Spiegel J, Ishimori ML, Wallace DJ, Weisman MH. [The lowest surviving birth weight reported in a systemic lupus erythematosus patient: a review of the literature](#). *Lupus*. 2007;16(1):52-5. doi: 10.1177/0961203306072382. Review. PubMed PMID: 17283586.
228. Hanly JG, Urowitz MB, Siannis F, Farewell V, Gordon C, Bae SC, Isenberg D, Dooley MA, Clarke A, Bernatsky S, Gladman D, Fortin PR, Manzi S, Steinsson K, Bruce IN, Ginzler E, Aranow C, Wallace DJ, Ramsey-Goldman R, van Vollenhoven R, Sturfelt G, Nived O, Sanchez-Guerrero J, Alarcón GS, Petri M, Khamashta M, Zoma A, Font J, Kalunian K, Douglas J, Qi Q, Thompson K, Merrill JT. [Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study](#). *Arthritis Rheum*. 2008 Mar;58(3):843-53. doi: 10.1002/art.23218. PubMed PMID: 18311802; PubMed Central PMCID: PMC4656035.
229. Wallace DJ. [What's new in the management of lupus since 2000?](#) *J Clin Rheumatol*. 2006 Dec;12(6):307-13. doi: 10.1097/01.rhu.0000250481.90932.7b. PubMed PMID: 17149066.
230. McMahon M, Grossman J, FitzGerald J, Dahlin-Lee E, Wallace DJ, Thong BY, Badsha H, Kalunian K, Charles C, Navab M, Fogelman AM, Hahn BH. [Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis](#). *Arthritis Rheum*. 2006 Aug;54(8):2541-9. doi: 10.1002/art.21976. PubMed PMID: 16868975.
231. Wallace DJ. [New methods for antinuclear antibody testing: does it cut costs and corners without jeopardizing clinical reliability?](#) *Nat Clin Pract Rheumatol*. 2006 Aug;2(8):410-1. doi: 10.1038/ncprheum0253. PubMed PMID: 16932730.
232. Wallace DJ. [Is mycophenolate mofetil a safe and effective treatment for patients with systemic lupus erythematosus?](#) *Nat Clin Pract Rheumatol*. 2006 Jan;2(1):16-7. doi: 10.1038/ncprheum0089. PubMed PMID: 16932646.
233. Weisman MH, Furst DE, Park GS, Kremer JM, Smith KM, Wallace DJ, Caldwell JR, Dervieux T. [Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis](#). *Arthritis Rheum*. 2006 Feb;54(2):607-12. doi: 10.1002/art.21573. PubMed PMID: 16447238.
234. Liang MH, Schur PH, Fortin P, St Clair EW, Balow JE, Costenbader K, Crofford L, Pablo PD, Dooley MA, Finckh A, Gordon CP, Lundberg IE, Meyrier A, Nived O, Ponticelli C, Schneider MK, Singh A, Wallace DJ. [The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials](#). *Arthritis Rheum*. 2006 Feb;54(2):421-32. doi: 10.1002/art.21625. PubMed PMID: 16453282.
235. Wallace DJ. [Is there a role for cytokine based therapies in fibromyalgia](#). *Curr Pharm Des*. 2006;12(1):17-22. Review. PubMed PMID: 16454720.
236. Vina ER, Fang AJ, Wallace DJ, Weisman MH. [Chronic inflammatory demyelinating polyneuropathy in patients with systemic lupus erythematosus: prognosis and outcome](#). *Semin Arthritis Rheum*. 2005 Dec;35(3):175-84. doi: 10.1016/j.semarthrit.2005.08.008. Review. PubMed PMID: 16325658.
237. Lu CS, Horizon AA, Hwang KK, FitzGerald J, Lin WS, Hahn BH, Wallace DJ, Metzger AL, Weisman MH, Chen PP. [Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome](#). *Arthritis Rheum*. 2005 Dec;52(12):4018-27. doi: 10.1002/art.21485. PubMed PMID: 16320350; PubMed Central PMCID: PMC1950581.
238. Chiou CF, Weisman M, Sherbourne CD, Reyes C, Dylan M, Ofman J, Wallace DJ, Mizutani W, Suarez-Almazor ME. [Measuring preference weights for American college of rheumatology](#)

- [response criteria for patients with rheumatoid arthritis](#). J Rheumatol. 2005 Dec;32(12):2326-9. PubMed PMID: 16331757.
239. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB. [Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis](#). N Engl J Med. 2005 Nov 24;353(21):2219-28. doi: 10.1056/NEJMoa043731. PubMed PMID: 16306519.
240. Wu H, Cantor RM, Graham DS, Lingren CM, Farwell L, Jager PL, Bottini N, Grossman JM, Wallace DJ, Hahn BH, Julkunen H, Hebert LA, Rovin BH, Birmingham DJ, Rioux JD, Yu CY, Kere J, Vyse TJ, Tsao BP. [Association analysis of the R620W polymorphism of protein tyrosine phosphatase PTPN22 in systemic lupus erythematosus families: increased T allele frequency in systemic lupus erythematosus patients with autoimmune thyroid disease](#). Arthritis Rheum. 2005 Aug;52(8):2396-402. doi: 10.1002/art.21223. PubMed PMID: 16052563.
241. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J. [Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial \(IMPACT\)](#). Arthritis Rheum. 2005 Apr;52(4):1227-36. doi: 10.1002/art.20967. PubMed PMID: 15818699.
242. Wallace DJ. [Rapid prevention of vertebral fractures associated with osteoporosis](#). Orthopedics. 2005 Mar;28(3):291-8. doi: 10.3928/0147-7447-20050301-14. Review. PubMed PMID: 15790088.
243. Wallace DJ. [Whiplash: a case of regretting being responsible for naming a condition](#). J Clin Rheumatol. 2005 Feb;11(1):61. doi: 10.1097/01.rhu.0000152196.12665.d8. PubMed PMID: 16357700.
244. Wallace DJ. [The end of an era: a commentary on the demise of the bulletin on rheumatic diseases \(1950-2004\)](#). J Clin Rheumatol. 2004 Dec;10(6):360. doi: 10.1097/01.rhu.0000147139.45003.e7. PubMed PMID: 17043552.
245. Nichol MB, Shi S, Knight TK, Wallace DJ, Weisman MH. [Eligibility, utilization, and costs in a California Medicaid lupus population](#). Arthritis Rheum. 2004 Dec 15;51(6):996-1003. doi: 10.1002/art.20819. PubMed PMID: 15593358.
246. Wallace DJ. [Railway spine, posttraumatic fibromyalgia, and junk science in the courtroom \(ca. 1975\)](#). J Clin Rheumatol. 2004 Oct;10(5):284. doi: 10.1097/01.rhu.0000141512.54213.a7. PubMed PMID: 17043531.
247. Wallace DJ, Hallegua DS. [Fibromyalgia: the gastrointestinal link](#). Curr Pain Headache Rep. 2004 Oct;8(5):364-8. doi: 10.1007/s11916-996-0009-z. Review. PubMed PMID: 15361320.
248. Wallace DJ. [Fever therapy for arthritis](#). J Clin Rheumatol. 2004 Aug;10(4):228. doi: 10.1097/01.rhu.0000135563.29540.cf. PubMed PMID: 17043516.
249. Horizon AA, Wallace DJ. [Risk:benefit ratio of nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus](#). Expert Opin Drug Saf. 2004 Jul;3(4):273-8. doi: 10.1517/14740338.3.4.273. Review. PubMed PMID: 15268645.
250. Wallace DJ, Tumlin JA. [LJP 394 \(abetimus sodium, Riquent\) in the management of systemic lupus erythematosus](#). Lupus. 2004;13(5):323-7. doi: 10.1191/0961203304lu1020oa. PubMed PMID: 15230286.
251. Wallace DJ. [To fibromyalgia nihilists: stop pontificating and test your hypothesis](#). J Rheumatol. 2004 Apr;31(4):632. PubMed PMID: 15088283.
252. Pimentel M, Wallace D, Hallegua D, Chow E, Kong Y, Park S, Lin HC. [A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath](#)

- [testing](#). Ann Rheum Dis. 2004 Apr;63(4):450-2. doi: 10.1136/ard.2003.011502. PubMed PMID: 15020342; PubMed Central PMCID: PMC1754959.
253. Wallace DJ. Advances in the management of systemic lupus erythematosus. Bulletin on the Rheumatic Diseases. 2004;51:(11)1-7.
254. Strand V, Aranow C, Cardiel MH, Alarcón-Segovia D, Furie R, Sherrer Y, Tumlin J, Wallace DJ, Crawford B. [Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo](#). Lupus. 2003;12(9):677-86. doi: 10.1191/0961203303lu440oa. PubMed PMID: 14514130.
255. Wallace DJ. [The use of etanercept and other tumor necrosis factor-alpha blockers in infertility: it's time to get serious](#). J Rheumatol. 2003 Sep;30(9):1897-9. PubMed PMID: 12966586.
256. Chen LX, Eberhardt R, Enzenauer RJ, Horwitz HM, Luk AJ, Melnicoff I, Pepmuellar PH, Queen KT, Ramanujam T, Straka PC, Svava C, Travers R, Wallace D, Watanabe W, Weiss T, Schumacher HR. [A look at rheumatology in China \(2002\)](#). J Clin Rheumatol. 2003 Aug;9(4):228-38. doi: 10.1097/01.rhu.0000081256.86721.d8. PubMed PMID: 17041463.
257. Wallace DJ. [Apheresis for rheumatic and other autoimmune conditions: where do we stand?](#) Ther Apher Dial. 2003 Apr;7(2):143-4. doi: 10.1046/j.1526-0968.2003.00046.x. PubMed PMID: 12918932.
258. Wallace DJ. [Historical vignette: Raynaud's phenomenon as perceived by musculoskeletal specialists \(1862-1957\)](#). J Clin Rheumatol. 2003 Apr;9(2):87. doi: 10.1097/00124743-200304000-00004. PubMed PMID: 17041435.
259. Wallace DJ. [When thought leaders mislead: "discoid lupus is not related to SLE"](#). J Clin Rheumatol. 2003 Apr;9(2):98. doi: 10.1097/00124743-200304000-00008. PubMed PMID: 17041439.
260. Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, Vaishnav A. [A short course of BG9588 \(anti-CD40 ligand antibody\) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis](#). Arthritis Rheum. 2003 Mar;48(3):719-27. doi: 10.1002/art.10856. PubMed PMID: 12632425.
261. Wallace DJ, Weisman MH. [The physician Hans Reiter as prisoner of war in Nuremberg: a contextual review of his interrogations \(1945-1947\)](#). Semin Arthritis Rheum. 2003 Feb;32(4):208-30. doi: 10.1053/sarh.2003.49995. PubMed PMID: 12621585.
262. Wallace DJ. [Pyridostigmine for fibromyalgia: comment on the article by Paiva and a historical vignette](#). Arthritis Rheum. 2003 Jan;48(1):277-8. doi: 10.1002/art.10708. PubMed PMID: 12528139.
263. Tsao BP, Cantor RM, Grossman JM, Kim SK, Strong N, Lau CS, Chen CJ, Shen N, Ginzler EM, Goldstein R, Kalunian KC, Arnett FC, Wallace DJ, Hahn BH. [Linkage and interaction of loci on 1q23 and 16q12 may contribute to susceptibility to systemic lupus erythematosus](#). Arthritis Rheum. 2002 Nov;46(11):2928-36. doi: 10.1002/art.10590. PubMed PMID: 12428234.
264. Tsao BP, Grossman JM, Riemekasten G, Strong N, Kalsi J, Wallace DJ, Chen CJ, Lau CS, Ginzler EM, Goldstein R, Kalunian KC, Harley JB, Arnett FC, Hahn BH, Cantor RM. [Familiality and co-occurrence of clinical features of systemic lupus erythematosus](#). Arthritis Rheum. 2002 Oct;46(10):2678-85. doi: 10.1002/art.10519. PubMed PMID: 12384927.
265. Wallace DJ. [Silicone breast implants do not cause rheumatic diseases, but can they influence them?](#) Arthritis Rheum. 2002 Sep;46(9):2545. doi: 10.1002/art.10376. PubMed PMID: 12355513.

266. Silver DS, Wallace DJ. [The management of fibromyalgia-associated syndromes](#). Rheum Dis Clin North Am. 2002 May;28(2):405-17. doi: 10.1016/s0889-857x(02)00003-0. Review. PubMed PMID: 12122927.
267. Lander SA, Wallace DJ, Weisman MH. [Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE](#). Lupus. 2002;11(6):340-7. doi: 10.1191/0961203302lu204oa. Review. PubMed PMID: 12139371.
268. Solsky MA, Wallace DJ. [New therapies in systemic lupus erythematosus](#). Best Pract Res Clin Rheumatol. 2002 Apr;16(2):293-312. doi: 10.1053/berh.2001.0227. Review. PubMed PMID: 12041955.
269. Wallace DJ. [Management of lupus erythematosus: recent insights](#). Curr Opin Rheumatol. 2002 May;14(3):212-9. doi: 10.1097/00002281-200205000-00003. Review. PubMed PMID: 11981315.
270. Wallace DJ. [Systemic lupus erythematosus](#). Drugs Today (Barc). 2002 Apr;38(4):259-63. doi: 10.1358/dot.2002.38.4.765369. Review. PubMed PMID: 12532194.
271. Wallace DJ. [Clinical correlates of avascular necrosis in systemic lupus erythematosus](#). J Rheumatol. 2001 Oct;28(10):2365-6. PubMed PMID: 11669186.
272. Dequet CR, Wallace DJ. [Novel therapies in the treatment of systemic lupus erythematosus](#). Curr Opin Investig Drugs. 2001 Aug;2(8):1045-53. PubMed PMID: 11892912.
273. Remer CF, Weisman MH, Wallace DJ. [Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study](#). Lupus. 2001;10(7):480-3. doi: 10.1191/096120301678416033. PubMed PMID: 11480845.
274. Wallace DJ, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman MH. [Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study](#). Rheumatology (Oxford). 2001 Jul;40(7):743-9. doi: 10.1093/rheumatology/40.7.743. PubMed PMID: 11477278.
275. Wallace DJ. [Antimalarials--the 'real' advance in lupus](#). Lupus. 2001;10(6):385-7. doi: 10.1191/096120301678646092. Review. PubMed PMID: 11434570.
276. Wallace DJ, Hallegua DS. [Quality-of-life, legal-financial, and disability issues in fibromyalgia](#). Curr Pain Headache Rep. 2001 Aug;5(4):313-9. doi: 10.1007/s11916-001-0020-3. Review. PubMed PMID: 11403734.
277. Honda M, Mengesha E, Albano S, Nichols WS, Wallace DJ, Metzger A, Klinenberg JR, Linker-Israeli M. [Telomere shortening and decreased replicative potential, contrasted by continued proliferation of telomerase-positive CD8+CD28\(lo\) T cells in patients with systemic lupus erythematosus](#). Clin Immunol. 2001 May;99(2):211-21. doi: 10.1006/clim.2001.5023. PubMed PMID: 11318593.
278. Linker-Israeli M, Elstner E, Klinenberg JR, Wallace DJ, Koeffler HP. [Vitamin D\(3\) and its synthetic analogs inhibit the spontaneous in vitro immunoglobulin production by SLE-derived PBMC](#). Clin Immunol. 2001 Apr;99(1):82-93. doi: 10.1006/clim.2000.4998. PubMed PMID: 11286544.
279. Wallace DJ. [Apheresis for lupus erythematosus: state of the art](#). Lupus. 2001;10(3):193-6. doi: 10.1191/096120301671920760. Review. PubMed PMID: 11315351.
280. Wallace DJ. [Clinical and pharmacological experience with LJP-394](#). Expert Opin Investig Drugs. 2001 Jan;10(1):111-7. doi: 10.1517/13543784.10.1.111. Review. PubMed PMID: 11116284.
281. Panush RS, Mihailescu GD, Gornisiewicz MT, Sutaria SH, Wallace DJ. [Sex and arthritis](#). Bull Rheum Dis. 2000 Jul;49(7):1-4. Review. PubMed PMID: 11126624.
282. Tsao BP, Cantor RM, Grossman JM, Shen N, Teophilov NI, Wallace DJ, Arnett FC, Hartung K, Goldstein R, Kalunian KC, Hahn BH, Rotter JI. PARP alleles within the linked chromosomal

- region are associated with systemic lupus erythematosus (Reply to letters). *J Clin Invest*. 2000;105:1501-6.
283. Linker-Israeli M, Wallace DJ, Prehn J, Michael D, Honda M, Taylor KD, Paul-Labrador M, Fischel-Ghodsian N, Fraser PA, Klinenberg JR. [Association of IL-6 gene alleles with systemic lupus erythematosus \(SLE\) and with elevated IL-6 expression](#). *Genes Immun*. 1999 Sep;1(1):45-52. doi: 10.1038/sj.gene.6363631. PubMed PMID: 11197305.
 284. Hallegua DS, Wallace DJ. [Gastrointestinal manifestations of systemic lupus erythematosus](#). *Curr Opin Rheumatol*. 2000 Sep;12(5):379-85. doi: 10.1097/00002281-200009000-00005. Review. PubMed PMID: 10990173.
 285. Neumann K, Wallace DJ, Metzger AL. [Osteoporosis--less than expected in patients with scleroderma?](#) *J Rheumatol*. 2000 Jul;27(7):1822-3. PubMed PMID: 10914882.
 286. Wallace DJ, Salonen EM, Avannis-Aghajani E, Morris R, Metzger AL, Pashinian N. [Anti-telomere antibodies in systemic lupus erythematosus: a new ELISA test for anti-DNA with potential pathogenetic implications](#). *Lupus*. 2000;9(5):328-32. doi: 10.1191/096120300678828343. PubMed PMID: 10878723.
 287. Hallegua D, Wallace DJ, Metzger AL, Rinaldi RZ, Klinenberg JR. [Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature](#). *Lupus*. 2000;9(4):241-51. doi: 10.1191/096120300680198935. Review. PubMed PMID: 10866094.
 288. Hallegua DS, Wallace DJ. [How accelerated atherosclerosis in SLE has changed our management of the disorder](#). *Lupus*. 2000;9(3):228-31. doi: 10.1191/096120300678828181. Review. PubMed PMID: 10805493.
 289. Wallace DJ. [Is there a role for quinacrine \(Atabrine\) in the new millennium?](#) *Lupus*. 2000;9(2):81-2. doi: 10.1191/096120300678828163. PubMed PMID: 10787002.
 290. Wallace DJ, Weisman M. [Should a war criminal be rewarded with eponymous distinction?: the double life of Hans Reiter \(1881-1969\)](#). *J Clin Rheumatol*. 2000 Feb;6(1):49-54. PubMed PMID: 19078450.
 291. Pachinian N, Wallace DJ, Klinenberg JR. [Mycophenolate mofetil for systemic lupus erythematosus](#). *J Clin Rheumatol*. 1999 Dec;5(6):374-6. doi: 10.1097/00124743-199912000-00019. PubMed PMID: 19078438.
 292. Wallace DJ. [Leukocytapheresis and rheumatoid arthritis: comment on the article by Hidaka et al](#). *Arthritis Rheum*. 1999 Oct;42(10):2255-6. doi: 10.1002/1529-0131(199910)42:10<2255::AID-ANR34>3.0.CO;2-X. PubMed PMID: 10524704.
 293. Wallace DJ. [What constitutes a mortality study? Comment on the article by Uramoto et al](#). *Arthritis Rheum*. 1999 Sep;42(9):2021-2. doi: 10.1002/1529-0131(199909)42:9<2021::aid-anr39>3.0.co;2-6. PubMed PMID: 10513827.
 294. Wallace DJ. [Lupus for the non-rheumatologist](#). *Bull Rheum Dis*. 1999;48(9):1-4. PubMed PMID: 10638034.
 295. Gladman DD, Urowitz MB, Esdaile JM, Hahn BH, Klippel JH, Lahita R, Liang MH, Schur P, Petri M, Wallace D. [Guidelines for referral and management of systemic lupus erythematosus in adults](#). American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. *Arthritis Rheum*. 1999 Sep;42(9):1785-96. doi: 10.1002/1529-0131(199909)42:9<1785::AID-ANR1>3.0.CO;2-#. PubMed PMID: 10513791.
 296. Wallace DJ. [Advances in the management of systemic lupus erythematosus](#). *Saudi Med J*. 1999 Jul;20(7):489-90. PubMed PMID: 27632447.
 297. Wallace DJ, Shapiro S, Panush RS. [Update on fibromyalgia syndrome](#). *Bull Rheum Dis*. 1999;48(5):1-4. Review. PubMed PMID: 10526425.

298. Wallace DJ. [Apheresis for lupus erythematosus](#). *Lupus*. 1999;8(3):174-80. doi: 10.1191/096120399678847669. Review. PubMed PMID: 10342709.
299. Tsao BP, Cantor RM, Grossman JM, Shen N, Teophilov NT, Wallace DJ, Arnett FC, Hartung K, Goldstein R, Kalunian KC, Hahn BH, Rotter JI. [PARP alleles within the linked chromosomal region are associated with systemic lupus erythematosus](#). *J Clin Invest*. 1999 Apr;103(8):1135-40. doi: 10.1172/JCI5967. PubMed PMID: 10207165; PubMed Central PMCID: PMC408279.
300. Wallace DJ, Lyon I. [Pierre Cazenave and the first detailed modern description of lupus erythematosus](#). *Semin Arthritis Rheum*. 1999 Apr;28(5):305-13. doi: 10.1016/s0049-0172(99)80014-6. PubMed PMID: 10342387.
301. Linker-Israeli M, Honda M, Nand R, Mandyam R, Mengesha E, Wallace DJ, Metzger A, Beharier B, Klinenberg JR. [Exogenous IL-10 and IL-4 down-regulate IL-6 production by SLE-derived PBMC](#). *Clin Immunol*. 1999 Apr;91(1):6-16. doi: 10.1006/clim.1998.4680. PubMed PMID: 10219249.
302. Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. [The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes](#). *Arthritis Rheum*. 1999 Apr;42(4):599-608. doi: 10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F. Review. PubMed PMID: 10211873.
303. Wallace DJ. [What constitutes a fibromyalgia expert?](#) *Arthritis Care Res*. 1999 Apr;12(2):82-4. doi: 10.1002/1529-0131(199904)12:2<82::aid-art2>3.0.co;2-7. PubMed PMID: 10513495.
304. Shai R, Quismorio FP Jr, Li L, Kwon OJ, Morrison J, Wallace DJ, Neuwelt CM, Brautbar C, Gauderman WJ, Jacob CO. [Genome-wide screen for systemic lupus erythematosus susceptibility genes in multiplex families](#). *Hum Mol Genet*. 1999 Apr;8(4):639-44. doi: 10.1093/hmg/8.4.639. PubMed PMID: 10072432.
305. Wallace DJ, Goldfinger D, Pepkowitz SH, Fichman M, Metzger AL, Schroeder JO, Euler HH. [Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis](#). *J Clin Apher*. 1998;13(4):163-6. doi: 10.1002/(sici)1098-1101(1998)13:4<163::aid-jca4>3.0.co;2-1. PubMed PMID: 9886795.
306. Wallace DJ. [Don't dumb down lupus patient literature!](#) *J Rheumatol*. 1998 Aug;25(8):1649-50. PubMed PMID: 9712116.
307. Post S, Wallace DJ. [A prevalence survey of lupus in moorpark, california is there any evidence for a lupus cluster?](#) *J Clin Rheumatol*. 1998 Jun;4(3):137-40. doi: 10.1097/00124743-199806000-00008. PubMed PMID: 19078273.
308. Cozen L, Wallace DJ. [Avascular necrosis in systemic lupus erythematosus: clinical associations and a 47-year perspective](#). *Am J Orthop (Belle Mead NJ)*. 1998 May;27(5):352-4. PubMed PMID: 9604106.
309. Wallace DJ. [A reason for the rarity of male lupus](#). *Lupus*. 1998;7(1):60. doi: 10.1191/096120398678919697. PubMed PMID: 9493153.
310. Cozen L, Wallace DJ. [Risk factors for avascular necrosis in systemic lupus erythematosus](#). *J Rheumatol*. 1998 Jan;25(1):188. PubMed PMID: 9458231.
311. Tsao BP, Cantor RM, Kalunian KC, Wallace DJ, Hahn BH, Rotter JI. [The genetic basis of systemic lupus erythematosus](#). *Proc Assoc Am Physicians*. 1998 Mar-Apr;110(2):113-7. Review. PubMed PMID: 9542766.
312. Wallace DJ. [Rethinking somatization](#). *Ann Intern Med*. 1997 Dec 15;127(12):1132; author reply 1133-4. doi: 10.7326/0003-4819-127-12-199712150-00028. PubMed PMID: 9412326.

313. Wallace DJ, Druzin M, Lahita RG. 'Expert opinion' versus hard science: comment on the review by Wallace et al: reply. *Arthritis Rheum.* 1997;40:1910-1.
314. Wallace DJ. [Chloroquine and cytokines.](#) *J Rheumatol.* 1997 Oct;24(10):2051-2. PubMed PMID: 9330956.
315. Clegg DO, Dietz F, Duffy J, Willkens RF, Hurd E, Germain BF, Wall B, Wallace DJ, Bell CL, Sleckman J. [Safety and efficacy of hydroxychloroquine as maintenance therapy for rheumatoid arthritis after combination therapy with methotrexate and hydroxychloroquine.](#) *J Rheumatol.* 1997 Oct;24(10):1896-902. PubMed PMID: 9330929.
316. Tsao BP, Wallace DJ. [Genetics of systemic lupus erythematosus.](#) *Curr Opin Rheumatol.* 1997 Sep;9(5):377-9. doi: 10.1097/00002281-199709000-00001. Review. PubMed PMID: 9309191.
317. Wallace DJ, Druzin ML, Lahita RG. [Clinical rheumatologic applications of reproductive immunology.](#) Facts, fiction, and fancy. *Arthritis Rheum.* 1997 Feb;40(2):209-16. doi: 10.1002/art.1780400205. Review. PubMed PMID: 9041932.
318. Wallace DJ. [Is hydroxychloroquine destined for a larger role in managing systemic lupus erythematosus?](#) *J Clin Rheumatol.* 1997 Feb;3(1):1-2. doi: 10.1097/00124743-199702000-00001. PubMed PMID: 19078109.
319. Wallace DJ. [The fibromyalgia syndrome.](#) *Ann Med.* 1997 Feb;29(1):9-21. doi: 10.3109/07853899708998739. Review. PubMed PMID: 9073320.
320. Tsao BP, Cantor RM, Kalunian KC, Chen CJ, Badsha H, Singh R, Wallace DJ, Kitridou RC, Chen SL, Shen N, Song YW, Isenberg DA, Yu CL, Hahn BH, Rotter JJ. [Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus.](#) *J Clin Invest.* 1997 Feb 15;99(4):725-31. doi: 10.1172/JCI119217. PubMed PMID: 9045876; PubMed Central PMCID: PMC507856.
321. Wallace DJ. Rheumatology case and comment going to extremities. *Patient Care.* 1997 Jan 15;31:145.
322. Barthel HR, Meier LG, Wallace DJ. [\[Antimalarial agents in rheumatic diseases. New therapeutic aspects of an old medication\].](#) *Dtsch Med Wochenschr.* 1996 Dec 13;121(50):1576-82. doi: 10.1055/s-2008-1043185. Review. PubMed PMID: 8998931.
323. Wallace DJ. Quismorio FPQ, geographic clusters of systemic lupus erythematosus: reply. *Arthritis Rheum.* 1996;39:1936-7.
324. Wallace DJ, Basbug E, Schwartz E, Clements P, Metzger AL, Furst DE, Klinenberg JR. [A comparison of systemic lupus erythematosus and scleroderma patients with and without silicone breast implants.](#) *J Clin Rheumatol.* 1996 Oct;2(5):257-61. doi: 10.1097/00124743-199610000-00005. PubMed PMID: 19078080.
325. Linker-Israeli M, Wallace DJ, Prehn JL, Nand R, Li L, Klinenberg JR. [A greater variability in the 3' flanking region of the IL-6 gene in patients with systemic lupus erythematosus \(SLE\).](#) *Autoimmunity.* 1996;23(3):199-209. doi: 10.3109/08916939608995343. PubMed PMID: 8879455.
326. Wallace DJ. [The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review.](#) *Lupus.* 1996 Jun;5 Suppl 1:S59-64. Review. PubMed PMID: 8803913.
327. Wallace DJ. [The history of antimalarials.](#) *Lupus.* 1996 Jun;5 Suppl 1:S2-3. PubMed PMID: 8803902.
328. Wallace DJ, Quismorio FP Jr. [The elusive search for geographic clusters of systemic lupus erythematosus. Critical review.](#) *Arthritis Rheum.* 1995 Nov;38(11):1564-7. doi: 10.1002/art.1780381107. Review. PubMed PMID: 7488276.
329. Wallace DJ. *Scientia. Arthritis/Rheumatology.* 1995; 1(1-4).

330. Neumann K, Wallace DJ, Azen C, Nessim S, Fichman M, Metzger AL, Klinenberg JR. [Lupus in the 1980s: III. Influence of clinical variables, biopsy, and treatment on the outcome in 150 patients with lupus nephritis seen at a single center.](#) Semin Arthritis Rheum. 1995 Aug;25(1):47-55. doi: 10.1016/s0049-0172(95)80017-4. PubMed PMID: 8525390.
331. Wallace DJ. [Lupus erythematosus cell test.](#) Am J Clin Pathol. 1995 Jul;104(1):110-1. doi: 10.1093/ajcp/104.1.110. PubMed PMID: 7611174.
332. Wallace DJ. [Clinical applications.](#) J Clin Apher. 1995;10(2):104-6. doi: 10.1002/jca.2920100212. PubMed PMID: 7592517.
333. Wallace DJ, Schwartz E, Chi-Lin H, Peter JB. [The 'rule out lupus' rheumatology consultation: clinical outcomes and perspectives.](#) J Clin Rheumatol. 1995 Jun;1(3):158-64. PubMed PMID: 19077969.
334. Barthel HR, Wallace DJ, Klinenberg JR. [Liver transplantation in patients with systemic lupus erythematosus.](#) Lupus. 1995 Feb;4(1):15-7. doi: 10.1177/096120339500400104. PubMed PMID: 7767333.
335. Wallace DJ. [Prevalence of fibromyalgia in systemic lupus erythematosus patients: comment on the article by Middleton et al.](#) Arthritis Rheum. 1995 Jun;38(6):872. doi: 10.1002/art.1780380627. PubMed PMID: 7779136.
336. Wallace DJ, Silverman S, Goldstein J, Hughes D. [Use of hyperbaric oxygen in rheumatic diseases: case report and critical analysis.](#) Lupus. 1995 Jun;4(3):172-5. doi: 10.1177/096120339500400302. Review. PubMed PMID: 7655485.
337. Wallace DJ, Metzger AL. [Successful use of nitrogen mustard for cyclophosphamide resistant diffuse proliferative lupus glomerulonephritis: report of 2 cases.](#) J Rheumatol. 1995 Apr;22(4):801-2. PubMed PMID: 7791198.
338. Wallace DJ. [Controversy over sclerotherapy for malignant pleural effusions.](#) Ann Intern Med. 1994 Jul 15;121(2):151. doi: 10.7326/0003-4819-121-2-199407150-00020. PubMed PMID: 8017734.
339. Harley JB, Sheldon P, Neas B, Murphy S, Wallace DJ, Scofield RH, Shaver TS, Moser KL. [Systemic lupus erythematosus: considerations for a genetic approach.](#) J Invest Dermatol. 1994 Nov;103(5 Suppl):144S-9S. doi: 10.1111/1523-1747.ep12399472. Review. PubMed PMID: 7963678.
340. Wallace DJ, Metzger AL. [Can an earthquake cause flares of rheumatoid arthritis or lupus nephritis?](#) Arthritis Rheum. 1994 Dec;37(12):1826-8. doi: 10.1002/art.1780371220. PubMed PMID: 7986232.
341. Wallace DJ, Lin HC, Shen GQ, Peter JB. [Antibodies to histone \(H2A-H2B\)-DNA complexes in the absence of antibodies to double-stranded DNA or to \(H2A-H2B\) complexes are more sensitive and specific for scleroderma-related disorders than for lupus.](#) Arthritis Rheum. 1994 Dec;37(12):1795-7. doi: 10.1002/art.1780371213. PubMed PMID: 7986226.
342. Wallace DJ. [Classifying cutaneous lupus erythematosus.](#) Int J Dermatol. 1994 Jul;33(7):524. doi: 10.1111/j.1365-4362.1994.tb02881.x. PubMed PMID: 7928049.
343. Wallace DJ, Schwartz E. [Breast implants and connective-tissue diseases.](#) N Engl J Med. 1994 Nov 3;331(18):1232-3; author reply 1233-4. PubMed PMID: 7935670.
344. Linker-Israeli M, Hyun S, Ozeri-Chen T, Wallace DJ, Banks K, Klinenberg JR. [Elevated in vivo and in vitro secretion of CD8-alpha molecules in patients with systemic lupus erythematosus.](#) J Immunol. 1994 Mar 15;152(6):3158-67. PubMed PMID: 8144910.
345. Wallace DJ, Linker-Israeli M, Hyun S, Klinenberg JR, Stecher V. [The effect of hydroxychloroquine therapy on serum levels of immunoregulatory molecules in patients with systemic lupus erythematosus.](#) J Rheumatol. 1994 Feb;21(2):375-6. PubMed PMID: 8182661.

346. Wallace DJ. [Persistent eosinophilia in 2 patients with eosinophilia-myalgia syndrome](#). Arthritis Rheum. 1993 Oct;36(10):1488. doi: 10.1002/art.1780361025. PubMed PMID: 8216410.
347. Barthel HR, Wallace DJ. [False-positive human immunodeficiency virus testing in patients with lupus erythematosus](#). Semin Arthritis Rheum. 1993 Aug;23(1):1-7. doi: 10.1016/s0049-0172(05)80021-6. Review. PubMed PMID: 8235661.
348. Wallace DJ. [Plasmapheresis in lupus](#). Lupus. 1993 Jun;2(3):141-3. doi: 10.1177/096120339300200302. PubMed PMID: 8369804.
349. Wallace DJ. Autologous pregnancy plasma transfusion in RA. Annals of the Rheumatic Diseases. 1993;52:316.
350. Wallace DJ, Linker-Israeli M, Metzger AL, Stecher VJ. [The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE](#). Lupus. 1993 Feb;2 Suppl 1:S13-5. Review. PubMed PMID: 8485565.
351. Robinson JA. [Plasmapheresis for lupus nephritis](#). N Engl J Med. 1992 Oct 1;327(14):1028-9; author reply 1029-30. doi: 10.1056/NEJM199210013271412. PubMed PMID: 1472252.
352. Wallace DJ. [A critique of the NIH lupus nephritis survey](#). Arthritis Rheum. 1992 May;35(5):605-7. doi: 10.1002/art.1780350520. PMID: 1575797.
353. Wallace DJ, Metzger AL. [Positive LE preps and negative ANA in brothers with SLE: is there still a role for the LE cell prep? A literature review](#). J Rheumatol. 1992 Mar;19(3):497. PubMed PMID: 1374474.
354. Wallace DJ, Pistiner M, Nessim S, Metzger AL, Klinenberg JR. [Cutaneous lupus erythematosus without systemic lupus erythematosus: clinical and laboratory features](#). Semin Arthritis Rheum. 1992 Feb;21(4):221-6. doi: 10.1016/0049-0172(92)90052-f. PMID: 1570517.
355. Chong P, Matzner WL, Yamiguchi D, Wallace D, Klinenberg JR, Jordan SC. [Inhibition of protein-kinase C in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: effect on spontaneous immunoglobulin production](#). Autoimmunity. 1991;10(3):227-31. doi: 10.3109/08916939109001893. PubMed PMID: 1756225.
356. Wallace DJ. [Active idiopathic systemic lupus erythematosus in a 90-year-old woman requiring corticosteroid therapy](#). J Rheumatol. 1991 Oct;18(10):1611-2. PMID: 1765990.
357. Pistiner M, Wallace DJ, Nessim S, Metzger AL, Klinenberg JR. [Lupus erythematosus in the 1980s: a survey of 570 patients](#). Semin Arthritis Rheum. 1991 Aug;21(1):55-64. doi: 10.1016/0049-0172(91)90057-7. PMID: 1948102.
358. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. [Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis](#). J Immunol. 1991 Jul 1;147(1):117-23. PubMed PMID: 2051017.
359. Clark WF, Dau PC, Euler HH, Guillevin L, Hasford J, Heer AH, Jones JV, Kashgarian M, Knatterud G, Lockwood CM, et al. [Plasmapheresis and subsequent pulse cyclophosphamide versus pulse cyclophosphamide alone in severe lupus: design of the LPSG trial](#). Lupus Plasmapheresis Study Group (LPSG). J Clin Apher. 1991;6(1):40-7. doi: 10.1002/jca.2920060109. PMID: 2045382.
360. Wallace DJ. [Lupus, acquired immunodeficiency syndrome, and antimalarial agents](#). Arthritis Rheum. 1991 Mar;34(3):372-3. doi: 10.1002/art.1780340318. PubMed PMID: 2003861.
361. Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA. [Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids](#). Am J Med. 1990 Sep;89(3):322-6. doi: 10.1016/0002-9343(90)90345-e. PMID: 2393036.
362. Wallace DJ. [Managing arthritis in the elderly](#). AORN J. 1990 Apr;51(4):1074, 1076-7, 1080. PMID: 2181931.

363. Wallace DJ. [Genitourinary manifestations of fibrositis: an increased association with the female urethral syndrome.](#) J Rheumatol. 1990 Feb;17(2):238-9. PubMed PMID: 2319522.
364. Chong PJ, Matzner WL, Wallace DJ, Klinenberg JR, Toyoda M, Jordan SC. [1,25 dihydroxyvitamin-D3 regulation of immunoglobulin production in peripheral blood mononuclear cells of patients with systemic lupus erythematosus.](#) J Autoimmun. 1989 Dec;2(6):861-7. doi: 10.1016/0896-8411(89)90012-7. PMID: 2695100.
365. Wallace DJ, Bowman RL, Wormsley SB, Peter JB. [Cytokines and immune regulation in patients with fibrositis.](#) Arthritis Rheum. 1989 Oct;32(10):1334-5. doi: 10.1002/anr.1780321024. Erratum in: Arthritis Rheum 1989 Dec;32(12):1607. PMID: 2679562.
366. Wallace DJ, Metzger AL, Klinenberg JR. [NSAID usage patterns by rheumatologists in the treatment of SLE.](#) J Rheumatol. 1989 Apr;16(4):557-60. PMID: 2664175.
367. Wallace DJ. [The use of quinacrine \(Atabrine\) in rheumatic diseases: a reexamination.](#) Semin Arthritis Rheum. 1989 May;18(4):282-96. doi: 10.1016/0049-0172(89)90050-4. PMID: 2658071.
368. Wallace DJ, Brachman M, Feldman G, Reichman R, Klinenberg JR. [Quantitative computerized joint scanning in rheumatoid arthritis: an accurate reproducible method of quantitating synovitis--preliminary report.](#) Mt Sinai J Med. 1989 Jan;56(1):46-52. PMID: 2784182.
369. Wallace DJ. [Comment on the article by Studenski et al.](#) Arthritis Rheum. 1988 Sep;31(9):1208-9. doi: 10.1002/art.1780310922. PubMed PMID: 3422019.
370. Wigfall DR, Sakai RS, Wallace DJ, Jordan SC. [Interleukin-2 receptor expression in peripheral blood lymphocytes from systemic lupus erythematosus patients: relationship to clinical activity.](#) Clin Immunol Immunopathol. 1988 Jun;47(3):354-62. doi: 10.1016/s0090-1229(88)80012-6. PMID: 3131053.
371. Wallace DJ, Goldfinger D, Savage G, Nichols S, Goodman D, Fichman M, Stewart M, Klinenberg JR. [Predictive value of clinical, laboratory, pathologic, and treatment variables in steroid/immunosuppressive resistant lupus nephritis.](#) J Clin Apher. 1988;4(1):30-4. doi: 10.1002/jca.2920040107. PMID: 3391988.
372. Wallace DJ, Margolin K, Waller P. [Fibromyalgia and interleukin-2 therapy for malignancy.](#) Ann Intern Med. 1988 Jun;108(6):909. doi: 10.7326/0003-4819-108-6-909_1. PMID: 3259412.
373. Wallace DJ. [Comment on the article by Lahita et al, on their finding of low plasma androgen levels in systemic lupus erythematosus \(SLE\) patients.](#) Arthritis Rheum. 1988 Jan;31(1):150-2. doi: 10.1002/art.1780310128. PubMed PMID: 3345227.
374. Weidmann CE, Wallace DJ, Peter JB, Knight PJ, Bear MB, Klinenberg JR. [Studies of IgG, IgM and IgA antiphospholipid antibody isotypes in systemic lupus erythematosus.](#) J Rheumatol. 1988 Jan;15(1):74-9. PMID: Weidmann CE, Wallace DJ, Peter JB, Knight PJ, Bear MB, Klinenberg JR. Studies of IgG, IgM and IgA antiphospholipid antibody isotypes in systemic lupus erythematosus. J Rheumatol. 1988 Jan;15(1):74-9. PMID: 3351842.
375. Wallace DJ. [Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?](#) Arthritis Rheum. 1987 Dec;30(12):1435-6. doi: 10.1002/art.1780301219. PMID: 3435574.
376. Wallace DJ, Goldfinger D, Klinenberg JR. [Use of autologous pregnancy plasma to treat a flare of juvenile rheumatoid arthritis: case report and literature review.](#) J Clin Apher. 1987;3(4):216-8. doi: 10.1002/jca.2920030405. PMID: 3316195.
377. Adelman DC, Wallace DJ, Klinenberg JR. [Thirty-four-year delayed-onset lupus nephritis: a case report.](#) Arthritis Rheum. 1987 Apr;30(4):479-80. doi: 10.1002/art.1780300423. PMID: 3580016.

378. Wallace DJ. [The role of stress and trauma in rheumatoid arthritis and systemic lupus erythematosus](#). Semin Arthritis Rheum. 1987 Feb;16(3):153-7. doi: 10.1016/0049-0172(87)90018-7. PMID: 3547654.
379. Wallace DJ. [Plasmapheresis in rheumatic diseases](#). Biomed Pharmacother. 1986;40(8):284-6. PMID: 3493039.
380. Wallace DJ. [Systemic lupus erythematosus, rheumatology and medical literature: current trends](#). J Rheumatol. 1985 Oct;12(5):913-5. PMID: 3910833.
381. Wallace DJ. [Immunofluorescence and fibromyalgia](#). Arthritis Rheum. 1985 Jul;28(7):836-7. doi: 10.1002/art.1780280720. PMID: 3893443.
382. Wallace DJ, Metzger AL, White KK. [Combination immunosuppressive treatment of steroid-resistant dermatomyositis/polymyositis](#). Arthritis Rheum. 1985 May;28(5):590-2. doi: 10.1002/art.1780280523. PubMed PMID: 4004968.
383. Wallace DJ, Medici MA, Nichols S, Klinenberg JR, Bick M, Gatti R, Goldfinger D. [Plasmapheresis versus lymphoplasmapheresis in rheumatoid arthritis: immunologic comparisons and literature review](#). J Clin Apher. 1984;2(2):184-9. doi: 10.1002/jca.2920020207. PMID: 6536669.
384. Wallace DJ. [Fibromyalgia: unusual historical aspects and new pathogenic insights](#). Mt Sinai J Med. 1984 Apr;51(2):124-31. PubMed PMID: 6374435.
385. Wallace DJ, Barnett EV, Nichols S, Hancock W, Vibert G, Curd J, Klinenberg JR, Goldfinger D. [Immunologic dynamics in cryopheresis for rheumatoid arthritis](#). J Rheumatol. 1983 Dec;10(6):894-900. PubMed PMID: 6607341.
386. Wallace DJ, Klinenberg JR, Goldfinger D. Plasmapheresis for rheumatoid arthritis. N Eng J Med. 1983;309:986-7.
387. Krakauer RS, Wysenbeek AJ, Wallace DJ, Jones JV, Smith JW, Malchesky P, Greenstreet R, Goldfinger D, Klinenberg JR, McLeod B, Nose Y. [Therapeutic trial of cryofiltration in patients with rheumatoid arthritis](#). Am J Med. 1983 Jun;74(6):951-5. doi: 10.1016/0002-9343(83)90788-x. PMID: 6407307.
388. Wallace DJ, Hamburger MI, Goldfinger D, Bennett RS, Klinenberg JR. Apheresis perspective for rheumatoid arthritis. Plasma Ther. 1982;3:395-400.
389. Wallace DJ, Goldfinger D, Klinenberg JR. [Current status of therapeutic apheresis in rheumatoid arthritis](#). Artif Organs. 1981 Aug;5(3):297-8. doi: 10.1111/j.1525-1594.1981.tb04005.x. PMID: 7305692.
390. Wallace DJ, Goldfinger D, Bluestone R, Klinenberg JR. [Plasmapheresis in lupus nephritis with nephrotic syndrome: a long-term followup](#). J Clin Apher. 1982;1(1):42-5. doi: 10.1002/jca.2920010109. PubMed PMID: 6927509.
391. Wallace DJ, Bluestone R, Klinenberg JR. [The biology of aging and the immune system](#). Bull Rheum Dis. 1982;32(2):13-9. PMID: 7049286.
392. Wallace D, Goldfinger D, Klinenberg J. Lymphoplasmapheresis in rheumatoid arthritis. N Eng J Med. 1982;307:1271.
393. Wallace D, Goldfinger D, Lowe C, Nichols S, Weiner J, Brachman M, Klinenberg JR. [A double-blind, controlled study of lymphoplasmapheresis versus sham apheresis in rheumatoid arthritis](#). N Engl J Med. 1982 Jun 10;306(23):1406-10. doi: 10.1056/NEJM198206103062307. PMID: 7043264.
394. Podell TE, Wallace DJ, Fishbein MC, Bransford K, Klinenberg JR, Levine S. [Severe giant cell valvulitis in a patient with Reiter's syndrome](#). Arthritis Rheum. 1982 Feb;25(2):232-4. doi: 10.1002/art.1780250220. PubMed PMID: 7066055.

395. Wallace DJ, Podell TE, Weiner JM, Cox MB, Klinenberg JR, Forouzesh S, Dubois EL. [Lupus nephritis. Experience with 230 patients in a private practice from 1950 to 1980.](#) Am J Med. 1982 Feb;72(2):209-20. doi: 10.1016/0002-9343(82)90812-9. PubMed PMID: 7058833.
396. Wallace DJ, Goldfinger D, Klinenberg J. Current status of therapeutic apheresis in rheumatoid arthritis. Artif Organs. 1981;5:297-8.
397. Wallace D, Brachman M, Klinenberg J. Joint scanning in rheumatoid arthritis: a literature review. Semin Arthritis Rheum. 1981;11:172-6.
398. Wallace D. Survival patterns in systemic lupus erythematosus. JAMA. 1981;246:2223.
399. Wallace DJ, Podell T, Weiner J, Klinenberg JR, Forouzesh S, Dubois EL. [Systemic lupus erythematosus--survival patterns. Experience with 609 patients.](#) JAMA. 1981 Mar 6;245(9):934-8. doi: 10.1001/jama.245.9.934. PubMed PMID: 7463697.
400. Wallace D. Thomsonians: The people's doctors. Clio Med. 1980;14:169-86.
401. Wallace DJ, Goldfinger D, Thompson-Breton R, Martin V, Lowe CM, Bluestone R, Klinenberg JR. [Advances in the use of therapeutic pheresis for the management of rheumatic diseases.](#) Semin Arthritis Rheum. 1980 Nov;10(2):81-91. doi: 10.1016/0049-0172(80)90001-3. PubMed PMID: 7292020.
402. Somer T, Wallace DJ, Fan PT. [Immune complex mediated rheumatic diseases.](#) Ann Clin Res. 1980 Apr;12(2):77-86. Review. PubMed PMID: 6449901.
403. Somer T, Wallace D, Fan P. Immune complex mediated rheumatic diseases. Rounds, Journal of the Wadsworth General Hospital. 1980;19:1-13.
404. Wallace DJ, Goldfinger D, Gatti R, Lowe C, Fan P, Bluestone R, Klinenberg JR. [Plasmapheresis and lymphoplasmapheresis in the management of rheumatoid arthritis.](#) Arthritis Rheum. 1979 Jul;22(7):703-10. doi: 10.1002/art.1780220703. PubMed PMID: 454499.
405. Wallace D, Klinenberg J, Gatti R, Goldfinger D, Bluestone R. A therapeutic role for pheresis in the management of rheumatoid arthritis, Haemonetics Research Institute Advanced Component Seminar. 1979.
406. Wallace D, Klinenberg J, Morhaim D, Berlanstein B, Biren P, Callis G. Coexistent gout and rheumatoid arthritis. Arthritis Rheum. 1979;22:81-6.
407. Klinenberg JR, Wallace D. [Plasmapheresis in Raynaud's disease.](#) Lancet. 1978 Jun 17;1(8077):1310-1. doi: 10.1016/s0140-6736(78)91294-1. PubMed PMID: 78071.
408. Wallace DJ. [The biology of aging: 1976, an overview.](#) J Am Geriatr Soc. 1977 Mar;25(3):104-11. doi: 10.1111/j.1532-5415.1977.tb00271.x. PubMed PMID: 839041.
409. Wallace DJ. [Aging research: yesterday and today. Commentary and opinion by a medical student.](#) Gerontologist. 1974 Apr;14(2):110-3. doi: 10.1093/geront/14.2.110. PubMed PMID: 4470469.

Publications not Listed in Index Medicus

1. Wallace DJ. A guide to successfully treating patients with SLE. Medscape Rheumatology. (SF 75820.1) 2012.
2. Editor of Up to Date sections since 2011 for: a) Antimalarial drugs in the treatment of rheumatic diseases, b) Diagnosis and differential diagnosis of systemic lupus erythematosus in adults, c) Musculoskeletal manifestations of systemic lupus erythematosus, d) Overview of therapy of the therapy and prognosis of systemic lupus erythematosus in adults, e) Patient education: Systemic lupus erythematosus (Beyond the Basics), Lippincott, USA
3. Wallace DJ, Clauw DJ, Hallegua DS. Addressing behavioral abnormalities in fibromyalgia. The Journal of Musculoskeletal Medicine. 2010 October; 27(10):S21-7.
4. Hallegua DS, Wallace DJ. Fighting fibromyalgia: five issues. J Musculoskeletal Medicine. 2010;27:S3-9.

5. Up to Date (E publication) chapters: Antimalarial drugs in the treatment of rheumatic disease, Differential diagnosis of systemic lupus erythematosus (with Peter Schur) for 2007, 2008 and 2009 editions.
6. Venuturupalli RS, Wallace DJ. Lupus Fibromyalgia: five key issues. *J Musculoskeletal Medicine*. 2008;25:172-84.
7. Hanly JG, Urowitz MB, Siannis F, Farewell V, Gordon C, Bae SC, Isenberg D, Dooley MA, Clarke A, Bernatsky S, Gladman D, Fortin PR, Manzi S, Steinsson K, Bruce IN, Ginzler E, Aranow C, Wallace DJ, Ramsey-Goldman R, van Vollenhoven R, Sturfelt G. Niv nephritis—an update. *US Renal Disease 2007. Touch Briefings*. 2008;63-6.
8. Horizon AA, Wallace DJ. Lupus case studies shed light on key challenges. *J Musculoskeletal Medicine*. 2007;24:454-60.
9. Wallace DJ. Neuro-Behcet's syndrome: finally, new insights. *Curr Rheumatology Reviews*. 2007;3:242.
10. Wallace DJ. Biologic and innovative therapies for systemic lupus erythematosus. *Rheumatic Disease Clinics Updates*. 2007;2:-12.
11. Wallace DJ. Why is Current Rheumatology Reviews different than other rheumatology journals?. *Curr Rheum Reviews*. 2007; 3(3):171.
12. Wallace DJ. Future management of systemic lupus erythematosus. *Future Rheumatol*. 2007;2(3):229-231. doi: 10.2217/17460816.2.3.229 .
13. Wallace DJ. Editorial: Hot topic: at long last: a viable biomedical model for fibromyalgia. *Current Rheumatology Reviews*. 2007;3:93.
14. Wallace DJ. Editorial: to immunize or not? *Current Rheumatology Reports*. 2007;3:1.
15. Wallace DJ. Antimalarial drugs in the treatment of rheumatic diseases. *UpToDate*. 2006 Sep 11;14.3.
16. Wallace DJ. Scleroderma associated inflammatory arthritis: common and painful, but ignored by researchers. *Current Rheumatology Reviews*. 2006;2:309.
17. Wallace DJ. UCTD and unfinished business (Editorial). *Current Rheumatology Reviews*. 2006;2:i
18. Wallace DJ, Clauw DJ, Hallegua DS. Addressing behavioral problems in fibromyalgia. *J Musculoskeletal Medicine*. 2005;22:562-79.
19. Hallegua DS, Wallace DJ. Managing fibromyalgia: a comprehensive approach. *J Musculoskeletal Medicine*. 2005;22:382-90.
20. Wallace DJ, Weisman MH. The role of environmental factors in rheumatic diseases. *Bulletin on the Rheumatic Diseases*. 2002;51(10).
21. Hallegua DS, Wallace DJ, Silverman S, Bonert V, Mathur JR. Prevalence of fibromyalgia in growth hormone deficient adults. *J Musculoskeletal Pain*. 2001 Jan 10;35-42.
22. Pimentel M, Chow EJ, Hallegua D, Wallace D, Lin HC. Small intestinal bacterial overgrowth: a possible association with fibromyalgia. *J Musculoskeletal Pain*. 2001;9:105-13.
23. Wallace DJ. SLE--a prospect for the 21st century: lessons from the past. *The Ryumachi*. 2001;41:174.
24. Wallace DJ, Weisman MH. Comments regarding Hans Reiter's role in Nazi Germany. Response to letter to the editor. *J Clin Rheumatol*. 2001;7:127-30.
25. Albano SA, Wallace DJ. Managing fatigue in patients with SLE. *J Musculoskeletal Medicine*. 2001;18-149-52.
26. Wallace DJ. Current care for systemic lupus erythematosus. *J Musculoskeletal Medicine*. 1999;16:531-9.
27. Wallace DJ, Linker-Israeli M. It's not the same old lupus or Sjogren's anymore: one hundred new insights, approaches and options since 1990. *Current Opinion Rheumatol*. 1999;11:321-9.
28. Wallace DJ. Systemic lupus erythematosus. *Science & Medicine*. 1999;6:18-27.

29. Wallace DJ. Editorial overview: ten important topics relating to systemic lupus erythematosus and Sjogren's syndrome. *Curr Opin Rheumatol*. 1998;10:397-8.
30. Lahita RG, Pisetsky DS, Wallace DJ. Lupus: High-stakes Dx, broad treatment options. *Patient Care*. 1998 Feb 28;105-23.
31. Wallace DJ. Editorial overview: systemic lupus erythematosus and Sjogren's syndrome. *Current Opinion in Rheumatology*. 1996;8:393-4.
32. Barthels HR, Wallace DJ. Lupus erythematosus and the liver. *Resident & Staff Physician*. 1996;42:30-4.
33. Wallace DJ. Rheumatology: A wolf at the door. *Patient Care*. 1995 Sep 15;148-9.
34. Wallace DJ. Book review: the fibromyalgia syndrome: current research and future directions in epidemiology, pathogenesis and treatment. *N Eng J Med*. 1995;333:603.
35. Wallace DJ. Systemic lupus erythematosus and Sjogren's syndrome: editorial overview. *Current Opinion in Rheumatology*. 1995;7:369-70.
36. Wallace DJ. Systemic lupus erythematosus and Sjogren's syndrome, editorial overview. *Current Opinion in Rheumatology*. 1994;6:459-60.
37. Wallace DJ. Biography: Edmund Lawrence Dubois (1923-1985). *Rheumatology Review*. 1994;3:49-50.
38. Wallace DJ. Is fibromyalgia a legitimate diagnosis? *Journal of Musculoskeletal Medicine*. 1993 Jul;10(7):13-4.
39. Silverman SS, Wallace DJ. Calcitonin may have some effect in fibromyalgia. *J Musculoskeletal Medicine*. 1992;9:10.
40. Wallace DJ. Fibromyalgia: Clinical care and disability (Editorial). *Journal of Musculoskeletal Medicine*. 1992 Apr;9:3-23.
41. Wallace DJ. Dubois' Lupus Erythematosus. Review. *Ann Internal Med*. 1988;109:436-7.
42. Wallace DJ, Klinenberg JR. Apheresis, Disease-a-Month. 1984;30:1-45.
43. Wallace DJ. What to do when the SLE patient is a child. *J Musculoskeletal Med*. 1984;1:11.

Meeting Abstracts:

1. Dorner T, van Vollenhoven R, Doria A, Bocharo J, Fantini D, Terres JR, de Bono S, Fischer, Wallace DJ, Baricitinib decreases anti ds-DNA and IgG antibodies in adults with systemic lupus erythematosus from a Phase 2 double-blind, randomized, placebo-controlled trial, *Ann Rheum Dis* 2021; 80:S1, abstract 1015
2. Wallace DJ, Atsumi T, Daniels M, Hammer A, Meizlik P, Quasny H, Schwarting A, Zhang F, Roth D, Safety of belimumab in adult patients with systemic lupus erythematosus: A large integrated safety analysis of controlled clinical trial data, *Ann Rheum Dis* 2021; 80: S1, abstract 2373
3. Ugarte-Gil MF, Hanly J, Urowitz MB, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke AE, Wallace DJ, Isenberg D, Rihman A, Merrill JT, Fortin P, Gladman DD, Bruce IN, Petri MA, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jonsen A, van Bollenhoven R, Aranow C, Mackey M, Ruiz-Irastorza, Lim SS, Inanc M, Kalunian KC, Jacobsen S, Peschken C, Kamen DL, Askanase A, Pons-Estel P, Alarcon GS, LLDAS (Low Lupus Disease Activity State), Low Disease Activity (LDA) and remission (on or off treatment) prevent damage accrual in systemic lupus erythematosus (SLE) patients in a multinational multicenter cohort), *Ann Rheum Dis* 2021: 80:S1, OP0289.
4. Johnson S, Brinks R, Costenbader K, Daikh D, Mosca R, Ramsey-Goldman J, Smolen JLS, Cervera N, Costedoat-Chalumeau Diamond D, Gladman DD, Hahn BH, Hiepe S, Jacobsen S, Ruiz-Irastorza G, Sanchez-Guerrero, Schnbeider M, Urowitz MG, Bestsias G, Hower BF, Anic B, Assan F, Chan T, Clarke AE, Crow MK, Czirkak L, Doria A, Granninger B, Baida B, Mariette X, Padien I, Pego-Reigosa JM, Romero-Diaz J, Rua-Figueroa, Wallace DJ, Sero R, *Ann Rheum Dis*, THU071, EULAR 6/3/20

5. Dorner T, Tanaks Y, Petri M, Smolen JS, Wallace DJ, Crowe B, Dow ER, Higgs RE, Rocha G, Benschop RJ, Silk ME, de Bono S, Hoffman RW, Fantini D, Delineation of a proinflammatory cytokine profile targeted by JAK ½ inhibition using baricitinib in a Phase 2 SLE Trial, *Ann Rheum Dis*, OP0045, EULAR 6/3/20
6. Aringer M, Brinks R, Costenbader K, Daikh D, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Cziráj L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR. *Lupus Sci Med* 10.1136/lupus2020-eurolupus21.
7. Dorner T, Tanaka Y, Petri M, Smolen JS, Wallace DJ, Dow ER, Fantini D, Higgs RE, rocha G., Crowe B, Benschop RJ, Byers NL, Silk ME, de Bono, Hoffman RW, Baricitinib-induced changes in STAT-associated gene expression in systemic lupus erythematosus, *Lupus Sci Med* <http://dx.doi.org/10.1136/lupus-2020-eurolupus.18>
8. Tumurkhuu G, Chen S, Montano E, Lane M, Yamashita M, Markman J, Blanco L, Kaplan M, Shimada K, Crother T, Ishimori M, Wallace D, Jefferies C, Arditi M. Oxidative DNA Damage Accelerates Skin Inflammation in Pristane-induced Lupus Model [abstract]. *Arthritis Rheumatol*. 2020; 72 (suppl 10). <https://acrabstracts.org/abstract/oxidative-dna-damage-accelerates-skin-inflammation-in-pristane-induced-lupus-model/>. Accessed October 10, 2020.
9. Yu J, Tumurkhuu G, Montano E, de los Santos G, Wallace D, Ishimori M, Jefferies C. Expression of the cGAMP Transporter SLC19A1 Is Altered in Systemic Lupus Erythematosus [abstract]. *Arthritis Rheumatol*. 2020; 72 (suppl 10). <https://acrabstracts.org/abstract/expression-of-the-cgamp-transporter-slc19a1-is-altered-in-systemic-lupus-erythematosus/>. Accessed October 10, 2020.
10. Rainey H, Bell K, Rus V, Wallace D, Dykas C, Mora M, Comberg M, Lipsky P. Delayed and Immediate Release Prednisone Decrease Fatigue Comparably in Patients with Systemic Lupus Erythematosus [abstract]. *Arthritis Rheumatol*. 2020; 72 (suppl 10). <https://acrabstracts.org/abstract/delayed-and-immediate-release-prednisone-decrease-fatigue-comparably-in-patients-with-systemic-lupus-erythematosus/>. Accessed October 9, 2020.
11. Munroe M, Young K, Norris J, Guthridge J, Kamen D, Niewold T, Gilkeson G, Weisman M, Ishimori M, Wallace D, Karp D, Harley J, James J. Clinical Features and Select Dysregulated Immune Parameters Distinguish Blood Relatives Who Remain Clinically Stable or Progress to Incomplete Lupus or Classified SLE in the Lupus Autoimmunity in Relatives (LAUREL) Follow-up Cohort [abstract]. *Arthritis Rheumatol*. 2020; 72 (suppl 10). <https://acrabstracts.org/abstract/clinical-features-and-select-dysregulated-immune-parameters-distinguish-blood-relatives-who-remain-clinically-stable-or-progress-to-incomplete-lupus-or-classified-sle-in-the-lupus-autoimmunity-in-rela/>. Accessed October 9, 2020.
12. Choi M, Clarke A, Costenbader K, Urowitz M, Hanly J, Gordon C, St. Pierre Y, Bae S, Romero-Díaz J, Sanchez-Guerrero F, Bernatsky S, Wallace D, Isenberg D, Rahman A, Merrill J, Fortin P, Gladman D, Bruce I, Petri M, Ginzler E, Dooley M, Ramsey-Goldman R, Manzi S, Jönsen A, Alarcón G, Van Vollenhoven R, Aranow C, Mackay M, Ruiz-Irastorza G, Lim S, Inanc M, Kalunian K, Jacobsen S, Peschken C, Kamen D, Askanase A, Fritzler M. Longitudinal Analysis of ANA Assay Performance in SLE from the SLICC Inception Cohort [abstract]. *Arthritis Rheumatol*. 2020; 72 (suppl 10). <https://acrabstracts.org/abstract/longitudinal-analysis-of-ana-assay-performance-in-sle-from-the-slicc-inception-cohort/>. Accessed October 9, 2020.

13. Dörner T, Tanaka Y, Petri M, Smolen J, Wallace D, Crowe B, Dow E, Higgs R, Rocha G, Benschop R, Silk M, de Bono S, Hoffman R, Fantini D. Delineation of a Proinflammatory Cytokine Profile Targeted by Janus Kinase 1/2 Inhibition Using Baricitinib in a Phase 2 Systemic Lupus Erythematosus Trial [abstract]. *Arthritis Rheumatol.* 2020; 72 (suppl 10). <https://acrabstracts.org/abstract/delineation-of-a-proinflammatory-cytokine-profile-targeted-by-janus-kinase-1-2-inhibition-using-baricitinib-in-a-phase-2-systemic-lupus-erythematosus-trial/>. Accessed October 9, 2020.
14. Choi M, Fritzler M, Costenbader K, Urowitz M, Hanly J, Gordon C, St. Pierre Y, Bae S, Romero-Díaz J, Sanchez-Guerrero F, Bernatsky S, Wallace D, Isenberg D, Rahman A, Merrill J, Fortin P, Gladman D, Bruce I, Petri M, Ginzler E, Dooley M, Ramsey-Goldman R, Manzi S, Jönsen A, Alarcón G, Van Vollenhoven R, Aranow C, Mackay M, Ruiz-Irastorza G, Lim S, Inanc M, Kalunian K, Jacobsen S, Peschken C, Kamen D, Askanase A, Clarke A. Dynamics of Anti-Nuclear Antibodies in a Longitudinal Study of a Large Systemic Lupus Erythematosus Cohort [abstract]. *Arthritis Rheumatol.* 2020; 72 (suppl 10). <https://acrabstracts.org/abstract/dynamics-of-anti-nuclear-antibodies-in-a-longitudinal-study-of-a-large-systemic-lupus-erythematosus-cohort/>. Accessed October 9, 2020.
15. Hanly J, Qiuju L, Su L, Urowitz MB, Gordon C, Bae S-C, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke AE, Wallace DJ, et al. Neuropathies in systemic lupus erythematosus: Results from an International inception cohort study, *Ann Rheum Dis* 2019; 78 (suppl 2): A206.
16. Dervieux T, Wallace DJ, Putterman C, Arriers C, Kalunian KC, Massorotti EM, Alexander RV, Ibarra C, Ramsay-Goldman R, Weinstein A, Narain S, Saxena A, Collins CE, Ahearn JM, Manzi S, Cell bound complement activation products in combination with low complement C3 and C4 have high diagnostic yield in systemic lupus erythematosus, *Lupus Science & Medicine* 2019; 6: (Suppl) A175-176.
17. Silk JME, Wallace DJ, Furie R, Tanaka Y, Kalunian KC, Mosca MM, Petri M, Dörner T, Cardiel MH, Bruce IN, Gomez, De Lozier AM, Janes JM, Linnik MD, de Bono S, Hoffman RW, Baricitinib in patients with systemic lupus erythematosus: Results from a Phase 2, randomized, double-blind, placebo-controlled study, *Lupus Science & Medicine* 2019; 6: (Suppl 1) A148.
18. A Randomized Prospective Trial to Assess the Clinical Utility of Multianalyte Assay with Complement Activation Products in Diagnosing Systemic Lupus Erythematosus Date: Sunday, November 10, 2019 Wallace D, Alexander R, O'Malley T, Khosroshahi A, Hojjati M, Loupasakis K, Alper J, Sherrer Y, Fondal M, Kataria R, Powell T, Ibarra C, Narain S, Massarotti E, Weinstein A, Dervieux T. A Randomized Prospective Trial to Assess the Clinical Utility of Multianalyte Assay with Complement Activation Products in Diagnosing Systemic Lupus Erythematosus [abstract]. *Arthritis Rheumatol.* 2019; 71 (suppl 10). <https://acrabstracts/abstract/a-randomized-prospective-trial-to-assess-the-clinical-utility-of-multianalyte-assay-with-complement-activation-products-diagnosing-systemic-lupus-erythematosus/>. Accessed October 2, 2019.
19. Is ANA-status at Disease Inception Associated with Long-term Damage Accrual and Direct and Indirect Health Care Costs in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort? Choi M, Barber M, Fritzler M, Hanly J, Urowitz M, St-Pierre Y, Romero-Diaz J, Gordon C, Bae S, Bernatsky S, Wallace D, Isenberg D, Rahman A, Ginzler E, Petri M, Bruce I, Fortin P, Gladman D, Sanchez-Guerrero J, Ramsey-Goldman R, Khanmashta M, Aranow C, Mackay M, Alarcon G, Manzi S, Nived O, Jonsen A, Zoma A, Van Vollenhoven R, Ramos-Casals M, Ruiz-Irastorza G, Lim S, Kalunian K, Inanc M, Kamen D, Peschken C, Jacobsen S, Askanase A, Farewell V, Clarke A. Is ANA-status at Disease Inception Associated with Long-term Damage Accrual and Direct and Indirect Health Care Costs in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort? [abstract]. *Arthritis Rheumatol.* 2019; 71 (suppl 10). <https://acrabstracts.org/abstract/is-ana-status-at-disease-inception-associated-with-long-term->

damage-accrual-and-direct-and-indirect-with-long-term-damage-accrual-and-direct-and-indirect-health-care-costs-in-the-systemic-lupus-international-collaborating-clinics-slicc-inception-cohort/. Accessed October 2, 2019.

20. Complement Activation in Probable Systemic Lupus Erythematosus (pSLE) May Predict Progression to SLE Defined by Fulfillment of ACR Classification Criteria Ramsey-Goldman R, Alexander R, Narain S, Arriens C, Massarotti E, Wallace D, Saxena A, Collins C, Putterman C, Kalunian K, O'Malley T, Sace A, Lafron R, Ligayon J, Ibarra C, Conklin J, Dervieux T, Weinstein A. Complement Activation in Probable Systemic Lupus Erythematosus (pSLE) May Predict Progression to SLE Defined by Fulfillment of ACR Classification Criteria [abstract]. *Arthritis Rheumatol.* 2019; 71 (suppl 10). <https://acrabstracts.org/abstracts/complement-activation-in-probable-systemic-lupus-erythematosus-psle-may-predict-progression-to-sle-defined-by-fulfillment-or-acr-classification-criteria/>. Accessed October 2, 2019.
21. Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results from an International, Inception Cohort Study Hanly J, Li Q, Su L, Urowitz M, Gordon C, Bae S, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke A, Wallace D, Isenberg D, Rahman A, Merrill J, Fortin P, Gladman D, Bruce I, Petri M, Ginzler E, Dooley M, Steinsson K, Ramsey-Goldman R, Zoma A, Manzi S, Nived O, Jonsen A, Khamashta M, Alarcon G, Svenungsson E, Van Vollenhoven R, Aranow C, Mackay M, Ruiz-Irastorza G, Ramos-Casals M, Lim S, Inanc M, Kalunian K, Jacobsen S, Peschken C, Kamen D, Askanase A, Theriault C, Farewekk V. Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results from an International, Inception Cohort Study [abstract]. *Arthritis Rheumatol.* 2019; 71 (suppl 10). <https://acrabstracts.org/abstracts/peripheral-nervous-system-disease-in-systemic-lupus-erythematosus-results-from-an-international-inception-cohort-study/>. Accessed October 2, 2019.
22. The Contribution of Disease Activity, Depression, and Anxiety to Health-Related and Non-Health-Related Quality of Life in US and Filipino Patients with SLE Watts A, Azizoddin D, Gholizadeh S, Mills S, Zamora G, Wallace D, Jolly M, Weisman M, Nicassio P. The Contribution of Disease Activity, Depression, and Anxiety to Health-Related and Non-Health-Related Quality of Life in US and Filipino Patients with SLE [abstract]. *Arthritis Rheumatol.* 2019; 71 (suppl 10). <https://acrabstracts.org/abstracts/the-contribution-of-disease-activity-depression-and-anxiety-to-health-related-and-non-health-related-quality-of-life-in-us-and-filipino-patients-with-sle/>. Accessed October 2, 2019.
23. Performance of the Eular/Acr 2019 Classification Criteria for Systemic Lupus Erythematosus in Men, Diverse Ethnicities, and Early Disease Aringer M, Brinks R, Costenbader K, Daikh D, Boumpas D, Jayne D, Kame D, Mosca M, Ramsey-Goldman R, Smolen J, Wofsy D, Diamond B, Jacobsen S, McCune W, Ruiz-Irastorza G, Schneider M, Urowitz M, Bersias G, Hoyer B, Leuchten N, Tani C, Tedschi S, Touma Z, Anic B, Assan F, Chan D, Clarke A, Crow M, Czirjak L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly P, Jung M, Kumanovics G, Mariette X, Padjen I, Pego-Reigosa J, Romero-Diaz J, Rua Figueroa I, Seror R, Stummvoll G, Tanaka Y, Tektonidou M, Vasconcelos C, Vital E, Wallace D, Yavuz S, Naden R, Dorner T, Johnson S. Performance of the EULAR/ACR 2019 Classification Criteria for Systemic Lupus Erythematosus in Men, Diverse Ethnicities, and Early Disease [Abstract]. *Arthritis Rheumatol.* 2019; 71 (suppl 10). <https://acrabstracts.org/abstracts/performance-of-the-eular-acr-2019-classification-criteria-for-systemic-lupus-erythematosus-in-men-diverse-ethnicities-and-early-disease/>. Accessed October 2, 2019.
24. Incidence and Predictors of Atherosclerotic Vascular Events in a Multicentre Inception SLE Cohort Urowitz M, Gladman D, Su J, Farewell V, Sanchez-Guerrero J, Romero-Diaz J, Bae S, Fortin P, Nived O, Clarke A, Bernatsky S, Gordon C, Hanly J, Wallace D, Isenberg D, Rahman A, Merrill J,

- Ginzler E, Alacron G, Petri M, Bruce I, Khanmashta M, Aranow C, Manzi S, Dooley M, Ramsey-Goldman R, Jonsen A, Steinsson K, Zoma A, Ruiz-Irastorza G, Lim S, Kalunian K, Inanc M, Van Vollenhoven R, Ramos M, Kamen D, Jacobsen S, Peschken C, Askanase A, Stroll T.
<https://acrabstracts.org/abstracts/incidence-and-predictors-of-atherosclerotic-vascular-events-in-a-multicentre-inception-sle-cohort/>. Accessed October 2, 2019.
25. Molecular Profiling Identifies Immunologic Subgroups and Informs Mechanism of Action of Baricitinib in SLE Dorner T, Tanaka Y, Petri M, Smolen J, Wallace D, Dow E, Fantini D, Rocha G, Crowe B, Benschop R, Abel A, Byers N, Silk M, De Bono S, Hoffman R. Molecular Profiling Identifies Immunologic Subgroups and Informs Mechanism of Action of Baricitinib in SLE [abstract]. *Arthritis Rheumatol.* 2019; 71 (suppl10).<https://acrabstract.org/abstract/molecular-profiling-identifies-immunologic-subgroups-and-informs-mechanism-of-action-of-barticitinib-in-sle/>. Accessed October 2, 2019.
 26. Cell-bound Complement Activation Products in Combination with Low Complement C3 or C4 Have Superior Diagnostic Performance in Systemic Lupus Erythematosus Narain S, Wallace D, Putterman C, Arriens C, Askanase A, Kalunian K, Collins C, Saxena A, Massarotti E, Alexander R, Ibarra C, O'Malley T, Conklin J, Ramsey-Goldman R, Ahearn J, Manzi S, Weinstein A, Dervieux T. Cell-bound Complement Activation Products in Combination with Low Complement C3 or C4 Have Superior Diagnostic Performance in Systemic Lupus Erythematosus [abstract]. *Arthritis Rheumatol.* 2019; 71 (suppl 10). <https://acrabstracts.org/abstract/cell-bound-complement-activation-products-in-combination-with-low-complement-c3-or-c4-have-superior-diagnostic-performance-in-systemic-lupus-erythematosus/>. Accessed October 2, 2019.
 27. Cancer Risk in a Large Inception SLE Cohort: Effects of Age, Smoking, and Medications Bernatsky S, Ramsey-Goldman R, Urowitz M, Hanly J, Gordon C, Petri M, Ginzler E, Wallace D, Bae S, Romero-Diaz J, Dooley M, Peschken C, Isenberg D, Rahman A, Manzi S, Jacobsen S, Lim S, Van Vollenhoven R, Nived O, Kamen D, Aranow C, Buyon J, Ruiz-Irastorza G, Bruce I, Gladman D, Fortin P, Merrill J, Sanchez-Guerrero J, Kalunian K, Steinsson K, Ramos M, Zoma A, Stoll T, Khamashta M, Inanc M, Clarke A. Cancer Risk in a Large Inception SLE Cohort; Effects of Age, Smoking, and Medications [abstract]. *Arthritis Rheumatol.* 2019; 71 (suppl 10). <https://acrabstracts.org/abstract/cancer-risk-in-a-large-inception-sle-cohort-effects-of-age-smoking-and-medication/>. Accessed October 2, 2019.
 28. Prediction of Organ Damage Accrual in Systemic Lupus Erythematosus Using a Frailty Index. Legge A, Kirkland S, Rockwood K, Andreou P, Bae S, Gordon C, Romero-Diaz J, Sanchez-Guerrero J, Wallace D, Bernatsky S, Clarke A, Merrill J, Ginzler E, Fortin P, Gladman D, Urowitz M, Bruce I, Isenberg D, Rahman A, Alarcon G, Petri M, Khamashta M, Dooley M, Ramsey-Goldman R, Manzi S, Steinsson K, Zoma A, Aranow C, Mackay M, Ruiz-Irastorza G, Lim S, Inanc M, Van Vollenhoven R, Jonsen A, Nived O, Ramos-Casals M, Karmen D, Kalunian K, Jacobsen S, Peschken C, Askanase A, Hanly J. Prediction of Organ Damage Accrual in Systemic Lupus Erythematosus Using a Frailty Index [abstract]. *Arthritis Rheumatol.* 2019; 71 (suppl 10). Prediction of Organ Damage Accrual in Systemic Lupus Erythematosus Using a Frailty Index [abstract]. *Arthritis Rheumatol.* 2019; 71 (suppl 10). <https://acrabstracts.org/abstract/prediction-of-organ-damage-accrual-in-systemic-lupus-erthematosus-using-a-frailty-index/>. Accessed October 2, 2019.
 29. Glucocorticosteroid Usage and Major Organ Damage in Patients with Systemic Lupus Erythematosus –Meta – analyses of Observational Studies Published Between 1979 and 2018 Mak A, Cheung M, Leong W, Dharmadhikari B, Kow N, Petri M, Manzi S, Clarke A, Aranow C, Arnaud L, Askanase A, Bae S, Bernatsky S, Bruce I, Buyon J, Chatham W, Costedoat-Chalumeau N, Dooley M, Fortin P, Ginzler E, Gladman D, Gordon C, Hanly J, Inanc M, Isenberg D, Jacobsen S, James J, Jonsen A, Kalunian K, Kamen D, Lim S, Morand E, Peschken C, Pons-Estel B, Rahman A, Ramsey-Goldman R, Romero-Diaz J, Ruiz-Irastorza G, Sanchez-Guerrero J, Steinsson K,

- Svenungsson E, Urowitz M, van Vollenhoven R, Vinet E, Voskuyl A, Wallace D, Alarcon G. Glucocorticosteroid Usage and Major Organ Damage in Patients with Systemic Lupus Erythematosus – Meta – analyses of Observational Studies Published Between 1979 and 2018 [abstract]. *Arthritis Rheumatol.* 2019; 71 (suppl 10). <https://acrabstracts.org/abstract/glucocorticosteroid-usage-and-major-organ-damage-in-patients-with-systemic-lupus-erythematosus-meta-analyses-of-observational-studies-published-between-1979-and-2018/>. Accessed October 2, 2019.
30. Design and Development of an Online Intervention for Lupus Self-Management Gilman S, Levesque D, Cummins C, Wallace D, Werth V, Davidson P. Design and Development of an Online Intervention for Lupus Self-Management Based on the Transtheoretical Model of Change [abstract]. *Arthritis Rheumatol.* 2019; 71 (suppl 10). <https://acrabstracts.org/abstract/design-and-development-of-an-online-intervention-for-lupus-self-management-based-on-the-transtheoretical-model-of-change/>. Accessed October 2, 2019.
 31. Wallace DJ, Venuturupalli RS. Best practices and challenges to the practice of rheumatologists. *Rheum Dis Clin North Am.* 2019 Feb;45(1)
 32. Clarke AE, Bruce IN, Urowitz MB, Hanly JG, Romero-Diaz, Gordon C, Bae Sang-Cheol, Bernatsky S, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Oetri M, Dooley MA, Fortin P, Gladman DD, et al, Economic evaluation of damage accrual in an International SLE Inception Cohort, *Lupus Science & Medicine* 2018; 5: Supp2, 71:A24A
 33. Smith S, Wallace DJ, Jefferies CA, Novel IL-16/MIR-125 Axis controls neutrophil recruitment in pristine-induced inflammation, *Lupus Science & Medicine* 2018; 5: Supp 2, 71.
 34. Aringer M, Costenbader K, Brinks R, Boumpas D, Daikh D, Jayne D, Kamen DL, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Diamond B, Jacobsen S, McCune WJ, Ruiz-Irastorza G, Schneider M, Urowitz M, Bertsias G, Hoyer B, Leuchten N, Tani C, Tedeschi SK, Touma Z, Anic B, Assan F, Chan TM, Clarke AE, Crow P, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni SA, Izmirly PM, Jung M, Kumanovics G, Mariette X, Padjen I, Pego-Reigosa J, Romero-Díaz J, Rúa-Figueroa I, Seror R, Stummvoll G, Tanaka Y, Tektonidou M, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Naden RP, Dörner T, Johnson S. Validation of New Systemic Lupus Erythematosus Classification Criteria [abstract]. *Arthritis Rheumatol.* 2018; 70 (suppl 10). <https://acrabstracts.org/abstract/validation-of-new-systemic-lupus-erythematosus-classification-criteria/>. Accessed September 11, 2018.
 35. Hanly JG, Li Q, Su L, Urowitz M, Gordon C, Bae SC, Romero-Díaz J, Sanchez-Guerrero J, Bernatsky S, Clarke AE, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley M, Steinsson K, Ramsey-Goldman R, Zoma AA, Manzi S, Nived O, Jönsen A, Khamashta MA, Alarcón GS, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Ramos-Casals M, Lim SS, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Theriault C, Farewell V. Psychosis in Systemic Lupus Erythematosus: Results from an International, Inception Cohort Study [abstract]. *Arthritis Rheumatol.* 2018; 70 (suppl 10). <https://acrabstracts.org/abstract/psychosis-in-systemic-lupus-erythematosus-results-from-an-international-inception-cohort-study/>. Accessed September 11, 2018.
 36. Ramsey-Goldman R, Alexander R, Massarotti E, Wallace DJ, Narain S, Arriens C, Collins CE, Saxena A, Putterman C, Kalunian KC, Sace A, Lafon R, O'Malley T, Ligayon J, Ibarra C, Conklin J, Dervieux T, Weinstein A. Complement Activation Is a Feature of Diseases in the Lupus Spectrum [abstract]. *Arthritis Rheumatol.* 2018; 70 (suppl 10). <https://acrabstracts.org/abstract/complement-activation-is-a-feature-of-diseases-in-the-lupus-spectrum/>. Accessed September 11, 2018.
 37. McMahon MA, Grossman JM, Sahakian L, Charles-Schoeman C, Fitzgerald J, Taylor M, Gorn A, Olmos E, Wallace DJ, Hahn BH, Skaggs B. A High Cardiovascular Biomarker Panel Risk Score Is

- Associated with Increased 10-Year Risk of Cardiovascular Events and Death in SLE [abstract]. *Arthritis Rheumatol.* 2018; 70 (suppl 10). <https://acrabstracts.org/abstract/a-high-cardiovascular-biomarker-panel-risk-score-is-associated-with-increased-10-year-risk-of-cardiovascular-events-and-death-in-sle/>. Accessed September 11, 2018.
38. Morand E, Merrill JT, Isenberg DA, Kao AH, Vazquez-Mateo C, Wax S, Chang P, Pudota K, Aranow C, Wallace DJ. Attainment of Low Disease Activity and Remission in SLE Patients Who Started with High Disease Activity in the Atacicept Phase IIb Address II Study and Its Long-Term Extension [abstract]. *Arthritis Rheumatol.* 2018; 70 (suppl 10). <https://acrabstracts.org/abstract/attainment-of-low-disease-activity-and-remission-in-sle-patients-who-started-with-high-disease-activity-in-the-atacicept-phase-iib-address-ii-study-and-its-long-term-extension/>. Accessed September 12, 2018.
 39. Gilman S, Levesque D, Cummins C, Wallace DJ, Werth VP, Ramsey-Goldman R, Kaniewski M, Davidson P. Development of an Online Lupus Self-Management Program Based on the Transtheoretical Model of Change [abstract]. *Arthritis Rheumatol.* 2018; 70 (suppl 10). <https://acrabstracts.org/abstract/development-of-an-online-lupus-self-management-program-based-on-the-transtheoretical-model-of-change/>. Accessed September 12, 2018.
 40. Legge A, Kirkland S, Rockwood K, Andreou P, Bae SC, Gordon C, Romero-Díaz J, Sanchez-Guerrero J, Wallace DJ, Bernatsky S, Clarke AE, Merrill JT, Ginzler EM, Fortin PR, Gladman DD, Urowitz M, Bruce IN, Isenberg DA, Rahman A, Alarcón GS, Petri M, Khamashta MA, Dooley M, Ramsey-Goldman R, Manzi S, Steinsson K, Zoma AA, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, van Vollenhoven RF, Jönsen A, Nived O, Ramos-Casals M, Kamen DL, Kalunian KC, Jacobsen S, Peschken CA, Askanase A, Hanly JG. Construction and Validation of a Frailty Index As a Novel Health Measure in Systemic Lupus Erythematosus [abstract]. *Arthritis Rheumatol.* 2018; 70 (suppl 10). <https://acrabstracts.org/abstract/construction-and-validation-of-a-frailty-index-as-a-novel-health-measure-in-systemic-lupus-erythematosus/>. Accessed September 12, 2018.
 41. Wallace DJ, Furie R, Tanaka Y, Kalunian KC, Mosca M, Petri M, Dorner T, Cardiel MH, Bruce IN, Gomez E, DeLozier AM, Janes J, Linnik MD, de Bono S, Silk ME, Hoffman RW. Baricitinib in Patients with Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study [abstract]. *Arthritis Rheumatol.* 2018; 70 (suppl 10). <https://acrabstracts.org/abstract/baricitinib-in-patients-with-systemic-lupus-erythematosus-results-from-a-phase-2-randomized-double-blind-placebo-controlled-study/>. Accessed September 12, 2018.
 42. Lee CCJ, Forbess LJ, Wallace DJ, Jefferies C, Ishimori M. Assessing Dyspnea in Patients with Systemic Lupus Erythematosus [abstract]. *Arthritis Rheumatol.* 2018; 70 (suppl 10). <https://acrabstracts.org/abstract/assessing-dyspnea-in-patients-with-systemic-lupus-erythematosus/>. Accessed September 11, 2018.
 43. Gholizadeh S, Azizoddin DR, Mills SD, Racaza GZ, Kala'aukahi Potemra HM, Wallace DJ, Weisman M, Nicassio PM. Psychometric Validation of the Arthritis Helplessness Index in Systemic Lupus Erythematosus [abstract]. *Arthritis Rheumatol.* 2018; 70 (suppl 10). <https://acrabstracts.org/abstract/psychometric-validation-of-the-arthritis-helplessness-index-in-systemic-lupus-erythematosus/>. Accessed September 11, 2018.
 44. Wallace DJ. Debate: Outcome Measures in Sjogren's Clinical Trials, *Clinical Exp Rheumatol* 2018 May-Jun; 36: Suppl 112 (3): 241-255. Epub 2018 A8g 27.
 45. Aringer A, Costenbader KH, Brinks R, Boumpas D, Daikh D, Jayne D, Kamen D, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Diamond B, Jacobsen, Mc Cune WJ, Ruiz-Irastorza G, Schneider M, Urowitz MB, Bertsias G, Hoyer B, Leuchten N, Tani C, Tedeschi S, Touma Z, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirjak L, Doria A, Graninger W, Hasni S, Izmirly P, Jung M, Kiss B, Mariette X, Padjen I, Peggy-Regiosa JM, Romero-Diaz J, Roa- Figueroa I, Seror R, Stummvoll G,

- Tanaka Y, Tektonidou, Vasconcelos C, Vital E, Wallace DJ, Yavuz S, Naden RP, Dorner T, Johnson SR, Validation of new systemic lupus erythematosus classification criteria, 1.1136/annrheumdis-2018-eular.3679
46. Morand E, Merrill JT, Isenberg DA, Kao AH, Vazquez-Mateo C, Wax S, Chang P, Pudota K, Aranow C, Wallace D, Attainment of low disease activity with remission in systemic lupus erythematosus patients with high disease activity in the atacicept Phase IIB Address II Study and its long-term extension, DOI 10.1136/annrheumdis-2018-eular.2618.
 47. Wallace JD, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, Dorner T, Cardiel MH, Bruce IN, Gomez E, Carmack T, Janes JM, Linnik MD, Silk M, Hoffman R, Baricitinib in systemic lupus erythematosus c Disease-2018- EULAR 1918m doi 10.1136.
 48. Clarke AE, Bruce IN, Urowitz M, Hanly JG, St Pierre Y, Bae S-C, Bernatsky S, Gladman DD, Sanchez-Guerrero J, Fortin P, Romero-diaz J, Petri M, Ramsey-Goldman R, Aranow C, Jacobsen S, Wallace DJ, et al, Economic evaluation of damage accrual in the SLICC inception cohort, *Arthritis Rheumatol* 2017, suppl 10. *Arthritis Rheumatology* 2018; 70:1478-1487
 49. Young KA, Munroe ME, Guthridge JM, KJamen DL, Gilkeson GS, Weisman M, Karp D, Harley JB, Wallace DJ, James JA, Norris JM, Identification of key screening characteristic for systemic lupus erythematosus natural history, *Arthritis Rheumatol* 2017, suppl 10
 50. James JA, Guthridge JM, Chen H, Lu R, Bourn RL, Baer AN, Noasieh G, Parke A, Coca A, Utset T, Genovese MC, Aberle T, Wallace DJ, Bopyle K, Keyes-Eistein L, Franchmont N, St Clair E, Pascual V, Utz PJ, Sivlis KL, Molecular features define unique Sjogren's syndrome patient subsets, *Arthritis Rheumatol* 2017; Suppl 10
 51. Bernatsky S, Urowitz M, Hanly JG, Clarke AE, Fritzler MJ, Gordon C, Romero-Diaz J, Alarcon GS, Bae S-C, Petri M, Merrill JT, Wallace DJ, et al, Cancer in an SLE inception cohort: Smoking may out-perform tumor markers as a risk predictor, *Arthritis Rheumatol* 2017; suppl 10. *Arthritis Rheumatology* 2018; 70: 1294-1302
 52. Hanly JG, Li Q, Su L, Urowitz M, Romero-Diaz J, Gordon C, Bae S-C, Bernatsky S, Clarke AE, Wallace DJ et al , Risk factors for cerebrovascular events in systemic lupus erythematosus: Results from an international, inception cohort study, *Arthritis Rheumatol* 2017, Suppl 10.
 53. Wallace DJ, Massarotti E, Ramsey-Goldman R, Collins CE, Askanase A, Buyon JP, Furie R, Narian S, Saxena A, Kalunian KC, Arriens C, Putterman C, Conklin J, Alexander R, Ibarra C, O'Malley T, Chandra T, Ahearn J, Manzi S, Weinstein A, Devrieux T, Cell bound complement activation products distinguish systemic lupus erythematosus from other diseases among patients with high antinuclear antibody titers and normal complement, *Arthritis Rheumatol* 2017; Suppl 10.
 54. Sethl B, Nika A, Sequeira W, Block JA, Toloza S, Bertoli A, Blazevic I, Vila LM, Moldovan I, Torralba K, Mazzoni D, Cicognani E, Hasni S, Goker B, Haznedaroglu S, Bourre-Tesler, Navarra SV, Mok CC, Clarke A, Weisman M, Wallace DJ, Jolly M, Drivers of satisfaction with care in lupus, *Arthritis Rheumatol* 2017; suppl 10.
 55. Young KA, Munroe ME, Guthridge JM, Kamen DL, Gilkeson GS, Weisman M, Karp D, Harley JB, Wallace DJ, James JA, Norris JM, Less than seven hours of sleep per night is associated with transitioning to lupus, *Arthritis Rheumatol* 2017, suppl 10
 56. Arriens C, Narain S, Saxena A, Colliins CE, Wallace DJ, Massorotti E, Conklin J, Alexander R, Kalunian KC, Putterman C, Ramsey-Goldman R, Buyon JP, Askanase A, Furie R, Manzi S, Ahearn J, Weinstein A, Devrieux T, Abnormalities in complement system are related to disease severity in systemic lupus erythematosus, *Arthritis Rheumatol* 2017; 60 suppl 10
 57. Merrill JT, Wallace DJ, Vazquez-Mateo C, Kao KH, Fleuranceau-Morel P, Chang P, Isenberg DA, Safety profile in SLE patients treated with atacicept in a Phase IIB Study (ADDRESS II) and its extension study, *Arthritis Rheumatol* 2017; 69: suppl 10.

58. Wallace DJ, Ginzler EM, Merrill JT, Furie RA, Stohl W, Chatham W, Weinstein A, McKay J, Mc Cune WJ, Petri M, Fettiplace J, Roth D, Ji B, Heth A, Sustained safety and efficacy over 10 years with belimumab (BEL) plus standard systemic lupus erythemaotuss (SLE) therapy (SOC) in patients with SLE, *Ann Rheum Dis* 2017; 75: OP0232, Supp.
59. Wallace DJ, Isenberg D, Wax S, Kao A, Chang P, Fraser PA, Merrill JT, Safety and disease activity changes in an extension of a Phase IIb study of atacicept in patients with SLE (ADDRESS II), *Ann Rheum Dis* 2017, 75: SAT0236, sup.
60. Merrill JT, Wallace DJ, Kao A, Vazquez Mateo C, Fraser PA, Chang P, Isenberg D, Efficacy and safety of atacicepet in patients with high disese activity in a 24-week, randomized, placebo-controlled, Phase IIB study (ADDRESS II), *Ann Rheum Dis* 75: SAT0219, Supp, 2017
61. Wallace DJ, Biologics for systemic lupus erythematosus, *Journal of Rheumatic Disease*, 2017; 24: 536, Supp1.
62. Bernatsky S, Urowitz M, Hanly J, Clarke AE, Gordon C, Romero-Diaz J, Alarcon GS, Bae S-C, Petri M, Merrill M, Wallace DJ, et al, *Arthritis Rheum* 2016; 68: Abst 2690.
63. Munroe M, Young KA, Norris JM, Aberle T, Roberts VC, Guthridge JM, Kamen DL, Gilkeson GS, Weisman M, Ishimori M, Wallace DJ, et al, Unaffected lupus relatives are distinguished from SLE patients and unaffected individuals not related to SLE patients by lupus-specific connective tissue disease questionnaire scores, autoantibodies and distinct soluble markers, *Arthritis Rheum* 2016; 68: Abst 2871.
64. Furie R, Askanase AD, Kalunian K, Massarotti E, Ramsey-Goldman R, Wallace DJ, et al, Multicenter validation of platet bound C4d, a biomarker for systemic lupus erythematosus, *Arthritis Rheum* 2016; 68: Abst 2798.
65. Wallace DJ, Ramsey-Goldman R, Askanases AD, Manzi S, Ahearn J, Furie R, Weinstein A, Putterman C, Massarotti E, Collins C, Kalunian K, Arriens C, Silverman SL, Reddy S, Chitkara P, Ibarra C, Barken D, Alexander R, Cohlkin J, Devrieux T, Prospective validation of panel of autoantibodies in combination with C4d bound complement activation products for the differential diagnosis of systemic lupus erythematosus, *Arthritis Rheum* 2016; 68: Abst 2797.
66. Rasmussen A, Stone DU, Fife D, Brown M, Earley K, Radfar L, Kaufman CE, Lewis DM, Rhodus NL, Begal BM, Wallace DJ, et al, Effect of tobacco smoking on the clinical, histopathological and serological manifestations of Sjogren's syndrome, *Arthritis Rheum* 2016; 68: Abst 2662.
67. Hany JG, Li Q, Urowitz M, Romero-Diaz J, Gordon C, Bae S-C, Bernatsky S, Clarke AE, Wallace DJ, et al, Risk factors for cerebrovascular events in systemic lupus erythematosus: Results from an International, Inception cohort study, *Arthritis Rheum* 2016; 68: Abst 1773.
68. Sharma R, Harris VM, Cavett J, Kurien BT, Liu K, Koelsch KA, Radfar L, Lewis DM, Stone DU, Kaufman CE, Li S, Segal BM, Wallace DJ et al, Very rare X chromosome abnormalities in SLE and Sjogren's may localize X gene dose effect, *Arthritis Rhem* 2016; 68: Abst 66.
69. Barber M, Bruce IN, Urowitz M, Hanly JG, Su L, Romero-Diaz J, Gordon C, Bae S-C, Bernatsky S, Wallace DJ, et al, Economic evaluation of damage accrual in an international SLE Inception Cohort, *Arthritis Rheum* 2016; 68: Abst 3168.
70. Bernatsky S, Urowitz MB, Hanly J, Clarke AE, Gordon, Romero-Diaz J, Alarcon GS, Bae SC, Petri, Merrill J, Wallace DJ, et al, Cancer in systemic lupus erythematosus: Results from the SLICC inception cohort, *Lupus Sci Med* 2016; 3: A57-58.
71. Choi M, Clarke A, Hanly JG, Urowitz M, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, et al, The prevalence and determinants of anti DFS-70 antibodies in an international inception cohort of patients with systemic lupus erythematosus (SLE) patients, *Lupus Sci Med* 2016; 3: A55-A57, Supp 1
72. Urowitz M, Gladman D, Anderson N, Su J, Romero-Diaz J, Bae SC, Fortin P, Sanchez-Guererro J, Clarke A, Bernatsky S, Gordon C, Hanly J, Wallace D, et al, Cardiovascular events prior to or early

- after diagnosis of systemic lupus erythematosus in the Systemic Lupus Erythematosus Collaborating Clinics Cohort, *Lupus Sci Med* 2016; 3: A 47-48, Supp 1
73. Wallace DJ, Wegener WA, Horne H, Goldenberg DM, Phase IB study of Immu-115 (humanized anti CD74 antibody) targeting antigen presenting cells in patients with systemic lupus erythematosus, *Lupus Sci Med* 2016; 3:A37-38, Supp 1
 74. Clowse MEB, Wallace DJ, Furie R, Petri M, Pike M, Leszczynski P, Neuwelt CM, Hobbs K, Keiserman M, Duca L, Kalunian K, Bongardt S, Stach C, Beaudot C, Kilgallen B, Galatenu C, Gordon C, Efficacy and safety of epratuzumab in patients with moderate-to-severe systemic lupus erythematosus: Results from two Phase 3 randomized, placebo- controlled trials, *Arthritis Rheumatol* 2015; 67: S10, abstract 4L
 75. Hanly JG, Li Q, Su L, Urowitz M, Romero-Diaz J, Gordon C, Bae SC, Bernastsky S, Clarke A, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Dooley MA, Fortin P, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta M, Aranow C, Alarcon GS, Fesler BJ, Manzi S, Nived O, Sturfelt GK, Zoma A, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Theriault C, Farewell V, An initial presentation of cerebrovascular disease attributed to lupus is most frequent early in the disease course: Results from an international inception cohort study, *Arthritis Rheum* 2015; 67: S 10, Abst 2902
 76. Barber M, Hanly JG, O'keefe A, Su L, Urowitz M, St Pierre Y, Romero-Diaz J, Gordon C, Bae SC, Bernastsky S, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Dooley MA, Fortin P, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta M, Aranow C, Alarcon GS, Fesler BJ, Manzi S, Nived O, Sturfelt GK, Zoma A, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Theriault C, Farewell V, Clarke AE, Economic evaluation of lupus nephritis in an international inception cohort: Comparing the hospitalization, medication, dialysis and procedure costs of those with and without nephritis, *Arthritis Rheum* 2015; 67: S 10, Abst 989
 77. Hanly JG, Su L, Urowitz M, Romero-Diaz J, Gordon C, Bae SC, Bernastsky S, Clarke A, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Dooley MA, Fortin P, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta M, Aranow C, Alarcon GS, Fesler BJ, Manzi S, Nived O, Sturfelt GK, Zoma A, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Theriault C, Farewell V, Longitudinal analysis of change in lupus nephritis in an international inception cohort using a multistate Markov model approach, *Arthritis Rheum* 2015; 67: S 10, Abst 3122
 78. Rasmussen A, Lessard CJ, Adrianto I, Wiley GB, Stone DU, Kaufman CE, Radfar L, Lewis DM, Young SK, Weisman MH, Wallace DJ, Venuturupalli S, Segal BM, Ice JA, Anaya JM, Rohrer MD, Gopalakrishnan R, Houston GD, Chodosh J, Hughes PJ, Rhodus NL, Kelly JA, Grundahl K, Hefner K, Scofield RH, Sivlis KL, Characterization of early and progressive autoimmunity in Sjogren's syndrome: The incomplete Sjogren's syndrome model; *Arthritis Rheumatol* 2015; 67: S 10, Abst 3200.
 79. Wilhelm M, Wang F, Schall N, Faludi M, Kleinmann JF, Nashi EP, Martin T, Sibia J, Pasquali JL, Wallace D, Muller S, Autophagy pathway as a target of therapeutic P140 peptide used in lupus, *Arthritis Rheumatol* 2015; 67: S 10, abst 1934.
 80. Mc Mahon MA, Grossman JM, Sahakian L, Laurencio E, FitzGerald J, Charles-Schoeman C, Gorn A, Weisman M, Wallace DJ, Hahn BH, Skaggs B, Plasma myeloperoxidase levels are inversely associated with carotid plaque in SLE, *Arthritis Rheumatol* 2015; 67:S 10, 2015.

81. Haw J, Ishimori ML, Sandhu VK, Sharif B, Thomson L, Li D, Schapira J, Wallace D, Bairey Merz N, Weisman M, Berman D, Myocardial tissue characterization with native myocardial T1 mapping in SLE patients with chest pain, *Arthritis Rheumatol* 2015; 67: S 10, abst 1817.
82. Sandhu VK, Ishimori ML, Wei J, Thompson L, Berman D, Schapira J, Bairey Merz, Wallace DJ, Weisman, A 5 year follow up of microvascular dysfunction and coronary artery disease in SLE: Results from a community-based lupus cohort, *Arthritis Rheumatol* 2015; 67: S10, abst 1810.
83. Wallace D, Silverman SL, Barken D, Conklin J, Dervieux T, Cell bound complement activation products in multianalyte assay with algorithm have utility in distinguishing primary fibromyalgia from systemic lupus erythematosus, *Arthritis Rheumatol* 2015; 67: S 10, abst 3087.
84. St Clair EW, Baer AN, Nosaiseh G, Parke A, Coca A, Utset T, Genovese MC, Wallace DJ, Mc Namara J, Boyle K, Keyes-Elstein L, Fraichimont N, James JA, The clinical efficacy and safety of baminercept, a lymphotoxin-beta receptor fusion protein in primary Sjogren's syndrome, Results from a randomized, double-blinded, placebo-controlled Phase II trial, *Arthritis Rheumatol* 2015; 67: S10, abst 2013
85. Choi M, Hanly JG, Urowitz M, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Fortin PR, Gladman D, Sancehez-Guerrero J, Petri M, Bruce IN, Dooley MA, Ramsey- Goldman R, Aranow C, Alarcon GS, Steinsson K, Nived O, Sturfelt GK, Manzi S, Khamashta M, van Vollenhoven RF, Zoma A, Ruiz-Irastorza G, Lim SS, Stoll T, Inanc M, Kalunian KC, Kamen DL, Maddison P, Peschken CA, Jacobsen S, Askanase A, Buyon JP, Chatham WW, Ramos-Casals M, St Pierre Y, Clarke AE, Fritzler MJ, The prevalence of anti- DFS70 antibodies in an international inception cohort of systemic lupus erythematosus, *Arthritis Rheumatol* 2015; 67: S10, abst 740.
86. Sturgess J, Allen E, Isenberg DA, Aranow C, Aringer M, Askanase A, Bae SC, Bernatsky R, Bruce IN, Buyon JP, Cervera R, Clarke A, Dooley MA, Fortin PR, Giles I, Ginzler EM, Gladman D, Gordon C, Griffiths B, Hanly JG, Inanc M, Jacobsen S, Kamen DL, Khamashta M, Lanyon P, Lim SS, Manzi S, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Steinsson K, Sturfelt GK, Urowitz M, van Vollenhoven F, Vasconcelos C, Wallace DJ, Zoma A, Merrill GJ, Morand E, Chambers S, Costedoat-Chalumeau N, Croca S, A paper patient-based flare study in SLE, *Arthritis Rheumatol* 2015; 67: S10, abst 737
87. Rasmussen A, Radfar L, Grundahl K, Lewis DM, Stone DU, Kaufman CE, Wallace DJ, Weisman MH, Venuturupalli S, Lessard CJ, Kurien B, Anaya JM, Rohrer MD, Gopalakrishnan R, Houston GD, Chodosh J, Hughes PJ, Rhodus NL, Ise J, Hefner K, Kelly JA, Sivilis KL, Scofield RH, Previous diagnosis of Sjogren's syndrome as rheumatoid arthritis or systemic lupus erythematosus, *Arthritis Rheumatol* 2015; 67: S10, abst 621
88. Young KA, Munroe ME, Guthridge JM, Kamen DL, Niewold TB, Gilkeson GS, Weisman MH, Ishimori ML, Wallace DJ, Karp DR, Harley JB, James JA, Norris JM, Investigating the role of vitamin D in the transition to systemic lupus erythematosus in individuals at risk for the disease, *Arthritis Rheumatol* 2015; 67: S10, abst 24
89. Munroe MD, Young KA, Norris JM, Aberle T, Roberts VC, Guthridge JM, Kamen DL, Gilkeson GS, Weisman MH, Ishimori ML, Wallace DJ, Karp DR, Sivilis KL, Harley JB, James JA, Altered soluble mediators, autoantibodies and lupus-specific connective disease questionnaire scores distinguish blood relatives from incomplete lupus from unaffected relatives and relatives with classified SLE, *Arthritis Rheumatol* 2015; 67: S 10 abst 13.
90. Mc Mahon MA, Grossman J, Lorenzo E, Sakakian L, FitzGerald J, Weisman M, Wallace D, Hahn B, Skaggs B, Plasma myeloperoxidase levels are inversely associated with future pHDl formation in women with SLE, *Clin Exp Rheumatol* 2015; 33 (supp9c): S47.
91. Wallace DJ, Biologicals: evidence, trials, state of the art, *Clin Exp Rheumatol* 2015; 33 (supp9c): S5.

92. Smolen J, Popa S, Szombati I, Wallace D, Petri M, Lipsky P, Merrill J, Strand V, Healey P, Li C, Christensen J, Diehl A, Beebe J, Vincent M, Wajdula I, Sridharan S, Significant clinical improvement and reduction of severe flares following administration of an IL-6 monoclonal antibody in systemic lupus erythematosus (SLE) subjects with high disease activity, *Annals Rheum Dis* 2015; 74: OP0185, S2, 141-142.
93. Isenberg D, Merrill J, Hoffman R, Linnik M, Morgan-Cox M, Veenhuizen M, Ilkuni N, Dickson C, Silk M, Wallace D, Dorner T, Efficacy and safety of tabalumab in patients with systemic lupus erythematosus (SLE): results from 2 phase 3, 52 week, multicenter, randomized, placebo-controlled trials, *Annals Rheum Dis* 2015; 74: OP0184, s2 p 141
94. Wallace DJ, Popa S, Spindler AJ, Eimon A, Gonzalez-Rivera T, Utset TO, Petri M, Lipsky PE, Merrill JT, Strand V, Wajdula J, Christensen J, Li C, Diehl A, Vincent M, Beebe, Sridharan S, Improvement of disease activity and reduction of severe flares following subcutaneous administration of an IL-6 monoclonal antibody in subjects with active generalized systemic lupus erythematosus (SLE), *Arthritis Rheum* 2014; 66: 3531
95. Hanly JG, O'Keefe AO, Su L, Urowitz MB, Romero-Diaz J, Gordon C, Bae S-C, Bernatsky SR, Clarke AE, Wallace DJ, et al, Outcome of lupus nephritis and impact on health related quality of life: Results from an international, prospective, inception cohort study, *Arthritis Rheum* 2014; 66: S 428.
96. Hanly JG, Su L, Urowitz M, Romero-Diaz J, Gordon C, Bae S-C, Bernatsky S, Clarke AE, Wallace DJ et al, Mood disorders in systemic lupus erythematosus (SLE): Results from an international inception cohort study, *Arthritis Rheum* 2014; 66: S1158-1159.
97. Furie RA, Petri MA, Gordon C, Strand V, Galatenu C, Bongardt S, Koetse W, Wallace DJ, Correlation of laboratory and clinical parameters with British Isles Lupus Assessment Group response in an open-label extension of epratuzumab in systemic lupus erythematosus, *Arthritis Rheum* 2014; 66: S 1238.
98. Munroe ME, Young KA, Fessler J, Fife D, Kamen DL, Guthridge J, Niewold TB, Weisman MH, Ishimori ML, Wallace DJ, Karp DR, Harley JB, Gilkeson GS, Norris JM, James J, Elevated levels of soluble inflammatory mediators and lupus-specific connective tissue disease questionnaire scores discern unaffected first degree relatives of lupus patient from unaffected individuals not related to lupus patients, *Arthritis Rheum* 2014; 66: S 1258.
99. Mok CC, Tolaza S, Goker B, Clarke AE, Navarra S, Wallace DJ, Weisman MH, Jolly M, Disease specific quality of life in patients with lupus nephritis, *Arthritis Rheum* 2014; 66: S736.
100. Myung G, Forbess LJ, Ishimori ML, Wallace DJ, Weisman MH, Prevalence of cardiac arrhythmias in systemic lupus erythematosus, *Arthritis Rheum* 2014; 66: S 476.
101. Modi M, Ishimori ML, Wallace DJ, Weisman M, Lupus chest pain in the emergency department: a common diagnostic dilemma, *Arthritis Rheum* 2014; 66: S 307-308.
102. Jolly M, Sequira W, Hansi S, Ali Z, Toloza S, Bertoli AM, Blazevic I, Vila LM, Moldovan I, Torralba KD, Goker B, Bourre-Tessier J, Navarra S, Wallace D, Weisman MH, Clarke AE, Mok CC, Hydroxychloroquine use is associated independently with improved quality of life in systemic lupus erythematosus, *Arthritis Rheum* 2014; 66: S297-298
103. Jolly M, Sequira W, Toloza S, Bertoli AM, Vila LM, Blazevic I, Moldovan I, Torralba KD, Goker B, Bourre-Tessier, Navarra SV, Wallace DJ, Weisman MH, Clarke AE, Mok CC, Block JA, Simple disease assessment for people with lupus erythematosus, *Arthritis Rheum* 2014; 66: S312-313.
104. Reddy A, Li X-Q, Buyon JP, Franks AG, Furie RA, Kamen DL, Manzi S, Petri M, Ramsey-Goldman R, Tseng C-E, van Vollenhoven R, Wallace DJ, Askanase AD, Clinical response to belimumab in academic clinical practices, *Arthritis Research & Therapy* 2014; 16: A 49

105. Forbess L, Wallace D, Ishimori M, Weisman M, Outcome measures in systemic lupus erythematosus: constructing a meaningful response index from existing trial data, *Arthritis Res & Therapy* 2014; 16: (S1) A43.
106. Bernatsky S, Ramsey-Goldman R, Boivin J-F, Joseph L, Petri MA, Zoma A, Manzi S, Urowity MB, Gladman DD, Fortin PR, Ginzler EM, Yeli E, Bae S-C, Wallace DJ, Edwourthy SM, Jacobsen S, Gordon C, Dooley MA, Peschken CA, Hanly JG, Alarcon GS, Nived O, Ruiz-Irasdozza G, Isenberg D, Rahman A, witte T, Aranow C, Kamen DK, Steinsson K, Askanase A, Barr SG, Criswell CA, Sturfelt G, Patel NM, Senecal J-L, Zummer M, Pope JE, Ensworth S, El-Gabalwy J-L, Mc Carthy T, St-Pierre Y, Clarke AR=E, Cancer risk factors in systemic lupus erythematosus: multivariate regression analysis in 16,409 patients, *Arthritis Res & Therapy* 2014; 16: (S1) A 35
107. Askanase A, Li X, Reddy A, Buyon J, Furie RA, Riachard DL, Manzi S, Petri M, Ramsey-Goldman R, van Vollenhoven RF, Wallace DJ, Clinical response to belimumab in academic clinical practices, *Ann Rheum Dis* 2015; 73: FRI0372. Supp 2
108. Furie RA, Petri M, Gordon C, Strand V, Galatenu C, Bondardt S, Koetse W, Wallace DJ, Correlation of laboratory and clinical parameters with British Lupus Assessment Group Response in an open-label extension study of epratuzumab in systemic lupus erythematosus, *Ann Rheum Dis* 2014; 73: THU023. Supp 2
109. Petri M, Gordon C, Kalunian K, Pike M, Houssiau F, Strand V, Leszczynski P, Keiserman M, Wagner WA, Wallace DJ, Bongardt S, Kilgallen B, Goldenberg DM, Immunologic response to epratuzumab in patients with systemic lupus erythematosus, *Lupus* 2014; 23: 487.
110. Wallace DJ, Odio-Ros J, Neuwelt M, Kalunian K, Kilgallen B, Bongardt S, Petri M, Jeka S, Gordon C, Strand V, Epratuzumab: Sustained long-term safety profile and effect on corticosteroid use in patients with moderate-to- severe systemic lupus erythematosus, *Lupus* 2014; 23: 486.
111. Clowse MDB, Houssiau F, Petri M, Kilgallen B, Kalunian K, Strand V, Bongardt S, Gordon C, Wallace DJ, Epratuzumab maintains improvements in disease activity for over 2 years in patients with moderate-to-severe systemic lupus erythematosus, *Lupus* 2014; 23: 485-486.
112. van Vollenhoven RF, Mild M, Jacobsen S, Bernatsky S, Wallace DJ, Bae SC, Ramos-Casals M, Garcia-Hernandez FJ, Ramsey-Goldman R, Doria A, Mosca M, Petri MA, Ayala-Gutierrez M, Hanly JG, Two year follow-up on biologics use in 13 centers: Data from the international registry for biologics in systemic lupus erythematosus, *Arthritis Rheum* 2013; 65: abst 1607.
113. van Vollenhoven RF, Petri M, Wallace DJ, Roth D, Molta CT, Hammer H, Tang T, Thompson A, Corticosteroid use across 52 weeks of belimumab therapy in patients with systemic lupus erythematosus: Combined analysis from the BLISS trials, *Arthritis Rheum* 2013; 65: abst 1585.
114. Hanly JG, Urowitz MB, O'Keefe A, Gordon C, Bae SC, Sanchez-Guerrero J, Romero-Diaz J, Clarke AE, Bernatsky S, Wallace DJ, et al, "Lupus Headache": Results from a prospective, international cohort study, *Arthritis Rheum* 2013; 65: 1592.
115. Munroe ME, Young KA, Norris JM, Guthridge JM, Kamen DL, Hiewold TB, Gilkeson GS, Weisman MH, Ishimori ML, Wallace DJ, Karp DR, Harley JB, James JA, Gender, race, and soluble mediators distinguish blood relatives who develop incomplete lupus or classified SLE in the Lupus Autoimmunity in Relatives (LAUREL) study, *Arthritis Rheum* 2013; 65: 1767.
116. Wallace DJ, Ordi-Ros J, Neuwelt CM, Kalunian K, Petri M, Slawomir J, van Vollenhoven R, Kigallen B, Bongardt S, Gordon C, Strand V, Overview of the safety of epratuzumab in systemic lupus erythematosus, *Arthritis Rheum* 2013; 65: abst 1606.
117. Han K, Nagar S, Patel J, Oh A, Walalce DJ, Molta CT, Continuous variables of treatment interventions in patients diagnosed with systemic lupus erythematosus among commercially and Medicaid insured populations in the US, *Arthritis Rheum* 2013; 65: abst 1587.

118. Askanase A, Reddy A, Buyon J, Franks A, Furie R, Kamen DL, Manzi S, Petri M, Ramsey-Goldman R, Tseng C-E, van Vollenhoven RF, Wallace DJ, Favorable clinical response to belimumab at three months, *Arthritis Rheum* 2013; 65: abst 1574.
119. Kalunian K, Clowse ME, Houssiau F, Petri M, Kigallen B, Gordon C, Strand V, Bongardt S, Wallace DJ, Sustained British Isles Assessment Group-measured improvement in moderate-to-severely affected body symptoms by epratuzumab: Results from an open-label extension study, *Arthritis Rheum* 2013; 65: abst 1739.
120. Clowse ME, Houssiau F, Petri M, Kilgallen B, Strand V, Bongardt S, Gordon C, Wallace DJ, Kalunian K, Epratuzumab maintains improvements in disease activity for over 2 years in patients with moderate-to-severe systemic lupus: Results from an open-label long-term extension study, *Arthritis Rheum* 2013; 65: abst 1738
121. Jolly M, Aouhab Z, Toloza S, Bertoli A, Blazevik I, Vila L, Modovan I, Torralba KM, Kaya A, Goker B, Tezcan M, Haznedaroglu S, Bourre-Tessier J, Clarke AE, Wallace DJ, Weisman MH, Alarcon GS, Disease specific quality of life domains are impaired in patients with lupus nephritis, *Arthritis Rheum* 2013; 65: abst 610.
122. Wallace DJ, Gillis BS, Gavin I, Karpenko O, A cytokine/chemokine multiplex assay that is sensitive and specific for fibromyalgia compared to controls, systemic lupus erythematosus and rheumatoid arthritis, *Arthritis Rheum* 2013; 65: abst 842
123. Goldenberg DM, Rossi EA, Michel R, Wallace DJ, Chang CH, Epratuzumab mediates BCR-antigen trogocytosis as potential mechanism of action in systemic lupus erythematosus (SLE), *Annals Rheum Dis* 2013; 72: OP0118.
124. Wallace DJ, Ordi-Ros J, Neuwelt M, Kalunian K, Kilgallen B, Bongardt S, Petri M, Pike M, Jeka S, Gordon C, Strand V, Epratuzumab: Sustained safety profile and effect on corticosteroid use on long-term treatment in patients with moderate-to-severe systemic lupus erythematosus: Results from an open-label, long-term extensions study (SL0008), *Annals Rheum Dis* 2013; 72: THU0277.
125. Gordon C, Clowse M, Houssiau F, Petri M, Kilgallen B, Kalunian K, Strand V, Bongardt S, Wallace DJ, Epratuzumab maintains improvements in disease activity for over two years in patients with moderate-to-severe systemic lupus erythematosus: Results from an open-label, long-term extensions study (SL0008), *Annals Rheum Dis* 2013; 72: THU0272.
126. Strand V, Leszczynski P, Keiserman M, Kilgallen B, Bongardt S, Wallace DJ, Gordon C, Immunologic response to long-term epratuzumab treatment in SL0008, an open-label long-term extension study in patients with moderate- to-severe systemic lupus erythematosus, *Annals Rheum Dis* 2013; 72: THU0286.
127. van Vollenhoven R, Mild M, Jacobsen S, Wallace DJ, Hanly JG, Petri MA, Bernatsky SR, Bae SC, Ramos-Casals M, Garcia-Hernandez F, Ayala-Guiterrez MDM, Ramsey-Goldman R, Doria A, Mosca M, Two year follow up on biologics use in 13 centers: Data from the International Registry for Biologics in SLE (IRBIS), *Ann Rheum Dis* 2013; 72:THU0283.
128. Reddy A, Buyon JP, Franks AG, Furie R, Kamen DL, Manzi S, Petri M, Ramsey-Goldman R, Tseng CE, van Vollenhoven FR, Wallace DJ, Askanase A, Favorable clinical response to belimumab at three months, *Ann Rheum Dis* 2013; 72: THU0271.
129. M Lu, Ramsey-Goldman R, Bernatsky S, Petri M, Manzi S, Urowitz MB, Gladman D, Fortin PR, Ginzler E, Yelin E, Bae S-C, Wallace DJ, Jacobsen S, Dooley MA, Peschken CA, Alarcon GS, Nived O, Gottesman L, Criswell L, Sturfelt G, Dreyer L, Lee JL, Clarke AE, Nonlymphoma hematological malignancies in systemic lupus erythematosus, *Arthritis Research & Therapy* 2012; 14: S3, A64

130. Ishimori M, Gal NJ, Rogatko A, Berman DS, Wilson A, Wallace DJ, Merz NB, Weisman MH, Prevalence of angina in patients with systemic lupus erythematosus, *Arthritis Research & Therapy*, 2012; 14: (S3); A62.
131. Clarke AE, Bernatsky S, Costenbader KH, Urowitz MB, Gladman DD, Fortin PR, Petri M, Manzi S, Isenberg DA, Rahman A, Wallace D, Gordon C, Peschken C, Dooley MA, Ginzler EM, Aranow C, Edworthy SM, Nived O, Jacobsen S, Ruiz-Irastorza, Yelin E, Barr SG, Criswell, Sturfelt G, Dreyer L, Blanco I, Gottesman L, Feldman CH, Ramsey-Goldman R, Lymphoma risk in systemic lupus: effects of treatment versus disease activity, *Arthritis Research & Therapy* 2012: 14: S3, A16.
132. M Jolly, M Kosinski, S Toloza J Block, R Mikolaitis, S Durán-Barragan, A M. Bertoli, I Blazevic, L M. Vila, D Cooray, E P. Katsaros, K. Torralba, I Moldovan, AKay, BGoker, S Haznedaroglu, ME. Tezcan, JBourré-Tessier, S Bernatsky, A E. Clarke, M H. Weisman, S V. Navarra, D J. Wallace16 Graciela S. Alarcon,; Equivalence of various language versions of lupus specific patient reported outcomes measure (Lupus PRO), *Arthritis Rheum* 2012; 64: S607-608
133. Munroe ME, J M. Norris, J M. Guthridge, DL. Kamen, K Moser Sivils, T B. Niewold, G S. Gilkeson5, M H. Weisman, M L. Ishimori, D J. Wallace, D R. Karp, J B. Harley, J A. James, Altered soluble mediators in individuals with incomplete lupus in the Lupus Autoimmunity in Relatives (LAUREL) study, *Arthritis Rheum* 2012; 64: S290
134. Bernatsky S, A E. Clarke, K Costenbader, M B. Urowitz, D. Gladman, P R. Fortin, M Petri, S Manzi, D.A. Isenberg, A Rahman, D Wallace, C Gordon, C Peschke, MA Dooley, E.M. Ginzler, C Aranow, S M. Edworthy, O Nived, S Jacobsen, G Ruiz-Irastorza, E Yelin, S G. Barr, I Blanco, C H. Feldman, R. Ramsey-Goldman Lymphoma risk in systemic lupus: Effects of disease activity versus treatment, *Arthritis Rheum* 2012; 64: S1087
135. Churchill M, Flores-Suarez LF, Wallace D, Phillips K, Martin RW, Cardiel M, Kane J, Bautista E, Salinger DH, Stevens E, Russell CB, Martin D, A Phase Ib multiple, ascending dose study evaluating safety, pharmacokinetics, and early clinical response to brodalumab, a human anti interleukin-17 receptor antibody in rheumatoid arthritis, *Arthritis Rheum* 2012; 64: S555
136. Mc Mahon M, Grossman JM, Skaggs B, Lourenco E, Lee C, Sahakian L, FitzGerald J, Charles-Schoeman C, Gorn AH, Karpouzas G, Weisman MH, Wallace DJ, Chen W, Hahn BH, Inflammatory biomarkers of atherosclerosis and oxidative stress are associated with disease flare in SLE, *Arthritis Rheum* 2012; 64: S272-273
137. Shum KM, Askanase A, Buyon JP, Belmont HM, Franks AG, Furie R, Kamen DL, Manzi S, Petri M, Ramsey-Goldman R, Tseng CE, van Vollenhoven RF, Wallace D, Favorable response to belimumab at 3 months, *Arthritis Rheum* 2012; 64: S610
138. Merrill JT, Furie RA, Wallace DJ, Stohl W, Chatham WW, Weinstein A, McKay JD, Ginzler EM, Zhong W, Freimuth WW, Petri MA, Sustained disease improvement and safety profile over 1745 patient-year (7 years) with belimumab in systemic lupus erythematosus patients, *Arthritis Rheum* 2012; 64: S1110-S1111
139. Strand V, Hobbs K, Wallace DJ, Kalunian K, Kilgallen B, Nikal E, Wegener WA, Goldenberg DM, Epratuzumab- treated systemic lupus erythematosus patients report improvements in health-related quality of life: Final results from an open-label extension study (SL006), *Arthritis Rheum* 2012; 64: S953-954
140. Hobbs K, Wallace DJ, Strand V, Kalunian K, Kilgallen B, Bongardt S, Wegener WA, Goldenberg DM, Safety and efficacy of epratuzumab in open-label extension study (SL006), *Arthritis Rheum* 2012; 64: S276-277
141. Zimmer R, Wallace DJ, Muller S, Randomized, double-blind, placebo-controlled studies of P140 peptide in mannitol (Lupozor) and trehalose (Forigerimod) in patients with SLE, *Arthritis Rheum* 2012; 64: S1110

142. Doria A, Sanchez-Guerrero J, Tegzova D, Ginzler EM, Zhong ZJ, Dennis G, Wallace DJ, Early clinical improvement in SLE patients treated with belimumab, *Annals Rheum Dis* 2012; 71 (S3), 535.
143. Orbai AM, Sturfelt GK, Nived O, Fang H, Alarcon GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg DA, Wallace DJ, Ramsey-Goldman R, Bae S-C, Hanly JG, Sanchez-Guerrero J, Clarke AE, Aranow C, Manzi S, Urowitz MB, Petri M, Anti –C1q antibody in systemic lupus erythematosus, *Arthritis Rheum* 2011; S538
144. Petri M, Orbai A-M, Alarcon GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg DA, Wallace DJ, Nived O, Sturfelt GK, Ramsey-Goldman R, Bae Sang-Choi, Janly JG, Sanchez-Guerrero, Clarke AE, Aranow C, Manzi S, Urowitz MB, Magder L, Derivation and validation of the SLICC classification for systemic lupus erythematosus, *Arthritis Rheum* 2011; 63: S669
145. Wallace D, Strand V, Furie R, Petri M, Kalunian K, Pike M, Kelley L, Gordon C, Evaluation of treatment success in systemic lupus erythematosus clinical trials: Development of the BILAG based composite lupus assessment endpoint, *Arthritis Rheum* 2011; 63: S885-886
146. Merrill JT, Furie RA, Wallace DJ, Stohl W, Chatham WW, Weinstein A, Mc Kay J, Ginzler DM, Zhong ZJ, Pineda L, Klein J, Freimuth W, Petri M, Sustained disease improvement and safety profile over the 1500 patient-year experience (6 years) with belimumab in patients with systemic lupus erythematosus, *Arthritis Rheum* 2011; 63: S222-S223
147. Hanly JG, Urowitz MB, Su L, Gordon C, Bae S-C, Sanchez-Guerrero J, Romero-Diz J, Wallace D, Clarke AE, Bernatsky S, Ginzler EM, Merrill JR, Isenberg DA, Rahman A, Gladman DD, Petri M, Fortin PR, Bruce IN, Steinisson K, Dooley MA, Khamashta MA, Alarcon GS, Fessler NJ, Ramsey-Goldman R, Manzi S, Zoma AA, Sturfelt GK, Aranow C, Ramos M, van Vollenhoven RF, Kalunian KC, Ruiz-Irastorza G, Lim SS, Kamen DL, Peschken CA, Inanc M, A prospective study of seizures in systemic lupus erythematosus, *Arthritis Rheum* 2011; 63L S226-S227
148. Hanly JG, Urowitz MB, Su L, Gordon C, Bae S-C, Sanchez-Guerrero J, Romero-Diz J, Wallace D, Clarke AE, Bernatsky S, Ginzler EM, Merrill JR, Isenberg DA, Rahman A, Gladman DD, Petri M, Fortin PR, Bruce IN, Steinisson K, Dooley MA, Khamashta MA, Alarcon GS, Fessler NJ, Ramsey-Goldman R, Manzi S, Zoma AA, Sturfelt GK, Aranow C, Ramos M, van Vollenhoven RF, Kalunian KC, Ruiz-Irastorza G, Lim SS, Kamen DL, Peschken CA, Inanc M, Predictors of seizures in systemic lupus erythematosus, *Arthritis Rheum* 2011; 63: 226
149. van Vollenhoven R, Jacobsen S, Wallace D, Hanly JG, Petri M, Isenberg DA, Clarke AE, Pineau CA, Bernatsky S, Simard JF, Bae S-C, Ramos-Casals M, Diaz-Ligares C, Ruiz-Irastorza G, Martinez-Berriotxo A, Garcia-Hernandez FJ, Gonzalez-Leon R, Castillo-Palma MJ, Saez L, Callejas JL, Rascon J, de Ramon E, Ayala-Gutierrez M, Camps M, Mild M, Inanc M, Artim-Esen B, Ramsay-Goldman R, Peschken Ca, Suartrito D, Emmi L, Kovacs L, Doria D, Skekanec Z, Ferraccioli G, Gremese E, Sato EI, Biologics use in 23 centers—Data from the International Registry for Biologics in SLE (IRBIS), *Arthritis Rheum* 2011; 63: S235
150. Mc Mahon M, Lorenzo E, Grossman JM, Sahakian L, FitzGerald J, Ragvendra N, Charles-Schoeman C, Gorn AH, Weisman MH, Wallace D, Hahn BH, Skaggs B, Plasma tumor necrosis factor-like inducer of apoptosis (sTWEAK) levels are associated with carotid plaque progression in women with SLE, *Arthritis Rheum* 2011; 63: S310
151. Wallace DJ, Safety profile of belimumab, a B-lymphocyte stimulator-specific inhibitor, in Phase 2 and 3 clinical trials of patients with active systemic lupus erythematosus, *Arthritis Rheum* 2011; 63:S220
152. Jolly M, Block JA, Mikolatis RA, Wallace D, Duran-Barragan S, Bertoli S, Toloza S, Blazevic I, Vila LM, Cooray D, Katsaros EP, Torralba K, Weisman MH, Alarcon GS, Spanish Lupus PRO; Cross cultural validation study for lupus, *Arthritis Rheum* 2011; 63: S725

153. Carr FN, Nicassio PM, Cooray D, Moldovan I, Katsoros EP, Torralba KD, Shinada S, Jolly M, Ishimori ML, Wilson AL, Wallace DJ, Weisman MH, The role of pain and depression in self-reported fatigue, *Arthritis Rheum* 2011; 63: S938
154. Munroe ME, Guthridge JM, Kamen DL, Norris JM, Moser KL, Niewold TB, Gilkeson GS, Karp DR, Weisman MH, Ishimori ML, Wallace DJ, Harley JB, James JA, Altered soluble mediators of inflammation at baseline in individuals who subsequently transition to systemic lupus erythematosus: Early studies from the Lupus Autoimmunity in Relatives (LAUREL) study, *Arthritis Rheum* 2011; 63: S650
155. Orbai AM, Fang H, Merrill JR, Alarson GS, Gordon C, Fortin PR, Bruce IN, Isenberg DA, Wallace DJ, Nived O, Sturfelt GK, Ramsay-Goldman R, Bae S-C, J-G, Sanchez-Guererro J, Clarke AE, Aranow C, Manzi Sm Urowitz MB, Gladman DG, Kalunian KC, Costner MI, Magder LS, Prevalence of direct Coombs test in systemic lupus erythematosus: Clinical and Immunologic associations, *Arthritis Rheum* 2011; S541
156. Orbai AM, Fang H, Merrill JR, Alarson GS, Gordon C, Fortin PR, Bruce IN, Isenberg DA, Wallace DJ, Nived O, Sturfelt GK, Ramsay-Goldman R, Bae S-C, J-G, Sanchez-Guererro J, Clarke AE, Aranow C, Manzi Sm Urowitz MB, Gladman DG, Kalunian KC, Costner MI, Magder LS, Anti beta-2 glycoprotein I IgA in systemic lupus erythematosus, *Arthritis Rheum* 2011; 63: S2
157. S Bernatsky, Ramsey-Goldman R, Foulkes W, Gordon C, Zoma A, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin P, Petri M, Yelin E, Wallace DJ, Edworthy S, Barr S, Jacobsen S, Bae S, Peschken C, Kalunian K, Istenberg D, Rahman A, Aranow C, Dooley M, Steinsson K, Nived O, Sturfelt G, Alarcon GS, Kamen D, Kanly J, Ensworth S, Pope J, Senecal J, Zummer M, Clarke AE, Breast, ovarian and endometrial malignancies in systemic lupus, *Annals Rheum Dis* 2011; 70 (S3): 506.
158. Jolly M, Kosinski M, Garris CP, Jhingan PM, Mikolatis RA, Dennis G, Wallace DJ, Clarke A, Parke A, Dooley MA, Strand V, Alarcon GS, Development of the lupus impact tracker: A tool for patients and physicians to assess and monitor the impact of SLE; *Annals Rheum Dis* 2011; 70 (S3): 501.
159. Jolly M, Kosinski M, Garris CP, Jhingan PM, Mikolatis RA, Dennis G, Wallace DJ, Clarke A, Parke A, Dooley MA, Strand V, Alarcon GS, Validation of the lupus impact tracker: A tool for patients to assess and monitor the impact of SLE; *Annals Rheum Dis* 2011; 70 (S3): 322.
160. Van Vollenhovem R, Jacobsen S, Wallace D, Hanly J, Petri M, Isenberg D, Clarke A, Pineau C, Bernatsky S, Simard J, Simon M, Bae S-C, Ramos-Casals M, Diaz-Lagres C, Ruiz-Irastorza G, Martinez-Berriotxo A, Garcia-Hernandez F, Gonzalez-Leon R, Castillo-Palma, de Ramon E, Saez L, Luis Callejas C, Rascon J, Inanc M, Artim-Esen B, Ramsay- Goldman R, Peschken C, Biologics use in SLE in 18 centers—Data from the International Registry for Biologics, *Annals Rheum Dis* 2011; 70 (S3):322.
161. Wallace D, Navarra S, Houssiau F, Gallacher A, Guzman R, Thomas M, Furie R, Zamani O, Levy R, van vollenhoven R, Cooper S, Zhong z, Freimuth W, Hough D, Cervera R, Safety profile of belimumab in patients with active systemic lupus erythematosus: Pooled Phase 2/3 data, *Ann Rheum Dis* 2011; 70 (S3); 318
162. Urowitz M, Isenberg D, Wallace DJ, Prelude—Edratide Phase-II study outcome—from predefined analyses to more recent assessment approaches, *Ann Rheum Dis* 2011; 70 (S3); 315.
163. Petri M, Furie R, Merrill J, Wallace D, Stohl W, Chatham W, Weinstein A, McKay J, Ginzler E, Zhong Z, Pineda L, Klein J, Freimuth W, Six-year experience with belimumab in patients with SLE; *Ann Rheum Dis* 2011; 70 (S3): 314
164. Petri M, Wallace D, Spindler A, Chindalore V, Wang L, Greth W, Sifalimumab, a fully human anti-interferon-alpha monoclonal antibody, in subjects with systemic lupus

- erythematosus (SLE): Results of a Phase IB randomized, placebo-controlled, dose-escalation intravenous study, *Ann Rheum Dis* 2011; 70 (S3); 125.
165. Van Vollenhoven R, Schneider M, Wallace D, Gallacher A, Roth D, Ji B, Kleodis C, Freimuth W, Hough D, Efficacy of belimumab in patients with systemic lupus erythematosus: Focus on patients with low complement and positive anti ds DNA antibodies—Results from Bliss 52/Bliss76, *Ann Rheum Dis* 2011; 70 (S3): 124.
 166. Wallace DJ, Chatham W, Stohl W, Latinis K, Manzi S, Mc Cune WJ, Tegzova D, Mc Kay J, Avila-Armengol HE, Utset TO, Zhong ZJ, Hough D, Freimuth W, Migone TS, Effect of belimumab on functional antibodies in pneumococcal, tetanus, and influenza vaccines, *Lupus* 2011; 20: 425-426.
 167. van vollenhoven R, Gallacher A, Navarra S, Ginzler EM, Dooley MA, Cervera R, Li EK, Levy RA, Guzman R, Zhong ZJ, Cooper S, Pineda L, Hough D, Wallace D, Belimumab reduced corticosteroid use in patients with SLE: Results from the phase 3 BLISS-52 and BLISS-76 studies, *Lupus* 2011; 20: 425.
 168. Furie R, Merrill JT, Wallace DJ, Stohl W, Chatham W, Mc Cune W, Weinstein A, Mc Kay J, Ginzler EM, Zhong ZJ, Pineda L, Klein J, Freimuth W, Petri M, Five-year experience with belimumab in SLE, *Lupus* 2011; 20: 425.
 169. Gordon C, Petri M, Kalunian K, Strand V, Houssiau F, Pike M, Kilgallen B, Kelley L, Wallace DJ, Epratuzumab demonstrates clinically meaningful improvements in patients with moderate-to-severe systemic lupus erythematosus: Results from Emblem, *Lupus* 2011; 20: 301.
 170. van Vollenhoven RF, Zamani O, Wallace D, Tegzova D, Petri M, Merrill JR, Chatham W, Stohl W, Schwarting A, Cooper S, Zhong ZJ, Freimuth W, Hough D, Furie R, Belimumab reduced disease activity in patients with SLE: BLISS-76, *Lupus* 2011; 20: 349.
 171. Urowitz MB, Gladman DD, Ibanez D, Gordon CP, Bae S-C, Clarke AE, Bernatsky SR, Sanchez-Gererro, Hanly JG, Isenberg DA, Rahman A, Fortin PR, Wallace DJ, Ginzler EM, Merrill JT, Alarcon GS, Fessler BJ, Bruce IN, Sturfelt GK, Nived O, Steinsson K, Khamashta MA, Petri MA, Ramsey-Goldman R, Manzi S, Dooley MA, Van Vollenhoven RV, Aranow CB, Stoll T, Ramos M, Kalunian KC, Zoma AA, Ruiz-Irastorza G, Maddison PJ, Kamen DL, Lim SS, Peschken CA, SLE and atherosclerotic risk factors by ethnicity and geographic distribution at inception in an international cohort of SLE, *Arthritis Rheum* 2010; 62: S784-785.
 172. Hanly JG, Urowitz MB, Su L, Gladman DD, Bae S-C, Gordon C, Clarke AE, Bernatsky SR, Sanchez-Guererro, Hanly JG, Isenberg DA, Rahman A, Fortin PR, Wallace DJ, Ginzler EM, Alarcon GS, Fessler BJ, Bruce IN, Sturfelt GK, Nived O, Steinsson K, Khamashta MA, Petri MA, Ramsey-Goldman R, Manzi S, Dooley MA, Van Vollenhoven RV, Aranow CB, Stoll T, Ramos M, Kalunian KC, Zoma AA, Ruiz-Irastorza G, Maddison PJ, Kamen DL, Lim SS, Peschken CA, Farewell, Thompson K, Theriault C, Merrill J, Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus, *Arthritis Rheum* 2010; 62: S943.
 173. Urowitz MB, Gladman DD, Ibanez D, Bruce IN Gordon CP, Bae S-C, Clarke AE, Bernatsky SR, Sanchez-Guererro, Hanly JG, Isenberg DA, Rahman A, Fortin PR, Wallace DJ, Ginzler EM, Merrill JT, Alarcon GS, Fessler BJ, Bruce IN, Sturfelt GK, Nived O, Steinsson K, Khamashta MA, Petri MA, Ramsey-Goldman R, Manzi S, Dooley MA, Van Vollenhoven RV, Aranow CB, Stoll T, Ramos M, Kalunian KC, Zoma AA, Ruiz-Irastorza G, Maddison PJ, Kamen DL, Lim SS, Peschken CA, *Arthritis Rheum* 2010; 62: S941
 174. Merrill JT, Wallace DJ, Furie RA, Petri MA, Stohl W, Chatham WW, Mc Cune J, Weinstein A, McKay J, Zhong ZJ, Pineda L, Klein J, Freimuth W, Ginzler EM, Five-year experience with belimumab, a BlyS-specific inhibitor, in patients with SLE, *Arthritis Rheum* 2010; 62: S608.
 175. Furie RA, Zamani O, Wallace DJ, Tegzova D, Petri M, Merrill JT, Chatham WW, Stohl W, Schwarting A, Cooper S, Zhong ZJ, Freimuth W, Hough DR, van Vollenhoven R, Belimumab, a

- BlyS-specific inhibitor, reduced disease activity and severe flares in seropositive SLE patients: BLISS-76 study results through week 76, *Arthritis Rheum* 2010; 62:S606.
176. Wallace DJ, Kalunian KC, Petri MA, Strand V, Kilgallen B, Kelley L, Gordon CP, Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): Results from EMBLEM, a Phase IIb study, *Arthritis Rheum* 2010; 62: S605.
 177. Wallace DJ, Navarra S, Gallacher A, Guzman R, Thomas M, Furie RA, Zamani O, Levy RA, van Vollenhoven R, Cooper S, Zhong ZJ, Freimuth W, Pineda L, Cervera R, Safety profile of belimumab, a BlyS-specific inhibitor in patients with active systemic lupus erythematosus (SLE): Pooled data from phase 2 and 3 studies, *Arthritis Rheum* 2010; 62: S491.
 178. Urowitz MB, Gladman DD, Ibanez D, Bruce IN, Gordon CP, Bae S-C, Clarke AE, Bernatsky SR, Sanchez-Guerrero, Hanly JG, Isenberg DA, Rahman A, Fortin PR, Wallace DJ, Ginzler EM, Merrill JT, Alarcon GS, Fessler BJ, Bruce IN, Sturfelt GK, Nived O, Steinsson K, Khamashta MA, Petri MA, Ramsey-Goldman R, Manzi S, Dooley MA, Van Vollenhoven RV, Aranow CB, Stoll T, Ramos M, Kalunian KC, Zoma AA, Ruiz-Irastorza G, Maddison PJ, Kamen DL, Lim SS, Peschken CA, Prevalence and persistence of metabolic syndrome in a multicentre international inception cohort of patients with SLE, *Arthritis Rheum* 2010, S200.
 179. Mc Mahon MA, Grossman JM, Sahakian L, Skaggs B, FitzGerald JD, Charles-Schoeman C, Gorn AH, Weisman MH, Wallace DJ, Hahn BH, PiHDL and high plasma leptin levels are predictors of longitudinal progression of subclinical atherosclerosis in SLE, *Arthritis Rheum* 2010; 62: S197-198.
 180. Chatham WW, Wallace DJ, Stohl W, Latinis K, Manzi S, Mc Cune J, Tegzova D, McKay J, Avila-Armengol, Utset TO, Zhong ZJ, Hough D, Freimuth W, Migone TS, Effect of belimumab, a B-lymphocyte stimulator-specific inhibitor, on functional antibodies to pneumococcal, tetanus and influenza vaccines, *Arthritis Rheum* 2010; 62:S192
 181. Van Vollenhoven R, Jacobsen S, Wallace DJ, Hanly JG, Petri MA, Isenberg DA, Clarke AE, Simard JF, Pineau CA, Bernatsky SR, Biologics use in SLE in 7 centers---Data from the International Registry for Biologics in SLE (IBRIS), *Arthritis Rheum* 2010; 62:S191
 182. Kalunian KC, Wallace DJ, Petri MA, Houssiau FA, Pike MC, Kilgallen B, Kelley L, Gordon CA, BILAG-measured improvement in moderately and severely affected body systems in patients with systemic lupus erythematosus (SLE) by epratuzumab: Results from EMBLEM, a Phase III study, *Arthritis Rheum* 2010; 62:S190
 183. Van Vollenhoven FR, Gallacher A, Navarra S, Ginzler EM, Dooley MA, Cervera R, Li EK, Levy RA, Guzman R, Zhong ZJ, Cooper S, Pineda L, Hough D, Wallace DJ, Belimumab, a BlyS-specific inhibitor, reduced corticosteroid use in patients with active SLE: Results from the Phase 3 BLISS-52 and -76 studies, *Arthritis Rheum* 2010; 62:S189
 184. Urowitz MB, Gladman DD, Ibanez D, Gordon CP, Bae S-C, Clarke AE, Bernatsky SR, Sanchez-Guerrero, Hanly JG, Isenberg DA, Rahman A, Fortin PR, Wallace DJ, Ginzler EM, Merrill JT, Alarcon GS, Fessler BJ, Bruce IN, Sturfelt GK, Nived O, Steinsson K, Khamashta MA, Petri MA, Ramsey-Goldman R, Manzi S, Dooley MA, Van Vollenhoven RV, Aranow CB, Stoll T, Ramos M, Kalunian KC, Zoma AA, Ruiz-Irastorza G, Maddison PJ, Kamen DL, Lim SS, Peschken CA, Atherosclerotic vascular events in a multinational inception cohort of SLE: Description and attribution over an 8 year period, *Arthritis Rheum* 2010; 62:S188
 185. Ting MHX, Donn RP, Lunt M, Urowitz MB, Gladman DD, Ibanez D, Gordon C, Bae SC, Clarke A, Bernatsky S, Hanly J, Isenberg D, Rahman A, Sanchez-Guerrero J, Romero-Dia J, Fortin PR, Wallace D, Ginzler E, Vasudevan A, Merrill J, Alarcon GS, Fessler B, Sturfelt G, Nived O, Steinsson K, Khamashta M, Petri M, Manzi S, Dooley M, Ramsey-Goldman R, Aranow C, Van Vollenhoven R, Ramos M, Stoll T, Kalunian, Zoma A, Maddison P, Bruce IN, Antimalarials may

- attenuate the risk of metabolic syndrome in SLE: Results from an International Inception Cohort Registry, *Arthritis Rheum* 2010, 62:S187
186. Wallace D, Kalunian K, Petri M, Strand V, Kilgallen B, Barry A, Gordon C, Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): Results from EMBLEM, a Phase IIb study, *Annals Rheum Dis* 2010; 69 (Supp 3): 558
 187. Kalunian K, Wallace D, Petri M, Houssiau F, Pike M, Kilgallen B, Barry A, Gordon C, BILAG-measured improvement in moderately and severely affected body systems with systemic lupus erythematosus (SLE) by epratuzumab: Results from EMBLEM, a Phase IIB study, *Annals Rheum Dis* 2010: 69 (Supp 3), 553.
 188. Van Vollenhoven RF, Zamani O, Wallace D, Tegzova D, Merrill JT, Chatham WW, Schwarting A, Hiepe F, Doria A, Sanchez-Guerrero J, Jeka S, Dyczek A, Furie R, Petri M, d’Cruz D, Fojtik Z, Pineda L, Zhong ZJ, Hough D, Freimuth W, Cervera R, Belimumab, a BlyS-specific inhibitor reduces disease activity and severe flares in seropositive SLE patients: BLISS-76 study, *Annals Rheum Dis* 2010; 69 (Supp 3), 74-75.
 189. Chatham W, Weinstein A, Petri M, Merrill JT, Furie R, Wallace DJ, Ginzler EM, Stohl W, Mc Cune J, Pineda L, Zhong ZJ, Klein J, Hough D, Freimuth W, Five years of treatment with belimumab, a BlyS-specific inhibitor, in patients with systemic lupus erythematosus (SLE): Long-term safety and efficacy analyses, *Annals Rheum Dis (Supp 3)* 2010; 69: 147-148.
 190. Urowitz MB, Gladman DD, Ibanez D, Gordon C, Bae SC, Clarke A, Bernatsky S, Hanly J, Isenberg D, Rahman A, Sanchez-Guerrero J, Fortin PR, Wallace D, Vasudevan A, Merrill J, Alarcon GS, Bruce IN, Sturfelt F, Nived O, Steinsson K, Khamashta MA, Petri M, Manzi S, Dooley MA, Ramsey-Goldman R, Aranow C, van Vollenhoven R, Ramos-Casals M, Stoll T, Kalunian K, Zoma A, Maddison P, Bruce I, Prevalence and persistence of metabolic syndrome in a multicentre international inception cohort of patients with SLE, *Lupus* 2010; 19S, 144.
 191. Urowitz MB, Gladman DD, Ibanez D, Gordon C, Bae SC, Clarke A, Bernatsky S, Hanly J, Isenberg D, Rahman A, Sanchez-Guerrero J, Fortin PR, Wallace D, Vasudevan A, Merrill J, Alarcon GS, Bruce IN, Sturfelt F, Nived O, Steinsson K, Khamashta MA, Petri M, Manzi S, Dooley MA, Ramsey-Goldman R, Aranow C, van Vollenhoven R, Ramos-Casals M, Stoll T, Kalunian K, Zoma A, Maddison P, Damage due to glucocorticoids in an SLE inception cohort, *Lupus* 2010; 19S: 144.
 192. Urowitz MB, Gladman DD, Ibanez D, Gordon C, Bae SC, Clarke A, Bernatsky S, Hanly J, Isenberg D, Rahman A, Sanchez-Guerrero J, Fortin PR, Wallace D, Vasudevan A, Merrill J, Alarcon GS, Bruce IN, Sturfelt F, Nived O, Steinsson K, Khamashta MA, Petri M, Manzi S, Dooley MA, Ramsey-Goldman R, Aranow C, van Vollenhoven R, Ramos-Casals M, Stoll T, Kalunian K, Zoma A, Maddison P, Clinical-serologic discordance in a multicentre, international cohort of patients with SLE, *Lupus* 2010; 19S: 143.
 193. Urowitz MB, Gladman DD, Ibanez D, Gordon C, Bae SC, Clarke A, Bernatsky S, Hanly J, Isenberg D, Rahman A, Sanchez-Guerrero J, Fortin PR, Wallace D, Vasudevan A, Merrill J, Alarcon GS, Bruce IN, Sturfelt F, Nived O, Steinsson K, Khamashta MA, Petri M, Manzi S, Dooley MA, Ramsey-Goldman R, Aranow C, van Vollenhoven R, Ramos-Casals M, Stoll T, Kalunian K, Zoma A, Maddison P, ACR criteria at inception and accumulation over 5 years in SLE, *Lupus* 2010; 19S: 142-3.
 194. Petri M, Wallace D, Furie R, Merrill JT, Ginzler E, Stohl W, Chatham WW, Mc Cune J, Weinstein A, Klein J, ZJ Zhong, Freimuth W, Five-year experience with belimumab, a BlyS-specific inhibitor, in patients with systemic lupus erythematosus (SLE), *Lupus* 2010; 19S: 153.
 195. Hanly JG, Urowitz MB, Jackson D, Bae SC, Gordon C, Wallace D, Clarke A, Bernatsky S, Basudevan A, Isenberg D, Rahman A, Sanchez-Guerrero J, Romero-Diaz J, Alarcon GS, Merrill JT, Fortin P, Gladman D, Bruce I, Steinsson K, Khamashta M, Petri M, Sturfelt G, Nived O, Ramsey-

- Goldman Rm Dooley MA, Aranow C, van Vollenhoven R, Ramos-Casals M, Zoma A, Kalunian K, Farewell V, Change in SF-36 summary and sub-scale scores in SLE patients who have clinical improvement and deterioration in neuropsychiatric (NP) events; *Lupus* 2010; 19S: 139.
196. Jolly M, Pickard AS, Mikolatis r, Wilke CF, Rodby R, Fogg R, Sequeira W, Utset TO, Cash TF, Moldovan Im Kataros E, Nicassio P, Ishmori M, Wallace DJ, Block JA, The Lupus PRO: a disease specific patient reported outcome measure for systemic lupus erythematosus in the USA, *Lupus* 2010; 19S: 134
 197. Jolly M, Pickard AS, Mc Elhone K, The SL, Mikoliatitis RA, Rodby R, Sequeira W, Utset TO, Nicassio P, Ishimori M, Wallace DJ, Weisman MH, Block JA, Disease specific patient reported outcome benchmarks for US lupus patients: Lupus PRO and Lupus QoL-US, *Lupus* 2010; 19S: 134.
 198. Mc Bride J, Wallace DJ, Morimoto AY, Zhenling Y, Abbas A, Romeo M, Jiang J, Drappa J, Safety and pharmacodynamic response with administration of single and repeat doses of rontiluzmab in a phase I, placebo, controlled, double-blind, dose escalation study in SLE, *Lupus* 2010; 19S:15.
 199. Gordon C, Wallace DJ, Petri M, Houssiau F, Pike M, Kilgallen B, Barry A, Kalunian K, BILAG measured improvement in moderately and severely affected body systems in patients with systemic lupus erythematosus (SLE): results from EMBLEM, a phase IIb study, *Lupus* 2010: 19S, 14.
 200. Wallace DJ, Kalunian K, Petri M, Strand V, Kilgallen B, Barry A, Gordon A, Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): Results from the EMBLEM, a phase IIb study, *Lupus* 2010: 19S, 14.
 201. Furie RA, Gladman D, d’Cruz D, Zamani O, Wallace D, von Vollenhoven R, Tegzova D, Merrill JT, Schwarting A, Clarke AE, Doria AE, Sanchez-Guerrero J, Chatham WW, Manzi S, Ginzler E, Mc Kay J, Stohl W, Zhong ZJ, Hough D, Cooper SM, Freimuth W, Petri M, Belimumab, a BLYS specific inhibitor, reduced disease activity and severe flares with seropositive SLE: BLISS-76 study, *Lupus* 2010 19S: 13.
 202. Furie RA, Merrill J, Wallace D, Ginzler E, Stohl W, Chatham W, Mc Cune J, Weinstein A, Petri M, Pineda L, Zhong ZJ, Klein J, Freimuth W, Four-year experience with belimumab, a BLYS specific inhibitor, in patients with systemic lupus erythematosus (SLE) LBS02/99 study, *J Clin Rheumatol* 2010; 16: S58-S59.
 203. Goykhman P, Thompson LEF, Yang Y, Shaw LJ, Berman DS, Gill E, Ishimori ML, Martin R, Wallace DJ, Schapira JM, Shufelt CL, Weisman MH, Bairey Merz CN, The utility of adenosine stress-rest cardiac magnetic resonance imaging in evaluating cardiac function and perfusion in women with systemic lupus erythematosus, *J Am College Cardiology* 2010; 55: A127E1190 (supp 1).
 204. Jolly M, Ishimori M, Moldovan I, Katsaros EP, Torralba KD, Cooray D, Shinada S, Block JA, Wallace DJ, Weisman MH, Nicassio P, What does patient-reported Systemic Lupus Activity Questionnaire (SLAQ) measure? *Arthritis Rheum* 2009; S775
 205. Gordon C, Merrill JT, Wallace DJ, Hsieh H, Brunetta P, BILAG versus SELENA-SLEDAI scoring in systemic lupus erythematosus (SLE) patients in EXPLORER, *Arthritis Rheum* 2009; S774
 206. Cervera J, Ishimori ML, Cooray D, Jolly M, Katsaros E, Moldovan I, Shinada S, Torralba KD, Wallace DJ, Block JA, Weisman MH, Nicassio P, Predictors of SF36 scores in a new lupus cohort in Southern California, *Arthritis Rheum* 2009; 60: S 721
 207. Volkmann ER, Grossman JM, Sahakian LJ, Skaggs BJ, FitzGeraald JD, Ragavendra N, Charles-Schoeman C, Chen W, Gorn AH, Karpouzis GA, Weisman MA, Wallace DJ, Hahn BH, Mc Mahon MA, Low physical activity is associated with proinflammatory dhgh-density lipoprotein

- and increased subclinical atherosclerosis in women with systemic lupus erythematosus, *Arthritis Rheum* 2009; S 590
208. Vinet E, Clarke AE, Gordon C, Urowitz MB, Pineau CA, Isenberg DA, Rahman A, Wallace DJ, Alarcon GS, Bruce IN, Petri MA, Dooley MA, Aranow C, van Vollenhoven RF, Decreased live births in women with SLE, *Arth Rheum* 2009; 60: S584
 209. Petri M, Furie R, Merrill J, Wallace DJ, Ginzler EM, Stohl W, Chatham W, Mc Cune J, Weinstein A, Pineda L, Zhong ZJ, Klein J, Hough D, Freimuth W, Four-year experience of belimumab, a BlyS specific inhibitor, in systemic lupus erythematosus (SLE), *Arthritis Rheum* 2009; S515-516
 210. Mc Mahon M, Sahakian LJ, Grossman JM, Skaggs BJ, FitzGerald JD, Charles-Schoeman C, Ragavendra N, Gorn AH, Karpouzis GA, Volkman ER, Weisman M, Wallace D, Hahn BH, PiHDL is associated with a 19-fold increased risk of progression of subclinical atherosclerosis in SLE, *Arthritis Rheum* 2009; 50: S108-109
 211. Merrill JT, Wallace DJ, Latinis KM, Utset TO, Furie R, Neuwelt CM, Looney RJ, Hsieh H, Wagner B, Brunetta P, Treatment of systemic lupus erythematosus (SLE) with rituximab: 78-week safety data from the Phase II/III EXPLORER Trial, *Arthritis Rheum* 2009; 60: S103-104
 212. Merrill J, Shanahan J, Neuwelt C, Latinis K., Hsieh HJ, Isener D, Brunetta P, Gordon C, Wallace D, Zhang D, Oates J, Utset T, Rituximab in extra-renal SLE patients showed no significant difference compared to placebo at 52 weeks in the randomized, double-blind phase Phase II/III Explorer, *Ann Rheum Dis* 2009; 68: THU0230.
 213. Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D’Cruz D, Wallace DJ, Bae SC, Sigal LH, Becker JC, Kelly S, Raghupathi K, Li T, Peng Y, Kinaszuk M, Nash P, Activity of abatacept in SLE: Results of a 12 month phase II exploratory study, *Ann Rheum Dis* 2009; 68: OP0009.
 214. Merrill JT, Furie R, Wallace DJ, Mc Kay J, Ginzler EM, Wellborne F, Aranow C, Burnette M, Mishra N, Pineda L, Zhong J, Hough D, Freimuth W, 4 year experience of belimumab, a fully human monoclonal antibody, in the treatment of systemic lupus erythematosus, *Ann Rheum Dis* 2009; 68: THU245
 215. Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D’Cruz D, Wallace D, Bae SC, Sigal L, Becker J-C, Kelly S, Raghupathi K, Peng Y, Kinaszczuk M, Nash P, The efficacy and safety of abatacept in SLE: Results of a 12 month- exploratory study, *Arthritis Rheum* 2008; 58:
 216. Jolly M, Pickard AS, Fogg L, Wilke CT, Lin HW, Mikolaitis RA, Sequeira W, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG, Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus (SLE): Results from the randomized, double-blind phase II/III study EXPLORER, *Arthritis Rheum* 2008; 58:
 217. Petri M, Sturfeldt G, Nived O, Wallace DJ, Weisman M, Gladman D, et al, The relationship of anti-C1q to the ACR Classification Criteria for SLE, *Arthritis Rheum* 2008; 58: S 1256
 218. Petri M, Naqibuddin M, Wallace DJ, Weisman MH, Holliday SL, Sampedro MM, Carson K, Padilla P, Brey RL, Cognitive function over time in SLE: The Brain CONNECTIONS inception cohort, *Arthritis Rheum* 2008; 58: S 1094
 219. Chatham W, Furie R, Petri M, Ginzler EM, Wallace DJ, Stohl W, Strand V, Weinstein A, Zhong J, Hough D, Freimuth W, Belimumab (Fully human monoclonal antibody to BlyS) improved or stabilized systemic lupus erythematosus (SLE) disease activity over 3 years of therapy, *Arthritis Rheum* 2008; 58: S 1088
 220. Wallace DJ, Hobbs K, Houssiau F, Strand V, Tak PP, Wegner WA, Kelly L, Barry A, Epratuzumab (anti-CD22 mAb targeting B-cells) provides clinically meaningful reductions in corticosteroid (CS) use with a favorable safety profile in patients with moderate/severe flaring SLE: Results from randomized controlled trials (RCTs), *Arthritis Rheum* 2008; 58: S 1087

221. Petri M, Hobbs K, Gordon C, Strand V, Wallace DJ, Kelly L, Wegener W, Barry A, Clinical meaningful improvements with epratuzumab (Anti-CD22 mAB targeting B cells) in patients with moderate/severe SLE flares: Results from 2 randomized controlled trials, *Arthritis Rheum* 2008; 58: S 1084
222. Utowitz M, Gladman DD, Ibanez D, Bae SC, Gordon C, Fortin PR, Clarke A, Hanly JG, Wallace D, et al, Changes in Quality of Life in the first 5 years of disease in a multicentre cohort of patients with systemic lupus erythematosus (SLE), *Arthritis Rheum* 2008; 58: S 1072
223. Stohl W, Merrill JT, Looney RJ, Buyon J, Wallace DJ, Weisman M, Ginzler EM, et al, Phase Ia single- and phase Ib multiple-dose studies of AMG 623 (an anti-BAFF peptibody) in systemic lupus erythematosus, (SLE), *Arthritis Rheum* 2008; 58: S 1065
224. Mc Kay J, Merrill JT, Wallace DJ, Furie R, Stohl W, Latinis K, Wellborne F, Wolfe Sm Angelly T, Chen A, Pineda L, Hough D, Long-term safety profile of belimumab (Fully human monoclonal antibody to BlyS) in patients with systemic lupus erythematosus (SLE), *Arthritis Rheum* 2008; 58: S 1064
225. Au K, Sahakian L, Skaggs B, Grossman J, Fitzgerald J, Wallace D, Hahn B, Lipid biomarkers may be associated with osteoporosis in systemic lupus erythematosus, *Arthritis Rheum* 2008; 58: S 665
226. Urowitz MB, Gladman DD, Ibanez D, Sanchez-Guererro J, Bae SC, Gordon C, Fortin PR, Clarke A, Hanly JG, Wallace D, et al, Artherosclerotic vascular events in a multinational inception cohort of SLE: description and attribution over an 8 year period, *Arthritis Rheum* 2008; 58: S 664
227. Mc Mahon M, Grossman JM, Sahakian L, Skaggs BJ, FitzGerald DJ, Charles-Schoeman C, Ragavendra N, Wallace DJ, Weisman M, Witzum J, Hahn BH, PiHDL is a stronger predictor for atherosclerosis than other high-risk inflammatory lipids, and is associated with a 17-fold risk of subclinical atherosclerosis in SLE, *Arthritis Rheum* 2008;58: S 571
228. Hanly JG, Urowitz MB, Su L, Sanchez-Guererro J, Bae SC, Gordon C, Wallace DJ, Short-term outcome of neuropsychiatric events in SLE patients upon enrollment into an international inception cohort study, *Arthritis Rheum* 2008; 58: S 460
229. Urowitz MB, Gladman DD, Ibanez d, Sanchez-Guererro J, Bae SC, Gordon C, Fortin PR, Clarke A, Hanly JG, Wallace D, et al, Predictors of atherosclerotic vascular events (AVE) in a multnational inception cohort of SLE: a time to event analysis, *Arthritis Rheum* 2008; 58: S 431
230. Urowitz MB, Gladman DD, Ibanez D, Sanchez-Guererro J, Bae SC, Gordon C, Fortin PR, Clarke, Hanly JG, Wallace D, et al, Accumulation of atherosclerotic risk factors and lupus disease risk factors in the first 5 years of SLE: Results from the SLICC inception cohort, *Arthritis Rheum* 2008; 430
231. Burge D, Martin RW, Bookbinder S, Littlejohn T, Wallace D, Kirsch T, Bass D, Shu C, TRU-015 administered every 24 weeks for 2 years is well tolerated and maintains consistent pharmacodynamic effects in rheumatoid arthritis patients, *Arthritis Rheum* 2008; 58: S 374
232. Wallace D, Hobbs K, Houssiau F, Strand V, Tak P, Wegener W, Kelley L, Barry A, Randomized controlled trials of epratuzumab (anti CD22 MAB targeting B cells) reveal clinically meaningful reductions in corticosteroid (CS) use with favorable safety profile in moderate and severe flaring SLE patients, *Ann Rheum Dis* 2008; 67 supp 2; 212.
233. Wallace DJ, Merrill JT, Stohl W, Furie R, Ginzler EM, Petri M, Wolfe SM, Mc Kay J, Dooley M, Pineda L, Ronniger J, Freimuth W, Long term safety profile of belimumab (fully human monoclonal antibody to BlyS) in patients with systemic lupus erythematosus (SLE), *Lupus* 2008; 17: 483
234. Ginzler EM, Chatham W, Stohl W, Wallace DJ, Merrill JT, Petri M, Furie R, Aranow C, Mc Cune J, Mc Cain A, Weinstein A, Diskin K, Zhong J, Pineda J, Freimuth W, Correlation of biomarker changes with clinical improvement over 2.5 years of belimumab (fully human

- monoclonal antibody to BlyS) therapy in systemic lupus erythematosus patients, *Lupus* 2008; 17: 457.
235. Petri M, Furie R, Ginzler EM, Wallace DJ, Weisman MH, Stohl W, Mc Kay J, Strand V, Clarke A, Burnetter MC, Wellborne F, Dooley M, Mc Cune J, Latnis K, Zhong J, Penda L, Freimuth, Belimumab (fully human monoclonal antibody to BlyS) improved or stabilized systemic lupus erythematosus (SLE) disease activity over 2.5 years of therapy, *Lupus* 2008; 17: 453.
236. Merrill J, Wallace D, Mc Cain A, Lisse J, Lee E, Mc Kay J, Ginzler E, Pineda L, Wellborne F, Freimuth W, Ronniger J, Mishra N, Long-term safety profile of belimumab (fully human monoclonal antibody to BlyS) in patient with systemic lupus erythematosus (SLE), *Annals Rheum Dis* 2008; 217
237. Ginzler E, Wallace DJ, Freimuth W, Hough D, Dooley M, Martin D, Zhong J, Wolfe S, Mc Cune J, Merrill J, Furie R, Mc Kay J, Chatham W, Belimumab (fully human monoclonal antibody to BlyS) reduced steroid dose in systemic lupus erythematosus (SLE) patients during 3 years of therapy, *Annals Rheum Dis* 2008; 67 suppl 2; 217
238. Petri M, Barry A, Kelley L, Strand V, Wallace DJ, Houssiau F, Hobbs K, Tak PP, Wegener W, Randomized controlled trials of epratuzumab (Anti CD22 MAB targeting B cells) reveal clinically meaningful reductions in corticosteroid (CS) use with favorable safety profile in moderate and severe flaring SLE patients, *Annals Rheum Dis* 2008; 67 suppl 2; 53
239. Merrill J, Lantis K, Wallace DJ, Shanahan J, Utset T, Neuwelt C, Wallace D, Gordon C, Oates J, Isenberg D, Zhang D, Brunetta P, Design and baseline characteristics of patients in a randomized double-blind, placebo-controlled Phase II/III study (Explorer) to evaluate the efficacy and safety of rituximab in patients with moderate to severely active systemic lupus erythematosus (SLE), *Annals Rheum Dis* 2008; 67 suppl 2: 347
240. Burge D, Martin R, Wallace DJ, Bookbinder S, Kirsch T, Bass D, Littlejohn T, Repeated therapy with TRU-015 is well tolerated and results in consistent pharmacodynamic effects in rheumatoid arthritis patients, *Annals Rheum Dis* 2008; 67 suppl 2; 128.
241. Urowitz M, Gladman DD, Ibanez D, Fortin PR, Sanchez-Guerrero J, Bae S-C, Gordon CP, Clarke AE, Hanly JG, Wallace DJ, Isenberg DA, Merrill JT, Ginzler EM, Alarcon GS, Steinsson K, Petri MA, Khamashta MA, Bruce I, Dooley MA, Manzi S, Ramsey-Goldman R, Sturfelt GK, Nived O, Zoma AA, Maddison PJ, Font J, van Vollenhoven R, Aranow C, Kalunian KC, Stoll T, Wofsy D, Buyon JP, Arteriosclerotic vascular events in a multinational inception cohort of SLE: Description and attribution, *Arthritis Rheum* 2007; 55: S454-455
242. Naqibuddin M, Sampedro M, Carson KA, Wallace DJ, Weisman MH, Brey RL, Holliday SL, Petri M, Cognitive function changes in newly diagnosed systemic lupus erythematosus, *Arthritis Rheum* 2007; 56: S823.
243. Petri M, Narayana S, Naqibuddin M, Sampedro M, Brey RL, Holliday SL, Kochunov P, Franklin C, Wallace DJ, Weisman MH, Fox PT, White matter inflammation revealed by FDG-PET as a marker of SLE disease activity, *Arthritis Rheum* 2007; 56: S797.
244. Hanly JG, Urowitz MB, Siannis F, Farewell V, Gordon C, Bae SC, Isenberg D, Dooley MA, Clarke AE, Bernatsky S, Gladman D, Fortin PR, Manzi S, Steinsson K, Bruce I, Ginzler E, Aranow C, Wallace DJ, Ramsey-Goldman R, Van Vollenhoven R, Sturfelt F, Nived O, Sanchez-Guererro J, Alarcon GS, Petri M, Khamashta M, Zoma A, Font J, Kalunian K, Qi DQ, Merrill JT, Autoantibodies and neuropsychiatric events at diagnosis of systemic lupus erythematosus, *Arthritis Rheum* 2007; 56: S749.
245. Petri M, Furie R, Ginzler E, Wallace DJ, Stohl W, Strand V, Weinstein A, Mc Kay J, Zhong J, Fernandez V, Freimuth W, Novel combined response endpoint and systemic lupus erythematosus (SLE) flare index (SFI) demonstrate belimumab (Fully human monoclonal

- antibody to BlyS) improves or stabilizes SLE disease activity and reduces flare rate over 2.5 years, *Arthritis Rheum* 2007; 56: S527.
246. Wallace DJ, Petri M, Olsen N, Kyriou K, Dennis G, Yao Y, Jallal B, Coyle A, Zeng L, White B, MEDI-545, an anti- interferon alpha monoclonal antibody, shows evidence of clinical activity in systemic lupus erythematosus, *Arthritis Rheum* 2007; 56: S526.
 247. Posalski J, Ishimori ML, Wallace DJ, Weisman MH, Mycophenolate mofetil in SLE: Results from treatment of 75 patients in a community practice, *Arthritis Rheum* 2007; 56: 4290-4291.
 248. Ishimori ML, Schoenwetter M, Aguilar D, Dubois RW, Hector R, Niccasio P, Russak S, Ress RM, Wallace DJ, Eisenberg D, Robinson D Jr, Getsy JA, Patients and clinical perceptions of importance differ on physical and psychosocial issues in systemic lupus erythematosus (SLE), *Arthritis Rheum* 2007; 56: S457.
 249. Mc Mahon MA, Grossman J, Skaggs B, Li M, Fitzgerald J, Charles C, Ragavendra R, Wallace D, Weisman M, Chen W, Hahn BH, Accelerated atherosclerosis in women with SLE and pro-inflammatory HDL may in part be explained by reduced Apo3 activity, *Arthritis Rheum* 2007; 56: S216-217.
 250. Petri M, Wallace DJ, Weisman M, Gladman D, Fortin P, Urowitz M, Werth V, Costner M, Gordon C, Alarcon GS, Ramsey-Goldman R, Maddison P, Clarke A, Manzi S, Bae S-C, Merrill JT, Ginzler E, Hanly J, Nived O, Sturfelt G, Sanchez-Guerrero J, Bruce I, Aranow C, Isenberg D, Zoma A, The association between reference laboratory values and the classification of SLE, *Arthritis Rheum* 2007; 56: S218.
 251. Mundwiler ML, Brown DL, Silverman JM, Furst DE, Khanna D, Leibling M, Louie JS, Wallace DJ, Weisman MH, What is the utility of the MRI in predicting radiographic erosions in the rheumatoid foot, *Arthritis Rheum* 2007; 56:S276-277
 252. Merrill JR, Wallace DJ, Stohl W, Furie R, Ginzler E, Stern S, Lisse J, Lee E, Mc Cain A, Pineda L, Ronniger J, Freimuth W, Safety profile of belimumab (fully human monoclonal antibody to BlyS) in patients with systemic lupus erythematosus (SLE) treated during a placebo-controlled trial and in a long-term continuation study, *Arthritis Rheum* 2007; 56: S210
 253. Urowitz M, Gladman DD, Ibanez D, Fortin PR, Sanchez-Guerrero J, Bae S-C, Gordon CP, Clarke AE, Hanly JG, Wallace DJ, Isenberg DA, Merrill JT, Ginzler EM, Alarcon GS, Steinsson K, Petri MA, Khamashta MA, Bruce I, Dooley MA, Manzi S, Ramsey-Goldman R, Sturfelt GK, Nived O, Zoma AA, Maddison PJ, Font J, van Vollenhoven R, Aranow C, Kalunian KC, Stoll T, Wofsy D, Buyon JP, Accumulation of atherosclerotic risk factors over 3 years by ethnicity in an International Inception Cohort, *Arthritis Rheum* 2007; 56:S455.
 254. Urowitz M, Gladman DD, Ibanez D, Fortin PR, Sanchez-Guerrero J, Bae S-C, Gordon CP, Clarke AE, Hanly JG, Wallace DJ, Isenberg DA, Merrill JT, Ginzler EM, Alarcon GS, Steinsson K, Petri MA, Khamashta MA, Bruce I, Dooley MA, Manzi S, Ramsey-Goldman R, Sturfelt GK, Nived O, Zoma AA, Maddison PJ, Font J, van Vollenhoven R, Aranow C, Kalunian KC, Stoll T, Wofsy D, Buyon JP, Disease outcomes in the first 4 years of SLE: Results from the SLICC inception cohort, *Arthritis Rheum* 2007; 56: S454-455
 255. Burge D, Martin R, Wallace D, Littlejohn T, Bookbinder S, Bannink J, Shu C, Safety and pharmacodynamics of repeat administration of TRU-015, a CD20-directed SMIP therapeutic, in subjects with rheumatoid arthritis, *Arthritis Rheum* 2007; 56: S168-169.
 256. Wallace D, Gotto J, Bipolar illness with complaints of chronic musculoskeletal pain is a form of pseudofibromyalgia. *J Musculoskeletal Pain* 2007; 15: Supp: 59.
 257. Nestrorov I, Pena Rossi C, Manafo A, Papasouliotios O, Rogge M, Dall'Era M, Wofsy D, Chakravarty E, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Nasanov E, Stanislav M, Yakusevich V, Ershova O, Lomareva N, Wallace D, Pharmacokinetics and biological activity of

- atacept after intravenous and subcutaneous administration to SLE patients, *Ann Rheum Dis* 2007; 0P0021
258. Ginzler E, Furie R, Wallace D, Strand V, Lisse J, Stohl W, Merrill J, Petri M, Aranow C, Weinstein A, Fernandez V, Zhong J, Freimuth W, Novel combined response endpoint shows that belimumab (fully human monoclonal antibody to B-lymphocyte stimulator (BLyS) improves or stabilizes SLE activity in a phase II trial, *Ann Rheum Dis* 2007; 62. 0P0018
 259. Wallace D, Levin R, Matheson R, Merrill R, White B, Early safety results of MEDI-545, an anti-interferon-alpha- monoclonal antibody, in patients with systemic lupus erythematosus in the MI-CP126 trial, *Lupus* 2007 16: 233 (supp)
 260. Wu H, Yu Y, Hanvivadhanakul P, Johnson BB, Qian XX, Feng X, Grossman JM, Cantor RM, Hebert LA, Rovin BH, Birmingham DJ, Chen CJ, Badsha HM, Bernard YH, Ching HH, Wallace DJ, Hahn BH, Goodship THJ, Shen N, Tsao BP, Association between the Y402H polymorphism of complement factor H and lupus nephritis is identified and confirmed in Chinese families, *Lupus* 2007; 16: 153 (supp)
 261. Hanly JG, Urowitz MB, Sanchez-Guererro J, Bae SC, Gordon C, Wallace DJ, Isenberg D, Alarcon G, Clarke A, Bernatsky S, Merrill JT, Petri M, Dooley MA, Gladman D, Fortin P, Steinsson E, Bruce I, Manzi S, Khamashta M, Zoma A, Aranow C, Ginzler E, Van Vollenhoven R, Font J, Sturfelt G, Nived O, Ramsay-Goldman R, Kalunian K, Douglas J, Thompson K, Farewell V, Clinical significance of neuropsychiatric (NP) events at the time of diagnosis of systemic lupus erythematosus (SLE), *Lupus* 2007; 16: 116-117 (supp)
 262. Wu H, Grossman JM, Cantor RM, Herbert LA, Rovin BH, Birmingham DJ, Wallace DJ, Yu CY, Hahn BH, Tsao BP, Evidence for SLE susceptibility gene(s) at 1q23-24, *Lupus* 2007; 16: 63 (supp) Ishimori M, Schoenwetter M, Aguilar D, Dubois RW, Hector R, Nicassion P, Russak SM, Ress RM, 180. Wallace DJ, Eisenberg D, Robinson D Jr, Getsy JA, Weisman MH, Differences between patient and clinician perceptions of physical and psychosocial issues in systemic lupus erythematosus, *Lupus* 2007; 16: 107 (supp)
 263. Furie R, Wallace D, Lisse J, Stohl W, Merrill J, Petri M, Ginzler E, Aranow C, Weinstein A, Strand V, Fernandez V, Zhong J, Freimuth W, Novel combined response endpoint shows that belimumab (fully human monoclonal antibody to B lymphocyte stimulator <BLyS> improves or stabilizes SLE disease activity in a Phase II trial, *Lupus* 2007; 16: 43-44 (supp)
 264. Wallace DJ, Preventive strategies without using lupus medicine and newer concepts for older lupus medications, *Lupus* 2007; 16: 39 (supp)
 265. Dall'Era M, Chakravarty E, Genovese M, Wallace D, Kavanaugh A, Kalunian K, Dhar P, Pena-Rossi C, Wofsy D, Trial of atacept in patients with systemic lupus erythematosus, *Arthritis Rheum* 2006; 54: 4042-4043.
 266. Shoenwetter M, Aguilar D, Dubois RW, Hector R, Russak SM, Ress RM, Wallace DJ, Eisenberg D, Robinson D Jr, Calimlim BM, Weisman MH, Content development for a new SLE quality of life questionnaire: Use of open and closed-ended patient inputs to identify important themes perceived to be most important among SLE patients, *Arthritis Rheum* 2006; 54: 4100-4101.
 267. Shoenwetter M, Aguilar D, Dubois RW, Hector R, Russak SM, Ress RM, Wallace DJ, Eisenberg D, Weisman MH, Content development for a new SLE quality of life questionnaire: Use of open and closed-ended patient inputs to identify important themes in daily functioning among SLE patients, *Arthritis Rheum* 2006: 54: 4048-4049.
 268. Wallace DJ, Lisse J, Stohl W, McKay J, Boling E, Merrill JT, Furie R, Petri M, Ginzler E, Chatham W, Fernandez V, Zhong J, Chevrier M, Freimuth W, Belimumab (BmAb) reduces SLE disease activity and demonstrates durable bioactivity at 76 weeks, *Arthritis Rheum* 2006; 53: S790

269. Stohl W, Wallace DJ, Merrill JT, Chatham W, Gruhn W, Aranow C, Burnette M, Pogue B, Mc Cune W, Petrone D, Zhong J, Migone TS, Freimuth, Chevrier M, Changes in circulating B-cell counts, autoantibody levels and immunoglobulins that associate with therapeutic responsiveness in SLE to BLYS protein antagonism by belimumab, *Arthritis Rheum* 2006; 53: S780
270. Nazibuddin M, Carson KA, Sampedro MM, Wallace DJ, Weisman MH, Brey RL, Holliday SL, Narayana S, Fox PT, Franklin C, Padilla PA, Petri M, Brain imaging (MRI and FDG-PET) and cognitive function in newly diagnosed SLE, *Arthritis Rheum* 2006; 53: S623
271. Ishimori ML, Metzger AL, Wallace DJ, Morris RI, Sama J, Weisman MH, Screening for autoantibodies: the significance of ANA titer and its relationship to other antibodies, *Arthritis Rheum* 2006; 53: S441-442
272. Wu H, Boackie S, Hanvivadhanakul P, Ulgiati D, Grossman J, Lee Y, Shen N, Abraham L, Mercer T, Park E, Herbert L, Rovin B, Birmingham D, Chang C, Chen C, Mc Curdy D, Badsha H, Thong B, Ching H, Arnett F, Wallace D, Yu CY, Hahn BH, Cantor R, Tsao B, Association of a common haplotype of complement receptor 2 (CR2) with increased risk of SLE, *Arthritis Rheum* 2006; 53: S291
273. Hanvivadhanakul P, Johnson B, Wu H, Grossman JM, Cantor RM, Hebert LA, Rovin BH, Birmingham DJ, Yung Yu c, Wallace DJ, Goodship THJ, Hahn BH, Feng X, Tsao BP, Association between 2 functional single polymorphisms (SNPs) in complement factor H (CFH) and SLE, *Arthritis Rheum* 2006; 53: S297
274. Hanly JG, Urowitz MB, Sanchez-Guerrero J, Bae S-C, Gordon C, Wallace DJ, Isenberg D, Alarcon G, Clarke A, Bernatsky S, Merrill JT, Petri M, Dooley MA, Gladman D, Fortin PR, Steinsson K, Bruce I, Manzi S, Khamashta M, Zoma A, Aranow C, Ginzler E, Van Vollenhoven R, Font J, Sturfelt, Nived O, Ramsey-Goldman R, Kalunian K, Douglas J, Thompson K, Farewell V, Clinical significance of neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus, *Arthritis Rheum* 2006; 53: S274
275. Driver CB, Forbess CJ, Pourabbani S, Wallace DJ, Waxman AD, Liou D, Minoshima S, Weisman MH, Clinical validation of the watershed sign as a marker for neuropsychiatric systemic lupus erythematosus, *Arthritis Rheum* 2006; 53: S620
276. Brey RL, Naqubuddin M, Holliday, SL, Padilla PA, Fox PT, Narayana S, Franklin C, Samerdro M, Wallace DJ, Weisman MH, Petri M, Matrix metalloproteinase-9 level, brain imaging findings and cognitive dysfunction in an SLE inception cohort: Brain CONNECTIONS, *Arthritis Rheum* 2006; 53: S552
277. Urowitz M, Gladman D, Fortin P, Ibanez D, Sanchez-Guerrero J, Bae SC, Clarke A, Gordon C, Hanly J, Isenberg D, Wallace D, Ginzler E, Merrill J, Alarcon G, Steinsson K, Petri M, Dooley MA, Bruce I, Manzi S, Ramsey-Goldman R, Nived O, Sturfelt G, Maddison P, Khamashta M, Font J, Zoma A, Aranow C, van Vollenhoven R, Kalunian K, Stoll T, Systemic lupus international collaborating clinics (SLICC) inception cohort registry to study risk factors for atherosclerosis: accumulation of atherosclerotic risk factors over 3 years, *Arthritis Rheum* 2006; 53: S521
278. Petri M, Hewitt A, Wallace DJ, Celecoxib does not increase hypercoagulability in serum nor decrease urinary 2,3-dinor-6-keto-PGF1 alpha in SLE, *Arthritis Rheum* 2006; 53: S446
279. Petri M, Kasitanon N, Magder LS, Bae SC, Hanly JG, Isenberg D, Nived O, Sturfelt G, van Vollenhoven R, Wallace DJ, Alarcon G, Adu J, Avila-Casado, Bernatsky S, Bruce I, Clarke A, Contreras G, Fine DM, Gladman D, Gordon C, Kalunian K, Madaio MP, Rovin BH, Sanchez-Guererro J, Steinsson K, Systemic lupus international collaborating clinics (SLICC) renal activity/response exercise (RARE): Developing a renal activity index and a renal response index, *Arthritis Rheum* 2006; 53: S444

280. Petri M, Kasitanon N, Magder LS, Bae SC, Hanly JG, Isenberg D, Nived O, Sturfelt G, van Volenhoven R, Wallace DJ, Alarcon G, Adu J, Avila-Casado, Bernatsky S, Bruce I, Clarke A, Contreras G, Fine DM, Gladman D, Gordon C, Kalunian K, Madaio MP, Rovin BH, Sanchez-Guerrero J, Steinsson K, Systemic lupus international collaborating clinics (SLICC) renal activity/response exercise (RARE): Comparison of agreement in renal response, *Arthritis Rheum* 2006; 53: S444
281. Urowitz M, Gladman D, Fortin P, Ibanez D, Sanchez-Guerrero J, Bae SC, Clarke A, Gordon C, Hanly J, Isenberg D, Wallace D, Ginzler E, Merrill J, Alarcon G, Steinsson K, Petri M, Dooley MA, Bruce I, Manzi S, Ramsey-Goldman R, Nived O, Sturfelt G, Maddison P, Khamashta M, Font J, Zoma A, Aranow C, van Vollenhoven R, Kalunian K, Stoll T, Systemic lupus international collaborating clinics inception cohort registry to study risk factors for atherosclerosis: Metabolic syndrome, prevalence and associated features, *Arthritis Rheum* 2006; 53: S282
282. Urowitz MB, Gladman DD, Ibanez D, Fortin PR, Sanchez-Guerrero J, Bae S, Clarke A, Cordon C, Hanly J, Isenberg D, Wallace D, Ginzler E, Merrill J, Alarcon G, Steinsson K, Petri M, Dooley M, Bruce I, Manzi S, Ramsey-Goldman R, Nived O, Sturfelt G, Maddison P, Khamashta M, Font J, Zoma A, Aranow C, van Vollenhoven R, Kalunian K, Stoll T, Systemic lupus international collaborating clinics (SLICC) inception cohort registry to study risk factors for atherosclerosis: Report on the first 582 patients, *Arthritis Rheum* 2006; 53: S281
283. Ostergaard M, Wiell C, Sierakowski S, Wallace D, HuMax-CD20, a novel fully human monoclonal IgG1 antibody in the treatment of rheumatoid arthritis, *Arthritis Rheum* 2006; 53: S832
284. Burge DJ, Shu C, Martin RW, Littlejohn TW, Wallace DJ, Taborn J, Palmer WR, Kivitz A, TRU-015, a small modular immunopharmaceutical (SMIP-TM) drug candidate directed against CD20, demonstrates clinical improvement in subjects with rheumatoid arthritis, *Arthritis Rheum* 2006; 53: S230
285. Wallace DJ, Lisse J, Stohl W, McKay J, Boling E, Merrill JT, Furie R, Petri M, Ginzler E, Chatham W, Fernandez V, Zhong J, Chevrier M, Freimuth W, Belimumab (BMAB), a fully human monoclonal antibody to B-lymphocyte stimulator (BlyS), shows bioactivity and reduces systemic lupus erythematosus disease activity, *Annals Rheum Dis* 2006; 65: 62-63, s.11
286. Petri M, Wallace DJ, Stohl W, McKay J, Stern S, Furie R, McCain A, Ginzler E, Chatham W, Hall L, Migone T, Pineda L, Freimuth W, Chevrier M, SLE patients with active production of antinuclear autoantibodies (ANA) have distinct patterns of lupus activity and peripheral B cell biomarkers compared to ANA negative patients, *Annals Rheum Dis* 2006; 65: 356, s.11
287. Rojas J, Visvanathan S, Weisman M, Troum O, Bray V, Wallace D, Gaylis N, Ritter J, Yocum D, Hegedus R, Gilmer KE, Furst DE, Open, randomized study of rheumatoid arthritis patients switched from etanercept to infliximab compared with those who remained on etanercept: Changes in serum inflammatory, bone, and cartilage markers correlated with efficacy, *Annals Rheum Dis* 2006; 65: 464, s. 11
288. Ferbas J, Wallace DJ, Weisman MH, Belouski SS, Kessler JP, Vincent M, Ma J, Zack D, Hendricks L, Chung J, A systemic analysis of circulating B cell populations in healthy and SLE subjects, *Annals Rheum Dis* 2006; 65: 584, s.11
289. Gordon C, Wallace DJ, Kalunian KC, Shinada S, Forbess L, Braunstein GD, Weisman MH, Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus, *Arthritis Rheum* 2005; 52: S741.
290. Hanly JG, Urowitz MB, Sanchez-Guerrero J, Bae SC, Clarke A, Gordon C, Isenberg D, Alarcon G, Wallace DJ, Petri MA, Dooley MA, Gladman D, Fortin P, Merrill JT, Manzi S, Steinsson K, Bruce I, Aranow C, Zoma A, Van Vollenhoven R, Sturfelt G, Nived O, Ramsey-Goldman R,

- Khamashta M, Attribution of neuropsychiatric events at diagnosis of systemic lupus erythematosus, *Arthritis Rheum* 2005; 52: S727.
291. Weisman M, Furst D, Park G, Kremer J, Smith K, Smith-Riggs M, Meyer G, Barham R, Caldwell J, Wallace D, Hettinger K, Dervieux T, Risk genotypes in folate-dependent enzymes profile rheumatoid arthritis patients with side effects to methotrexate therapy, *Arthritis Rheum* 2005; 52: S722-723.
292. Mc Mahon M, Grossman J, Fitzgerald J, Dahlin-Lee E, Ebling F, Thong B, Badsha H, Wallace DJ, Kalunian K, Hahn BH, Pro-inflammatory HDL as a biomarker for atherosclerosis in SLE and RA, *Arthritis Rheum* 2005; 52: S697-698.
293. Naqibuddin M, Sampedro M, Wallace DJ, Weisman MH, Brey RL, Holliday SL, Carson KA, Anti-NR2 and anti ds DNA in newly diagnosed systemic lupus erythematosus: Analysis of cognitive function, brain MRI and PET, *Arthritis Rheum* 2005; 52: S621-S622
294. Urowitz MB, Sanchez-Guerrero J, Gladman DD, Fortin PR, Clarke A, Bae SC, Gordon C, Isenberg D, Hanly J, Merrill J, Ginzler E, Alarcon G, Wallace DJ, Petri M, Steinsson K, Dooley MA, Manzi S, Bruce, Maddison P, Sturfelt G, Nived O, Zoma A, Aranow C, Ramsey-Goldman R, van Vollenhoven R, Khamashta M, Stoll T, Systemic Lupus International Collaborating Clinics (SLICC) inception cohort registry to study risk factors for atherosclerosis (SLICC RAS): First follow up report, *Arthritis Rheum* 2005; 52: S608.
295. Naqibuddin M, Wallace DJ, Weisman MH, Brey RL, Sampedro M, Carson KA, Holliday SL, Petri M, Change in cognitive function in newly diagnosed systemic lupus erythematosus patients, *Arthritis Rheum* 2005; 52: S380
296. Naqibuddin M, Wallace DJ, Weisman MH, Brey RL, Sampedro M, Carson KA, Holliday SL, Petri M, Depression is associated with poorer cognitive function in newly diagnosed systemic lupus erythematosus patients, *Arthritis Rheum* 2005; 52: S379-S380
297. Hanly JG, Urowitz MB, Sanchez-Guerrero S, Bae SC, Clarke A, Gordon C, Isenberg D, Alarcon G, Wallace DJ, Petri M, Dooley MA, Gladman D, Fortin P, Merrill JT, Steinsson I, Bruce I, Aranow C, Zoma A, Van Vollenhoven R, Sturfelt G, Nived O, Ramsey-Goldman R, Khamashta M, Neuropsychiatric events at diagnosis of systemic lupus erythematosus, *Arthritis Rheum* 2005; 52: S379
298. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu ZN, Burmeister G, Schneider U, Furst DE, Moliter J, Keystone EC, Gladman D, Manger M, Wassenberg S, Weier R, Wallace D, Weisman M, Kalden JR, Smolen JS, 2 year data: Infliximab maintains clinical response in psoriatic arthritis patients—data from the infliximab multinational psoriatic arthritis controlled trial (IMPACT), *Arthritis Rheum* 2005; 52: S209
299. Binder SR, Homberger HA, Moder KG, Wener MH, Weisman MH, Wallace DJ, Multi-Site evaluation of the BioPoex™ ANA Screen Kit, *Clinical Chemistry* 2005;
300. Furst D, Yocum D, Weisman M, Troum O, Bray V, Wallace D, Gaylis N, Ritter J, Yeilding N, Gilmer K, Infliximab provides additional clinical and radiographical benefits in RA patients who have an inadequate response to etanercept, *Annals Rheum Dis* 2005; 64: 427.
301. Antoni Ca, Kavanaugh A, Birkham B, Tutuncu Z, Burmeister GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace D, Weisman MH, Kalden JR, Smolen J, Two year data: Infliximab maintains clinical response in psoriatic arthritis patients: an analysis of the year 2 data from the infliximab multinational psoriatic arthritis controlled trial (IMPACT), *Annals Rheum Dis* 2005; 64: 82.
302. Lee YH, Wu H, Cantor RM, Grossman JM, Rumbin AA, Park E, Shen N, Chen CJ, Hadsha HM, Thong BYH, Chong HH, Wallace DJ, Hahn BH, Tsao BP, Evidence for SLE susceptibility gene(s) at 1q32, *Arthritis Rheum* 2004; 50: 607- 608.

303. Wu H, Cantor RM, Grossman JA, Park E, Rumbn AA, Wallace DJ, Hahn BH, Tsao B, Toll-like receptor 9 gene polymorphisms protective for SLE, *Arthritis Rheum* 2004; 50: S459.
304. Keilbrunn KR, Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Hura C, Strand V, Joh T, The effect of LJP 394 and concomitant immunosuppressive agents on levels of anti ds DNA antibodies in SLE patients, *Arthritis Rheum* 2004; 50: S406.
305. Naqibuddin M, Wallace DJ, Weisman MH, Holliday SL, Wing NF, Brey RL, Petri M, Cognitive functioning in recently diagnosed systemic lupus erythematosus, *Arthritis Rheum* 2004; 50: S195.
306. Paulus HE, Weaver A, Wallace DJ, Whitmore JB, Leff JA, The CORONA patient registry for patients with rheumatic diseases, *Arthritis Rheum* 2004; 50: S376.
307. Brey RL, Fox PT, Narayana S, Martinez MJ, Naqibuddin M, Holliday SL, Wallace DJ, Weisman MH, Brain imaging findings in an SLE inception cohort: Brain CONNECTIONS, *Arthritis Rheum* 2004; 50: S194.
308. Mc Mahon M, Grossman J, Fitzgerald J, Ebling F, Dahlin-Lee E, Thong B, Kalunian K, Wallace DJ, Badsha H, Navab M, Fogelman AM, Hahn BH, Atherosclerosis in SLE may relate to abnormal protective capacity of HDL, *Arthritis Rheum* 2004; 5: S192.
309. Chiou C, Weisman M, Sherbourne C, Reyes R, Dylan M, Ofman J, Wallace DJ, Miszutani W, Suarez-Almazor ME, Measuring preference weights for health states with rheumatoid arthritis, *Annals Rheum Dis* 2004; 63: 534, supp 1.
310. Antoni CE, Kavanaugh A, Kirkham, Burmeister G, Manger B, Schneider U, Tutuncu Z, Ebner W, Wassenberg S, Furst D, Molitor J, Keystone E, Gladman D, Weisman M, Wallace D, Weier R, Kalden JR, Smolen J, The infliximab multinational psoriatic arthritis controlled trial (Impact 1): The concomitant use of DMARDs does not influence the efficacy and safety of infliximab over a one year period, *Annals Rheum Dis* 2004; 63: 411, supp 1.
311. Wallace DJ, Weaver A, Stein B, Campbell D, Huston J, Goldman J, Xia HA, Louie J, Etanercept of infliximab in combination with methotrexate (MTX) in the treatment of rheumatoid arthritis—results from the Radius registry, *Annals Rheum Dis* 2004 63: 251, supp1.
312. Bombardieri S, CardielMA, Tumlin JA, Furie RA, Wallace DJ, Hura C, Schneider M, Hieppe F, Strand V, Joh T, Foster T, Yushmanova I, Keilbrunn KR, Summary of safety results from studies of LJP 394 in SLE patients, *Annals Rheum Dis* 2004 63: 216 supp1.
313. Wallace DJ, Cardiel MH, Tumlin JA, Furie J, Hura C, Strand V, Wang S, Yushmanova I, Heilbrunn KR, Safety results from a RCT of LJP 394 in SLE patients with a history of renal disease, *Am J Soc Nephrol* 2003.
314. Wu H, Cantor RM, Shen N, Arnett FC, Grossman JM, Lau CS, Badsha HM, Rumbin AA, Wallace DJ, Ching HH, Linkage and association of systemic-lupus-erythematosus (SLE) on 1q23,2, *Am J Hu Gen* 2003; 73: 1950.
315. Ginzler EM, Aranow C, Buyon J, Dooley MA, Merrill JT, Petri M, Allep G, Cilekson G, Wallace D, Weisman M, A multicenter study of mycophenolate mofetil (MMF) vs intravenous cyclophosphamide (IVC) as induction therapy for severe lupus nephritis (LN): Preliminary results, *Arthritis Rheum* 2003; 47: S647.
316. Wallace DJ, Cardiel MH, Tumlin JA, Furie RA, Hura C, Strand V, Wang S-L, Yushmanova I, Heilbrunn KR, Safety results from a randomized, controlled trial (RCT) of LJP 394 in systemic lupus erythematosus (SLE) patients with a history of renal disease, *Arthritis Rheum* 2003; 47: S583.
317. Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Hura C, Strand V, Foster V, Hu J, Heilbrunn KR, Linnik MD, Clinical efficacy results from a RCT of LJP 394 in SLE patients with history of renal disease, *Arthritis Rheum* 2003; 47: S582-S583.

318. Linnik MD, Joh T, Strand V, Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Hura C, SLE patients with sustained reductions in anti-DNA antibodies have a reduced risk of renal flare and major SLE flare, *Arthritis Rheum* 2003; 47:S582.
319. Horizon AA, Yu X, Hwang KK, Fitzgerald J, Wallace DJ, Metzger AL, Weisman MH, The application of the CL154C peptide-mimetic to study disease—relevant antiphospholipid antibodies in patients with APS and SLE, *Arthritis Rheum* 2003; 47: 3638-3639.
320. Horizon A, Weisman MH, Wallace DJ, Merrill JT, Linnik MD, Cockerill K, Furie RA, Results of a randomized, placebo, controlled, double-blind phase ½ clinical trial (RCT) to assess the safety and tolerability of LJP 1082 in patients with antiphospholipid syndrome, *Arthritis Rheum* 2003; 47: 364-365.
321. Lannik MD, Salter-Cid L, Miller AC, Furie RA, Horizon A, Weisman MH, Wallace DJ, Merrill JT, Cockerill K, Domain specificity of autoantibodies to beta2-glycoprotein 1 in patients with antiphospholipid syndrome enrolled in a phase½ trial with LJP, *Arthritis Rheum* 2003; 47: S356.
322. Antoni C, Kavanaugh A, Kirkham B, Burmeister G, Manger B, Schneider U, Tutuncu Z, Ebner W, Wassenberg S, Furst D, Molitor J, Keystone E, Gladman D, Weisman M, Wallace D, Kalden J, Smolen J, The one year results of the infliximab multinational psoriatic arthritis controlled trial (IMPACT), *Arthritis* 2003; 47: S265-266.
323. Wu H, Cantor RM, Grossman JM, Rumbin AA, Shen A, Lau CS, Wallace DJ, Arnett FC, Badsha HM, Chng HH, Hahn BH, Tsao BP, Markers in a 1-Mb interval within 1q23.2 are associated with systemic lupus susceptibility, *Arthritis Rheum* 2003; 47: S256.
324. Antoni CE, Kavanaugh A, Kirkham B, Burmeistr G, Manger B, Tituncu Z, Schneider U, Ebner W, Wassenberg S, Furst D, Molitor J, Weisman M, Wallace D, Keystone E, Kalden JR, Smolen J, The Infliximab multinational psoriatic arthritis controlled trial (IMPACT): Substantial efficacy of synovitis and psoriatic lesions with or without concomitant DMARD therapy, *Ann Rheum Dis* 2003; 62: 90.
325. Strand V, Aranow C, Cardiel M, Furie R, Sherrer Y, Tumlin J, Wallace DJ, Crawford B, Improvement in health related quality of life in SLE patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo, *Arthritis Rheum* 2002; 46: S119.
326. Tsao BP, Grossman JM, Riemekasten G, Kasli J, Wallace DJ, Chen CJ, Lau CS, Ginzler EM, Goldstein RM, Arnett FC, Kalunian KC, Hahn BH, Familialty of clinical features of SLE in affected sib pairs, *Arthritis Rheum* 2001; 44: S248.
327. Grossman JM, Kim SK, Wallace DJ, Chen CJ, Lau CS, Ginzler DM, Goldstein R, Shen N, Kalunian KC, Arnett FC, Hahn BH, Interaction of loci at 1Q23 and IBD.1 may contribute to lupus susceptibility, *Arthritis Rheum* 2001; 44: S248.
328. Wallace DJ, Telomere antibodies and telomere biology in autoimmunity, *The Ryumachi* 2001; 41:209. 113. Wallace DJ, Do cytokines play a pathogenetic role in fibromyalgia? A hypothesis and pilot study, *Journal of Musculoskeletal Pain* 2001; 9: 80 (supp5).
329. Remer CF, Weisman MH, Wallace DJ, Benefits of leflunomide (LEF) in systemic lupus erythematosus, *Lupus* 2001; 10: S10.
330. Linker-Israeli M, Honda M, Wallace DJ, Albano S, Mengesha E, Nichols S, Klinenberg JR, Metzger A, Morris R, Loss of telomeric DNA and fewer proliferative cycles, contrasted by continuous in vitro cycling of non-senescent, CD28- CD8+ T cells in patients with systemic lupus erythematosus, *Arthritis Rheum* 2000; 43: S273.
331. Tsao BP, Grossman JM, Arnett FC, Chak S, Wallace DJ, Ginzler DM, Goldstein R, Kalunian KC, Hahn BH, Cantor RM, Investigation of SLE-linked regions identified by genome scans: Support for 1q24, 16q13 and 20p12, *Arthritis Rheum* 2000; 43: S278.

332. Lander S, Wallace S, Weisman MH, Is celecoxib safe in SLE with or without sulfa allergy? A pilot study, *Arthritis Rheum* 2000; 43: S242.
333. Wallace DJ, Linker-Israeli M, Hallegua D, Silverman SL, Silver D, Weisman MH, Cytokines play an etiopathogenetic role in fibromyalgia: A pilot study, *Arthritis Rheum* 2000; 43: S212.
334. Pimentel M, Chow EJ, Bonorris G, Hallegua D, Wallace D, Lin HC, Eradication of small-intestinal bacterial overgrowth decreases the gastrointestinal symptoms in fibromyalgia, *Gastroenterology* 2000; 118: 2143.
335. Linker-Israeli M, Wallace DJ, Mengesha E, Taylor KE, Fischelg N, Mueller C, SLE-associated alleles of the IL-6 3' flanking region contribute to IL-6 gene regulation. *FASEB J*, 2000; 14: 1206.
336. Weinreb A, Grossman JM, Cantor RM, Theophil N, Wallace DJ, Hahn BH, Tsao BP, Association of the interleukin-1 receptor antagonist IL-1RN*1 allele with systemic lupus erythematosus (SLE) clinical phenotypes. *Am J Hum Genet* 1999; 65: 2277.
337. Grossman JM, Hahn BH, Kalunian KC, Wallace DJ, Arnett FC, Rubin RL, Tsao BP, IgG anti-chromatin antibodies are associated with lupus nephritis, *Arthritis Rheum* 1999; 42: S215.
338. Albano S, Hallegua D, Wallace DJ, Klinenberg JR, Lin HC, Small intestinal bacterial overgrowth in systemic lupus erythematosus (SLE), *Arthritis Rheum* 1999; 42: S305.
339. Linker-Israeli M, Wallace DJ, Mengesha E, Taylor K, Fishel-Ghodossian N, Klinenberg JR, SLE-associated alleles of the IL-6 3' flanking region modulate IL-6 expression, *Arthritis Rheum* 1999; 42: S309.
340. Pimentel M, Hallegua D, Wallace D, Bonorris G, Chow E, Tabibzadeh S, Lin HC, Eradication of small intestinal bacterial overgrowth decreases symptoms in fibromyalgia, *Arthritis Rheum* 1999; 42:S343.
341. Honda M, Wallace DJ, Metzger A, Morris R, Behariar B, Klinenberg JR, Linker-Israeli M, Contrasting effects of IL-10 and IL-4 on IL-6 content of SLE PBMC subsets, *FASEB J* 1998; 12:3524.
342. Linker-Israeli M, Wallace DJ, Michael D, Nand R, Honda M, Klinenberg JR, IL-6 minisatellite alleles are associated with SLE and with up-regulated IL-6 expression, *FASEB J* 1998; 12: 3521.
343. Tsao BP, Cantor RM, Grossman JM, Theophilov N, Wallace DJ, Arnett FC, Hartung K, Goldstein R, Kalunian KC, Hahn BH, Rotter JL, "ADPRT alleles from the chromosome 1q41-q42 linked region are associated with SLE", *Arthritis Rheum* 1998; 41: S80.
344. Moser KL, Neas BR, Salmon JE, Yu H, McGuire C, Asundi N, Gruner GR, Fox J, Kelly J, Henshall S, Bacino D, Dietz M, Hogue R, Koelsch G, Nightingale L, Abdou N, Albert D, Carson C, Ginzler E, McKowen K, Petri M, Ramsey- Goldman R, Treadwall E, Wallace D, Wilson J, Wolf R, Sahver T, James JA, Harley JB, "Genome scan of human systemic lupus erythematosus (SLE) identifies multiple loci influenced by racial origin", *Arthritis Rheum* 1998; 41:S283.
345. Hallegua D, Wallace DJ, Metzger AL, Klinenberg JR, "Association of goat milk exposure with autoantibodies", *Arthritis Rheum* 1998; 41:S331.
346. Grossman JM, Teophilov N, Kalunian KC, Wallace DJ, Arnett FC, Hartung K, Goldstein R, Lin HY, Hahn BH, Tsao BP, "Comparison of clinical manifestations of lupus patients in simplex and multiplex families", *Arthritis Rheum* 1998; 41:S329.
347. Weinreb A, Grossman JM, Theophilov N, Zhao Y, Wallace DJ, Hahn BH, Tsao BP, "Family-based and case-control association studies of the interleukin-1 receptor antagonist (IL-1RA) ILRN*2 allele in North-American caucasian and han-Chinese populations with systemic lupus erythematosus (SLE) and glomerulonephritis", *Arthritis Rheum* 1998; 41: S285.
348. Linker-Israeli M, Wallace DJ, Michael D, Prehn J, Nand P, Taylor KD, Paul-Labrador M, Honda M, Fishel- Ghodsian N, Fraser PA, Klinenberg JR, "Novel alleles of the IL-6 gene

- minisatellite are associated with systemic lupus erythematosus (SLE) and with differential IL-6 expression", *Arthritis Rheum* 1998; 41:S282.
349. Hallegua D, Bonert V, Mathur R, Silverman S, Wallace DJ, Klinenberg JR, "Prevalence of fibromyalgia (FM) in growth hormone deficient (GH) adults", *Arthritis Rheum* 1998; 41:S256.
 350. Salonen E-M, Wallace DJ, Metzger AL, Avannis-Aghajani E, "Anti-telomere antibodies are highly specific for systemic lupus erythematosus (SLE)", *Arthritis Rheum* 1998; 41: S247.
 351. Neumann K, Golde G, Wallace DJ, Metzger AL, "Osteoporosis--less than expected in scleroderma?", *Arthritis Rheum* 1998; 41:S216.
 352. Pachinian N, Wallace DJ, Klinenberg JR, "Mycophenolate mofetil for systemic lupus erythematosus", *Arthritis Rheum* 1998; 41: S110.
 353. Shai R, Quismorio FP Jr, Li L, Kwon OJ, Morrison J, Wallace DJ, Neuwelt CM, Gauderman WJ, Jacob CO, "Multigenic control of disease in multiplex families with systemic lupus erythematosus", *Arthritis Rheum* 1998; 41:S80.
 354. Honda M, Nand R, Mandyam R, Mengesha E, Wallace DJ, Metzger A, Bharler, Klinenberg JR, Morris R, Linker-Israeli M, "IL-6, IL-10 and IL-4 expression and cross talk in patients with systemic lupus erythematosus", *Arthritis Rheum* 1998; 41: S39.
 355. Moser KL, Neas BR, Bruner G, Salmon J, Harley JB, Wallace D, Petri M, Mc Kown K, Carson C, Albert D, "Scanning the genome for human SLE genes: Design and candidate regions", *Lupus* 7: 13, 1998, Supp 1
 356. Wallace DJ, Goldfinger D, Pepkowitz S, Fichman M, Metzger AL," A randomized controlled trial of pulse/ synchronization cyclophosphamide/apheresis for proliferative nephritis", *Lupus* 1998; 7: 79, supp 1.
 357. Wallace DJ Post S, "An epidemiologic survey of Moorpark, California", *Lupus* 1998; 7: 23, Supp 1.
 358. Moser KL, Yu H, Asunde N, Koelsch G, Salmon JE, Wallace D, Ginzler E, Wolf RE, Bruner G, Neas BR, Harley JB, "Evidence for racial differences in genetic linkage to multiple loci spanning chromosome 1q in human systemic lupus", *Arthritis Rheum* 1997; 40: S315.
 359. Tsao BP, Cantor RM, Badsha H, Grossman JM, Kalunian KC, Hartung K, Arnett FC, Wallace DJ, Hahn BH, Rotter JL, "A susceptibility gene for SLE maps to a 5 cM region of chromosome 1q", *Arthritis Rheum* 1997; 40 S315.
 360. Wallace D, Goldfinger D, Pepkowitz S, "A prospective, controlled trial of pulse synchronization cyclophosphamide (CTX)/apheresis for proliferative lupus nephritis", *Arthritis Rheum* 1997; 40: S58.
 361. Hallegua D, Wallace DJ, Metzger AL, Klinenberg JR, "Cyclosporine for membranous lupus nephritis", *Arthritis Rheum* 1997; 40 S57.
 362. Linker-Israeli M, Ebling F, Wallace DJ, Nand R, Singh RR, Lin P, Klinenberg JR, Hahn BH, "T cells of SLE patients recognize VH determinants of anti ds DNA autoantibodies," *Arthritis Rheum* 1996; 39:S267.
 363. Tsao BP, Cantor RM, Kalunian KC, Chen C-J, Singh R, Wallace DJ, Kitridou RC, Chen SI, Shen N, SongYW, Isenberg DA, Yu C-I, Hahn BH, Rotter JL, "Evidence for linkage of a candidate chromosome 1region to systemic lupus erythematosus (SLE)," *Arthritis Rheum* 1996; 39:S217.
 364. Linker-Israeli M, Wallace DJ, Prehn J, Michael D, Yang H, Nand R, Klinenberg JR, "Aberrant distribution of the IL-6 gene minisatellite alleles in SLE patients: Population and multiplex family studies," *Arthritis Rheum* 1996; 39:S128.
 365. Linker-Israeli M, Wallace DJ, Prehn J, Michael D, Yang H, Klinenberg JR, "Skewed allele distribution of the IL-6 gene associated minisatellite in patients with SLE," *J Experimental Med* 1996; 44:A276.

366. Wallace DJ, Cozen LJ, "Avascular necrosis in SLE: Lack of association with antiphospholipid antibodies and other clinical correlates," *Arthritis Rheum* 1996; 39:R4.
367. Basbug E, Schwartz E, Wallace DJ, Nessim S, Klinenberg JR, "Clinical and laboratory features of 30 patients with systemic lupus erythematosus and silicone breast implants," *Arthritis Rheum* 1995;38:S265.
368. Basbug E, Wallace DJ, Nessim S, Klinenberg JR, "Clinical and laboratory features of 24 patients with systemic lupus erythematosus and silicone breast implants," *Arthritis Rheum* 38:R8, 1995 (suppl).
369. Schwartz EF, Wallace DJ, Klinenberg JR, "Clinical and laboratory features of 20 patients with scleroderma and silicone breast implants," *Arthritis Rheum* 38: RS, 1995 (suppl).
370. Wallace DJ, Pepkowitz S, Goldfinger D, "Pulse synchronization plasmapheresis for proliferative lupus nephritis with nephrotic syndrome: A randomized trial progress report," *J Clin Apheresis* 10:55, 1995.
371. Linker-Israeli M, Wallace D, Elstner E, Koefiler P, Klinenberg J, "Vitamin D3 inhibits immunoglobulin production by peripheral blood mononuclear cells (PBMC) of systemic lupus erythematosus (SLE) patients," *Lupus* 4:63, 1995 (suppl 2).
372. Linker-Israeli M, Prehn J, Toyoda H, Wallace D, "The interleukin-6 gene; Studies in patients with systemic lupus erythematosus (SLE)," *Lupus* 4:7, 1995 (suppl 2).
373. Linker-Israeli M, Hyun S, Ozeri-Chen T, Wallace D, Klinenberg J, "Elevated in vivo and in vitro secretion of CD8-a molecules in patients with systemic lupus erythematosus," *Lupus* 4:48, 1995 (suppl 2).
374. Shen GQ, Lin H-C, Wallace DJ, Shoenfeld Y, Lai N, Peter JB, "Detection of (H2A-H2B)-DNA histone-complex antibodies in autoimmune-diseases and drug-induced lupus," *J Am S Nephrol* 5:769, 1994.
375. Stecher VJ, Wallace DJ, Metzger AL, "Antihyperlipidemic actions of hydroxychloroquine (Plaquenil)," *Rev Bras Rheumatol* 34:S88 (suppl), 1994.
376. Linker-Israeli M, Prehn J, Wallace DJ, Klinenberg JR, "Cytokine genes of lupus patients: Do they differ from normal?," *Arthritis Rheum* 37:S168, 1994.
377. Linker-Israeli M, Prehn J, Li L, Wallace DJ, Klinenberg JR, "IL-6 gene polymorphisms in SLE (systemic lupus erythematosus)," *J Immunol* 150 A40, 1993.
378. Linker-Israeli M, Prehn J, Wallace DJ, Li L, Klinenberg JR, "Study of an IL-6 gene XBAI restriction fragment associated with systemic lupus erythematosus," *Arthritis Rheum* 36:S 111, 1993.
379. Wallace DJ, Linker-Israeli M, Hyun S, Stecher V, Klinenberg JR, "The effect of hydroxychloroquine (HC) therapy on serum levels of immunoregulatory molecules in patients with systemic lupus erythematosus," *Arthritis Rheum* 36:S231, 1993.
380. Allosachie I, Lin H-C, Shoenfeld Y, Wallace DJ, "Evaluation of neuronal antibody reactivity in neuropsychiatric systemic lupus by flow cytometry," *Arthritis Rheum* 36:S185, 1993.
381. Wallace DJ, Lin H-C, Peter JB, "The 'does she or doesn't have lupus' consultation: Improving diagnostic acumen," *Arthritis Rheum* 36:S185, 1993.
382. Liven L, Shen G, Wallace DJ, "A rapid and specific enzyme immunoassay to measure serum hyaluronic acid concentration," *Arthritis Rheum* 36:S126, 1993.
383. Shen G, Li L, Wallace DJ, Lin H-C, "Combined measurements of serum hyaluronic acid and IgM RF levels increase the sensitivity for the diagnosis of rheumatoid arthritis without sacrificins~ the specificity," *Arthritis Rheum* 36:S125, 1993.
384. Neumann K, Wallace DJ, Klinenberg JR, "Influence of clinical variables, biopsy and treatment on the outcome of 150 patients with lupus nephritis seen at a single center in the 1980s," *Arthritis Rheum* 36:S229, 1993.

385. Wallace DJ, Linker-Israeli M, Stecher V, Klinenberg JR, "The effect of hydroxychloroquine (HC) on soluble accessory molecules and cytokines in systemic lupus erythematosus (SLE)," *Arthritis Rheum* 36:R6,1993 (supp).
386. Wallace DJ, Metzger AL, "Antimalarials decrease the risk of thromboembolic events in anticardiolipin positive lupus patients," *Arthritis Rheum* 35:S110, 1992
387. Linker-Israeli M, Prehn J, Wallace DJ, Li L, Toyoda H, Klinenberg JR, "Novel polymorphisms of the IL-6 gene in systemic lupus erythematosus," *Arthritis Rheum* 35:S175, 1992.
388. Linker-Israeli M, Hyun S, Ozeri-Chen T, Wallace DJ, Klinenberg JR, "Soluble CD8 molecules in systemic lupus erythematosus," *Arthritis Rheum* 35:S138, 1992.
389. Neumann K, Wallace D, Azen C, Goodman D, Fichman M, Klinenberg J, "Influence of treatment and biopsy variables on outcome of 150 lupus nephritis patients seen in a private practice between 1950 and 1980," *Arthritis Rheum* 35:S357, 1992.
390. Wallace DJ, "A new role for hydroxychloroquine in the 1990s?," *Lupus* 1:98 (S1), 1992.
391. Hyun S, Linker-Israeli M, Ozeri-Chen T, Wallace DJ, Klinenberg JR, "Do soluble accessory molecules play a role in autoimmunity?" *FASEB J* 6: 1980, 1992.
392. Lahita RG, Rivkin E, Wallace DJ, Cavanagh L, "Low LDL cholesterol and apolipoprotein A1 levels in patients with SLE and IgG cardiolipin antibodies: A possible etiologic factor in atherosclerosis," *Arthritis Rheum* 34:S42, 1991.
393. Linker-Israeli M, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR, "Elevated levels of endogenous IL-6 in systemic lupus erythematosus (SLE): A putative role in pathogenesis," *Arthritis Rheum* 34:S141, 1991.
394. Wallace, DJ, Pistiner M, Nessim S, Metzger AL, Klinenberg JR, "Chronic cutaneous (Discoid) lupus (DLE): Clinical and laboratory parameters in 67 patients followed in a private practice (1980-1989)," *Arthritis Rheum* 34:S130, 1991.
395. Silverman SL, Wallace DJ, "Calcitonin helps a subset of patients with fibromyalgia," *Arthritis Rheum* 34:R21, 1991.
396. Linker-Israeli M, Wallace DJ, Jordan SC, Klinenberg JR, "Demonstration of IL-1, IL-6 and IFN gamma in SLE kidney biopsies," *Arthritis Rheum* 34:R20, 1991.
397. Linker-Israeli M, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR, "Elevated levels of endogenous IL 6 in systemic lupus erythematosus (SLE): A putative role in pathogenesis," *Arthritis Rheum* 34:R15, 1991.
398. Linker-Israeli M, Wallace DJ, Ozeri-Chen T, Klinenberg JR, "Soluble CD4 and CD 8 in SLE sera: Possible new markers for disease activity and nephritis," *Arthritis Rheum* 34:R15, 1991.
399. Wallace DJ, Metzger AL, Stecher V, Kern P, "Cholesterol lowering effect of hydroxychloroquine in rheumatic disease patients. Reversal of deleterious effects of steroids on lipids," *Arthritis Rheum* 33: S165, 1990.
400. Wallace DJ, Pistiner M, Klinenberg JR, "464 patients with idiopathic SLE: Natural course, treatment and causes of death," *Arthritis Rheum* 33: S130,1990.
401. Wallace DJ, Pistiner M, Klinenberg JR, "464 patients with idiopathic SLE: Clinical and laboratory findings," *Arthritis Rheum* 33:S130, 1990.
402. Linker-Israeli M, Deans RJ, Wallace DJ, Jordan S, Quismorio FP, Klinenberg JR, Ozeri-Chen T, "Up-regulation of spontaneous IgG by endogenous cytokines in systemic lupus erythematosus," *FASEB J* 4:A2104, 1990.
403. Wallace, D.J., "Genitourinary manifestations of fibromyalgia: an increased association with the female urethral syndrome," *Arthritis Rheum* 33:R8, 1990.
404. Wallace, D.J., Metzger, AL., "Antihyperlipidemic actions of hydroxychloroquine (Plaquenil)," *Arthritis Rheum* 33:R7, 1990.

405. Pistiner, M., Wallace, D.J., Klinenberg, J.R., "A survey of 536 patients with lupus erythematosus," *Arthritis Rheum* 33:R5, 1990.
406. Chong, P.J., Matzner, W.L., Wallace, D.J., Klinenberg, J.R, Jordan, S.C., "Protein kinase-C pathway regulation of immunoglobulin synthesis in peripheral blood mononuclear cells of patients with SLE," *Arthritis Rheum* 32: S92, 1989.
407. Wallace, D.J., Bowman, R, Wormley, S.B., Peter, J.B., "Are there immunoregulatory abnormalities in the primary fibromyalgia (fibrositis) syndrome?" *Arthritis Rheum* 32:S69, 1989
408. Peter, J.B., Wallace, D.J., "Abnormal immune regulation in fibromyalgia," *Arthritis Rheum* 31: S24, 1988.
409. Wallace, D.J., Margolin, K., "Acute-onset fibromyalgia as a complication of interleukin-2 therapy," *Arthritis Rheum* 31: S24, 1988.
410. Wigfall, D.R, Wallace, D.J., Sakai, RS., Jordan S.C., "B-cell interleukin-2 (IL-2) receptor expression in systemic lupus erythematosus (SLE)," *Arthritis Rheum* 31:S106, 1988.
411. Wallace D.J., Goldfinger, D., Dubois, E.L., Klinenberg, J.R, "Refractory lupus nephritis: A controlled study on the use of plasmapheresis in 59 patients," *Artificial Organs* 12:286, 1988.
412. Wigfall, D.R, Wallace, D.J., Sakai, RJ., Jordan, S.C., "Interleukin-2 receptor expression in peripheral blood lymphocytes in SLE patients, relationship to clinical activity," *Arthritis Rheum*, 32:R22, 1988.
413. Peter, J.B., Lee, C.T., Wallace, D.J., "Studies of immune regulation in primary fibromyalgia syndrome," *Arthritis Rheum*, 31 :R18, 1988.
414. Wigfall, D.R, Wallace, D.J., Sakai, RS., and Jordan, S.C., "In vitro interleukin-2 receptor expression by PBL isolated from SLE patients," *Kidney Int.* 33: 331, 1988.
415. Wallace, D.J., Goldfinger, D., Goodman, D., and Fichman, M., "Predictive value of outcome variables in immunosuppressive resistant lupus nephritis," *Arthritis Rheum* 30:S70, 1987.
416. Wallace, D.J., Wiedmann, C.E., Peter, J.B., Knight, P.K., and Klinenberg, J.R, "Antiphospholipid antibody isotypes in SLE," *Arthritis Rheum*, 30:S55, 1987.
417. Wigfall, D.R, Wallace, D.J., Sakai, RS., and Jordan, S.C., "In vitro interleukin-2 receptor generation by PBL isolated from SLE patients," *Pediat. Res.*, 21:A486, 1987.
418. Wallace, D. J., Wiedmann, C., Peter, J., Knight P., and Klinenberg, J.R, "Anticardiolipin isotypes in SLE," *Arthritis Rheum*, 30:S29, 1987 (Suppl 1).
419. Wallace, D.J., Goldfinger, D., Goodman, D., Fichman, M., and Klinenberg, J.R, "A controlled study on the use of plasmapheresis in steroid immunosuppressive resistant SLE patients with nephrotic syndrome," *Arthritis Rheum*, 30:S26, 1987 (Suppl 1).
420. Wallace, D. J., Peter, J.B., Wiedmann, C. R, Knight, P.J., and Klinenberg, J.R, "Antibodies to non-cardiolipin antibodies in SLE: Clinical associations," *Arthritis Rheum*, 30:S26, 1987 (Suppl 1).
421. Wallace, D. J., Goldfinger, D., and Klinenberg, J.R, "Plasmapheresis in lupus nephritis: A controlled study— preliminary results," *Plasma Therapy*, 7:418, 1986.
422. Wallace D. J., Brachman, M., Feldman, G., Reichman, R, and Klinenberg, J.R, "Quantitative computerized joint scanning in rheumatoid arthritis: An accurate, reproducible method of quantitating synovitis," *Arthritis Rheum*, 29: S81. 1986.
423. Wallace D., Goldfinger, D., and Klinenberg, J.R, "Plasmapheresis in lupus nephritis: A controlled study, Preliminary results," *Arthritis Rheum*, 28:S46, 1985.
424. Wallace, D., "Plasmapheresis vs lymphoplasmapheresis: Immunologic difference," *J Clin. Apheresis*, 2:141, 1984.
425. Wallace, D., Goldfinger, D., Klinenberg, J., Barnett, E., and Curd, J., "Immunologic regulation in selective plasmapheresis in rheumatoid arthritis," *Arthritis Rheum*, 26:S44, 1983.

426. Wallace, D., Goldfinger, D., and Klinenberg, J., "Therapeutic plasmapheresis in systemic lupus with nephrotic syndrome," *Arthritis Rheum*, 25: S81, 1982.
427. Wallace, D., Goldfinger, D., Brachman, M., and Klinenberg, J., "A double-blind controlled study of lymphoplasmapheresis in rheumatoid arthritis," *Arthritis Rheum*, 25:3S, 1982.
428. Brachman, M.B., Wallace, D.J., Garcia, E., Klinenberg, J., Brown, D. E., Tanasescu, D.E., Ramanna, L., and Waxman, A-D., "Quantitative joint scanning in rheumatoid arthritis," *Clin. Nuclear Med.* 6: 455, 1981.
429. Podell, T., Wallace, D., Forouzesh, S., Cox, M., Weiner, J., and Dubois, E., "Experience with 230 lupus nephritis patients: 1950-1980," *Arthritis Rheum*, 24: 121S, 1981.
430. Wallace, D., Podell, T., and Dubois, E., "Nitrogen mustard in lupus nephritis," *Arthritis*, 24: 70S, 1981.
431. Wallace, D., Goldfinger, D., Thompson-Breton, R, Martin, V., Lowe, C., and Klinenberg, J., "A double blind controlled study of lymphoplasmapheresis in rheumatoid arthritis," *Arthritis Rheum*, 24:S125, 1981.
432. Brachman, M.B., Wallace, D., Tanasescu, D., Ramanna, L., and Waxman, A., "Rheumatoid arthritis: Can quantitative joint scanning be used to evaluate the response to therapy?" *Clin. Nuclear Med.*, 5:S38-29, 1980.
433. Podell, T., Wallace, D., Forouzesh, S., Cox, M., Weiner, J., Klinenberg, J., and Dubois, E., "SLE: A retrospective study of 443 patients followed in a private practice with emphasis on survival," *Arthritis Rheum*, 23: 732, 1980.
434. Wallace, D., Goldfinger, D., Bluestone, R, and Klinenberg, J.R, "Therapeutic pheresis in the management of rheumatoid arthritis," *Arthritis Rheum* 23:759, 1980.
435. Wallace, D., Podell, T., Forouzesh, S., Cox, M., Weiner, J., and Dubois, E., "Systemic lupus erythematosus: A retrospective study of 443 patients followed in private practice with emphasis on survival," *Clin. Res.*, 28:77A, 1980.
436. Wallace, D., Goldfinger, D., Brachman, M., Bluestone, R, and Klinenberg, J., "Therapeutic pheresis in the management of rheumatoid arthritis," *Clin. Res.*, 28:77A, 1980.
437. Wallace, D., Goldfinger, D., Gatti, R, Fan, P., Klinenberg, J., and Bluestone, R, "Long term plasmapheresis and lymphoplasmapheresis in the management of rheumatoid arthritis," *Arthritis Rheum*,22:670, 1979.
438. Wallace, D., Fan, P., Gatti, R, Goldfinger, D., Klinenberg, J., and Bluestone, R, "Effects of lymphoplasmapheresis on immunologic status," *Arthritis Rheum* 22:670, 1979.
439. Wallace, D., "RNA tumor viruses and aging," *Clin. Res.*, 22:198A, 1974.